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Hypertension increases the risk of cardiovascular disease. Whilst blood 
pressure (BP) lowering can reduce this risk, it can also cause adverse 
effects. This PhD study uses mixed methods to explore the utility of frailty to 
identify older people for whom the association of BP and outcomes is 
different.  
Methods 
Meta-analysis summarised observational studies to date. A retrospective 
cohort study used linked electronic health records from the Welsh Secure 
Anonymised Information Linkage (SAIL) databank. Frailty was measured 
using the electronic frailty index. Time to event analysis measured first ever 
major adverse cardiovascular event (MACE), all-cause mortality and 
injurious falls. Narrative interviews explored the perspectives of ten older 
people on the utility of frailty in managing hypertension on their terms. 
Results 
Meta-analysis identified that all-cause mortality was lower for older people 
who were not frail with systolic BP < 140 mm Hg compared to > 140 mm Hg, 
but there was no association in the context of frailty. In a population of 
145,598 people with hypertension over the age of 65, compared to 
participants who were fit, people with frailty were associated with 
significantly higher MACE events despite adjustment for known 
cardiovascular risk factors (increased risk of 38% in mild frailty, 84% in 
moderate frailty, 117% in severe frailty). Frailty did not modify the 
association of BP and outcomes, but frailty did modify the association of BP-
lowering medication and outcomes. Narrative interviews explored ways in 
which frailty could guide hypertension management towards what matters 




Findings provide evidence that frailty can usefully identify older people with 
increased risk of cardiovascular and non-cardiovascular outcomes in the 
context of hypertension management and suggest that the modifying effect 
of frailty in this context is in the degree to which someone sustains benefit or 
suffers adverse effects of BP-lowering treatment.  
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Chapter 1 will review the current understanding of the pathophysiology of 
hypertension in the context of ageing. In Chapter 2, the available evidence 
will be critically appraised in a systematic review and meta-analysis. The 
methodology for the routine data study will be outlined in Chapter 3, and 
main findings in Chapter 4. In Chapter 5, I will present the methods and 
findings from a series of narrative interviews undertaken to explore a 
patient’s perspective on the utility of frailty in hypertension management. 
The findings of the review, quantitative and qualitative studies will be 
presented and analysed in the context of current literature in Chapter 6, 
identifying implications for future research, policy and clinical practice. 
1 
 




The understanding of hypertension as a disease of vascular ageing is new and 
evolving. In this chapter, recent advances are outlined in the understanding of 
vascular ageing as central to the aetiology of hypertension. I will consider each 
of the major pathological risk factors for hypertension in the context of vascular 
ageing. The role of treatment for hypertension is explored, both in terms of the 
benefits and the harms of BP-lowering medication. Following on from this, I 
outline grounds to consider the role of frailty in hypertension management from 
each perspective, with respect to the underlying biology and the challenges of 
identifying when and how to treat hypertension.  
 
1.2 Definition of hypertension 
 
Hypertension describes persistently raised arterial blood pressure (1). 
Hypertension may be best defined as the level at which the benefits of 
treatment exceed those of withholding treatment (2).  International guidelines 
differ in their diagnostic criteria for hypertension, in the UK the National Institute 
for Health and Care Excellence (NICE) guidelines define hypertension as blood 
pressure > 140 / 90 millimetres of mercury (mm Hg). It is the most common 
preventable risk factor for mortality worldwide, and it is also a leading cause of 
global disparity in life years (3), disability (4), and, cardiovascular disease (5). 
Ranked by risk associated disability-adjusted life year, hypertension is the 
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leading cause of death overall, accountable for an estimated 10.4 million deaths 




The prevalence of hypertension in the adult population in England is 30% 
among men, and 26% among women (8) making it the most common long-term 
condition nationally (9). In the context of the UK, approximately 19 million 
people are estimated to have hypertension. Second only to upper respiratory 
tract infections, hypertension is the most common reason to attend primary care 
(10). In people older than 45 years hypertension is the most prevalent long-term 
condition (11). In the UK, the cost of hypertension management was estimated 
at £2.1 billion of the £120 billion NHS budget in 2014 (12).  
 
Worldwide, the number of people with hypertension has increased with 
population growth since 1975 (13) when it affected 594 million (15%) of the 
world’s population. Over the next ten years the proportion of the population who 
have hypertension is anticipated to increase significantly from 1.13 billion (15%) 
in 2015 to 1.56 billion (19%) in 2025 (14). Whilst prevalence in high income 
countries is stable or in decline (15), the prevalence in low and middle income 
countries is on the rise (16).  
 
The rise in hypertension prevalence is understood to relate to population 
ageing, increasingly sedentary lifestyles and a global shift towards urbanisation. 
Hypertension rises in a community or society where there is also a fall in 
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calorific energy expenditure and consequent change in body composition – for 
example, before and after the mechanisation of sleds in the Inuit community in 
Canada (17).  
 
There is marked variation of blood pressure between individuals some of which 
depends on characteristics of the population studied, for example, ethnicity and 
age. Hypertension, in the USA varies significantly by ethnicity: prevalence is 
42% among African Americans, and 26% among Hispanic Americans, 28% 
among White, and 25% Asian Americans (18). Hypertension in African 
Americans is also associated with a higher mortality than hypertension in White 
Americans (19, 20). In England, there is also variation in the prevalence of 
hypertension among those of the same age and ethnic group – with 3 fold 
variation in prevalence among middle aged men (21). Deprivation is also 
associated with disproportionately poor outcomes in hypertension (22). 
 
1.4 Changes over the life-course 
 
The systolic blood pressure trajectory across a life course has been described 
as having four distinct stages (23). During childhood and adolescence rising 
blood pressure follows rapid growth in a regular manner, with an interval delay 
of 1-2 years (24). Longitudinal studies demonstrate that blood pressure then 
increases further through middle age and into older age, characterised by 
systolic and diastolic hypertension (23, 25). After the age of 50 years, the 
diastolic component seems to plateau before tending to decline thereafter (26). 
Hence there is an increase in pulse pressure (the difference between systolic 
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and diastolic blood pressures), described as isolated systolic hypertension. In 
the majority of these patients, hypertension develops ‘de novo’. For example, in 
the Framingham cohort, in the absence of high blood pressures earlier in life 
(27), people aged between 55 and 65 years had a remaining lifetime risk of 
developing hypertension of 93% in men and 91% in women (28).  
 
More than two thirds of men and three quarters of women in the USA who are 
over the age of 75 years have a diagnosis of hypertension (29). Over the age of 
70 years, the blood pressure of some people continues to increase, whereas for 
others blood pressure is in decline up to 15 to 18 years prior to death (30-32). 
Life course trajectories of systolic blood pressure demonstrate deceleration and 
eventual decline in later life (1). 
 
These age related changes are not necessarily inevitable as there is evidence 
they are not present in certain populations. This difference has been attributed 
to more active lifestyles, leaner physique and diets containing less sugar and 
salt (33). 
 
1.5 Hypertension pathogenesis 
 
Whilst the majority of hypertension (90-95%) is referred to as primary 
hypertension – it is highly heterogeneous and multi-factorial. The remainder 
constitutes secondary hypertension (5-10%), i.e. secondary to another disorder. 




Hypertension represents an extreme of the normal spectrum of physiology that 
identifies a state of heightened risk resulting from multiple interacting 
pathophysiological mechanisms (34). In his highly cited paper in JAMA in 1949, 
Irvine Page, having himself investigated renal, hormonal and neural 
mechanisms underlying hypertension, concluded that “even the simplest 
hypertension is a mosaic in which many mechanisms are to a greater or lesser 
extent involved” (35). This theory, known as the mosaic theory of hypertension 
(36), has withstood much scrutiny, and the molecular and cellular interactions 
are now better delineated (36). (Figure 1-1). However, ageing has not been 
considered among these factors, other than as a measure of greater exposure 
over time to interacting environmental and genetic risk factors. 
 
Figure 1-1 Representation of the Mosaic theory of hypertension  
 
Mosaic Theory adapted from Page (35), and Harrison (36): RAAS = Renin Angiotensin 




The understanding of hypertension as a disease of vascular ageing is new and 
evolving. I will now outline recent advances in the understanding of vascular 
ageing, as central to the aetiology of hypertension and consider each of the 
mosaic factors with respect to vascular ageing. 
 
1.5.1 Blood pressure control 
 
Blood pressure varies constantly - across the cardiac cycle and in response to 
highly tuned physiological regulation. Typically blood pressure is characterised 
by its highest and lowest levels, namely systolic pressure at the point of 
maximum pressure exerted on the arterial wall when the heart contracts, and 
diastolic pressure, the pressure exerted when the ventricle is maximally relaxed 
(37). Blood pressure (BP) has both steady state and dynamic components, 
relating to separate functions.  
 
The function of the steady BP component is to deliver blood to capillary beds 
throughout the body. The steady state, defined as the average of the systolic 
and diastolic pressures (mean arterial pressure(mAP)) is important for the first 
of BP’s functions, to enable conduit (38), to deliver blood to capillary beds 
through the body. Steady state BP is determined by Darcy’s law – the level of 
volume (cardiac output) and the level of resistance (systemic vascular 
resistance) (see Equation 1-1). This replicates Ohm’s law for electrical current 





Equation 1-1Darcy’s Law (39):  
Mean Arterial Blood Pressure = Systemic Vascular Resistance x Cardiac 
Output 
 
The function of the dynamic BP component is to cushion the oscillatory function 
of the heart through the coupling of the heart and vasculature (41). The dynamic 
component is represented by pulse pressure (PP), that is the difference 
between the systolic and diastolic blood pressure, and is measured by the pulse 
wave (42). The power generating the pulse wave is determined by the left 
ventricle, while the form of the wave is determined by the central arteries where 
it is first received (43).  
 
1.5.2 Vascular architecture 
 
In cross-section, the blood vessel wall consists three structural layers (40): 
- Tunica Intima – innermost is the thin layer closest to the lumen 
containing a single cell layer of endothelium on a basement membrane 
with a scaffold of thin extracellular matrix composed of elastin and 
collagen (44). 
- Tunica Media – organised by longitudinal vascular smooth muscle cells 
interwoven in elastic lamellae and a collagenous ground substance (45). 
This structure is regulated by a slow, stable but dynamic cycling of 
production and degradation of crosslinking with a scaffold of proteins, 
collagen and elastin. The matrix is influenced by levels of sodium, 
aldosterone, and collagen accumulation stimulated by angiotensin II. 
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Thickening of the intima and media may occur at places of vascular 
curvature. 
- Tunica Adventitia – collagen containing connective tissue with the 
proportion of collagen higher at sites of bifurcations contributing to 
stiffness at these points (45). 
 
Arterial architecture also varies axially, along the length of the arterial tree (42). 
Arteries may be broadly distinguished as proximal and distal according to 
differences in function (40).  
 
Proximal arteries constitute the aorta and its main branches. Proximal arteries 
evolve from the embryological neural crest (46) and contain high proportions of 
elastic laminae. Vascular smooth muscle cells in proximal arteries tend to be 
proliferative in phenotype. Proximal arteries are distinguished by being highly 
sensitive to changes in blood pressure, with high levels of elastic recoil 
particularly in the levels of the tunica media and adventitia (47). The 
architecture is dynamic in response to the level of blood pressure: engaging 
elastin at a lower pressure and collagen at a higher pressure (42). 
 
In contrast, distal arteries evolve from the embryological mesoderm (46). 
Collagen is better represented in the medial wall and vascular smooth muscle 
cells tend to have a contractile or synthetic phenotype (45). The vascular 
smooth muscle cells phenotype is closely allied to their active mechanical 
properties in distal arteries which tend to be stiffer. Distal arteries are 
distinguished by their sensitivity and responsiveness to vasoactive mediators, 
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particularly those emanating from the vascular endothelium (nitric oxide, 
angiotensin, noradrenaline and endothelin) (48). 
 
Anatomically the distinction between proximal and distal exists somewhere at 
the level of the diaphragm, but in reality there is a gradual change across the 
length of the arterial tree which is dynamic in response to location, local 
pathogenic environment and the process of ageing (40). 
 
In summary, proximal vessels have high recoil, being adapted to their role of 
cushioning to dampen central artery pulsations. Distal arteries are adapted to 
maintain constant pressure with higher resistance and falling compliance (49). 
These design features enable mean arterial pressure to be maintained at the 
same level throughout the arterial tree (86). The cross-sectional area of blood 
vessels reduces with increasing distance from the heart, the vascular wall 
becomes more rigid and pulse pressure increases because of increasing wave 
reflection (40). In health, there is a significant difference in pulse pressure 




Ageing induces intrinsic changes to the vascular wall. These changes play a 
dominant role in affecting vascular change, potentially affecting BP (51). Arterial 
wall thickens particularly at the levels of the tunica intima and media (52-54), 
causing a doubling to tripling of vessel wall thickness between the ages of 20 




Elastin has a long half-life counting as one of the most inert constituents of 
mammals (55). However, elastin still fatigues as a result of accumulated sheer 
stress (42). Increasing pressure load over time increases elastin stretch, elastin 
fractures and extra-cellular matrix changes, stimulating a proliferation of 
collagen, fibrosis and the deposition of calcium (arterial calcification) (56). The 
elastin/ collagen ratio in the media of the arterial wall changes with age 
therefore. This is the process of arteriosclerosis.  
 
Arteriosclerosis is distinct from atherosclerosis, which in contrast, is primarily an 
inflammatory process associated with plaque formation (57). However, 
arteriosclerosis can accelerate and reduce the threshold for atherosclerosis in 
the context of risk factors such as a high-lipid diet (58). Arteriosclerosis involves 
collagen cross-linking, matrix metalloproteinases (MMPs), and the deposition of 
other substances including chondroitin which act to stiffen the extra-cellular 
matrix (59-63). The resultant disruption of the extra-cellular matrix leads to a 
pro-inflammatory environment which can progress the atherosclerotic process 
and plaque formation (64). Indeed arteriosclerosis is likely to be a dominant 
cause underlying atherosclerosis as evidenced by the examination of Egyptian 
mummies which demonstrate atherosclerotic change in association with age, 
despite the lack of modern dietary risk factors in the society in which they lived 
(65). 
 
As a result of arteriosclerosis arterial compliance of the blood vessel falls (66). 
In rigid vessels, a relatively slight increase/ decrease in intra-vascular volume 
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will greatly increase/ decrease intra-vascular pressure (67). Functional stiffness 
increases with higher pressures and loss of arterial compliance leads to 
increasing pulsatile load. With decreasing compliance, the left ventricle must 
work much harder to propel the blood forward without the aid of elastic recoil. 
 
1.5.3 Pulse wave 
 
The pulse wave, like any pressure wave, can be characterised by its amplitude 
and frequency. 
 
1.5.3.1 Pulse wave amplitude 
 
Amplitude is determined by vessel wall compliance and elasticity. Compliance is 
defined as the ability of a vessel to expand with an increased volume of blood 
(68). When the rate of blood entering these vessels exceeds that leaving them 
(equal to the net discharge of blood in systole and that discharged during 
diastole), the arterial wall acts as the mechanical equivalent of an electrical 
capacitor (69). Approximately half the contractile force of the heart is driven into 
capillary forward flow and approximately half is converted into elastic recoil in 
the vessel wall (70). In this way, energy is stored in the walls, and then during 
recoil, energy is restored to further propulsive action during diastole 
(Windkessel effect (Figure 1-2)) (71). This enables large vessels such as the 
aorta to convert the intermittent output of the heart to a steady outflow at the 





Figure 1-2 An explanation of the ‘Windkessel’ effect 
 
Windkessel effect or elastic reservoir, taken from Otto Frank’s use of the term in 
German meaning ‘air chamber’ as used by a fire engine in the 18th century. Figure 
taken from paper by Westerhof, Lankhaar & Westerhof 2008 (72), reproduced under 
the terms of the Creative Commons Attribution Noncommercial License 
(https://creativecommons.org/licenses/by-nc/2.0). 
 
1.5.3.2 Pulse wave frequency 
 
The normal pulse waveform constitutes a forward travelling wave following the 
cardiac contraction and a backward travelling wave due to reflection from 
peripheral arteries (42).  
 
The frequency of the wave is determined by reflections which occur at 
bifurcations of vessels and at the transition points where elastic arteries become 
resistance vessels (73). Wave reflections start distally at arterioles, and are 
affected by arteriolar constriction. There is evidence that reflections occur more 
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quickly when the cross-sectional area of distal circulation is reduced (i.e. 
through vascular remodelling and wall hypertrophy) (74), rarefaction of 
branching arterioles and networks (75) and that these factors may be influenced 
by genetics, and early growth of the vascular architecture (40), as well as the 
‘length’ of the arterial tree, which tends to be shorter in women (76). The distal 
microvasculature therefore plays an important role in determining peripheral 
vascular resistance. 
 
Figure 1-3 The concept of laminar flow 
 
Reflections are minimised by laminar flow (Figure 1-3), so called because flow 
is ordered in layers, with each layer of blood remaining at the same distance 
from the vessel wall (77). The centremost layer stays central, the layers are in 
parallel, and there is no interaction between layers (39). Fluid molecules 
touching the wall move more slowly because of adherence to the vessel wall; so 
the next layer slips over these molecules; the middle layer can move rapidly 
because of the lesser friction (68). This enables the flow at the centre of the 
vessel to be far greater than in those layers towards the edge with a parabolic 
profile for velocity of blood flow (77). Where laminar flow is disrupted it leads to 
reflections – thereby affecting the frequency of the pulse waveform.  
 
Arterial pressure waves become distorted as they are transmitted down the 
arterial system, changing their configuration (Figure 1-4). As a result of 
amplification, as blood travels further from the heart, the systolic blood pressure 
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and pulse wave pressure increase to reach a higher level at the distal artery 
than proximally (78). Amplification develops along the length of the aorta so that 
the mean arterial pressure stays the same throughout.  
 
 
Figure 1-4 Amplification of the pulse wave across the length of the arterial 
tree 
 
As blood travels further from the heart, pulse pressure amplifies as it is a sum of both 
the forward pressure from the heart and the backward pressure from reflections of the 
forward waves as the pulse travels more distally The notch at the end of ventricular 
contraction soon disappears while the systolic portions become narrow and elevated 
and a hump appears on the diastolic portion. Such wave characteristics are 
pronounced in the young (79). Reproduced with permission from Karger, licence 




First, there is a reduction in the maximum cardiac output achieved by the heart 
with advancing age (80). The acceleration of heart rate in response to exercise 
decreases, the left ventricle becomes stiffer and increasingly fails to relax 
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sufficiently, leading to reduced exercise capacity (80, 81). As the power of the 
left ventricle ejection wanes with age, the role of the central artery wall becomes 
more important, in terms of both affecting amplitude and frequency of the 
pressure wave. 
 
Second, arteriosclerosis predominantly affects the central arteries. Central 
arterial stiffening reduces the cushioning function of these vessels (49). Central 
artery stiffening disrupts the variation of wall function along the length of the 
arterial tree. A defining efficiency of blood pressure physiology in youth is the 
timing of reflective waves in diastole, described as pressure wave amplification 
(40). Central arterial stiffening acts to lessen the difference in pulse pressure 
between proximal and distal arteries, and therefore cause a loss of the 
amplification seen in youth.  
 
Third, the point of reflection becomes more proximal with age. Therefore, a 
reflected wave reaches the aortic valve before valve closure leading to 
increases in systolic pressure and reductions in diastolic pressure. Instead of 
dampening high initial pressures, these altered vessel walls now reflect back, 
causing an early return of the pulsatile wave. This reduces the period of systole 
(82, 83), augments the aortic systolic pressure wave, and reduces the diastolic 
pressure, thereby increasing pulse pressure (84, 85). Wide pulse pressure, 
characterises the ‘de novo’ hypertension diagnosed most often in old age (86). 
Both changes in amplitude (as measured by pulse wave velocity ) and in 
frequency (as measured by reflected waves) are themselves associated with 




Fourth, higher central pulsatility is associated with damage when transmitted to 
target organs. High pulsatile pressures, turbulent flow, and the intensification of 
blood flow during systole lead to cyclical stress or shearing forces on the arterial 
wall (89, 90). Shear stress causes vascular remodelling through processes of 
inflammation, endothelial damage, oxidative stress and vasoconstriction, 
activating the growth of additional smooth muscle cells. Vascular luminal 
enlargement can be seen as a compensating phenomenon to normalise 
circumferential wall stress, enabling the maintenance of compliance, in spite of 
aortic stiffening and increasing intra-mural thickness.  
 
Finally, the change in the timing of the loading sequence on vessels alters the 
ventricular-vascular coupling. End-systolic wall stretch must contend not only 
with the afterload of systemic vascular resistance, but also the afterload of wave 
reflection. This causes an increased cardiac afterload, leading to left ventricular 
hypertrophy (91) and decreasing coronary perfusion during diastole. As a 
consequence, diastolic cardiac relaxation is incomplete, manifesting functionally 
as decreased early diastolic filling rate and volume, characterising diastolic 




The endothelium provides an important barrier function between blood and 
tissues, while also impacting on lamellar flow and selective permeability (92). 
Molecules released from the endothelium affect vasomotor tone, coagulation, 




The endothelium produces an array of vasoactive substances. Chief amongst 
these is nitric oxide (NO) which plays a pivotal role in controlling vascular tone. 
This is in addition to its role in salt sensitivity (discussed further in Section 
1.5.6). Shear stress triggers the production of endothelial nitric oxide synthetase 
(eNOS) (94), converting L-arginine into NO in the presence of 
tetrahydrobiopterin (BH4) (44). NO causes relaxation of the vascular smooth 
muscle cells via the release of cyclic guanosine monophosphate (cGMP) (95). 
Several other vasodilatory substances produced by the endothelium include 
adrenomedullin (96), prostacyclin and endothelium derived hyperpolarising 
factors (37). At the same time, shear stress causes a concomitant endothelial 
release of opposing superoxide anions (97). These are free radicals that bind to 
NO to inactivate it. 
 
To counter the vaodilatory substances, the endothelium also produces several 
vasoconstrictors. Predominant among them is endothelin I, which activates ET-
1 receptors in the vascular smooth muscle to cause them to contract (98). Other 
vasoconstrictors include prostanoids (thromboxane A2 and prostaglandin A2) 




The increasing pulse pressure that results from the arteriosclerosis and 
changes in pulse wave pressure, causes sheer stress and ensuing damage to 
the endothelium. Endothelial dysfunction is evident in those without clinical 
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hypertension but with a family history of hypertension, indicating it is a pathway 
to developing hypertension. Ageing is associated with changes in the primary 
endothelial wall functions that are protective and anti-atherosclerotic, causing it 
to become pro-sclerotic (99).  
 
Endothelial wall function is normally characterised by a constant secretion of 
nitric oxide in response to sheer stress, but this lessens with age. The release 
of free radicals in response to sheer stress increase and become dominant in 
the absence of NO (100). Several factors contribute to this loss of NO including 
the reduced production of eNOS species (101). As with somatic cells, 
endothelial cells are limited in their ability to divide (102), and so enter a 
senescent state associated with reduced eNOS activity (103). eNOS is 
modulated by oestrogen and growth hormone (104) both of which reduce with 
age. Indeed oestrogen therapy has been shown to preserve endothelial function 
in post-menopausal women. With age eNOS uncoupling reduces (105); BH4 
falls; and Arginine competition with eNOS to bind with L-Arginine increases 
(106).  
 
Simultaneously, a state of oxidative stress evolves in the endothelium where 
oxidative stress is defined as an imbalance of production and removal of 
reactive oxygen species. Superoxide ions are increasingly available and bind to 
NO to inactivate it. Endothelin I increases in potency as Endothelin type 1 
receptors become more sensitive with age (107). There is evidence that ET-1 
receptor antagonists are effective in reducing blood pressure in older but not 




This creates an imbalance, leading to dysfunctional endothelium throughout the 
vascular architecture (109), resulting in greater vasoconstriction and peripheral 
vascular resistance (110). Therefore, flow mediated dilation is reduced with age. 
In a study of 238 people aged 15-74, dilation in response to reactive 
hyperaemia was reduced by 0.21% per year in men from the age of 40, and 
0.49% per year in women from the age of 50, whilst the vasodilatory response 
to glyceryl tri-nitrate was unchanged (111). In older people, there were higher 
levels of pro-inflammatory nuclear factor κB (NFκB), interleukin-6 (IL-6), tumour 
necrosis factor-alpha (TNF-alpha) and monocyte chemoattractant protein-1 
(MCP-1) (112) associated with a lower endothelium dilator response. 
 
The inflammatory state of the dysfunctional endothelium has been implicated in 
some of the complications of hypertension in old age (113, 114). The loss of 
endothelium mediated dilation makes the endothelium more sensitive to the 
stress of increased blood volume, exacerbates the effects of shear stress and 
leads to pressure induced injury to the vascular wall, contributing to the 
potential for plaque deposition and atherosclerosis (115).  
 
Newly dominant reactive oxygen species (ROS) lead to DNA damage (116), 
while signalling pathways lead to a remodelling of the tunica media. This causes 
an increase in medial thickness and a decrease in luminal diameter (117). 
Released vascular mediators include the matrix metalloproteinases involved in 
the degradation of extra-cellular matrix, which enables the diapedis of 




There is a failure to repair this damage with age because the endothelial 
progenitor cells lose their capacity to migrate and repair (118). Senescence 
Associated Secretory Phenotype (SASP) cells promote the degeneration of 
endothelium to engender a state of chronic endothelial stress (119).  
 
1.5.5 Regulatory systems 
 
The regulation of arterial blood pressure varies across a time course (68). 
Immediately (over seconds to minutes), BP is controlled by the central and 
autonomic nervous systems. In the short to medium term (over minutes to 
hours), BP is regulated by volume status (intravascular volume) and it’s renal 
and endocrine control (the renin angiotensin aldosterone system). In the long 
term (over days to months), BP level is influenced by changes in the vascular 
environment (the endothelium) (37). The role of each of these will now be 
considered, not in temporal order, but in order of the magnitude of their 
contribution to hypertension. The context of ageing will be evaluated for each in 
turn. 
 
1.5.6 Intravascular volume 
 
Sodium is the principal cation in the extracellular fluid compartment. Therefore 
regulation of total body sodium plays a central role in long term blood pressure 
control (68). Raised sodium stimulates water retention, increasing blood volume 
which raises blood pressure. The process of auto-regulation (120) means that 
an increased blood volume leads to increased systemic vascular resistance 
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(121). When BP rises, renal excretion of sodium and water increase and 
mechanisms act to reduce peripheral and renal blood pressure to reduce 
vascular resistance (122). The pressure-natriuesis curve is central to normal 
blood pressure control. Whichever the causal pathway of hypertension, for high 
blood pressure to be maintained, the set-point of the pressure-natriuesis curve 
must be increased (123). This describes the volume dependent mechanisms of 
hypertension.  
 
The role of salt in association with high BP is long established (124). A Western 
diet typically includes 150 mmol / day of salt. In contrast, populations with intake 
<50 mmol/ day have substantially lower blood pressure (125). Evidence of a 
linear dose response relationship between salt and BP had been demonstrated 
in a meta-analysis of intervention trials (126), studies of human and animal 
physiology (127) and public health interventions at the population level (128).  
 
Nitric oxide released from the endothelium plays a central role in the pressure-
natriuesis compensatory mechanism (37). In the event NO is not released, the 
regulatory mechanism fails and hypertension persists. This describes a state of 
‘salt sensitivity’, a phenotype that can be triggered by genetic and 
environmental factors. Salt sensitivity is operationally defined as an increase in 
mean arterial blood pressure (5 mm Hg) or more during a high compared to a 
low dietary sodium intake (110). In a ‘salt sensitive’ state, small increments or 
normal intake of salt can alone trigger hypertension. Chronic salt ingestion (129) 
can itself cause salt sensitivity by causing endothelial dysfunction resulting in a 






Within the kidney, sodium reabsorption occurs predominantly in the ascending 
loop of Henle which is located in the renal medulla (131). Sodium transporters 
are highly energy dependent and therefore vulnerable to ischaemic insult at low 
pressure. Ageing kidneys receive less cortical blood flow (10% reduction per 
decade), leading to an impaired ability of the kidney to excrete sodium (132). 
Age-related progressive deterioration in the ability to excrete salt efficiently 
leads to higher blood pressure (133).  
 
The majority of older individuals have salt sensitivity (134). Endothelial 
dysfunction is a key characteristic of vascular ageing, meaning more people are 
salt sensitive with salt intakes that would not ordinarily have been problematic. 
Loss of compensatory mechanisms (via NO) mean older individuals are far 
more susceptible to the BP effects of changing sodium intake, having not been 
sensitive during their earlier life. 
 
Premature vascular ageing may be precipitated by predisposing genetic and 
early environmental exposures, which can make an individual more susceptible 
to sodium retention, particularly if there are factors predisposing to endothelial 
dysfunction. One factor for example, is oligo-nephropathy in people who are 
born with low birth weight (132). A compression of the period of active growth 
until puberty leads to a mismatch of the growth related renal function to meet 
metabolic demands (135). This perinatal programming results in the under-
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development of the medullary micro-circulation and cortical afferent arterioles 
that are so important in managing sodium levels throughout life (136).  
 
1.5.7 Renin Angiotensin Aldosterone System 
 
Renin, angiotensin and aldosterone have central roles in regulating sodium, 
affecting the pressure-natriuesis relationship and therefore blood pressure. The 
Renin Angiotensin Aldosterone System (RAAS) is stimulated in the context of 
volume depletion, and inhibited in fluid overload (137). The RAAS is present 
throughout all tissues of the body, although its role in systemic blood pressure 
control lies predominantly in the kidney.  
 
Renin is an enzyme cleaved from its precursor, prorenin in smooth muscle cells 
of the afferent arteriole of the juxta-glomerular apparatus (39). This process is 
triggered by a fall in sodium levels, a fall in renal artery perfusion pressures, or 
an increased sympathetic activity in response to a fall in arterial blood pressure 
(37). Renin enables the conversion of Angiotensinogen to Angiotensin I. 
Angiotensin I is converted by Angiotensin Converting Enzyme (ACE) to form 
Angiotensin II (Figure 1-5).  
 
Angiotensin II has a crucial role in hypertension (138), with differential effects on 
AT-1 receptors, where it acts to raise blood pressure, and on AT-2 receptors, 
where it acts to reduce blood pressure. Key mechanisms of the AT-1 receptor 
are the stimulation of sodium absorption and the inhibition of sodium excretion, 
part of which is achieved through its stimulation of aldosterone release from the 
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adrenal glomerulosa. Aldosterone binds to the mineralocorticoid receptor, and 
activates sodium reabsorption at the level of the collecting duct (139), as well as 
in the colon. Aldosterone has broad effects on endothelial function, vascular 
wall architecture and as a vasoconstrictor. Also aldosterone stimulates sodium 
resorption in the collecting duct (139). 
 
Renin is higher in those with a family member who has hypertension, and 
among Africans compared to Europeans for whom the same salt intake is 
associated with a greater rise in blood pressure (140). Differences in the sexes 
are observed too. Increasing hypertension in women post-menopause 
correlates with the loss of oestrogen which is a modulator of the Renin 
Angiotensin Aldosterone System (141). 
 
Figure 1-5 A schematic of the Renin Angiotensin Aldosterone System 
 
Angiotensin converting enzyme (ACE); Angiotensin type I receptor (AT1 R); 
angiotensin type II receptor (AT2 R). Reproduced with permission from Wolters 




Angiotensin II causes smooth muscle cell contraction, vasoconstriction at the 
level of arterioles, and activation of the Na+-K+ ATPase, Na+/H+ exchanger III 
and NaHCO3 cotransporter 1 to enable active transport of Na+ at the proximal 
tubule, enabling sodium re-absorption, and reducing medullary blood flow. 
Better understanding is currently emerging of the protective effects of ACE II, 
and the conversion of Angiotensin II to Angiotensin 1-7, which have opposing 




From the age of 30 years upward, glomeruli become replaced by fibrous tissue, 
glomerular capillaries are pruned, to be replaced with mesangium, and the 
basement membrane thickens (144). These changes are associated with 
increased release of Angiotensin II, tied in with an increasing glomerular 
filtration fraction and increasing sodium reabsorption at the proximal tubule. 
Normally, Angiotensin II has the potential for causing oxidative stress only in 
specific and regulated scenarios (142). The chronic activation of Angiotensin II 
leads to Angiotensin II dependent production of Reactive Oxygen Species 
(ROS) (145), thereby driving a persistent pro-inflammatory state of oxidative 
stress. This promotes senescence, reducing the availability of NO thereby 
impacting salt sensitivity driven hypertension.  
 
With age, the production of ACE in endothelial cells and vascular smooth 
muscle cells increases (146-148). As a result, Angiotensin II rises markedly with 
age and in association with the rise in ACE. The production of renin (149) and 
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aldosterone also fall with age. Overall the modulating dynamic of the renin-
angiotensin system wanes (150). The chronic activation in old age of ACE and 
angiotensin II may underlie the increased effectiveness of their inhibition by 
ACE-inhibitors and angiotensin receptor blockers to prevent end-organ damage 
associated with hypertension in later life (142, 151). The decline of Aldosterone 
is associated with a fall in sodium reabsorption at the cortical collecting duct – 
normally responsible for the fine tuning of Na+ levels alongside K+ and other 
protons. With age therefore, urinary Na+ excretion increases and it is for that 
reason the risks of hyponatraemia and hypovolaemia become increased in the 
context of reduced salt diets or on prescription with potent diuretics (152).  
 
1.5.8 Sympathetic Autonomic Nervous System 
 
Neural control has a short term effect on blood pressure through total peripheral 
vascular resistance and capacitance as well as cardiac pumping activity (68). 
Neural control is predominantly operated through the Sympaethic Autonomic 
Nervous System via the control of venous capacitance. Neural innervation of 
both arteries and veins can exploit differences between them in the volume – 
pressure relationships to shift blood volume from one part of the circulation (e.g. 
systemic) to central (e.g. heart). Nearly one third of the blood volume of a tissue 
can be mobilised by stimulating sympathetic nerves at physiologic frequencies. 
This can be highly effective, for example, in the context of haemorrhage (153).  
 
Arterial afferent receptors stimulate negative feedback via the brain to engage 
the autonomic nervous system (39). Afferent receptors take various forms: 
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- High pressure (arterial) baroreceptors involve spray like sensory nerve 
endings in the vessel walls (68). These detect vessel wall distension of 
major vessels in the neck and thoracic cavity, particularly at the carotid 
sinus and the aortic arch (132). Low pressure baroreceptors are located 
in the atria, ventricles and the pulmonary arteries, and are activated by 
increases in volume and filling. When stretched by elevated BP, these 
receptors reduce nerve firing, inhibiting sympathetic activity. 
- Peripheral chemoreceptors also lie in the aortic arch and carotid and are 
stimulated by hypoxia, hypercapnoea and acidosis. They trigger 
vasoconstriction at resistance and capacitance vessels (154). Central 
chemoreceptors in the medulla are excited by cerebral ischaemia and 
elevate arterial pressure causing sudden and absolute peripheral 
vasoconstriction.  
- Sensory afferents in the kidneys trigger the Nucleus Tractus Solitarii 
(NTS) to stimulate reflex sympathetic activation in the presence of 
ischaemic metabolites (adenosine or urea). In the skin and viscera, 
painful stimuli evoke a pressor response, while distention of the viscera 
can evoke a depressor response. In the lungs, pulmonary reflexes 
relating to inflation cause systemic vasodilation and a decrease in arterial 
BP.  
 
Afferents (via the vagus (X) and glossopharyngeal (IX) nerves) are received at 
the vasomotor centre in the medulla oblongata, to trigger a negative feedback 
loop. Signals are relayed to the NTS and transmitted to the vasomotor centre, 
specifically to the vasoconstrictor centre (rostral ventro-lateral nuclei) and the 




The efferent vasoconstrictor pathways exit via the spinal cord along the 
paravertebral sympathetic chain or the prevertebral ganglion in the abdomen. 
Triggered by low blood pressure, sympathetic activation increases the 
contractility of the heart (via adrenaline binding to beta-receptors), and causes 
vasoconstriction of the arterioles and venous circulation (via noradrenaline 
binding to alpha-receptors to cause smooth muscle contraction) (153). 
Sympathetic activation thereby increases stroke volume. The major efferent 
vasodilator pathway is parasympathetic, via the vagus nerve which innervates 
the heart to release acetyl-choline (ACh). ACh binds to cholinergic receptors at 
the sino-atrial and atrio-ventricular nodes to slow conduction, reducing heart 
rate and contractility. Parasympathetic activation also inhibits sympathetic 
activation at the vasomotor centre (5).  
 
An imbalance of sympathetic over parasympathetic activation is associated with 
hypertension (155), with obesity (156), and with renal failure (157). Over time 
chronic sympathetic over-activity is associated with a tendency for greater 
sodium reabsorption. High chronic levels of catecholamines are associated with 
renal injury which predispose a long term salt sensitivity that persists long after 
the sympathetic over-activity has normalised (37, 130). Chronic activation of 
alpha adreno-receptor in the endothelium is also known to pre-dispose to 
proliferation of vascular smooth muscle cells and endothelial dysfunction (158).  
 
Stimulation of multiple regions of the cerebral cortex control the vasomotor 
centre (68). There is evidence that central nervous system control has input 
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from multiple BP regulating systems. Animal studies demonstrate feedback of 
serum levels of sodium and angiotensin II at the sub-fornical organ and the 
organum vasculosum of the lamina terminalis (159). These nuclei are 
remarkable for their poorly formed blood brain barrier. As such they are very 
sensitive to levels of Angiotensin II and sodium levels in the peripheral 
circulation. Their higher firing activates, via the hypothalamus, the 
vasoconstrictor centre in the rostral ventrolateral medulla. In hypertension, high 
levels of Angiotensin II have been described, and systemic blood pressure has 





There is evidence of age related decline in the sensitivity of the arterial 
baroreceptor, affecting the regulation of peripheral vascular resistance in two 
important ways (110). Firstly, a larger change in blood pressure is required to 
stimulate the baroreceptors to invoke the appropriate compensatory response 
(161). Baroreceptors become less responsive to high blood pressure (162, 163) 
low blood pressure (164), following exercise (165), a meal (166), or, a change in 
posture (167). Secondly, a loss of the night time fall in blood pressure and a rise 
of the early morning surge is seen with increasing age that suggests diminishing 
circadian control of baroreceptor function (168). This is consistent with the 
increasing vascular wall stiffness which may mean that higher pressures are 




As a consequence of being less inhibited by the baroreceptor negative 
feedback, there is a chronic over-activation of the sympathetic nervous system 
outflow for any given level of blood pressure. Noradrenaline release in tracer 
kinetic studies are higher and there is evidence of higher levels of sympathetic 
nerve activity (170). In older adults with hypertension, arterial alpha adreno-
receptor responsiveness is also increased. With age, noradrenaline production 
is increased (171), and there are decreases in its clearance (172) contributing 
to an amplified response in terms of both degree and duration to hypotensive 
stimuli (171).  
 
End-organ responsiveness is unequally reduced with age, with a shift of 
balance between alpha versus beta receptor responsiveness that favours 
vasoconstriction. The ability of a vessel to dilate, mediated by beta-2 adrenergic 
receptors is impaired with age. The number of receptors is unchanged, for 
example on rat myocytes (173), or human lymphocytes (174) but the beta 
receptor response is blunted (175, 176) and on human lymphocytes their affinity 
for agonists reduce with age (177). In contrast, the vasoconstrictor ability that is 
mediated via alpha adrenergic receptors is preserved with age (176). Overall 
this leads to a greater predilection for vasoconstriction with age, contributing to 
higher systemic vascular resistance. 
 
1.5.9 Summary of biology 
 
Primary hypertension is a mosaic of multiple causes (35). Until recently, the 
widely accepted theory was that the growing risk of hypertension associated 
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with age was related primarily to prolonged exposure to the environment, for 
example, through greater opportunity to develop obesity and therefore 
hypertension.  
 
The influence of ageing on the development of hypertension has been 
described in two respects: 
1. Firstly in respect of ageing vasculature: recent advances in the 
understanding of genetic and molecular vascular physiology have 
supported vascular ageing as central to the aetiology of hypertension. 
Vascular ageing is understood as the common pathway on which various 
agents of the mosaic act. It is a process that is not inevitable, but is 
accelerated by various pathologies which trigger the development of 
hypertension in early or mid-life.  
2. Secondly in respect of the dysregulation associated with ageing of 
normal homeostatic mechanisms of fluid balance, sympathetic negative 
feedback and modulation by RAAS. The loss of these regulatory 
mechanisms make it more difficult to maintain stable blood pressure and 
the individual more vulnerable to perturbations of blood pressure in the 
context of stressor events, including salt and water loss or physiological 
challenge. 
 
The available evidence indicates that ageing frames the context of 
hypertension, in each of the major pathways of pathogenesis. Until this point, 
this chapter has focused on biology and the relevance of ageing. However, 
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considering ageing as a framework is also justifiable when one considers its 
application to patient care, as discussed below. 
 
1.6 Hypertension disease status 
 
From a clinical perspective, the concept of hypertension is defined primarily by 
its relation to future cardiovascular end-organ disease. Hypertension has been 
associated with poor prognosis for more than four thousand years (178), and 
associated with end-organ damage, specifically renal disease since as early as 
the 6th century (179). However, it was not until the development of microscopy 
and more liberal attitudes to autopsy in Europe, that renal and cardiac end 
organ damage became measurable (179-181). With evidence that persistent 
high blood pressure preceded the development of associated renal disease, Dr 
Frederick Akbar Mahomed defined hypertension as a disease in 1874 (182). 
 
Hypertension remained an academic interest and only became clinically 
relevant once BP was measurable. In 1760, Stephen Hales recorded the first 
measurement of BP by attaching the windpipe of a goose to the carotid of a 
horse, itself tied to a fallen gate, to measure a column of eight feet of blood 
whose pressure proceeded to decline until the horse died (179, 183). Non-
invasive, more practical means soon developed, with the use of mercury whose 
greater atomic weight enabled pressure differences to be measured on a 
shorter distance (184), a float to ascertain a level (185), and the inflatable 
rubber balloon to tourniquet the arm (186). It was Kortokoff, a Russian army 
general who developed the method of measuring BP in 1901 by auscultating for 
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the obliteration of the pulse, with increasing pressure applied using the 
tourniquet to discern systolic and diastolic pressures by using the stethoscope 
(187). 
 
In the 1960’s there was significant controversy about the disease status of 
hypertension. Weitz, Platt, Morrison and Morris were impressed by the 
Mendelian dominant behaviour of hypertension with clear dichotomies of blood 
pressure defining hypertension. By contrast, Pickering and Oldham advanced 
the case of hypertension, by contrast representing a quantitative not a 
qualitative deviation from the norm, with no natural dividing line between normal 
and abnormal, but a state of continued or reducing risk across a spectrum 
(188).  
 
Although they have limitations, thresholds still have utility in clinical practice in 
guiding treatment. However, as will be discussed, the linearity of the association 
of BP with risk remains an area of significant uncertainty that this thesis hopes 
to address.  
 
1.6.1 Blood pressure measurement 
 
The measurement of BP is influenced by the environment the patient is in, when 
they have their BP measured. Discrepancies between home or ambulatory 
readings and BP readings in the clinic are common. Clinic readings can over-
estimate a person’s true BP, for example because of the anxiety of a patient in 
a clinical setting – often called the ‘white coat effect’ (189). This may lead to a 
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false positive diagnosis of hypertension and over-treatment in a person with 
already normal BP. Clinic readings can also under-estimate a person’s true BP, 
leading to a missed diagnosis of hypertension, so called masked hypertension. 
Masked hypertension is associated with increased cardiovascular risk. Both 
white coat and masked hypertension are more common with ageing (190).  
 
A further challenge to the accurate measurement of BP is its variability across 
time. BP variability which increases with age. Short term variability is 
understood to relate to a person’s behaviour, emotion, postural change and 
circadian rhythm (191). Long term variability may relate to the type and dose of 
prescribed medications, degree of adherence, and other factors which are not 
well understood. Long-term BP variability is itself a risk factor for the 
development of future cardiovascular disease, and the inclusion of BP variability 
improves the prognostic ability of cardiovascular risk models (192). 
 
1.6.2 Cardiovascular risk 
 
There are a wider set of mediating factors involved in the causal pathway from 
hypertension to cardiovascular disease. Hence hypertension is often 
characterised as part of a wider cardiovascular risk profile involving a number of 
interacting factors in a multiplicative way (193). The concurrence of 
cardiovascular risk factors has collectively been termed the metabolic 
syndrome. Cardiovascular risk factors cannot therefore be conbsiderede in 
isolation and a comprehensive approach is required to ameliorate 
cardiovascular risk across all factors(194). Key related cardiovascular risk 






Obesity is defined as a body mass index of 30 kg/m2 or more. After adjusting for 
age, the increased prevalence in hypertension in men and women worldwide 
(Section 1.3) can be attributed to the rising prevalence of obesity (195). Obesity 
represents a salt-sensitive state(196), as a consequence of the activation of the 
RAAS (197) and the SANS systems (198). In a meta-analysis of 18 trials, 
overall weight loss between 3 – 9% of body weight reduced BP by 3 mm Hg 
(199). The average age of trial participants was 55 years (range 18 to 80 years). 
In observational studies of older people, the association of obesity and 
hypertension is less clear. In the INVEST study which included a well-treated 
cohort: higher Body Mass Index (BMI) was associated with decreased 




Hyperlipidaemia is defined as a total cholesterol of 240 mg/dl or higher. 
Increase in lipid levels and BP are closely related: between one third and two 
thirds of people with hypertension also have hyperlipidaemia (201). Compared 
to patients with hypertension or hyperlipidaemia only, those with both had a two 
to three times higher risk of atherosclerotic disease and three to four times 
higher risk of myocardial infarction (202). Total cholesterol increases with age, 
and associated with an increased risk in men (203), but this risk attenuates with 
age (204), and the role of dyslipidaemia in cardiovascular risk is less well 




1.6.2.3 Diabetes mellitus 
 
Hypertension is associated with insulin resistance, and the co-pathology of 
hypertension has an amplifying effect on microvascular and macrovascular  
diabetic end-organ damage (206). Diabetes nearly doubles the risk of 
cardiovascular death, hospitalisation for myocardial infarction and stroke 
compared to people without diabetes (207). Diabetes mellitus is the leading 
cause of end-stage renal disease in high, middle and many low-income 
countries(208), and hypertension accelerates the progression of diabetic kidney 
disease. Higher mean arterial pressure is associated with increased annual 
decline in glomerular filtration rate (209). Therefore the prevalence of 
hypertension in people with diabetes is closely related to markers of diabetic 
nephropathy: in those with microalbuminuria, prevalence of hypertension is 40-





Smoking tobacco causes damage to the vascular endothelium through 
increased platelet aggregability and reactivity as well as free radical production 
(211). Smoking is associated with increased systolic blood pressure, particularly 
over the age of 60 years old (212). Smoking cessation reduces blood pressure 
(213) and is associated with a reduction in cardiovascular risk (214) and these 






Of the environmental factors influencing BP, diet is predominant. Evidence 
exists for the benefit associated specifically with sodium, potassium, and 
alcohol intake as well as particular dietary patterns (216).  
- Sodium intake: an increase in daily sodium intake is associated with an 
increase in BP. In adults with treated hypertension a reduction of 4.5g 
salt per day in the diet was associated with a  reduction in BP of 22.7 / 
9.1 mm Hg (217).  
- Potassium intake: increasing potassium intake is associated with a 
reduction in BP. Fruit and vegetables are rich in potassium. Increasing 
potassium intake by 50 mmol/day was associated with a reduction in BP 
in people with hypertension of 4.4  / 2.5 mm Hg (218). 
- Alcohol intake above two drinks per day is associated with increased BP, 
and decreased consumption by a median of 76% lowered BP by 3.3 / 2.0 
mm Hg(219).  
- Diets associated with lower BP include the vegetarian diet (220). The 
Mediterranean diet has been associated with a reduction in 
cardiovascular disease but modest reductions in BP (221). The Dietary 
Approaches to Stop Hypertension (DASH)  emphasizes the intake of fruit 
vegetables, low fat dairy and reduced saturated and total fats. The trial 
reduced blood pressure and is recommended to reduce cardiovascular 
disease (222). 
 




Broadly, exercise has been associated with BP reduction and reduction in CV 
risk (223). The effective of exercise in reducing BP depends on the type of BP : 
1. Dynamic aerobic exercise defined as repetitive movement to increase 
cardiovascular workload.  Within 8-12 weeks meta-analysis of 105 trials 
have demonstrated that aerobic exercise can reduced BP by 3.5 / 2.5 
mm Hg in those without hypertension, and by 8.3 / 6.8 mm Hg in those 
with hypertension(224). There is some evidence that aerobic interval 
training is superior to continuous training in reducing BP(225), and that 
the effectiveness of aerobic versus resistance training may vary 
depending on sex(226). The optimal intensity and ideal duration remains 
uncertain, but AHA guidelines recommend 30 minutes per day of aerobic 
exercise to reduced BP(227). 
2. Dynamic resistance training represents for example weight lifting or 
stretching bands. There is an association of this form of exercise 
modestly reducing BP - -1.8/ - 3.2 mm Hg but the mechanism is not 
understood, and the quality of evidence inferior to that for aerobic 
exercise. AHA guidelines recommend 2-3 times per week added to 
aerobic exercise but recognise that the quality of evidence is inferior 
(Class II) 
3. Isometric resistance training represents muscles contracted at increased 
tension but without shortening for example using a handgrip 
dynamometer. A meta-analysis of 11 trials in only 302 participants 
recently demonstrated highly effective reduction of BP – 5.2 / 3.9 mm Hg 
with greater effect in those with established hypertension. AHA 
guidelines recommend undertaking this for 12 – 15 minutes 3 – 5 times 
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per week but that the evidence quality to support this recommendation is 
less good (IIB). 
 
1.7 Hypertension treatment 
 
With notable exceptions (alpha-blockers, beta-blockers, renin inhibitors) (228), 
the choice of which BP-lowering treatment prescribed to reduce cardiovascular 
risk is understood to be less important to the level of BP (229-231). In older 
people, calcium antagonists and diuretics tend to represent treatments of first 
choice (232). A clinician’s choice of agent may be informed by various factors 
including the target for secondary prevention, a patients’ comorbidities, ethnicity 
and potential for suffering side effects (233). There remains uncertainty whether 
the effect of reducing cardiovascular mortality can be attributed solely to 
lowering blood pressure, as many BP-lowering medications have multiple 
effects which may be cardio-protective. The focus of this PhD is on BP lowering 
and not on the merits/ harms of particular BP-lowering agents. There are 
benefits and harms to BP lowering, which will be considered in turn. 
 
1.7.1 Treatment benefits 
 
Hypertension is estimated to be a key contributing factor in up to half of 
myocardial infarctions, heart failure and strokes (234): 
 
- Stroke: levels of high blood pressure have been correlated with both 
ischaemic and haemorrhagic stroke. A reduction of diastolic blood 
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pressure by 5 mm Hg reduces the risk of stroke by one third (235). The 
association with BP declines with increasing age, despite stroke disease 
becoming more common. 
- Myocardial infarction: blood pressure is positively and continuously 
associated with the risk of death due to coronary artery disease or non-
fatal myocardial infarction (235). This association is smaller than that with 
stroke. A 5 mm Hg reduction in diastolic blood pressure was associated 
with a one fifth reduction in the risk of coronary disease events (235). 
- Heart failure: in the Framingham cohort, hypertension was associated 
with a 2 to 6 fold increase in the risk of developing heart failure (236). 
- Renal failure: whilst renal failure is not often the outcome of 
hypertension, renal failure increases with degree of hypertension and 
hypertension appears to exacerbate and cause a more rapid progression 
of renal damage, regardless of aetiology (237).  
- High blood pressure has been implicated in the development of vascular 
dementia (the second commonest form of dementia) (238) and 
increasingly also in levels of Alzheimer’s pathology in the brain (239-
241). 
- Higher than average blood pressure in mid to late life is associated in 
longitudinal studies with mild intellectual dysfunction, particularly 
executive function, as demonstrated by impairments in word fluency and 
delayed word recall, as well as poor visuo-motor skills (242-244). 
However, other studies into advanced old age have demonstrated that 
these findings are inconsistent and some studies have failed to 
demonstrate the association of BP and cognitive outcomes persisting in 
those aged 75 years and older (245-247). The Hypertension in the Very 
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Elderly Trial (HYVET) demonstrated no statically significant benefit from 
BP-lowering therapy on the development of dementia in those over the 
age of 80 years, while a meta-analysis demonstrated therapy had a 
favourable effect of borderline significance HR 0.87 CI 0.76 to 1.00] (248-
250). Nevertheless, there is evidence of some association with 
hypertension and overall physical and cognitive decline – particularly in 




A previous school of clinical thought considered hypertension an adaptive 
response, whose treatment may cause more harm (179, 253). This was 
disproved by the first intervention trial published in 1970 which demonstrated 
that hypertension was indeed reversible. Since this, hypertension management 
has been led by randomised control trial evidence. Clinical practice continued to 
be more conservative in older adults, until, more recently, trials have 
demonstrated reversibility extending into advanced old age. Table 1-1 and 
Table 1-2 compare the effects of BP-lowering medication on outcomes found by 
large scale interventional trials. The median follow up time, population 
characteristics, and BP targets are compared with evidence of treatment benefit 
and harm. Whereas trials targeting systolic blood pressure to a level of less 
than 150 mm Hg (listed in Table 1-1 ) (254) show benefit in cardiovascular risk 
prevention; the findings of trials targeting systolic BP to less than 140 mm Hg 
are more mixed in their findings (Table 1-1 & Table 1-2). It is also evident from 
the summary of trials that adverse effects, especially in early trials were not 
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reported. More recent trials do report adverse effects but without the same 




Table 1-1 Summary of RCTs with sBP targets over 140 mm Hg 
Trial Population/design Design  Baseline BP & achieved 
BP 




Mean 51y (30-73y) 
USA all male 
n= 143 
F/u: 1.1y 
B/L: dBP (mean) 115-
129 
Achieved: ↓sBP 43; sBP 
30  
↓ Stroke/ MI/  
↑death 








B/L: sBP 200 / dBP 95 










B/L: sBP 183/ dBP 101 
Achieved 150/85 (5y) 
= mortality 








B/L (m) 158/98 (f) 165/99 
Target dBP <90  
= mortality 
= coronary events 
↓ stroke 
↑Glucose intolerance, 









B/L BP 196/99 




↑ Glucose, Urea, 
Creatinine, Urate 
= adverse symptoms 
SHEP(261, 
262) 1991 
Mean 72y USA n= 4,736 
F/u: 14.3y 













B/L BP: 195/102  
Achieved BP: 167/87 
↓stroke  
↓mortality 
= withdrawals because of 
side effects 
MRC (264)  
1992 

















Achieved BP: 151/79 
↓ stroke 
↓ mortality  
↓heart failure 










Achieved: (3 arms) 
144/85; 141/83; 140/81 
= MACE  2% had adverse events. 
Difference between groups 
not reported.  




B/L BP 170/86  




= non-cardiovascular and 






F/u: 1.8y  
B/L 173/91  
Achieved: 144/78 
↓stroke ↓cv death 
↓ mortality 




2008 Australia, Tunisia ↓heart failure 
Trials: EWPHE = European Working Party for Hypertension in Elderly; HOT = Hypertension Optimal Treatment; HYVET = Hypertension in 
the Very Elderly Trial; MRC = Medical Research Council (UK); SHEP  = Systolic Hypertension in the Elderly Program; STOP = Swedish 
trial in old patients with hypertension; Syst-China 1998(268) = Systolic Hypertension in China; Syst-Eur  = Systolic Hypertension in 
Europe trial;  
All blood pressure recordings are in mm Hg; B/L = baseline; cv = cardiovascular; CVD  = cerebrovascular disease; CV mortality = 




Table 1-2 Summary of RCTs with sBP targets under 140 mm Hg 
Trial Population/design Design  Baseline BP & achieved 
BP 
Effect of treatment Harms of treatment 
AASK 
2002(269) 




B/L (I)152/96 (U) 149/95 











B/L BP: 172/89 
Achieved BP: 136/75 
 
= CV disease &renal 
failure 
= mortality 












↓composite of 13 CV 
outcomes 










Achieved: sBP 119 
= MI, stroke CV death 
↓ stroke 
↑ low BP 
↑ low K+ \ 
↑ AKI  
SPS3 Trial 
2013(273) 
Mean 63y  














Mean 76y (70-84y) 
Japan 
n= 3,079  
F/u: 2.85y 
B/L: 170/ 82 
Achieved: 137/75 
= Composite MI, HF, 
CV death, renal failure 









B/L 140/78  
Achieved: 121.4  
↓MACE,  
↓ACM 
↑low BP, ↑syncope 
↑AKI 









B/L BP 138/82 
Achieved sBP 128 v.s 124 
= CV Death/ MI/ 
Stroke 












Tableː Trials: AASK = African American Study of Kidney Disease and Hypertension; ACCORD = Action to Control Cardiovascular Risk in 
Diabetes; Cardio-SIS = Studio Italiano Sugli Effetti CARDIOvascolari del Controllo della Pressione Arteriosa SIStolica; HOPE-3 = Heart 
Outcomes Prevention Evaluation; JATOS = Japanese Trial to Assess Optimal Systolic Blood Pressure in Elderly Hypertensive Patients; 
SPRINT = Systolic Blood Pressure Intervention Trial; SPS3 = Secondary Prevention of Small Subcortical Strokes; VALISH = Valsartan in 
Elderly Isolated Systolic Hypertension Study. 
All abbreviations: All blood pressure recordings are in mm Hg; ACM= All-cause mortality; AKI = Acute kidney injury; DM = Diabetes 
mellitus ; e- = electrolyte abnormalities; ECG = Electrocardiogram; ESRD = End stage renal disease ˑ GFR slope=ESRD = Glomerular 
Filtration Rate; HF = Heart failure; K+ = potassium;  LVH = Left ventricular hypertrophy; I = Intervention; OH = Orthostatic hypotension; 
RCT = Randomised controlled trials; U = Usual treatment; y = years 
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Whilst older people are included in the age ranges of these trials, people with 
frailty, co-existing conditions and polypharmacy are less likely to have been 
recruited (277). Characteristic features of frailty include: dependence on others 
for activities of daily living, and having cognitive impairment. These 
characteristics often also form part of exclusion criteria in randomised control 
trials (278). Even when older people with frailty are targeted in trial recruitment 
as in the recent OPtimising Treatment for MIld Systolic hypertension in the 
Elderly (OPTIMISE) treatment withdrawal trial, a minority of those invited are 
enrolled (279). 
 
The success of increasingly interventionist trial strategies is taken by some as 
evidence of a linear risk of BP, i.e. ‘the lower the better’. The SPRINT trial in 
particular does provide evidence, that for some older people, in terms of the 
end-points measured, lower sBP is associated with benefit. However, the 
general application of trial findings to the wide heterogeneity of risk and disease 
presented among older people with hypertension remains problematic. 
Concerns centre around two major limitations of the current trial evidence base:  
 
1. Trial populations may not be representative of the patient population as a 
whole. Explicit or implicit exclusion of older people with competing health 
problems by trial design mean that the trial populations are highly 
selective (280), and particularly exclude people with multi-morbidity and 
frailty. 
2. Outcomes measured prioritise cardiovascular end-points. It remains 
unclear how fastidiously adverse effects are asked about. There has only 
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been limited enquiry about the tolerability and degree to which patients 
suffered side effects (281). 
3. BP measurement and titration of therapy in a trial setting is not 
necessarily replicable in routine clinical care. 
 
A 2019 Cochrane systematic review and meta-analysis reported on randomised 
control trials of hypertension treatment specifically in people over the age of 60 
(282). The synthesis involved 26,795 participants with a mean age of 73 years, 
in 16 trials with a mean duration of 4 years. The mean baseline blood pressure 
was 182/95 mm Hg. The synthesis of these trials demonstrated that treatment 
was associated with a reduction in all-cause mortality (from ARR 11% to 10%), 
and cardiovascular morbidity and mortality (from 13.6% to 9.6%). However, 
alongside there was an increase in the proportion withdrawing from the trial 
because of treatment side effects from 15.7% in the treatment arm, to 5.4% in 
placebo.  
 
The reduction in mortality observed was due mostly to a reduction in the 60- to 
79-year-old patient subgroup (RR 0.86, 95% CI 0.79 to 0.95). Cardiovascular 
mortality and morbidity was significantly reduced both in the subgroup aged 60 
to 79 years old (moderate-certainty evidence; RR 0.71, 95% CI 0.65 to 0.77) 
and the subgroup aged 80 years or older (moderate-certainty evidence; RR 
0.75, 95% CI 0.65 to 0.87). The reduction in vascular mortality and morbidity 
was primarily due to a reduction in cerebrovascular mortality and morbidity. The 
Cochrane synthesis identified that the magnitude of absolute risk reduction was 
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higher among 60- to 79-year-old patients compared to over 80 year olds (3.8% 
vs 2.9%).  
 
1.7.2 Treatment harms  
 
Treatment harm may relate to specific adverse effects relating to a particular 
drug or to the more general consequences of systemic BP lowering.  
 
1.7.2.1.1 Drug side effects 
 
Cardiovascular medications are among the most common causative treatments 
among adverse drug reactions (ADR) related hospitalisations (283). The 
principle known adverse treatment effects relating to BP-lowering medications 
are listed in Table 1-3. 
 




1.7.2.1.2 General effects of BP-lowering 
 
The trials demonstrate strong evidence for maintaining systolic BP lower than 
between 140 – 150 mm Hg depending on the population investigated and the 
outcomes measured. However much less is known on where the lower limit of 
treatment benefit lies: that is the BP level below which treatment may cause 
more harm than benefit (286). The J-curve describes the observation in some 
studies that at very low blood pressures there is an inversion of the normal 
positive linear association between increasing BP and adverse outcomes. 
Instead evidence of a J- curve would suggest that the association of BP and 
outcomes is non-linear: that below a certain BP threshold, the risk of outcome 
Diuretics 
Hypokalaemia in 5-20% (284) 
Urinary frequency, erectile dysfunction 
Disruption of magnesium, sodium, uric acid, calcium, glucose intolerance, insulin 
resistance 
Contributes to deterioration in renal function (285) 
Angiotensin-Converting Enzyme inhibitors (ACE-i) or Angtiotensin Receptor 
Blockers (ARB) 
ACEi: 
First dose hypotension,  
Disruption of potassium, glycaemic control 
Interference with erythropoietin, Deterioration of renal function,  
Cough and bronchospasm, Angioedema, 
ARB: rash 
Calcium channel blockers 
Short acting first generation drugs associated with increase in CV mortality, 
Pedal oedema 
Headaches flushing  
Gingival hyperplasia 
Beta-blockers 
Fatigue, bradycardia. diminished exercise tolerance, weight gain,  
Disruption of insulin sensitivity, triglycerides, potassium 
Bronchospasm;  
Central sympatholytics 
Depression, confusion, somnolence  
Alpha blockers  
Dizziness, syncope, orthostatic hypotension,  
Inferior cardiovascular risk reduction 
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starts to increase with lower BP. The J-curve was initially described in the 
Framingham cohort (287). 
 
The J-curve also correlates with understanding of physiology that describes a 
lower BP threshold of auto-regulation which is elevated in chronic hypertension, 
so that low BP may cause under-perfusion of end-organs (288). Investigation of 
a J-shaped or U-shaped phenomenon for systolic BP has not been undertaken 
in trials. To do so, a trial would require a minimum of three thresholds (286), the 
exception is the Hypertension Optimal Treatment (HOT) trial which used three 
diastolic targets (226). It is evident from review of Table 1-1 and Table 1-2 that 
more recent interventions at lower BP in Table 1-2 have demonstrated smaller 
treatment effects (286).  
 
At which level of BP the J-point is located will also conceivably vary depending 
on the target organ of interest (289). For example, the myocardium is 
particularly at risk at low systemic blood pressure, because, unusually, it is 
perfused during diastole. Below a diastolic blood pressure of 60 mm Hg the risk 
of a Type II myocardial infarction increases (290). A type II myocardial infarction 
is defined as myocardial ischaemia in the absence of coronary artery disease 







Older people may come to harm because they are more vulnerable to the 
adverse effects of treatment and the adverse event itself may be more 
catastrophic. For example, orthostatic hypotension may lead to a younger 
person having a simple fall, but an older person fracturing their hip and requiring 
an emergency hip replacement operation. 
 
Falls affect 1 in 3 people aged over 65 years in the UK every year (292), and 
represent the leading cause of emergency hospital admission in this age group 
(293). Falls are most often due to multiple interacting conditions (294), and risk 
factors for falls overlap with other geriatric syndromes (incontinence, delirium, 
poor mobility), but include postural hypotension. 
 
The lower baroreceptor responsiveness seen in old age, as well as seen in 
chronic hypertension, means that low BP does not induce immediate increases 
in heart rate and/or systemic vascular resistance to maintain BP in the face of a 
hypotensive trigger. This makes older people more susceptible to BP variability 
leading to episodes of hypertension and hypotension. Hypotension is defined by 
as “a blood pressure that is below the norm expected in a given environment” 
(295). Hypotension may be absolute (systolic < 90 mm Hg, diastolic< 65 mm 
Hg); relative (drop in BP > 40 mm Hg); orthostatic (>20m mm Hg in systolic or 
10 mm Hg diastolic on standing)(296), or may be a feature of shock. Low blood 
pressure is not problematic unless it is associated with other symptoms (e.g. 
vasovagal or post-prandial syncope), leading to syncope and falls. Orthostatic 
hypotension is exacerbated by particular BP-lowering treatment and contributes 




1.7.2.2.1 Drug side effects 
 
Adverse drug reactions (ADR) are a significant burden in later life. In a meta-
analysis of 17 studies comprising a total of 7,553 hospitalisations of older 
adults, an average 16.6% of admissions were judged to be related to adverse 
drug reactions (297). BP lowering treatments are commonly prescribed and 
contribute significantly to the polypharmacy seen in old age, increasing the 
overall risk of harm (298). Whether the associated harm of BP-lowering 
medication is modifiable with de-prescribing is unclear (279, 299, 300).  
 
1.7.2.2.2 General effects of BP-lowering 
 
Recent epidemiological studies demonstrating a non-linear association of BP 
and outcomes (the J-curve): are listed in Table 1-4 whereby low BP is 
associated with higher risk of adverse outcome (301-304). These studies are in 
populations which have explicitly included older adults with high multi-morbidity 
and high cardiovascular risk. Post-hoc analyses of trials have also extended the 
finding of a non-linear association between BP and outcome to people with high 
cardiovascular burden (305-307). The non-linear association described in these 
studies has generally been interpreted to be the consequence of the harms of 
treatment or to reverse causality. Reverse causality describes that low blood 
pressure in the context of disease burden is a marker of proximity to death due 
to failure of multiple physiological systems. This latter interpretation may have 
recently been challenged by the finding that risk associated with low sBP is 
reversible with revascularisation of the coronary arteries (305).
54 
 
Table 1-4 Observational Cohort studies demonstrating non-linear 
associations between BP and Outcomes 
Study 1st author, 
location 







Systolic BP < 120 mm Hg was associated 
with longest survival 
Heikinheimo (309)  
Tampere, Finland 
Recruit 1981-4 
Age: 84– 88y 
n: 541 
F/u: 3y 
Mortality rate was higher in those with very 
high and very low sBP levels 
Satish (30)  
USA 




Among those >85y risk of death was 
higher with an sBP < 130 mm Hg than with 
an sBP >180 mm Hg, not in the sub-







Increased dBP was associated with 






n: 601; F/u 9y 
sBP < 140 mm Hg associated with 
increased risk (HR 1.35 (95% CI 1.04 – 







dBP < 70 mm Hg associated with 
increased risk of death compared to dBP > 
90 mm Hg (RR 2.47 (95% CI 1.07 – 5.70)) 
van Bemmel (313),  





sBP < 140 mm Hg, with a diagnosis of 
hypertension associated with an increased 
risk of mortality 






sBP > 164 mm Hg (95% CI 154 –183.8) 
associated with lowest mortality, increased 








sBP < 150 mm Hg associated with 
increased mortality HR 2.0 (95%CI 1.1, 
3.4) compared to an sBP > 150 mm Hg 






sBP <130 mm Hg associated with 
increased risk of death compared to sBP 
140 to 159 mm Hg (HR 0.39; 95% CI: 0.21 
- 0.72) 






In treated hypertension, BP < 140/ 90 mm 
Hg increased risk of all-cause mortality 
(HR 1.26 (95% CI 1.04 – 1.54), compared 
to BP >140/90 






U shaped association between BP and all-
cause mortality: lowest mortality risk 





1.7.3 Balancing benefit over risk with age 
 
International treatment guidelines indicate treatment for hypertension on the 
basis of at least two factors: the level of a person’s BP, and the level of a 
person’s overall cardiovascular risk. 
 
Regarding BP target, current guidelines diverge (Table 1-5). For adults over the 
age of 80 years for example, the UK National Institute for Healthcare 
Excellence (NICE) guidelines (8), and the American Academy of Family 
Physicians (9) recommend treating systolic blood pressure to less than 150 mm 
Hg; the American College of Cardiologists recommend treatment to a target of 
less than 130 mm Hg systolic blood pressure (10); and, the European Society 
of Cardiology recommend maintaining systolic blood pressure below 140 mm 
Hg above 130 mm Hg (11). 
 
Cardiovascular risk models were initially developed in the Framingham cohort, 
following which more than three hundred predictive models have been 
developed to anticipate risk for developing cardiovascular disease (319). The 
level of cardiovascular risk at which treatment is deemed to have greater benefit 
over harm has been recently reduced in the majority of guidelines. A 
cardiovascular risk level of 10% over ten years is recommended by the most 



























ABPM: <130/80  
Clinic <140/90 
>80: 160  




adults >65: 130 (av.) 
Low CV risk: 160 
Mod CV risk: 140 
Minimum BP 
on treatment 
135/85 None; Caution if 
Standing sBP < 110 
<65: 120/70 
>65: 130/70  
None None  
Target BP ABPM , standing BP: 
<80: <135/85 
>80:<145/85  
High CV Risk: <120 
Low CV risk:<140 
Diabetes mellitus: <130 
Target ABPM <65 
130/79; >65 139/79  
 
Low risk < 140 
Mod/ high risk<130 
All: <140 





80y with frailty or 
multi-morbidity 
Institutionalised elderly 65y - 80y: clinical 
condition, concomitant 
treatments and frailty 
>65y & multi-
morbidity, limited life 
expectancy 
75y 
Guideline committees: ACC = American College of Cardiology; AHA = American Heart Association; ESC = European Society of Cardiology ; NHFA 
= National Heart Foundation of Australia; NICE = National Institute for Health and Care Excellence 
Table abbreviations: av. = average; ABPM: Ambulatory Blood Pressure monitoring; av.: average; BP: blood pressure; CV Risk: Cardiovascular risk; 




1.8 Considering ageing as central to cardiovascular risk 
 
The evidence presented in this chapter demonstrates the relevance of the 
process of ageing both to the pathophysiology of hypertension and to the 
balance of treatment benefits and harms (Figure 1-6). This thesis will 
investigate the potential role of frailty as a measure of biological ageing to 
inform the management of hypertension. In the following section I will outline 
how frailty is defined and conceptualised in recent literature, and present 
grounds to consider a person’s frailty status in the management of 
hypertension. 
 
Figure 1-6 Hypertension in the context of ageing: A proposed modification 






1.8.1 What is frailty? 
 
The concept of frailty describes a loss of physiological reserve with age and a 
failure of homeostasis to maintain a steady state in the face of stressors (325). 
Frailty develops because ageing physiological systems loose complexity: they 
become less dynamic; they are unstable and reactive to perturbations; and, this 
ultimately results in loss of physiological function (326). Clinically, people with 
frailty are characterised by prolonged and incomplete recovery to a stressor 
event. People with frailty therefore spend longer in hospital, experience more 
peri-operative complications, and are discharged from hospital with greater 
functional needs, long term disability and mortality (327).  
 
The stressor may include a wide range of precipitants, examples include an 
infection, a fall, or a new medication. Disease in the context of frailty therefore 
often presents with features that are less typical for the disease process (328) 
but more typical for diseases characteristic of ageing (329). Older people with 
frailty, in the face of what should be a minor stressor can change dramatically 
from being lucid to delirious, mobile to being bedbound, independent to 
requiring cares for basic daily needs (325). 
 
Allostatic load represents cumulative biological burden across the life-course, 
and the attempt of the body to adapt to this is allostasis (330). The 
accumulation of biological burden leads to multiple failures in signalling at the 
level of molecular mechanisms with ageing. As a result, the overall system 
loses its complexity and ability to respond to stressors (331). Adaptive 
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compensations fail and functional homeostatic mechanisms are in jeopardy. 
The clinical features of this process present as frailty.  
 
The cumulative deficit model of frailty is an internationally established 
theoretical model, operationalised as the additive effects of health deficits on 
the overall health of an individual (332). It is based on the understanding that 
with ageing, people are more likely to accumulate a variety of general health 
deficits (325). Deficits may include diseases, but also more minor impairments 
that do not meet disease criteria, including biochemical aberrations or evidence 
of physiological decline (6). An accumulation of deficits going unrepaired leads 
to loss of reserve. Therefore, the frailty index (FI) represents a means of 
quantifying a person’s relative health state, and has utility in considering a large 
number of small effects on a person’s health status.  
 
An alternative approach is the frailty phenotype method (333). This approach 
regards frailty as a clinical syndrome, whose criteria include: unintentional 
weight loss, muscle weakness, self-reported exhaustion, slow walking speed, 
and low physical activity (333). Using the frailty phenotype model, frailty is 





Advantages of the cumulative deficit model over the phenotype mode are that 
the FI:  
- is on a continuous scale and therefore frailty can be graded; 
- can be measured in a diversity of clinical studies including in trial and 
routine healthcare data; and,  
- can be calculated retrospectively from available data if the data are 
sufficiently comprehensive (334). 
 
1.8.2 Why consider frailty in hypertension?  
 
1.8.2.1 Frailty as a measure to capture variation in population health 
 
A combination of improved survival rates and falling fertility rates means that 
the large majority of countries internationally are anticipating an increase in the 
size of their older populations (335). This is evidenced in the striking rise 
projected in the number of people globally aged over 65 years old from 0.7 
billion in 2019 to 1.55 billion in 2050, with the biggest regional increases in 
North Africa and Western Asia (120%) and smallest increases in Europe and 
North America (48%) (335). In the UK there are currently 12 million people over 
the age of 65, constituting 18% of the population and this is set to increase to 
24.8% by 2050 (336).  
 
However there is marked geographical variation within the UK, with inequalities 
in rates of survival to old age (337). Also, there is a large disparity between life 
expectancy (number of years that a person can be expected to live) and healthy 
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life expectancy (number of years that a person can be expected to live in “full 
health” taking into account years lived in less than full health due to disease or 
injury) (338). In the UK, a large percentage of men (44%) and women (47%) at 
the age of 65 years live in poor health (339). Approximately 55% of those over 
65 years have two or more long-term conditions (LTC), commonly known as 
multi-morbidity (340).  
 
Because people are living longer, and living for an extended proportion of that 
time with greater disability and comorbidity, there is a wide variation in the 
health of older people. Chronological age is insufficient to capture this variation 
in the ageing process among individuals.  
 
Frailty is easily measurable and available to practitioners in the current UK 
health system. Frailty is also now more easily identifiable in the UK, since the 
recent development, validation and implementation of an electronic Frailty Index 
(eFI) (341). This enables robust identification of frailty at a population level 
using routine primary care electronic health record data. 
 
A hypothesis explored in this PhD is whether frailty can characterise ageing in a 
way that is clinically applicable to hypertension management that is patient 
centred. 
 




There is significant variation in the rate of vascular ageing in later life 
throughout the population (342). The underlying aging process changes the 
substrate of the cardiovascular system in a way that lowers the threshold for 
common cardiovascular diseases to become clinically manifest in an individual. 
However, adverse outcomes, cardiovascular and non-cardiovascular in later life 
are predictable using measures that relate to the underlying ageing process 
(327). 
 
Frailty is a global measure of multi-system failure associated with ageing that is 
relevant to the management of hypertension. Many of the structural and 
molecular changes involved in hypertension are changes of ageing. Vascular 
health is influenced directly by the health of end-organs. The integrated 
physiology underlying BP control is evidence that many organ systems failing, 
rather than the degree of failure of one single system is relevant in the context 
of hypertension (40) (Figure 1-7). For example, baroreceptor function becomes 
impaired with age, also there is reduced diastolic ventricular filling and reduced 
vascular compliance which all act to increase BP variability in the context of 
reduced preload. In such a context ageing represents the common factor of 
each of these system failures contributing to BP and the associated risk.  
 
A hypothesis explored in this PhD is whether frailty can characterise ageing 
associated risk of key outcomes in relation to the management of hypertension 




Figure 1-7 A schematic representation of the relationship between BP and 
frailty across the life course 
Influences on BP control across the life course – these mechanisms of normal 
blood pressure control. Hypertension in younger life is characterised by 
increasing vascular resistance and relates to influences on increasing the set-
point of stable blood pressure control (represented by the circle). Hypertension in 
later life is characterised by rising pulse pressure which represent changes to the 
dynamic blood pressure control (d). Negative feedback loop of blood pressure 
regulatory mechanisms may also be less sensitive than in younger life 
(represented by broken circle) 
 
1.8.2.3 Frailty to identify a population in whom associations of BP and 
outcomes are different 
 
The BP target, at which a favourable balance of benefit over harm exists 
remains the subject of debate, particularly for older people, in the context of 
competing risks. There is a divergence in the nature of BP associated risk 
reported in trial and epidemiological literature, which it is proposed, relates to 
the population in whom the association is measured. In populations with a low 
disease burden, including older people who maintain good health, increasing 
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BP is associated with a linear increase in risk of adverse outcomes. In 
populations with a high disease burden, particularly in older people, risk of low 
BP is also associated with harm so that the association between BP and 
adverse outcomes overall is non-linear.  
 
A hypothesis explored in this PhD thesis is whether frailty can identify the 
population in whom BP associated risk is non-linear from the population in 
whom the BP associated risk is linear. 
 
1.9 Research question 
 
There is a evident uncertainty relating to the balance between benefit and harm 
of hypertension treatment for older people living with frailty. This is a clear 
research gap which is contributing to the divergence in guidelines which in the 
absence of evidence rely on expert opinion. Indeed the need for research in this 
area has been highlighted by all of the leading hypertension guideline 
committees worldwide (320, 322, 323).  
 
From the biological and clinical perspectives outlined in this chapter, it is 
evident that the relevance of a BP measurement depends on its context. 
Targets for treatment vary based on the clinical context: for example the choice 
of target BP is different whether it is in the context of diagnosis or long-term 
management, and whether it is in primary or secondary prevention. Therefore 
this PhD will investigate the role of frailty specifically in the context of patients 
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with hypertension which is being treated for the primary prevention of 
cardiovascular disease. 
 
Secondly, guidelines currently balance the benefit and harm of treatment on two 
factors: the level of a person’s overall cardiovascular risk and the level of blood 
pressure. This PhD will investigate the potential role of frailty in hypertension 
management in both respects: 
1. Frailty as a prognostic factor which alters a person’s level of overall risk 
of outcomes in relation to the management of hypertension 
2. Frailty as a factor that modifies the association of the level of BP with 
outcomes such that the balance of risk and harm may be different at 
particular levels of BP conditional on a person’s frailty status. 
 
Finally, the PhD will adopt a mixed methods approach to investigate the role of 
frailty in hypertension management both from the perspective of routine primary 
care as recorded in electronic health data, and also from the perspective of 
older people themselves who live with hypertension and frailty 
1.10 Aims and objectives 
 
The research questions, and associated objectives are as follows: 
 
1. What is the current level and quality of evidence to inform whether the 




Objective 1: to undertake a systematic review and meta-analysis of the 
available evidence from observational studies investigating the 
association of blood pressure and outcomes in the context of frailty. 
 
2. Is frailty useful as a prognostic marker in the management of 
hypertension in routine clinical care? 
Objective 2: to describe the normal blood pressure-outcome 
associations in this population 
Objective 3: to investigate in large scale routine primary care data 
whether frailty is a prognostic factor for relevant outcomes in the 
management of hypertension in older people. 
 
3. Is there evidence the association of blood pressure and outcomes is 
different in the context of frailty? 
Objective 4: to investigate in large scale routine primary care data, 
whether frailty causes effect modification of the association of blood 
pressure or blood pressure lowering treatment and outcomes in older 
people. 
 
4. Is frailty a useful measure to inform management of hypertension from 
the perspective of patients themselves? 
Objective 5: to explore the patient’s perspective using a series of 
narrative interviews to reveal how the concept frailty can inform shared 








Chapter 1 summarised the evidence base for hypertension treatment in the trial 
and observational literature. Chapter 2 specifically focuses the existing literature 
examining the role of frailty. Here I will address the first objective of this PhD 
which is to undertake a systematic review and meta-analysis of the available 
evidence investigating the association of blood pressure and outcomes in older 
adults with and without frailty. There is a paucity of trials recruiting older people 
with frailty and multi-morbidity, as discussed in the previous chapter (Section 
1.6.1). Therefore, a summary of observational studies is necessary, albeit with 
the caveat that their interpretation must account for their higher risk of reverse 
causality and residual confounding. This work has been published (343). 
 
2.2 Objective 1  
 
To undertake a systematic review and meta-analysis of the available evidence 
from observational studies investigating the association of blood pressure and 






Given the focus on observational evidence, the review methodology followed 
the Meta-analysis of Observational Studies in Epidemiology (MOOSE) guidance 
and is reported using Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses (PRISMA) recommendations (344, 345).The protocol was 
prospectively registered with Prospero http://www.crd.york.ac.uk/PROSPERO/ 
(reference CRD42017081635).  
 
2.3.1 Inclusion criteria 
 
Observational studies involving community-living older adults (mean age >65), 
with frailty identified using a validated measure, and participant follow-up for at 
least six months were eligible. A frailty measure was considered to be valid if it 
had been validated against a reference standard (346). Blood pressure was 
required to be measured at baseline with or without treatment, using a 
measurement standardised within the study. If a participant was unable to 
complete the frailty test, their data were excluded from meta-analysis. This is 
because non-participation does not represent a validated measure of frailty – 
non-completion of the test may be for reasons other than frailty.  
 
The primary outcome was all-cause mortality. A priori secondary outcomes 
included: falls; stroke; non-fatal myocardial infarction; secondary prevention 
outcomes (e.g. proteinuria); adverse treatment effects; non-cardiovascular 
mortality; and other markers of general morbidity (including unplanned 




2.3.2 Search methods for identification of studies 
 
An inclusive MEDLINE search strategy was developed with an experienced 
research librarian at the University of Leeds, and adapted for CINAHL, 
EMBASE, and Web of Science. All databases were searched for English 
language publications between 1st January 2000 and 13th June 2018. A start 
date of 2000 was chosen because the reference standard frailty measures first 
became available since then (332, 333). The search strategy for MEDLINE 
(Ovid SP) is available (Appendix A). Reference lists of included articles were 
also searched. PROSPERO, Research registry and NIHR research registries 
were searched for unpublished work. Authors were contacted if abstracts 
referred to unpublished work, and a forward citation search was undertaken of 
all included studies. 
 
Study eligibility was determined by two independent reviewers (OT, and Dr 
Chris Wilkinson (CW), or Dr Mark Perry (MP), or Dr Matthew Hale (MH)) with 
any disagreements settled by consensus discussion with a third reviewer 
(Professor Andrew Clegg (AC)). Reasons for exclusion of articles at the full-text 
review stage were collated using Covidence software (347). 
 
2.3.3 Data extraction 
 
Hazard ratios (HRs) were extracted with 95% confidence intervals (CIs) for time 
to event data (e.g. mortality) for different categories of baseline systolic and 
diastolic blood pressure, with and without frailty, adjusted for a minimum of age 
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and sex. Two independent reviewers extracted hazard ratios (OT, CW). A third 
reviewer (AC) settled any disagreements by consensus discussion. 
 
2.3.4 Assessment of risk of bias 
 
Two independent reviewers (OT, and CW or MH) assessed risk of bias for each 
study using the Risk of Bias Assessment tool for Non-randomized Studies 




Data were synthesized for meta-analysis by calculating natural logarithms of 
HRs, with standard errors to create summary forest plots by generic inverse 
variance random effects modelling using RevMan 5.3 software. Statistical 
heterogeneity was assessed using the I2 statistic to determine whether fixed 
effects (I2<50%) or random effects (I2≥50%) modelling should be used. Since 
fewer than 10 studies were identified to provide data for each outcome, 
assessment for publication bias with funnel plots was not appropriate (349). 
 
Where studies used different reference categories for blood pressure, estimates 
comparing groups were re-categorised according to thresholds for treatment 
recommended by NICE guidelines (systolic BP of 140 mm Hg, and diastolic BP 
of 90 mm Hg) (320). Where there was more than one category on either side of 
the threshold, risk estimates from directly neighbouring categories were 
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extracted and pooled using generic inverse variance methods (Appendix B). 
Data from ‘less than’ categories (<) were pooled with data from ‘less than or 
equal to’ (<=) categories and the same was done for ‘more than’ and ‘more than 
or equal to’ categories. Where continuous scales of measurement were used, 
the HR for events associated with 10 mm Hg difference in blood pressure at 




2.4 Results  
 
2.4.1 Literature search 
 
Details of the study selection are presented in Figure 2-1. Following detailed 
assessment, nine studies were eligible for inclusion in the review; eight were 
included in the meta-analysis (350-357) of which seven required further 
information, which was supplied by study authors (350, 352-357). It was not 
possible to make contact with the author of one study, which therefore had to be 
excluded from the meta-analysis (318). A forward citation search on 8th March 
2019 revealed 91 studies, none of which met eligibility criteria. 
 





2.4.2 Study characteristics 
 
The nine studies were all prospective cohort studies with a total of 21,906 
participants and mean follow-up period of 6 years (range 3 to 11 years) (Table 
2-1 & Table 2-2). All studies were rated as low or moderate risk of bias (Table 
2-3). Three studies were based on study populations in the United States (352, 
353, 357), five in Europe (350, 351, 354-356) and one in China (318) with study 
periods between 1989 and 2014. The studies recruited a mean of 58% (range 
20 – 92%) of eligible participants. The mean age was 81 years (74 – 92 years) 
and 59% (51-70%) were female. In the four studies in which it was reported, 
care home residents constituted 24% (10 - 39%) of the study population (354-
356), in two studies care home residents were excluded (352, 357). Frailty was 
identified in 37% (13 - 64%) of participants, and use of BP-lowering treatment 
was reported in 52% (26- 81%), and where reported, a diagnosis of 
hypertension in 48% (25 – 70%) (318, 355). Median annual mortality for the 
whole study population was reported to be 7% (range 4-17%).
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AF = atrial fibrillation; BMI = body mass index; CCF = congestive cardiac failure; CHD = coronary heart disease; CRP = C-reactive 
protein; CVD = cerebrovascular disease; dBP = diastolic blood pressure; f = female; Gait = Gait speed; Grip = Grip strength; GFI = 
Groeningen Frailty Index; HbA1c = glycated haemoglobin; LAPAQ = Longitudinal Aging Study Amsterdam (LASA) Physical Activity 
Questionnaire; MI = myocardial infarction; MMSE = Mini-mental status exam; m = male; n = sample size; OFI = Osteoporotic Fracture 




Each study compared both systolic and diastolic blood pressures, as an 
average of between one and four readings, all at the start of the study. Five 
studies analysed blood pressure as a continuous variable (352-355, 357) and 
seven studies categorized blood pressure (318, 350-353, 356, 357) into 2-5 
groups using thresholds used in the Joint National Committee (JNC) 7 (352), 
JNC 8 (357), or European Society for Cardiology (ESC) 2013 guidelines (350). 
In studies that did not report blood pressure categories using thresholds 
according to NICE guidelines (320) study authors were contacted to request 
access to the raw data. Frailty was measured using a variety of measures, and 
categorized using different thresholds (Table 2-1).  
 
All nine studies reported all-cause mortality as an outcome, in eight as a 
primary outcome. One study reported cardiovascular morbidity as a primary 
outcome, and mortality as secondary outcome (353). Other secondary 
outcomes included disease-specific mortality (318), cardiovascular mortality 
(355), and change in cognitive function (354). 
 
The consensus opinion of the PhD supervisory and collaborating team was that 
study eligibility criteria and included populations were sufficiently similar to allow 
pooling of findings from eight studies (n=17,248, mean duration 6 years) for 
comparison of all-cause mortality risk (350-357). There were too few studies to 
allow meta-regression (358). One study was excluded from meta-analysis 





2.4.3 Risk of Bias  
 
Comprehensive assessment of the risk of bias using the RoBANS tool 
highlighted deficiencies, but overall risk of bias was low or moderate for each of 
the included studies (Table 2-3). Three studies gave incomplete information on 
cohort recruitment (351, 355, 357). Four studies were rated as at high or 
unclear risk of bias for the measurement of exposure. In these, the frail sub-
cohort included participants who were unable to complete the frailty test (350, 
353, 354, 356). In two studies the clinical or statistical justification for the choice 
of confounding variables was not reported (318, 357). None of the studies 
referenced a published protocol with pre-specified methods. In all studies, 
mortality was determined by robust means: either in death registries or by a 
primary care physician. Missing data for covariates were not accounted for with 
one exception (318). In one study, more than 20% participants had some 
missing data on relevant covariates (350).
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Table 2-3 Risk of Bias Assessment 


















Low Low High Low Low Unclear Mod 
Hospers (351) Unclear Low Low Low Low Unclear Low 
Lv(318) Low Unclear Low Low Low Unclear Low 
Odden(352) Low Low Low Low Low Unclear Low 
Peralta(353) Low Low Unclear Low Low Unclear Low 
Streit(354) Low Low High Low Low Unclear Mod 
Vaes(355) Low Low Low Low Low Unclear Low 
Weidung(356) Low Low High Low Low Unclear Mod 
Wu(357) Unclear Unclear Low Low Low Unclear Low 
 
Risk of Bias Assessment using the Assessment tool for Non-randomized Studies (RoBANS) tool (348)
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2.4.4 Primary Outcome - all-cause mortality 
 
2.4.4.1 Categorical blood pressure comparisons 
 
Systolic Blood Pressure: Synthesis of data from six cohort studies (350-352, 
355-357) demonstrated that a systolic blood pressure less than 140 mm Hg had 
no association with mortality in older people with frailty compared to a systolic 
blood pressure more than 140 mm Hg (HR 1.02, 95% CI 0.90 to 1.16, n = 
2,362) (Figure 2-2). However, in the absence of frailty, a systolic blood 
pressure lower than 140 mm Hg was associated with lower mortality compared 
to a systolic blood pressure of more than 140 mm Hg (HR 0.86, 95% CI 0.77 to 
0.96, n= 8,012). There was no evidence of statistical heterogeneity across 
studies for sub-groups with frailty (I2=0%), and low heterogeneity in sub-groups 
without frailty (I2=42%). 
 
Diastolic Blood Pressure: Synthesis of data from five cohort studies (350-352, 
355, 357) demonstrated that a diastolic blood pressure lower than 90 mm Hg 
was not associated with a difference in mortality compared with a diastolic blood 
pressure greater than 90 mm Hg for those with frailty (HR 1.01, 95% CI 0.69 to 
1.46, n = 2,000) nor in those without frailty (HR 0.90 95% CI 0.76 to 1.07, n = 
8,267) (Figure 2-3). There was evidence of moderate heterogeneity for the sub-
group with frailty (I2=52%), but not the sub-group without frailty (I2=7%) so a 
random effects meta-analysis was performed.  
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Figure 2-2 Forrest Plot demonstrating association between all-cause mortality and systolic blood pressure <140 mm 




Figure 2-3 Forrest Plot demonstrating the association between all-cause mortality and diastolic BP <90 mm Hg 
compared to >90 mm Hg in older people without frailty (i) and older people with frailty (ii).  
82 
 
Legend for Figure 2-2 & Figure 2-3: <90 = diastolic BP <90 mm Hg; >90 = diastolic 
BP >90 mm Hg; <140 = systolic BP <140 mm Hg; >140 = systolic BP >140 mm Hg; CI 
= Confidence Interval; Fixed = Fixed Effects; IV = Inverse Variance; n = study 
population size; Random = Random Effects; * = these numbers are estimated using 
aggregate numbers reported.  
 
2.4.4.2 Continuous blood pressure comparisons 
 
Pooled risk estimates were calculated for a 10 mm Hg difference in systolic 
blood pressure (from five studies, n = 12,280) (352-355, 357) and diastolic 
blood pressure (four studies, n = 11,668) (352, 353, 355, 357).  
 
Systolic Blood Pressure: A 10 mm Hg difference in systolic blood pressure had 
no association with mortality in people with frailty (HR 1.02, 95% CI 0.96 to 
1.07, n = 3,138) or those without frailty (HR 1.00, 95% CI 0.97 to 1.04, n = 
9,142). There was evidence of heterogeneity in the association of continuous 
measurements of systolic blood pressure and mortality for both the sub-groups 
with frailty (I2==68%), and without frailty (I2=27%) so a random effects meta-
analysis was performed. 
 
Diastolic Blood Pressure: Similarly, a 10 mm Hg difference in diastolic blood 
pressure was not associated with mortality in people with frailty (HR 1.02, 95% 
CI 0.97 to 1.07, n = 2,748) or without frailty (HR 0.95, 95% CI 0.91 to 1.00, n = 
8,920). There was no evidence of heterogeneity in the association of continuous 
measurements of diastolic blood pressure and mortality for both the sub-groups 





2.4.5 Secondary Outcomes 
 
Only one study reported cardiovascular-specific mortality with respect to blood 
pressure and frailty (351). In this study, lower diastolic blood pressure was 
associated with increased cardiovascular disease mortality in patients over the 
age of 80 years and in those with slower walking speed. By contrast, high 
diastolic blood pressure was reported to be associated with higher 
cardiovascular disease mortality in patients under the age of 72 years, and in 
those without physical and cognitive impairment. Data were not available for the 
other pre-specified secondary outcomes.  
 
2.4.6 Sensitivity Analyses  
 
A high or uncertain risk of bias was identified in four studies in the measurement 
of exposure. The exclusion of these studies did not change the pooled 
estimates significantly in any of the four meta-analyses. The exclusion from the 
meta-analysis of the largest study (n=5,375) (357) for categorical comparisons 
of diastolic BP, changed the pooled estimate for those with frailty (HR 0.84 95% 
CI 0.70 to 1.02) and for those without frailty (HR 1.08 95% CI 0.7 to 1.68). 
However, there was no significant change in pooled estimates with and without 
frailty for: comparisons of categorical systolic BP; or, comparisons of continuous 





2.4.7 Effect modification 
 
Six studies assessed whether frailty had an interaction with the association of 
blood pressure and mortality. Only one study reported a significant interaction 
with systolic blood pressure (p <0.05 (318)), but it is unclear if this interaction 
was in the context of an adjusted model. Five studies reported no significant 
difference with the addition of an interaction between frailty and blood pressure 
on outcomes (351, 354-357). Three studies assessed whether BP-lowering 
treatment (318, 350, 352) or self-reported diagnosis of hypertension (318) 
modified the effect of frailty on blood pressure and mortality, but they found no 
evidence of effect modification. One study stratified continuous comparisons of 
systolic BP by BP-lowering treatment and found that frailty did not modify the 
effect (354). Five studies reported sensitivity analyses to exclude those dying 
within 1 year (350, 352, 354, 356) and 2 years (357), to test for evidence of 








In this meta-analysis of 21,906 participants across nine cohort studies, in older 
people with frailty, a systolic blood pressure less than 140 mm Hg was not 
associated with a difference in mortality compared to a systolic blood pressure 
greater than 140 mm Hg. In contrast, in older people without frailty, a systolic 
blood pressure < 140 mm Hg was associated with a 14% lower risk of death 
compared to a systolic blood pressure > 140 mm Hg.  
 
There was no association between diastolic blood pressure and mortality in 
older people overall (n=10,267), and this did not change when accounting for 
frailty. When measuring blood pressure as a linear variable, there was no 
difference in association with higher systolic (n=12,280) or diastolic blood 
pressure (n=11,668) and mortality after adjustment. 
 
2.5.1 Strengths and weaknesses 
 
The robust, inclusive search strategy identified studies that recruited an average 
of 58% of eligible participants. The study population was larger and more 
representative of community-dwelling older people than in recent randomised 
control trials (267, 359). Neighbouring categories were compared at thresholds 
defined by current NICE guidelines (320). This synthesis of adjusted data 





Whilst I set out to investigate a number of other outcomes in addition to 
mortality the available studies did not report non-fatal outcomes to enable 
pooled estimates of risk to be calculated. The proportion of the study population 
who were care home residents was reported in a minority of included studies, 
limiting conclusions about this important group with advanced frailty in which 
there is also a high prevalence of hypertension at over 80% (360). 
 
The study populations also included participants with hypertension and without, 
and those who were being treated for hypertension as primary cardiovascular 
disease prevention with those who were being treated for it as secondary 
prevention. This makes the findings of these studies difficult to apply to clinical 
care where these contextual factors influence how BP is measured and 
managed and therefore limits the external validity of these studies.  
 
All studies measured blood pressure at one sitting, but measurement error and 
short-term variability of blood pressure mean that single readings are unreliable. 
Whilst there was no evidence of a linear dose effect of blood pressure, 
exclusion of a nonlinear association was not possible, due to a lack of reported 
data, which could be relevant considering the reported J-shaped relationship 
between blood pressure and outcomes in other populations (Section 1.6.2.2) 
(306). 
 
Throughout the meta-analyses, patients were dichotomized as either frail or 




measures, however there is much evidence that frailty is graded. Frailty was 
inconsistently defined across studies with the use of a variety of measures.  
 
It is possible that the association reported in this review may be the result of 
reverse causality (see Section 1.6.2.2.2) (32). Observational studies 
investigating blood pressure and outcomes in the context of frailty have 
demonstrated that low blood pressure out with the context of hypertension is 
likely to be a marker of poor overall health and not reversible (361). Therefore, it 
would be important to re-examine these associations in populations who all 
have a diagnosis of hypertension. Although several studies performed 
sensitivity analyses to test the possibility of reverse causality, the numbers 
included were small, and therefore the analyses to determine this may have 
been underpowered.  
 
2.5.2 Findings in context of wider research literature 
 
2.5.2.1 Randomised control trials 
 
Findings of this systematic review contrast with the evidence from randomised 
control trials. There have been two treatment trials (267, 275) in which the 
modifying effect of frailty has been considered in retrospective analyses (359, 
362). Both of which were included in the discussion in Section 1.6.1.1. It was 
not possible to pool the results because of differences between the trials in: 





The Hypertension in the Very Elderly Trail (HYVET) randomised individuals 
over the age of 80 years, to target a systolic blood pressure of less than 150 
mm Hg using indapamide +/- perindopril (362). The post-hoc analysis of the 
HYVET trial was undertaken using a 60-item frailty index (FI) constructed 
according to established guidelines (334) using available trial data calculated at 
the time of study entry. This retrospective analysis was not powered or pre-
specified. The study population was smaller than the original trial because 
calculation of the Frailty Index (FI) relied on quality of life questionnaires which 
not all patients completed.  
 
The HYVET analysis was undertaken on 2,656 patients whose average age 
was 83 years, who were mostly female (61%), who had a median frailty index of 
0.17 (IQR 0.11 – 0.24) which equates to mild frailty (362). Cox regression was 
performed, stratified by a patient’s country of origin, adjusting for age and sex 
with the addition of frailty as a continuous variable as well as an interaction term 
between frailty and the treatment arm.  
 
Overall, among these 2,656 patients, the findings of the main trial were 
maintained, an sBP < 150 mmHg compared to an sBP 150 mm Hg was 
associated with reduction in stroke (HR 0.65 (95% CI 0.43, 0.98), 
cardiovascular events (HR 0.59 (95% CI 0.45, 0.77)) and all-cause mortality 
(HR 0.83 (95% CI 0.66, 1.05)). Adjusted for frailty, these point estimates 
associated with treatment did not significantly change: for stroke (HR 0.64 (95% 
CI 0.42, 0.96), cardiovascular events (HR 0.59 (95% CI 0.45, 0.77)) and all-




frailty, the treatment arm was associated with greater effect on stroke reduction, 
cardiovascular events and all-cause mortality (Table 2-4).There were also more 
withdrawals in the treatment arm among those with severe frailty. 
 














The Systolic Blood Pressure Intervention Trial (SPRINT) randomised individuals 
over the age of 50 years, with increased cardiovascular risk but no history of 
diabetes mellitus to a systolic blood pressure target of less than 120 mm Hg 
(359).  
 
Outcome Frailty index HR and 95% CI 
Stroke 0.1 0.75 (0.40 – 1.38) 
0.2 0.66 (0.43 – 1.01) 
0.3 0.59 (0.36 – 0.96) 
0.4 0.52 (0.25 – 1.09) 
0.5 0.47 (0.16 – 1.33) 
0.6 0.41 (0.10 – 1.65) 
CV events 0.1 0.62 (0.42 – 0.92) 
0.2 0.60 (0.45 – 0.78) 
0.3 0.57 (0.42 – 0.79) 
0.4 0.55 (0.42 – 0.79) 
0.5 0.53 (0.26 – 1.06) 
0.6 0.50 (0.20 – 1.27) 
ACM 0.1 0.89 (0.63 – 1.25) 
0.2 0.84 (0.66 – 1.07) 
0.3 0.80 (0.61 – 1.04) 
0.4 0.76 (0.50 – 1.14) 
0.5 0.72 (0.40 – 1.29) 




A retrospective analysis of the SPRINT trial sub-population over 75 years old, 
developed a post-hoc 37- item FI, using as its basis an FI from the African 
American Health Study (AAHS), to which was added a further 20 items used in 
HYVET (363). Frailty was categorised as fit (FI < 0.1); pre-frail (FI 0.1 < 0.21) 
and frail (FI > 0.21). Additionally the trial had included gait speed (also a proxy 
measure of frailty), which took the maximum speed of two tests which were 
completed with the person’s usual walking aid. A threshold of 0.8 m/s was used 
to distinguish those with slow versus normal walking speed. Cox proportional 
hazards analysis was undertaken with competing risks according to Fine and 
Gray sub-distribution hazards for Major Adverse Cardiovascular Events (MACE) 
outcomes with non-cardiovascular mortality as the competing risk. 
 
The analysis was undertaken on the 2,636 patients over 75 years in the 
SPRINT trial, of whom 2,510 (952%) completed follow up (359). The average 
age was 79.9 years, 37.9% of whom were female. Participants had a median FI 
of 0.17, as in HYVET, equating to mild frailty. More than 30% of the patients 
over the age of 75 years were described as frail. The study population was 
classified: 13.9 % as fit; 55.2% as less fit; and, 30.9% as frail. 28.1% had slow 
walking speed (i.e. > 0.8m/s). The difference in the sBP achieved in the 
intensive versus the standard treatment arms reduced with advancing frailty. In 
those who were fit: sBP 121.4 (120.3, 122.5) intensive arm, 134.9 (133.9, 
135.9) standard arm; less fit, sBP 123.3 (122.8 – 123.9) intensive arm, 134.7 
(134.1, 135.2) standard arm; frail,124.3 (123.5, 125) in intensive arm, 135.0 





Analysis of the outcomes demonstrate findings of the main trial were maintained 
in the retrospective study population, with an achieved sBP of 121.5 mm Hg 
associated with a reduction in major adverse cardiovascular events and all-
cause mortality compared to standard BP at 134.6 mm Hg, but with higher 
reported adverse effects in the intervention group. The sub-group analysis by 
frailty demonstrates more mixed results, with advancing frailty associated with 
less protective effects of BP lowering for major adverse cardiovascular events 





Table 2-5 SPRINT analysis by frailty  
 
ACM = All-cause mortality; AKI= Acute Kidney Injury e
-
=electrolyte disturbances; GS = Gait 
speed; MACE = Major Adverse Cardiovascular Events; OH = Orthostatic Hypotension; p = p-
value, significance test; pinteraction = p-value of interaction term; SAE = Significant Adverse 
Events;  
 










n (rate) 102 (2.59%) 148 (3.85%) 
HR 
 
0.66 [95% CI, 0.51–0.85] 
Deaths N 73 103 





SAE n (%) 637 (48.4%) 637 (48.3%) 
HR  
↓BP % 2.4% 1.4% 
HR 1.71 [95% CI, 0.97–3.09] 
Syncope  3.0% 2.4% 
HR 1.23 [95% CI, 0.76–2.00] 
e-  4.0%  2.7% 
HR 1.51 [95% CI, 0.99–2.33]  
AKI  5.5% 4.0% 
HR 1.41 [95% CI, 0.98–2.04]  
Falls  4.9% 5.5% 
HR 0.91 [95% CI, 0.65–1.29] 
OH  21.0%  21.8 % 
HR 0.90 [95% CI, 0.76–1.07] 
OH + 
dizziness 
 1.9% 1.3% 






MACE Fit 0.47 (0.13 – 
1.39) 
pinteract = 0.52 
Less Fit 0.63 (0.43 – 
0.91) 
Frail 0.68 (0.45 – 
1.01) 
Norm GS 0.67 (0.47 – 
0.94) 
pinteract = 0.85 
Slow GS 0.63 (0.40 – 
0.99) 
ACM Fit 0.95 (0.27 – 
3.15) 
pinteract = 0.88 
Less Fit 0.48 (0.29 – 
0.78) 
Frail 0.64 (0.41 – 
1.01) 
Norm GS 0.65 (0.43 – 
0.98) 
pinteract = 0.68 
Slow GS 0.75 (0.44 – 
1.26)  




Limitations of both retrospective secondary analyses of HYVET and SPRINT 
include that neither was pre-specified nor statistically powered for the analyses 
by frailty status.  
 
The frailty indices calculated retrospectively also deserve further scrutiny and 
may not generalise to frailty indices used in routine care. A recent study (which I 
co-authored) applied the SPRINT and HYVET eligibility criteria to a UK primary 
care population. The electronic frailty index (eFI) calculated of the 
corresponding UK population, was 0.09 which corresponds to fit (364). The 
frailty index developed both in SPRINT and HYVET did not include any non-
cardiovascular morbidities.  
 
Furthermore, of the 37 components of the SPRINT FI: 14/37 are cardiovascular 
risk factors although the population was recruited to all have moderate 
cardiovascular risk; 9/37 directly represent factors that are included in the 
exclusion criteria for trial recruitment; 11/37 are function measures but the 
choice may represent health behaviours more than functional abilities. For 
these reasons it is possible the frailty as measured in SPRINT may represent 
those with greater cardiovascular burden which may have a mediating role in 
the association between sBP and cardiovascular outcomes. 
 
In summary, consistent with the findings from this meta-analysis, these two 
trials have reported persistent benefit from low blood pressure extending into 
old age for those without frailty. Both analyses also reported that there was no 




(267, 359). In contrast with the findings of this meta-analysis, the HYVET trial 
analyses demonstrate that BP-lowering interventions maybe associated with 
greater reduction in cardiovascular outcomes. Importantly, neither of these two 
trial analyses were statistically powered and both used frailty indices which 
over-represented cardiovascular risk among their constituent items. 
 
2.5.2.2 Routine data studies 
 
Pooled findings from traditional cohort studies also contrast with those reported 
in large primary care studies (365, 366). The use of routine data from primary 
care mean that the study populations were highly representative of the overall 
population. However, the non-standardized measurement of BP in primary care 
meant that the routine data studies did not meet the criteria for inclusion in the 
meta-analysis. I will now examine both studies investigating whether 
associations of blood pressure and outcomes are different in the context of 
frailty. 
 
Ravindrarajah et al studied 144,403 participants, recorded in the primary care 
electronic health records of the Clinical Practice Research Database (CPRD) 
during the period 2001-2014 (365). An eFI was used to measure frailty (341). All 
patients were over the age of 80 and study entry point was at their 80th, 85th, 
90th or 95th birthday with random sampling to ensure weighting across age 
groups. Blood pressure was represented by monthly averages taken over the 
period of follow up to create trajectories. Frailty and BP-lowering treatment 




included categorised forms of: smoking, body mass index, total cholesterol and 
comorbidity clusters. Cox PH models were undertaken and all-cause mortality 
was the outcome of interest over 5 year follow up. Subgroup analyses were 
undertaken on sex, frailty and BP-lowering medications. Missing data were 
replaced with dummy / indicator variables. 
 
The study reported 51,808 deaths during 5 years follow up (35.9%) (365). 
Compared to a reference systolic blood pressure of 120 – 139 mm Hg, lower 
blood pressures were associated with higher mortality, and higher blood 
pressures with lower mortality. In the context of severe frailty, the association of 
low systolic blood pressure with higher mortality risk remained. In addition, with 
severe frailty, systolic BP categories above the reference range of 120-139 mm 
Hg were also associated with higher mortality.  
 
There are several limitations of note which may have influenced the findings. 
The study extended over a long period of time during which hypertension 
treatment has changed, and no adjustment was made for study year in the 
analysis. Missing data were not imputed and the consequent direction of bias in 
routine data is difficult to predict. Non-fatal outcomes were not measured. The 
inclusion of BP readings and treatment variables during follow up is a 
recognised method of repeating measures to reduce the impact of regression 
dilution (367, 368). However, as a result, the findings of the study are difficult to 
interpret in clinical practice, because none of: the study start time; the measure 
of BP; nor, the method of cardiovascular risk assessment resemble the clinical 




BP-lowering treatment, it was not clear if the indication of the BP-lowering 
treatment was for hypertension or another cause for which the therapy is also 
indicated. 
 
Masoli et al also used CPRD data but with a different design (366). In this study, 
415, 980 were included, all over the age of 75 years, with at least 3 BP 
measures in the 3 years prior to their 75th birthday, over a study period of 2000 
to 2014. The source period for the eFI is not reported. Covariates include sex, 
age, deprivation as measured by Index of Multiple Deprivation (IMD), and only 
in a sensitivity analysis, a measure of cardiovascular risk and BP trajectory. BP-
lowering treatment was not measured. Outcomes included incident 
cardiovascular disease and all–cause mortality. Follow-up was for 10 years. 
Survival analysis used Cox PH and Fine and Gray competing risks analysis. 
Subgroup analyses were undertaken according to groupings by age, 
hypertension, diabetes mellitus and heart failure, exclusion of events within 6 
months, cancer. How missing data was handled was not reported.  
 
For all-cause mortality, compared to a reference range of 130-139 mm Hg, 
lower systolic blood pressure was associated with higher risk. The pattern of 
association was not significantly different according to frailty status. The 
associations of sBP and cardiovascular outcomes are more diverse: for the risk 
of myocardial infarction, increasing frailty is associated with a more exaggerated 
increase in risk associated with increasing systolic BP. For stroke and heart 




outcome, except in the context of frailty where there is no association of sBP 
and outcome in the context of moderate or severe frailty. 
 
Limitations of the Masoli study include: the lack of adjustment for BP-lowering 
treatment; that the method of handling of missing data is not reported; and, that 
moderate and severe frailty groups are combined in the analysis without it being 
pre-specified in the methods. 
 
Furthermore, like the cohort studies analysed before it, both CPRD study 
populations are not recognisable as populations with hypertension for whom 
treatment is either targeting primary or secondary cardiovascular prevention. 
 
In summary, the findings of these two routine data studies build on the findings 
of the meta-analysis. Consistent with the meta-analysis, the Masoli study 
demonstrated a loss of the association of higher blood pressure with risk of 
cardiovascular outcomes with advancing frailty, but moderate and severe frailty 
groups were amalgamated causing concern of bias in the interpretation of 
findings (366). The Ravindrarajah study demonstrated that the pattern of 
association between systolic blood pressure and all-cause mortality is inverted 
and does not significantly change conditional on frailty status (365, 366). There 
remain concerns about generalisability of these studies. Whilst routine data 
studies are more representative of the overall population, these two studies are 
difficult to translate to clinical practice because their designs do not mimic 
clinical practice. Study populations were not limited to people with hypertension 




adjustments and handling of missing data mean that the interpretation of these 
studies must be cautioned by the strong possibility their findings are influenced 




It is possible that residual confounding may explain the findings of observational 
cohort and routine data studies. The frailty index represents a composite 
measure of risk, and contains within it factors that cluster. Some deficits 
represent mediators of the effect of BP on mortality, and others are potential 
confounders. For example, hypertension and cardiovascular disease could have 
developed before or after the onset of frailty. In these cases if frailty was 
evaluated using a frailty index, it would be useful to include sensitivity analyses 
with and without the items that are related to cardiovascular disease.  
 
The measurement of cardiovascular risk factors in routine data sets is 
potentially problematic given that high baseline values may lead to more 
intensive treatment and monitoring to reverse the baseline risk. To address this, 
summary measures of BP were used across the study period, but in so doing 
the BP measure is representative of BP trajectory, rather than a baseline 







This systematic review of observational studies has identified an association 
between low systolic blood pressure and lower all-cause mortality in older 
adults without frailty, but not in those with frailty. These findings indicate that in 
the absence of frailty blood pressure targets should be considered 
independently of age. In the presence of frailty there is ongoing uncertainty. The 
use of routine data can enable the investigation of the association of systolic 
blood pressure and frailty on their continuous scales, with a range of outcomes 
measured in routine care. However, the findings of routine data studies to date 
are inconsistent with one another and with the findings of this meta-analysis. 
These differences may relate to choice of methodological approach, and this 
deserves further enquiry. The available evidence reported in this systematic 
review and meta-analysis indicates a personalised approach based on 









Chapter 2 summarised the current evidence base investigating the role of frailty 
in the association between blood pressure and outcomes in older people. 
Chapter 3 will now detail the methodology adopted in this thesis, which is 
informed by the literature to date. This chapter outlines the design of a 
secondary analysis of electronic health records (EHR) from linked primary care 
data in Wales, UK. A pre-analytic protocol describing the planned methods for 
this PhD study was published online 
(https://clinicaltrials.gov/ct2/show/NCT04662203). The methods have been 
selected to address three key objectives. 
 
3.2 Objectives 2,3 & 4 
 
Objective 2: To describe the normal blood pressure-outcome 
associations in this population 
 
Objective 3: To investigate in large scale routine primary care data 
whether frailty is a prognostic factor for relevant outcomes in the 
management of hypertension in older people; 
 
Objective 4: To investigate in large scale routine primary care data, 




blood pressure, or blood pressure lowering treatment and outcomes in 
older people. 
 
3.3 Research methods 
 
The two research questions being asked in Objectives 3 and 4 require different 
methodologies. Objective 3 relates to an investigation of prognosis, while 
Objective 4 relates to an epidemiological investigation. 
 
3.3.1 Prognosis research methods 
 
Prognosis research aims to predict future outcomes in people with a given 
disease or health condition from the available data. Prognostic information can 
help anticipate outcomes: to prepare a patient for the occurrence of an 
outcome, or to indicate interventions to mitigate the risk of future outcomes. 
(369). The PROGnosis RESearch Strategy (PROGRESS) Partnership has 
outlined a framework for prognosis research, with four key themes, as depicted 
in (Figure 3-1) (370). The second of these themes is prognostic factor research 
which investigates which individual measure (a prognostic factor) at a given 
point, is associated with the outcome of interest, despite adjustment for the 






Figure 3-1 Four prognosis research themes 
 
I : Fundamental prognosis research describes the average clinical outcomes of patients with a 
certain disease, possibly distinguishing sub-groups; II: Prognostic factor research investigates 
the utility of individual measurements in predicting outcomes in order to identify different at-risk 
groups; III Prognostic model research combines prognostic factors to identify an individual’s 
risk, using a method that can be replicated in different populations; IV Stratified medicine 
research identifies sub-groups for whom different interventions may be indicated to attempt to 
reverse their risk of an outcome occurring.(371-374) 
 
This PhD applies prognostic factor research (PROGRESS II) methods to 
address Objective 3, to determine whether the measurement of frailty improves 
the prognostic utility of existing models such as QRISK-3 (373).  
 
Prognostic effect size will be estimated with increasing frailty adjusted for all 
other standard prognostic variables. In addition, model fit, fully adjusted for 
established covariates, will be assessed with and without the addition frailty as 
the prognostic factor, to determine whether the addition of the prognostic factor 





3.3.2 Epidemiological research methods 
 
Objective 4 is a distinctly different research question, calling for epidemiological 
or causal inference methodology. Causal inference methods aim to determine 
the likely change in an outcome due to a change in risk factor (375). Causal 
inference methods are key to identifying what is reversible and should be the 
target of prevention and/ or treatment. These methods are appropriate when the 
research question asks whether the level of BP has a different association with 
outcomes, in the context of frailty. The validity of any estimate of causal effect of 
exposure on the outcome is only as good as the causal assumptions underlying 
it.  
 
Effect modification by frailty of the association between BP and outcomes will 
be measured using the addition of an interaction term in a model already 
adjusted for known risk factors. Evidence of effect modification includes a 
change in the association of BP and outcome when frailty is added to the 
model, or evidence of improved fit when the interaction term is included in the 
model.(376) 
 
3.4 Target study population 
 
The study population targeted patients in whom hypertension was treated for 
primary prevention. These patients had a diagnosis of hypertension but had no 
previous diagnosis of established cardiovascular disease. The choice to restrict 




degree of uniformity in the patient encounter and clinical practice, to which 
particular guidelines are applicable. Furthermore, it was hoped that investigating 
a more targeted population would lead to findings that have greater applicability 
to a specific but common clinical scenario.  
 
The choice of a primary over secondary prevention was made for three 
reasons:  
- Firstly, a focus on primary prevention replicates the design of the 
Framingham heart study with which BP-outcome associations in this 
cohort can be compared. The Framingham Heart study is a landmark 
epidemiological prospective cohort study based in Framingham, 
Massachusetts, USA, started in 1948, currently in its fourth generation of 
participants (28).  
- Secondly, by excluding those with pre-existing vascular disease, the 
effects of vascular disease on blood pressure (reverse causality, see 
Section 1.6.2.2.2) are minimised (367).  
- Thirdly, the absolute risk reduction from BP-lowering treatment for 
primary prevention is smaller than that for secondary prevention (377). 
Therefore, the potential role of frailty in informing hypertension 
management was considered greater in those where treatment is 
informed by cardiovascular risk (primary prevention) than in those in 






The study focuses on the period between 2007-2008. This decision to focus on 
a narrow time period was made because of the potential influence of changing 
policies and guidelines altering hypertension practice, and the effects of these 
changes being difficult to predict and uneven over time. The time period 2007 – 
2008 was chosen because:  
 It enables ten year follow up of outcomes.  
 It represents a period of time during which no new major guidance or 
policy was introduced. At that time the NICE/ British Hypertension 
Society (BHS) guidelines on Hypertension (Clinical Guideline 19, 2004 
and Clinical Guideline 34, 2006) recommended treatment at a BP of 
>140/90 mm Hg in the context of a 10 year cardiovascular risk of > 20% 
(378, 379).  
 It followed the introduction of the Quality Outcomes Framework (QOF)  
which was introduced in 2003/2004 (380) and motivated stricter 
adherence to BP targets in primary care.  
 It preceded the introduction of the NHS Health Check in 2009, which 
involved more widespread BP review as part of general health screening 
(381). 
 
3.5 Routine data in primary care 
 
3.5.1 Primary care setting 
 
This study uses routine data from primary care in the UK where most treatment 





3.5.2 Routine data  
 
In the UK, most people presenting with a new symptom or health condition and 
most chronic diseases are managed by a general practitioner (GP) who are the 
‘gate-keepers’ to the National Health Service (382). Therefore, the primary care 
electronic record contains comprehensive demographic information, as well as 
a patient’s presenting complaints, investigations undertaken, diagnoses made, 
prescriptions issued and any referrals. There are over 300 million consultations 
annually in primary care in the UK (383) and 96% of practices have been using 
electronic health records (EHR) since 1996 (384). 
 
GPs in the UK use a variety of computer systems. (385). Of 7,526 GP practices 
in England in 2016: 56% used Egton Medical Information Systems (EMIS); 34% 
SystmOne; and, 9% Vision (385). 
 
The use of routine data collected in healthcare for research purposes, although 
recently growing, has been ongoing in the UK for more than three decades 
(386). Consent for the release of a patient’s data to be used for research 
purposes that has been collected during the course of normal care, follows an 
opt-out approach, enabling the individual to withdraw their data from databanks 
used for research or planning purposes if they so wish (387). The European 
Union General Data Protection Regulation (GDPR) requires consent be 
unambiguous, and, clearly affirmative. Clear information must be provided on 




challenge of the opt-out model in relation to older people is that there remains 
debate over whether people who do not have capacity have a realistic option of 
withdrawing their data. 
 
There are a range of primary care data sets available in the UK. In England, 
they include: CPRD (389), QRESEARCH (390), ResearchOne (391), and The 
Health Improvement Network (THIN) (392). These research databases extract 
anonymised data from consenting records from the major clinical computer 
systems. There is crossover, so that one person whose GP uses EMIS maybe 
represented both in both THIN and CPRD for example. In England, with the 
exception of CPRD, research data sets are managed as public-private 
partnerships between a University and private company. In Wales and Scotland 
by contrast, research data is managed by the devolved governments. These are 
the Secure Anonymised Information Linkage (SAIL) databank (393) in Wales, 
and the Scottish Primary Care Information Resource (SPIRE), in Scotland 
(394). Using a unique patient identifier, primary care data are linked in some of 
the data sets to records from an individual’s hospital attendances, social care 
interactions, census and death records. 
 
The main characteristics of these data sets are presented for comparison in 
Table 3-1, with the exception of the Scottish Primary Care Information 




Table 3-1 Major primary care research databanks in the UK 
Key information Coverage Linkage Access 
CPRD England (Vision and EMIS) 










Gold (Vision) 674 
GP, 11.3 m total, 
4.4 m active (2015) 
(395) 
 
Aurum (EMIS) 738 
GP,19.3m total, 







-MINAP (via CALIBER) 
High cost 
(397) 






University of Oxford/ 
EMIS 
 
#: 1,200 GP; 30m 
total; 22m (2017) 
(398) 
 























#: unclear; approx. 
8m active 
 
-Care home residence 
 
Low cost 
THIN England (Vision)  
Est. 2003 
 




(Private) & University 
College London 
 
# 744 GP; 15m 




















-Demographic data;  
-Care home residence  
Low cost 
 
Table: CALIBER = Cardiovascular disease research using linked bespoke studies and 
electronic; Est. = Established; GP = General Practitioner; HES = Hospital Episode 
Statistics; m = million; MINAP = Myocardial Ischaemia National Audit Project; ONS = 
Office for National Statistics; PPP = Public Private Partnership; SAIL = Secure 




3.5.3 Comparison with cohort data 
 
The studies synthesized in the meta-analysis in Chapter 2 were traditional 
cohort studies, and did not include routine data studies. There are differences 
between traditional cohort and routine data studies worthy of discussion, as 
follows.  
 
3.5.3.1 External validity 
 
External validity is a measure of how generalisable study findings can be in their 
application to settings other than the specific circumstances applicable to that 
study. Participating in traditional cohort studies may be burdensome for an 
individual (403, 404). Participation rates were 58% on average among the 
studies included in the meta-analysis presented in this thesis which is relatively 
high for traditional cohort studies (Section 2.5.1). Older people may choose not 
to take part in such a study because: they feel too unwell; they are already 
overcommitted with hospital appointments; or, for literacy reasons. These 
personal factors may themselves correlate with risk factors for outcomes, hence 
participant selection bias can affect the results.  
 
Routine data, by contrast, includes all patients presenting in a specified 
healthcare setting. Therefore use of routine data can overcome selection bias in 
this respect (405). Furthermore, use of routine data enables far larger study 
populations than would ever be affordable or practical in a traditional cohort 




context of complexity and multiple confounding factors. This is important in 
ageing research where ageing increases the number of competing risks so the 
point risk estimates attributable to individual risk factors may be small and 
therefore missed in smaller sample sizes. 
 
3.5.3.2 Internal Validity 
 
Internal validity is a test of how confident we can be that the statistical model 
developed in a study represents the underlying truth. Traditional cohort studies 
and routine data studies each have their own advantages and disadvantages in 
terms of internal validity.  
 
In traditional cohort studies, loss to follow-up can be significant, and data 
acquisition may rely on patient recall. The missing data resulting from non-
response and loss to follow up may reduce internal validity. However, if the 
study is prospective in design, the choice of covariates can be determined to 
best account for confounding. 
 
In routine data studies, the capacity for follow-up is higher because they do not 
require active participation on behalf of the patients. This means withdrawal is 
not so significant a problem as in the case of traditional cohort studies. The 
intensity and duration of follow-up provided by routine data would be 
prohibitively expensive in a traditional cohort study or in a trial based on 
participant-level data collection. However, in routine data, the choice of 




measured in routine care. Therefore there is significant scope for un-measured 
confounding to influence findings.  
 
3.5.3.3 Sampling restrictions 
 
Both traditional cohort and routine data studies will have sampling restrictions. 
In routine data studies, sampling may be informed by a start point which is more 
in keeping with the natural course of a person’s illness – e.g. at the time of a 
patient’s presentation with early signs and symptom ahead of a formal 
diagnosis. This lends routine data huge potential for prognostic research.  
 
However as a result of sampling being determined by health service use, an 
individual’s inclusion in routine data is not random: the individual is included in 
routine data because they are unwell and seek help from medical services. 
Therefore the population represented in routine health records is different from 
the general population. As such the findings of a routine data study must be 
interpreted in the context of informed presence bias. Informed presence bias 
describes the tendency for those assessed frequently in healthcare services, for 
example because of poor health, to have a greater recording of additional 
diagnoses (406). 
 
Furthermore, routine data sets are positive recording data sets, that is 
diagnoses are recorded, but the absence of diagnoses are not. This 
distinguishes routine data from traditional cohort studies, where the absence of 








3.5.3.4 Follow up 
 
Follow-up in traditional cohort studies will occur at pre-specified time points, 
while events occurring in between these time points will not be captured at the 
actual time they occur. In routine data, follow-up data can be collected 
continuously as and when patients use healthcare services.  
 
3.6 Study Data set 
 
3.6.1 Choice of SAIL 
 
The primary data source used in this PhD study to achieve Objectives 2, 3 and 
4 is the Secure Anonymised Information Linkage (SAIL) Databank. The choice 
of SAIL as the data source for the analysis in this PhD was determined by 
factors: relating to the data set itself; the training opportunities afforded by 
collaboration with the SAIL team; and, data access. 
 
Firstly, regarding the SAIL data set: the primary care data set in SAIL is linked 
to multiple secondary data sets which make outcome measurement more 
robust and reduces the risk of misclassification bias. Misclassification bias 
represents the risk a variable is incorrectly categorised, thereby altering the 
observation and potentially affecting overall research findings.  
 
The electronic frailty index (eFI) is a measure of frailty (see Section 1.7.2.1), 




accurate method of identifying care home residence in SAIL (408). Care home 
residents are an important sub-population of older people with advanced frailty 
for whom there has been no clear evidence base from observational research to 
date (see Section 2.5.1). 
 
Secondly, collaboration with data analysts and researchers at the SAIL 
Databank has been an important part of the training involved in this PhD 
fellowship. As part of the PhD fellowship, I spent a week with the SAIL team at 
the University of Swansea (hosted by Mr Ashley Akbari, Dr Joe Hollinghurst, 
and Professor Ronan Lyons), to learn how to link the data, and the basics of 
cleaning the data set using Microsoft SQL software. 
 
Thirdly, remote data access was possible using encrypted software and a 
platform which was accessible on any laptop device. 
 
3.6.2 Profile of SAIL 
 
SAIL is the national data safe haven for de-identified data-sets concerning the 
3.15 million people living in Wales (336). There is information posted at GP 
surgeries alerting patients to their ability to opt out so that their data is not 
included in SAIL. However, only 0.025% of the population had made this 
request by 2019 (409). Therefore, allowing for this small proportion and a 
minority who have had no contact with health services, the data set represents 




health and care data for more than 4 million people who have lived and 
received services in Wales since the database demographic records were 
created in 1990 (409).  
 
SAIL uses the Universal International Business Machines (IBM) Database 2 
(DB2) data warehouse because of its massively parallel processing architecture 
(MPP) which enables high computer processing power. Researchers access 
the data through a remote system using a VMware Horizon Gateway via a 
personal computer. This interface uses a Windows environment, alongside data 
analysis software, and on the interface there is access to the NHS Clinical 
Terminology Browser containing code dictionaries for codes commonly used in 
the primary care database (410).  
 
Patient records in SAIL are linked across multiple data sets using an 
anonymized linkage field (ALF) code. Data sets provided to the Health 
Information Research Unit (HIRU), which hosts SAIL at Swansea University, are 
split into ‘File 1’ - data which is commonly identifiable (name, date of birth etc.) 
and ‘File 2’ which includes descriptive data (clinical and event based data) 
(402). ‘File 2’ data is stored in SAIL. ‘File 1’ data enters a repository managed 
by the NHS Wales Informatics Service (NWIS) acting as a trusted third party 
(TTP) (411).  
 
An ALF is matched to a ‘File 1’ data set with minimal additional demographics to 
become the ‘File 3’ data set. ‘File 3’ is sent to SAIL for combination with ‘File 2’, 




ALF patient code is encrypted and the data undergoes quality checks (410). A 
parallel process is undertaken for a person’s address-related-information (e.g. 
care home residence status, deprivation code etc) using the regional 
anonymised linkage field per person (RALF_PE). 
 
This ‘split file approach’ enables linkage of a person’s various records including 
primary care data, secondary care data, demographic data-sets and mortality 
data whilst preventing identification of the individual (410).  
 
3.6.3 SAIL data sets 
 





Table 3-2 Summary of SAIL core data sets  




(WLGP) data set  
Codes: CTV2/ Read 
 
Symptoms, signs, clinical measurements (including blood 
pressure), previous history of disease, prescribed treatment 
and specialist referrals as well as social measures of a 
person’s home environment. Coverage ~ 80% of the 
population in Wales (412). Each person can therefore have 




Department data set 
(EDDS) 
Codes: local 
Demographic and attendance details, reasons for 
attendance and discharge location data from NHS Wales 
emergency department (ED) attendances in Wales. 
Available since 2009. Includes approximately 750,000 ED 
attendances per year. 
Hospital  
Patient Episode Data 
Wales (PEDW) 
Codes: ICD10 
Data recording demographics, admission details including 
length of stay, diagnoses and operations performed in 
secondary care (emergency, elective, maternity and day 
case services). Data collected by Central Patient 
Administrative System (PAS) available since 1997. Includes 
approximately 950,000 hospital admissions per year.  
Demographics 
Welsh Demographic 
Service data set 
(WDSD) 
Includes administrative data including LSOA data, 
demographics, dates of resident and registration in Wales 
including practice history, change of location, and RALF. 
These data are drawn from GP practices, acting as a proxy 
for the Welsh population register. Available since 1990. 
Coverage of approximately 5 million. 
Birth data 
Annual District Birth 
Extract (ADBE) 
This data set consists of all births recorded in Wales on the 
ONS register. Available since 2003. Recording of 
approximately 35,000 births per year. 
Mortality data ONS 
Annual District Death 
Extract (ADDE) 
This data set consists of death certification data from 
England and Wales, and therefore includes individuals who 
died in Wales as well as individuals from Wales who died in 
England. Data contain information regarding the 
approximate 32,000 deaths per year: date and primary 
cause and underlying causes of death as well as 
LSOA2011 location at time of death. ONS data used the 
ICD9 system until 2001 and the ICD10 thereafter. 
Care home lists Data using care home registry by Care Inspectorate Wales 
with missing details completed manually (413). Care homes 
were are assigned a RALF code (414) which can be linked 
to an individual’s address data in WDDS, to determine who 
lives in a care home and the date they moved there.  
Content retrieved from the SAIL website on 16th July 2020(415). CTV-2 = Read Version 
2 codesˑ GP = General Practitioner; ICD-10 = International Classification of Disease 
manual, 10th editionˑ LSOA = Lower super-output area ; ONS = Office of National 





3.6.4 Linkage process 
 
NWIS matches data to the Welsh Demographic Service (WDS). The WDS is an 
NHS administrative database and acts as a proxy for a Welsh population 
database (393, 402) to allocate each patient record an ALF. Matching uses the 
Matching Algorithm for Consistent Results in Anonymised Linkage (MACRAL) 
algorithm (393). This applies an automated ’black box’ method matching on the 
basis of a person’s NHS number (where available), first name, surname, sex, 
date of birth and post code. The MACRAL algorithm has been tested and 
refined to reach a high degree of accuracy (99.85%) (393, 416). The process 
undertaken by NWIS results in five pre-specified levels of matching (393) 
(Table 3-3):  
 
Table 3-3 Levels of matching in SAIL 
Level Matching required 
‘1’  Match to NHS number 
‘4’  Match on all of forename, surname, date of birth, sex, and 
postcode/address 
‘39’  ≥ 90% Match 
‘35’  <90% but ≥ 50% Match 
‘99’  No Match 
 
Level ‘1’ represents deterministic matching, possible in the presence of an 
unique NHS number. In the absence of an NHS number, probabilistic matching 
is undertaken. This study will only include linked records where linkage has a 




levels of ‘1’, ‘4’ and ‘39’ will be included. The matching in the data set provided 
for this PhD is detailed in Table 3-4. 
 
Table 3-4 Quality of linkage  
Matching  Number Total Percentage 
1 - NHS Number 4, 124, 808 4, 785, 194 86.2% 
4 - Exact Match on all 5 273, 340 4, 785, 194 5.7% 
39 - Probabilistic 90% 
Match 
387, 046 4, 785, 194 8.1% 
This linkage quality assessment represents data in the study extract ‘SAIL W0826V’, 




Clinical coding is the practice which translates medical terminology describing a 
patient’s presenting complaint, past medical history, diagnosis and 
management, into terms which can be organised and aggregated to enable 
statistical analysis (417). Taking into account the process of coding for each of 
the main coding systems is important to ascertain the presence and degree of 
potential misclassification bias (defined in Section 3.6.1). 
 
3.6.5.1 Read Codes 
 
The Welsh Longitudinal General Practice (WLGP) data set contains primary 
care data focused at the level of a ‘consultation’ which may represent an 
encounter face-to-face, over the telephone, or to another episode of 
involvement in a patient’s care (such as reading a hospital discharge letter). A 




stamped and will be linked to: a patient’s demographic details; practice 
demographic details; and staff description data. The clinical information coded 
includes: symptoms; signs; diagnostic tests; immunisations; diagnoses; 
referrals; treatments; and, operations. Numerical data (e.g. BP measurement) is 
linked to a parent code, where the parent code specifies a specific 
measurement variable (‘BP measurement’, ‘Hypertension review’ etc.). 
 
Data entry may be completed as part of a variety of roles including: the general 
practitioner; the practice or community nurse; other healthcare professionals; 
the practice manager; or, practice administrators. During the consultation, some 
code entry uses automated text recognition, or provides the clinician with a 
number of options on the screen on entering first letters. GPs may also enter 
informative details about the patient as free text, but this information is not 
available to research as it may be identifiable (395). Prescription data is 
automatically entered using British National Formulary (BNF) codes, along with 
drug quantities and doses prescribed. Results from laboratory investigations 
similarly tend to be automatically linked, updating the WLGP records from other 
databases. Data fed back to GPs from other sources (e.g. discharge letters or 
outpatient letters) will most likely be entered by practice staff (395).  
 
Coding systems used in WLGP records use Read Version 2 codes (CTV-2), 
and contain more than 96,000 codes (418). A key challenge of this coding 
scheme is that multiple codes relate to a single condition, so that an event such 
as a fall may be represented by over 100 different codes. This arises from the 




classes of disease within its own taxonomy that are limited to a fixed number of 
levels (each code may have a maximum of 5 offspring and 60 sibling data 
codes). Furthermore, the Read coding system has evolved over time: it was 
originally developed as 4 byte codes, later revised to 5 bytes (419). The next 
revision: Clinical Terms Version 3 (CTV-3) system is more flexible. UK primary 
care is currently transitioning to Systemised Nomenclature of Medicine-Clinical 
Terms (SNOMED-CT) codes. Read Version 2, CTV 3 and SNOMED codes will 
therefore not always map directly onto one another. Careful compilation of code 
lists is therefore required. 
 
3.6.5.2 ICD codes 
 
The Patient Episode Data Wales (PEDW) data set consists of hospital data, and 
represents the data warehouse for all inpatient activity in Wales. Originally 
PEDW, like Hospital Episode Statistics (HES) in England, was set up in 1989 
for the organisation and planning of hospital services, but it is now used 
primarily for reimbursing hospitals for the care delivered (420). Data entry is 
undertaken, often post-hoc, by clinical coders who work according to the 
National Clinical Coders standards (417). The quality of coding varies. Whilst 
coding error fell from 16% to 11% in the 3 years prior to 2010, the rate of errors 
varied widely (between 1 – 30% of records) across NHS trusts during the time 
period of this study (421). 
 
PEDW data fields include: clinical data, including diagnoses and procedures; 




admission information, including admission and discharge dates; and, 
geographical information used to ascertain area deprivation codes (422).  
 
For diagnoses, coding in hospital records use the International Classification of 
Disease manual, editions 9th (ICD-9) and 10th (ICD-10) systems adopted by the 
World Health Organisation (WHO). Each episode is given a primary diagnosis, 
also when this is unknown, and the rest of the codes constitute comorbidities. 
For operations and procedures, hospital records use the Office of Population 
Censuses and Surveys Classification of Surgical Operations and Procedures, 
4th revision (OPCS-4).  
 
PEDW, as HES, records data in episodes of care, called Finished Consultant 
Episodes (FCE). Since 2007 each episode may be associated with up to 20 
ICD-10 codes, and 24 operations. ICD-10 is a coding system using a logical 
hierarchy of codes using alphanumeric bytes – i.e. letters or numbers (423). 
ICD10 starts with a 3 byte rubric determining the category of disease such as 
disease of the nervous system. This is followed by a further 3 byte sequence 
determining the anatomical site/ laterality/ severity or aetiology. Finally, there is 
one character determining the visit encounter. Limitations of the ICD-10 coding 
system include: the lack of information provided on disease severity; lack of 
specific information on diagnosis, which affects some specialities of medicine 
more than others; and, the lack of capture of sub-diagnostic disease which 





3.6.5.3 Death data 
 
Deaths in England and Wales are recorded using a Medical Certificate of Cause 
of Death (MCCD), which includes two parts. Part 1 defines the primary cause of 
death and may constitute 3 more parts with the first of those being the 
precipitant or most proximal cause, and the last of those being the most distal or 
underlying cause. Part 2 reports associated conditions present in the individual 
that have not directly contributed to the death in individual. The MCCD is 
completed by a medical practitioner who was involved in that person’s care 
within the last two weeks of life. Data entered into the Annual District Death 
Extract (ADDE), include data derived from this or additional information entered 
by the local registrar of births and deaths for the district, or the coroner in cases 
where further investigation of the cause of death is undertaken, such as in the 
event of a post-mortem (424).  
 
The underlying cause of a person’s death is defined by the WHO as the 
“disease or injury initiating the train of events directly leading to death”, or, “the 
circumstances of an accident or violence producing a fatal injury” (425). This 
underlying cause of death is always singular, and most often derived from the 
lowest completed line on Part I of the certificate. Since 1993 the coding of this 
information to ADDE records has been automated in 80% of cases, with the 
remaining minority being undertaken by experienced coders (424). Since 2001, 
the underlying cause of death has been assigned an ICD10 code. Where the 




1(a) to (c) is unclear, or where there are multiple causes entered, the choice of 
which is the underlying cause is made according to a computer algorithm. This 
computer algorithm until 2014 was provided by the US National Center for 
Health statistics Mortality Medical Data System ICD10 version 2001.2 (426), 
and since 2014 by the IRIS system (2013 version) initially developed by the EU 
statistical institute Eurostat, now based in the German Institute of Medical 
Documentation and Information in Cologne (427). 
 
3.6.6 Ethical approval 
 
No new data was collected for this research. This secondary analysis of 
routinely collected patient data was carried out in accordance with section 254 
of the UK Health and Social Care Act 2012, and does not require Research 
Ethics Committee (REC) approval. This was clarified with Dr Alice Temple, the 
named advisor on the University Ethical Review at the Research and Innovation 
service, University of Leeds on 8th December 2017. 
 
The data used in this PhD are available in the SAIL databank at Swansea 
University. The proposal for this research was submitted for review by an 
Independent Governance Review Panel (IGRP) to ensure proper and 
appropriate use of SAIL data (415). The IGRP comprises a mix of lay members, 
professional and regulatory body members (402). SAIL operates in accordance 






3.6.7 Data application 
 
The data application was submitted to the SAIL IGRP on 28th August 2018. The 
project was approved by the IGRP as project reference SAIL0826 on the 12th 
September 2018. Applications were submitted for amendments to include care 
home residence data on the 10th September 2019 and to include ethnicity data, 
on 28th October 2019. Both amendments were approved by the IGRP. 
 
3.6.8 Data access 
 
To gain access to the SAIL databank, I undertook the Office for National 
Statistics (ONS) safe researcher training course on 3rd December 2018. Access 
to SAIL data is conditional on the completion of safe researcher training and 
assessment to ensure the safe and responsible use of sensitive data and 
awareness of data confidentiality breaches. Approved Researcher status was 
awarded following successful completion of an online assessment (AR 
reference number ONSF21146, expiring 3rd December 2023).  
 
3.6.9 Data analysis software 
 
Data cleaning was undertaken using Eclipse SQL Explorer software. 
Descriptive analysis, including the estimation of crude outcome rates, was 
performed in R (R Statistical Computing Environment (http://www.r-project.org) 
(53). Imputation for missing data was undertaken in R. Survival models were 







The repository is hosted on the UK Secure Research Platform (UKSeRP) which 
is a customised technology and analysis platform. I was provided a user 
account to log into the Gateway via a Virtual Private Network (VPN), as well as 
a Yubikey which when inserted into a USB port of the computer transmits a 
one-time hidden password, as if entered by the keyboard (428). Data transfer 
from the Gateway VPN is only possible via a portal that requires every file to be 
reviewed by a SAIL data guardian for approval before being released.  
 
3.7 Study design 
 
3.7.1 Inclusion and Exclusion criteria 
 
Individuals were included if they: 
1. Had been registered with a GP contributing to SAIL for at least one year. 
This was set as a minimum requirement to allow time for any records 
from previous notes to be transcribed to avoid items from a person’s past 
medical history being counted as early outcomes.  
2. Had their blood pressure recording at any time in 2007. The first GP 
encounter where BP measurement was undertaken after 1st January 
2007 and before 1st January 2008, was used as the individual’s index 




3. Were aged 65 years or older at the time of study entry. A threshold of 65 
years was chosen to define older people in this study because it is the 
minimum age of people for whom the eFI has been validated (341).  
 
Individuals were excluded if they: 
1. Did not have a diagnosis of hypertension or did not have blood pressure 
meeting criteria for hypertension (320); 
2. Had an established history of cardiovascular disease (previous stroke, 
heart failure or myocardial infarction) prior to the start date.  
 
These exclusions were applied to identify a study population of older adults with 
hypertension for whom treatment is for primary prevention.  
 
3.7.2 Analytic Cohort Derivation 
 
The study design is presented in Figure 3-2. A full definition of all study 
variables is given later in this Chapter (Section 3.8). Outcomes were measured 
during ten year follow up of primary care, secondary care and death records. 
Follow-up was censored at the earliest of: the date of the outcome occurrence; 
ten years since the index date; the date of de-registration from the practice; or, 





Figure 3-2 Setting of PhD study cohort. 
 
Entry date: First Encounter GP: date of first patient encounter at primary care where a BP was measured after 01.01.2007; Lowest Blood 
Pressure: BP reading with the lowest systolic reading recorded on that day was extracted; Previous BP measurements and treatment 
were extracted from 1 year prior to study start; cardiovascular risk measurement was extracted from 2 years prior to study start; 




3.7.3 Missing data 
 
Missing data refers to a situation where there is no information on a data point 
in the data set because of missing information (429). Missing data is a particular 
problem in routine health data (373). Data may be missing for multiple reasons: 
some patients do not appear in the database; some variables are not recorded 
(either predictors or outcome measures); or for others, values are simply 
missing in the record or implausible.  
 
Most covariates in this analysis are recorded and interpreted on the basis that a 
positive recording (as defined in Section 3.5.3.3) is assumed to be sufficiently 
representative of the disease being present. For the purpose of this research I 
have assumed the absence of recording of a particular diagnosis represents the 
absence of diagnosis. The alternative would be to treat everything where a 
diagnosis is absent as missing data and the risk of misclassification bias is then 
higher.  
 
However, this assumption cannot be made in cases of continuous variables 
which a person with a diagnosis of hypertension should ordinarily have 
measured according to guidelines, as part of a full assessment of 
cardiovascular risk (320). Continuous data that are part of cardiovascular risk 
assessment were therefore handled as missing data. 
 
Identifying the pattern of missing data is an important means of determining 




least bias in subsequent analysis. Missing data can be missing in at least three 
ways (430): 
- Missing completely at random. For example this may apply where a 
study has extracted a randomised sample of a population (431). Those 
included in the study have complete data. The rest of the population is 
not represented in the study and has missing data. If all had the exact 
same chance of being included in the study, the missing data would be 
truly random and none of the observed data would help to predict 
information about the un-observed data. 
- Missing at random. For example, this may apply in a study which 
involves a questionnaire, which upon completion, when asked some 
people don’t disclose their income, but there is another question in the 
questionnaire which asks about privacy over such matters (431). In these 
cases, the missing data depends on some observed data and any 
systemic differences between the observed and missing data can, at 
least partially, be explained by differences in the observed data. The 
higher the number of relevant variables included in the observed data, 
the more plausible is the assumption that differences in the missing data 
may be explained by observed data patterns (432). 
- Missing not at random. For example, this may apply to a study in which 
participants are asked about their attitudes about racial issues (431), 
missing data may relate to unobserved or partially observed variables in 
a way that cannot be fully predicted from the observed data because 





There are several methods of addressing missing data. Each method  has its 
own merits and flaws: 
 
- Complete case analysis involves not including in the analysis participants 
for whom at least one data point is missing. However, unless the amount 
of missing is very small, this will reduce the study size (degrees of 
freedom) for any summary statistics as those with missing data would 
have been informative.  
- Substituting missing with the mean or median of the existing 
observations in others. Whilst this method may not distort the mean, it 
will reduce the deviation from the mean (variance) and therefore cause 
bias. 
- Multiple imputation. This is a method that uses the distribution of the 
observed data to estimate multiple possibilities for the missing data 
points, thereby accounting for the uncertainty of estimates (431). This 
method reduces bias, but only on condition the pattern of missingness 
can be assumed to be missing completely at random or missing at 
random. 
 
Rubin set out the key principles of multiple imputation (MI) analysis (433): 
1. Values for missing data ascertained so as to keep the relationships in the 
observed data intact. 
2. Independently drawn imputations of the data set are taken multiple times 
(e.g. ten times), and averages of these values calculated to derive single 




3. Standard error (SE) is estimated using the variation across the multiple data 
sets to account for the uncertainty of these estimates. The SE is calculated 
as a combination of the SE of each missing data estimate (average of 
squared SEs of each estimate); together with the variance of all the missing 
value parameters across the sample. 
 
The choice of methods depends on the distribution of the data. If multivariate 
normal, joint multivariate normal distribution multiple imputation may be used (R 
packages Amelia and norm). Conditional multiple imputation represents an 
alternative, more flexible approach where missing values are replaced with 
plausible estimates (for example 10 imputations), each of which is modelled 
with different imputed values for the missing factors, and then these are pooled 




Figure 3-3 Key steps in multiple imputation process 
 
Schematic describing multiple imputation corresponding R commands. Figure adapted 
from multiple sources: short course materials on multiple imputations delivered by 
the MRC Biostatistics Unit, Cambridge, PhD by Marlous van Laar (434), and 
online material from the University of Virginia (431). Abbreviations: mids = 
multiply imputed data sets; mira = multiply imputed repeated analysis; mipo = 
multiple imputation pooled object. 
 
The stages of multiple imputations are as follows (431): 
1. Identify the missing values and their proportion of the whole data set 
2. Multiple imputation by chained equations (MICE) command completes 
multiple complete data sets, with each variable according to its own 
distribution. Complete data sets are stored in an object called mids 
(multiply imputed data set). These are copies of the original but with 




mice. At this stage, these independent data sets have no measure of the 
collective uncertainty they represent as a whole. 
3. Run a regression on each of these 10 data sets, using the with_mids 
command to run a regression coefficient for each data set. These 
analyses are stored in mira (multiply imputed repeated analysis). 
 
3.8 Key study variables 
 
This section defines key study variables for the analyses undertaken.  
 
3.8.1 Health condition: hypertension 
 
Hypertension is the health condition of interest in this PhD study, defined as 
either: 
1. A diagnosis recorded in a person’s EHR according to the code list 
(Appendix C) associated with a date, that precedes the study start date; 
or, 
2. Routinely collected blood pressure readings indicative of hypertension at 
the study start date, according to reference thresholds defined by the 
NICE guidelines (320). These define hypertension as a systolic and 
diastolic blood pressure > 140/90 mm Hg under the age of 80 years, and 





3.8.2 Primary exposure: systolic blood pressure 
 
Systolic and diastolic blood pressures were identified by code lists in the WLGP 
data set, and the associated numerical values for each code extracted. For 
descriptive purposes, the cohort is described by related measures of BP 
including the following calculations from the raw data: 
- Pulse pressure (systolic blood pressure – diastolic blood pressure);  
- Mean arterial pressure (diastolic blood pressure + 1/3 pulse pressure) 
 
The analysis focuses on systolic BP. Diastolic blood pressure has previously 
been given precedence, but more recent epidemiological research has 
demonstrated that systolic blood pressure is a greater risk factor for 
cardiovascular disease (435, 436), particularly in people over the age of 50 
years (40). 
 
Where there is more than one reading on the same day, the lowest reading was 
extracted. The merits and limitations of alternative methods to represent BP 
were considered (Table 3-5). The minimum BP was chosen because (according 
to guidelines), it is this reading that informed the clinical decision making at the 





Table 3-5 Profiles of alternative methods to represent BP 
Method  Advantages Disadvantages 
Time-dependent 
correction for “regression 
dilution” (235, 365, 368) 
using information on 
repeat measures during 
prolonged follow up (367) 
Can correct for effects of 
measurement error and 
short term variability in BP 
levels. 
Requires information not 
available to the GP at the 
time of patient encounter. 
Median BP of serial 
readings taken over a 2 – 
3 year follow up (366) 
Reduces effect of extreme 
values e.g. during 
concurrent illness 
There is a risk that 
regression to the mean 
from the inclusion of 
multiple readings will lead 
to a ‘concertina effect’ – 
misrepresenting the true 
variability of BP present in 
a population (437-439).  
Exposure over a period of 
time rather than a clear 
clinical encounter. 
Mean BP from each month 
(365), or year (32) of the 
duration of follow up 
included as trajectory 
To allow for decline in BP 
with age – as described in 
Chapter 1. 
Requires information not 
available to the GP at the 
time of patient encounter. 
Combination of single 
reading and trajectory 
(440, 441) 
May capture more 
information about BP 
associated risk 
Not currently available to 
GP in the clinical 
encounter. 
Minimum reading on day 
of measurement 
This is the measure that 
currently informs practice, 
according to clinical 
guidelines in UK clinical 
care (320) 
No correction for 
measurement error or BP 
variability over time, 
therefore may not 





Where systolic BP was categorised in the analysis, eight categories were 
created either side of the European Society of Cardiology (ESC) guideline 
target range (130-139 mm Hg) in ten mm Hg categories, as follows: < 120 mm 
Hg; 120 – 129 mm Hg; 130 – 139 mm Hg; 140 – 149 mm Hg; 150 – 159 mm 
Hg; 160 – 169 mm Hg; 170 – 179 mm Hg; > 180 mm Hg. This replicates 
categorisation in similar studies using UK routine data (366). The ESC guideline 
was chosen because it is the only hypertension guideline that currently 
stipulates a lower limit to the systolic BP target range (322). The target range 
stipulated by the ESC is the central sBP category used as reference in the 
models. 
 
3.8.3 Explanatory variable: frailty 
 
There are multiple measures for frailty as outlined in Chapter 2. The choice in 
this study to use the eFI (341) as a frailty measure was made on the basis of its 
availability in routine UK primary care data (uniquely among the frailty 
measures), and the validation of eFI in SAIL and other routine data sets (407). 
The eFI is based on the cumulative deficit model of frailty (332), including 36 
variables recorded as present or absent in the primary care electronic health 
record (Table 3-6).(341). The eFI score is calculated as an equally weighted 
proportion of the number of deficits present in an individual relative to the total 
possible deficits measured.  
 
In this study, the eFI score was measured over a period of 10 years on the 
basis that by 1997 the majority of GP practices in the UK had electronic records 




been available to the clinicians at the time, so treatment decisions could not 
have been directly influenced by the eFI.  
 
For the measurement of model fit, eFI is included as a continuous variable. 
Where frailty is categorised in the analysis, patients with an eFI score 0 < 0.12 
are identified as fit; ≥0.12 < 0.24 as having mild frailty; ≥0.24 <0.36 as having 





Table 3-6 Deficits included in the eFI 






Weight loss and anorexia 










Urinary system disease 
Cardiovascular Atrial fibrillation 
Cerebrovascular disease 
Chronic kidney disease 
Diabetes 
Heart failure 
Heart valve disease 
Hypertension 
Hypotension/syncope 
Ischaemic heart disease 
Peripheral vascular disease 
Polypharmacy Count of medications prescribed 
Functional impairments Activity limitation 
Hearing impairment 
Housebound 
Memory and cognitive problems  
Mobility and transfer problems 
Requirement for care 
Visual impairment 
Social vulnerability Social vulnerability 
Constituent deficits of the electronic frailty index (eFI) (341) Deficits are categorised to 
discern constituent parts of the eFI and allow comparison with the frailty indices 
developed in the post-hoc analyses of major trials SPRINT and HYVET (as discussed 







3.8.4.1 Primary outcomes  
 
Primary outcomes of interest in this thesis include major adverse cardiovascular 
events (MACE): myocardial infarction, new presentation of heart failure, stroke 
and cardiovascular death considered as a composite outcome. MACE was 
chosen as the primary outcome of choice given the relevance of cardiovascular 
risk in defining hypertension management, and its established use as a primary 
outcome in trials and observational data. 
 
3.8.4.1.1 Myocardial infarction 
 
Non-fatal myocardial infarction (MI) is defined as death of part of the 
myocardium due to coronary artery occlusion from any cause (spasm, embolus, 
thrombus, or rupture of a plaque) (442). This is recorded as either a diagnosis 
of an MI, or it’s definitive treatment (percutaneous coronary intervention (PCI) or 
coronary artery bypass grafting (CABG)) from hospital records along with the 
date of the hospital admission. 
 
3.8.4.1.2 New heart failure 
 
Fatal or non-fatal heart failure is defined as an inpatient visit requiring treatment 
with intravenous therapy for a clinical syndrome that presents with multiple 




cardiac pump function (443). The presence of such a diagnosis, including the 
date of the hospital admission were extracted from hospital records. Patients 
with a record of heart failure before the study start date were excluded, so the 




Fatal or non-fatal ischaemic and haemorrhagic stroke events are generally 
defined as a neurological deficit of cerebrovascular cause that has persisted 
beyond 24 hours or was interrupted by death within 24 hours (444). Codes that 
included terms for an episode of cerebral ischaemia, or intra-cerebral or 
subarachnoid haemorrhage were extracted from hospital inpatient records 
(PEDW) during follow up, together with the date of hospital admission. 
 
3.8.4.1.4 Cardiovascular death  
 
Death attributable to cardiovascular disease is defined in cases where the 
diagnosis of one of the above three cardio- or cerebrovascular diseases had 
been defined as the underlying cause of death on the death certificate. The 
underlying cause of death on the death certificate as well as the date of death 





3.8.4.2 Secondary outcomes  
 
A range of secondary outcomes were chosen as being implicated by blood 
pressure or by BP-lowering therapy. 
 
3.8.4.2.1 All-cause mortality 
 
All-cause mortality was defined as death from any cause listed on the death 




Defined as “an unexpected event in which the participant comes to rest on the 
ground, floor or lower level” (445), falls maybe the consequence of a trip, slip, 
overbalance, loss of consciousness or dizziness triggered by postural 
hypotension. Falls resulting in a hospital admission, usually as a consequence 
of fall related injury, were ascertained from hospital records using related ICD-
10 codes and extracting the first fall and date of admission.  
 
3.8.4.3 Additional descriptive outcomes 
 
Additional descriptive outcomes included other non-cardiovascular outcomes. 
Whilst these outcomes listed below were not assessed in formal survival 
analysis models, the rates of this wider group of outcomes were described for 




relevance to clinical management of hypertension. However, numbers in this 
data set are likely to be too small for more formal detailed analysis. These 
outcomes include: 
 
Orthostatic hypotension. This was identified from a related hospital admission 
during follow up.  
 
Acute kidney injury. This was extracted from hospital admissions during which 
it was recorded in hospital records.  
 
Delirium and new dementia. These were extracted from both primary (WLGP) 
or secondary care (PEDW) records, and considered valid where there was no 
record previously of a dementia diagnosis. When someone suffered delirium 
during a hospital admission this was also extracted from PEDW data.  
 
Urinary incontinence. This was extracted from hospital admissions when it 
was recorded.  
 
Functional decline. This was defined in patients who had a documented 






Electrolyte disturbance. This was extracted from hospital records where it was 
reported as a cause or comorbidity during a hospital stay. 
 
Hospital admission. This was recorded as the date of the first hospital 
admission for any cause during follow up extracted from the PEDW database. 
 
Emergency Department admission. This was documented as the date of the 
first admission for any cause to Accident and Emergency department recorded 
in the EDDS database. 
 
Care home admission. This was documented as a new transfer to a care 
home during the period of follow up where the previous address was not a care 
home. In SAIL there is a validated list of care homes in Wales, linked to primary 
care records which in turn are linked to RALF_PE codes. A new care home 
admission was identified by the change of a RALF_PE code to one identified as 
a care home residence using the SAIL care home registry (408). 
 
3.8.5 BP-lowering treatments 
 
Past prescriptions of BP-lowering drugs were extracted from WLGP according 
to the main five classes of BP-lowering medications, where the prescription 






Table 3-7 BP-lowering treatment by class and drug name 
 
Adrenergic neurone blocking drugs 
Alpha-adrenoceptor 
blocking drugs 
Bethanidine; Clonidine; Desbrisoquine; Doxazosin; 
Indoramin; Methyldopa; Metirosine; Phenoxybenzamine; 
Prazosin; Terazosin; 
Beta adrenoreceptor drugs 
Beta-blockers Acebutolol; Atenolol; Betaxolol; Bisoprolol, Carvedilol; 
Celiprolol; Esmolol; Labetolol; Metoprolol; Nadolol; Nebivolol; 




Renin Angiotensin System drugs 
ACEi Captopril; Cilazapril; Enalapril; Sodium Fosinopril; Imidapril; 
Lisinopril; Moexipril; Perindopril arginine; Quinapril; Ramipril; 
Trandolapril 
ARB Azilsartan; Candesartan cilexetil; Eprosartan; Irbesartan; 
Losartan; Olmesartan; Telmisartan Valsartan 
Calcium channel blockade  
Calcium channel 
blockers 
Amlodipine; Diltiazem; Felodipine; Isradipine; Lacidipine; 
Lercandipine; Mibefradil; Nicardipine; Nifedipine; Nimodipine; 
Nisolidipine; Slofedipine; Verapamil 
Combination with ACEi 
Diuretics 
Thiazides Bendroflumethiazide; Chlorothiazide; Chlorthalidone; 
Clopamide; Cyclopenthiazide; Hydrochlorothiazide; 
Hydroflumethiazide; Indapamide; Mefruside; 
Methylclothiazide; Metolazone; Polythiazide; Xipamide; 
Diuretics + Potassium supplements; Acetazolamide 
Loop diuretics Furosemide; Bumetanide; Etacrynic acid; Piretanide; 
Torasemide; Compound Potassium Sparing diuretic 
Potassium sparing & 
Aldosterone 
antagonists 







All relevant covariates including factors which may inform clinical management 
of blood pressure, are defined according to NICE guideline recommendations 
(320). UK NICE guidelines on hypertension management have been the subject 
of iterative changes during the period of this study’s follow-up time. Table 3-8 




Table 3-8 Summary of UK hypertension guidelines since 2007 
 Diagnosis Treatment indication Target BP Cardiovascular Risk Shared 
Decision 









BP>140/90 & ↑CVr 
  
























Stage 1 Office >140/90  
Home >135/85 
Stage 2 Office>160/100 
Home>150/95 



















Stage 1 Home>135/85 to 
149/94 
Stage 2 Home>150/95 
Start Office>180/120 
Home>150/95 
Discuss Home: 135/85 

























All BP measurements are measurements in millimetres of mercury (mm Hg) 
*Clinic: Office BP reading in the GP practice; 
±Home: Ambulatory BP monitoring/ Home BP monitoring average. CG: Clinical Guideline; CHD: Coronary Heart Disease; CVD: 
cardiovascular disease; CVr: Cardiovascular risk; DM: diabetes mellitus; GC: Guideline Committee; NG: National Guideline; NICE: 
National Institute for Health and Care Excellence; OH: Orthostatic Hypotension; QRISK: Q-Research Risk prognostic model; TOD: Target 




3.8.6.1 Cardiovascular risk 
 
The assessment of cardiovascular risk uses the risk factors outlined by the 
QRISK-3 cardiovascular risk algorithm developed in the QRESEARCH 
database (446). QRISK is widely used in the UK and recommended by NICE 
hypertension guidelines. The overall cardiovascular risk for each participant at 
the study start was calculated using QRISK-3 independently using the available 
data according to a published algorithm (447). QRISK-3 is the latest iteration of 
QRISK, and includes 22 variables. Continuous variables included in the QRISK-
3 score were extracted at their most recent date in the 2 years before study 




Age was measured at baseline as the difference between the index start date 








Sex was measured as a categorical variable, from WDDS, with categories of 
male and female. 
 
Atrial fibrillation (AF)  
AF was measured as a categorical variable. Hypertension increases the risk of 
atrial fibrillation through structural change of atrial remodelling (448), and atrial 
fibrillation is a major risk factor for stroke. Therefore AF also mediates some of 
the stroke risk associated with hypertension.  
 
Atypical antipsychotics  
As these are included in the NICE guideline on lipid modification and 
cardiovascular risk assessment (449), atypical antipsychotics were measured 
as present or absent in the prior 2 years. 
 
Corticosteroids 
Also included in the NICE guideline on lipid modification and cardiovascular risk 
assessment (449), steroids were measured as present or absent in the prior 2 
years.  
 




Studies have demonstrated the prognostic importance of erectile dysfunction for 
cardiovascular risk estimation (450-452). Erectile dysfunction was measured as 
present or absent in the prior 2 years.  
 
Migraine  
Migraine is associated with increased cardiovascular risk in women (453) 
.Migraine was measured as present or absent in the prior 2 years.  
 
Rheumatoid arthritis & systemic lupus erythematosus (SLE)  
Atherosclerotic disease is increased in people with rheumatoid arthritis (454) 
and systemic lupus erythematosus where this disease is active, and in relation 
to some of the long-term treatment of inflammation, most prominently with 
steroids. NICE guideline on lipid modification and cardiovascular risk 
assessment recommends measurement of SLE (449). These were measured 
as present or absent in the prior 2 years. 
 
Renal impairment  
Renal impairment was recommended as a relevant prognostic factor according 
to NICE guideline on lipid modification and cardiovascular risk assessment 
(449). Challenges exist with using morbidity codes to identify chronic kidney 
disease given the limited capacity to stage chronic kidney disease (CKD) in 
CTV-2 coding. An alternative would have been to use Creatinine to calculate 




this approach of misclassifying acute kidney injury (AKI) as chronic kidney 
disease. Renal failure was measured as present or absent in the prior 2 years. 
 
Severe mental illness  
Mental illness is included because it is recommended in the NICE guideline on 
lipid modification and cardiovascular risk assessment (449). QRISK-3 defines 
severe mental illness as moderate/severe depression, bipolar disease and 
schizophrenia. Moderate/severe depression may be identified by the 
prescription of anti-depressant medication. Codes for depression have been 
used in SAIL but it was not possible to grade the severity and therefore mild 
depression will have been included. Severe mental illness was measured as 
present or absent in the prior 2 years. 
 
Type I and type II diabetes mellitus  
The UK Prospective Diabetes Study Group (UKPDS) provided definitive 
evidence the incidence of micro- and macro-vascular complications of diabetes 
are significantly associated with blood pressure control. A10 mm Hg decrease 
in sBP was associated with a 12% (95%CI 10-14%) reduction of any 
complication of diabetes (455). Type I and type II diabetes were measured 
separately and collectively as present or absent in the prior 2 years. 
 
Weight  
Weight was recorded as continuous variable, measured in metres, and included 






Height was recorded as continuous variable, measured in kg, and included the 
most recent recording in the prior 2 years. 
 
Ethnicity  
Self-assigned ethnicity was extracted from ethnicity coded data only available 
from hospital electronic health records. Therefore ethnicity data were only 
available for those who had had a hospital admission during follow up. The 
most recent of these records throughout the course of the study was extracted. 
Ethnicity in this study was coded according to the UK 2011 Census, in the 
following 9 categories:  
1. White; 
2. Indian;  
3. Pakistani;  
4. Bangladeshi;  
5. Other Asian;  
6. Black Caribbean;  
7. Black African;  
8. Chinese;  
9. Other ethnic group. 
For the QRISK-3 algorithm, those with ‘undeclared’ ethnicity data, are 
categorised with ‘White’ ethnicity.  
 




This was defined as a history of angina or heart attack under the age of 60 
years old in a first degree family member recorded by the GP in the medical 
record as positive. Where this was missing it was assumed to be negative.  
 
Total cholesterol: HDL ratio  
Total cholesterol: HDL ratio is a better predictor of cardiovascular disease than 
total cholesterol alone (456). Recorded as the ratio of total serum cholesterol to 
high density lipoprotein, both were measured in millimoles per litre (mmol/l) 
within 2 years prior to the study start date. The most recent entry was extracted. 
 
BP variability  
BP variability was measured using the standard deviation of serial measures of 
blood pressure. Serial measures included the index BP recording and the most 
recent BP recording. 
 
Smoking history  
Smoking history was recorded as the most recent recording of any of the 
smoking codes describing smoking prior to the study start date. The most 
recent smoking status was then categorised according to the classification used 
in the QRISK-3 score, in the following 5 categories:  
- never smoker;  
- ex-smoker;  
- light smoker;  




- heavy smoker. 
 
Deprivation  
Deprivation was measured by Townsend score developed by sociologist Peter 
Townsend (457) and applied widely as an index of deprivation. The Townsend 
score incorporates four factors relating to material deprivation: non-car 
ownership, non-house ownership, unemployment and over-crowding. The score 
is calculated by region defined as a Lower Super Output Area (LSOA) which 
equates to approximately 125 households. This study will use the Townsend 
score from the 2011 census for the most recent address in the patient’s record 
prior to study start. The post-code may have a missing Townsend score if the 
person: has moved to newly built houses with new postcodes not yet linked to 
deprivation data; or, the person is homeless or has not been registered to a 
permanent address (192). Townsend scores at baseline for each individual 
were mapped to the individual’s latest LSOA recorded prior to the individual’s 
study entry date. 
 
3.8.6.2 Clinical decision making 
 
Covariates representing the clinical decision making process were 
characterised as follows: 
 
Associated measures of BP  
For descriptive purposes the total number of BP measurements in a 2 year 




reading on these dates, and an average of all readings during the two year 
period prior to the study start date.  
 
Attendance to clinic and frequency of BP monitoring  
The number of blood pressure recordings over the prior 2 year period were 
extracted; the interval between the index blood pressure recording and the 
subsequent one, and whether BP measured on the study start date was within 
the target set by NICE guidelines for hypertension. 
 
Level of treatment 
To calculate the QRISK-3 score, treatment was measured as present or absent 
where there was a prescription of any of the key classes of BP-lowering 
medications (458). BP-lowering medications were classified according to BNF 
categories (Table 3-7). Doses were not included. For inclusion as a covariate in 
the models, the number of classes of BP-lowering medication prescribed was 
included as a total drug count. The presence or absence of a prescription over 
the prior two years of lipid lowering therapy (statin, fibrate or ezetimibe) was 
also measured. 
 
GP practice code  
As guidelines recommend clinician discretion in older people, the role of the 
clinician is important and practices may vary. The GP practice code was 





The average number of patients registered at a GP practice in Wales was circa 
5,000 patients between January 2000 and October 2014 (409). Each record 
included in the study was allocated a GP practice according to the most recently 
recorded practice ahead of the individual’s study entry date. 
 
Comorbidity  
Comorbidity was measured according to clinical domains listed in the GP 
contract (459). There were 17 in total, excluding palliative care and 
hypertension. Categorical covariates qualified as present if the deficit was 
recorded in the patient’s electronic health records and not removed prior to the 
study entry date. The list included: asthma; atrial fibrillation; cancer (within the 
last 5 years); chronic kidney disease; chronic obstructive pulmonary disease 
(COPD); coronary heart disease; dementia; diabetes mellitus; heart failure; 
learning difficulty; mental health illness; osteoporosis; peripheral arterial 
disease; rheumatoid arthritis; and, stroke. 
 
Care home residence 
Residential addresses were derived from the Welsh Demographic Service data 
set (WDS). The most recent address (represented by the RALF_PE code) in a 
participant’s record on the study start date was extracted and matched to the 
care home registry. 
 
3.9 Data extraction and cleaning 
 





Code lists were created to derive variables from primary (WLGP) and 
secondary (PEDW) care records for risk factors and comorbidities recorded 
before or at study start, and for outcomes recorded after study start (Figure 
3-2). The choice of code list was made from what was available depending on 
the particular variable, and prioritised, in order of preference: 
 
(1) Code lists from an online clinical codes repository, including CALIBER 
(460), Clinical Codes (461) or Cambridge CPRD Code (462) 
(2) Code lists used by existing studies (463-467);  
(3) Recommended Read code lists from the UK Quality Outcomes 
Framework 
(4) Code lists derived from a manual review of the codes accessed via the 
Technology Reference data Update Distribution (TRUD) Data dictionary 
(468)  
 
Validated code lists from phenotype code repositories (e.g. CALIBER 
Phenotype) were given first preference, where they were available. However for 
outcomes, more sensitive lists (CALIBER Code lists) were also included to 
broaden inclusivity. 
 
The sources of codes for each variable are listed in the Appendix C.  
 
No code lists for BP-lowering treatments were available. Therefore, a novel list 




medications required a manual searching of the NHS Technology Reference 
data Update Distribution (TRUD) (468) code dictionary for relevant BP-lowering 
medications which were chosen according to the British National Formulary 
(469)  
 
3.9.2 Code extraction  
 
Code extraction was undertaken using Eclipse SQL Explorer within “IBM DB2” 
database architecture.  
 
3.9.2.1 Continuous data 
 
Continuous variables were extracted from a raw form in which they were 
combined in variable lengths of code. For example, BP was recorded as a total 
number combining systolic and diastolic readings. The number of digits was 
most commonly 8 but ranged from 1 to 10 numbers (Table 3-9) in the format 
‘12000080’ which combined systolic (120 mm Hg) with diastolic blood pressure 
(80 mm Hg) values, with an interval ‘00’ to distinguish the two. However, this 
proved problematic if the systolic reading was 2 digits, i.e. any systolic BP 
reading < 100 mm Hg, such as in a BP reading of 95/55 mm Hg, entered as 
‘09500055’. Because the system records values as numeric data, this would be 
saved as ‘9500050’, i.e. a 7 digit number. Other variations may also be the 
result of human error in data entry, such as a diastolic reading of 50 mmHg 






Table 3-9 Raw blood pressure data according to integer length 
Integers Frequency Proportion (%) 
1 7 <0.1 
2 517 0.2 
3 595 0.2 
4 1 <0.1 
5 7 <0.1 
6 15 <0.1 
7 2,658 0.8 
8 323,848 98.8 
9 10 <0.1 
10 1 <0.1 
 
Listed are the numbers of integer number in the raw BP recording in the SAIL study from a total 
data extract of 327,659 individuals, frequency as a number and as a proportion of the population 
extract. 
 
Explicit assumptions were made on what was deemed plausible: if the string started with a 
number more than or equal to 300, but less than or equal to 990, these were assumed 
unlikely to represent true systolic readings. They were more likely to represent systolic 
readings from 30 – 90 mm Hg. Therefore, only the first and second integer from the string 
were extracted to represent the systolic reading. Readings between 990 and 999 were not 
extracted, given the possibility these was entered to indicate the measurement was 
missing. If the three numbers at the start of the string were less than 300, the first, second 





Similarly with diastolic readings, if the diastolic reading was more than or equal to 200, or 
less than or equal to 990, the 6th and 7th numbers were extracted. However, if the number 
was less than 200, then the 6th, 7th and 8th numbers were extracted.  
 
3.9.2.2 Filtering outliers 
 
A representative measurement was extracted per patient for each continuous variable. 
Filtering of outlying measures had to be undertaken before data extraction, to ensure, 
where possible, the reading extracted was that most likely to be reliably recorded. The 
limits in Table 3-10 were pre-specified as the bounds of clinically plausible readings for all 
of the continuous variables in this analysis. Readings outside of these boundaries were 
considered unreliable and therefore treated as missing. All measurements extracted from 
specified time periods, were the first or a representative continuous reading where that 






Table 3-10 Pre-specified thresholds defining outliers in continuous measurements 
Variable Outliers thresholds Outlier rationale 
sBP  < 50; > 300 Clinically implausible  
dBP < 30; >200 Clinically implausible 
BP SD calculated directly 
Age (y) calculated directly 
BMI <0.15% & > 98.5% Statistical 
Height (m) <0.15% & > 98.5% Statistical 
Weight (kg) <0.15% & > 98.5% Statistical 
Chol: HDL <0.15% & > 98.5%  Statistical 
Townsend Not altered 
 
BMI = body mass index; BP SD = blood pressure standard deviation; dBP = diastolic blood 
pressure; Chol: HDL= Cholesterol to High Density Lipoprotein ratioː kg = kilograms; m = metres; 
sBP = systolic blood pressure 
 
 
3.9.2.3 Categorical data 
 
Given the positive recording assumption (see Section 3.5.3.3) where a categorical 
variable was missing it was deemed to be absent. For example, where a diagnosis of atrial 
fibrillation had not been made, the variable value was changed from missing to zero to 





3.9.2.4 Hospital episode data 
 
Primary and secondary outcomes were extracted from the Patient Episode Data Wales 
(PEDW) data set. Outcome data recording in PEDW is nested within the hospital database 
architecture, outlined in Figure 3-4.  
 
Periods of patient care on a particular ward (e.g. Medical Admissions) or under a single 
consultant are recorded in PEDW as discrete episodes of care. A hospital stay may 
consist of several inpatient transfers, but the duration of stay in a single hospital is defined 
as a spell. Spells, in turn are linked together to account for inter-hospital transfers, within 
an NHS trust for example, creating superspells. In this study, an admission is counted as a 
continuous period of care (whether a spell or superspell). Diagnoses and their associated 





Figure 3-4 Architecture of Hospital Records in PEDW 
 
This schematic attempts to explain the hierarchical architecture of PEDW hospital records using an illustrative example: where a patient is 
admitted from their GP to a Medical admissions ward (E1: Episode 1) before being transferred to a Geriatric Medicine Ward (Episode 2); 
thereafter waiting in the discharge lounge (E3: Episode 3) to transfer to a community hospital for rehabilitation which is undertaken at 
another hospital site but in the same NHS hospital trust. Episodes 1-3 represent Spell 1, and the stay in the community hospital 





3.9.2.5 Preparing time to event data 
 
If the event date for an outcome was valid, the outcome status was set to 1. If 
the event date for an outcome was not valid, the outcome status was set to 
zero. Time to event variables were then calculated as the difference in days 
between a person’s index start date, and the earliest of: the event date; the 
censor date; the migration date; or, the death date (as defined in Table 3-11). 
 
Table 3-11 Definitions of ‘time-to-event’ variables 
Date Definition 
Censor date  10 years after the study date;  
Migration date Move date, if predates death and censor dates, and post start 
date 
Death date Date of death, if predates censor, and post start date 
Event dates Date of event, if predates censor, migration and death dates 
 
 
3.9.2.6 Transforming data from ‘long format’ to ‘wide format’ 
 
Data were extracted from ‘long format’, that is lists of codes alongside dates 
and associated numerical variables with multiple rows per event and per 
patient, according to GP visit or hospital episode (396) (see Figure 3-5). Using 
the specified code lists, a specific diagnosis at a particular time point was 
extracted for each participant and entered into a dedicated table (Step 1). 
These new tables were created in ‘wide format’ data, so that each row 
represented an individual patient (Step 2). Each table represented only one 




linked using ALF_PE. All the tables were then combined per individual patient in 




Figure 3-5 Extracting Data from ‘Long format’ to ‘Wide format’ 
 
The extraction of long format to wide is described using another illustrative example. Step 1 involves extracting from the WLGP 
database all event codes and their associated dates for the first diagnosis of heart failure between certain dates, using a series of 
heart failure codes. Step 2 involves collating all positive cases in a ‘Heart Failure’ table where each row represents one patient (a 
single ALF_PE). Step 3 combines variable tables (such as the heart failure table) with other diagnostic tables, for each patient. 




3.10 Statistical analysis 
 
3.10.1 Deriving the study population 
 
The study data set required the linkage of multiple data sets in SAIL, as 
described in Figure 3-6. The number of patients included at each stage of the 
study cohort derivation was summarised in a Strengthening the Reporting of 
Observational Studies in Epidemiology (STROBE) diagram (Figure 4-1). This 
included the study cohort size:  
- At initial data extraction; 
- Following the application of exclusion criteria;  
- Following assessment of data quality; and,  





Figure 3-6 Schematic describing linkage of core data sets within SAIL data 
extract 
 
Schematic demonstrates on the left hand side: the core SAIL data sets from which the 
study data set extracted data for the study variables which are listed as groups on the 
right hand side. Linkage used the Anonymised Linkage Field (ALF) per individual, and 
for geographic information, and the Regional Anonymised Linkage Field (RALF) which 
indicated a person’s address by Lower Super Output Area. Data sets: ADDE = Annual 
District Death Extract; EDDS = Emergency Department data set; PEDW = Patient 
Episode Data Wales; WDSD = Welsh Demographic Service Data set; WLGP = Welsh 
Longitudinal General Practice data set. Other abbreviations: CH = Care home eFI = 




3.10.2 Cohort description: the study population 
 
The study population was summarised according to key demographics including 
age, sex, deprivation, care home residence, and ethnicity. Blood pressure; BP-
lowering treatment; cardiovascular risk; and comorbidity status were 
characterised stratified by frailty status or baseline sBP. QRISK-3 was 
calculated where constituent data were available in the observed data set. 
Missing data were reported for each variable. Each parameter was checked for 
its distribution, whether normal or non-normal to determine whether respective 
parametric or non-parametric summary measures should be applied.  
 
3.10.3 Missing data 
 
Patients with complete data were anticipated to have a different health status 
and cardiovascular risk to those with missing data. However, it is also plausible 
these differences could be explained from the other factors measured, including 
other cardiovascular and clinical decision making covariates that are listed in 
Section 3.8.6. In this context and according to the guiding principles outlined in 
Section 3.7.3, missing data were assumed to be missing at random. Therefore, 
principle models were fitted on the basis of multiple imputation by chained 
equations with interaction (470-472). 
 
A survival model was run using the observed data set to determine the quantity 
of observations excluded because of missing data. Each variable was named 




continuous. All variables were treated as factors. Each variable was assessed 
for the level of missing data. Variables included in the prediction matrix included 
all components of the cardiovascular risk models. As an auxiliary variable, the 
number of attendances to primary care in the year preceding start date was 
added in.  
 
All variables were included in the prediction matrix, and imputed with multiple 
imputations across 10 imputed data sets. All analyses were undertaken 
independently in each imputed data set before these were then combined 
according to Rubin’s Rules (473). The mice algorithm in the statistical package 
R was used as described in Section 3.7.3. The imputations were then checked 
visually against the observed data using stripplots to ensure they were 
plausible. 
 
3.10.4 Time to event analysis 
 
The proportional hazards assumption was tested for each variable. The 
assumption states the hazards of different exposure groups remain constant 
over time, and that risk sets can be followed up until an event occurs and 
therefore hazards are proportional across time. Where variables are continuous 
they were dichotomised, with each proportional hazard plotted. The assumption 
of proportional hazards was tested, and if this assumption was not met, 





Parametric statistical methods rely on estimates of the distribution of the data 
(e.g. summary measures such as the mean and standard deviation). In 
contrast, non-parametric models do not make assumptions regarding the 
distributions of parameters. Instead they use ordinal measures to rank the order 
of observations (e.g. median and quartiles) (474). 
 
Non parametric methods of modelling do not rely on estimates of the distribution 
of the data, but rely on assumptions that hazards are proportional throughout 
time (proportional hazards assumption). Parametric methods use different 
mathematical functions to estimate the baseline hazard function, to allow a 
hazard to be dependent on time. Models employing parametric methods are 
considered to be more robust as a result (475).  
 
In flexible parametric models, the number of degrees of freedom or knots are 
estimated as the best fitting to model the baseline hazard (476). A visual 
inspection of function and comparisons to the non-parametric estimate, as well 
as measures Akaike Information Criterion (AIC) and the Bayesian Information 
Criterion (BIC) were used to determine the best fitting model. 
 
AIC and BIC represent two methods of probabilistic model selection. The AIC 
was founded on Information theory which aims to quantify the amount of 
uncertainty in a random variable or outcome from a random process. The BIC is 
based on Bayesian theory whereby probability for a hypothesis is updated with 




the AIC and BIC both give estimates of the amount of information lost in a 
model, the less information that is lost, the higher quality the model. 
 
AIC and BIC estimate the likelihood of a model to predict future values using 
Maximum Likelihood Estimations, and both include a penalty for the complexity 
of the model (477). The absolute numbers calculated as AIC and BIC have no 
meaning in themselves, but the lower value across models indicates the best 
fitting model. Use of AIC and BIC rely on certain assumptions: that they are 
applied to models using equivalent data and outcomes; and that the sample is 
sufficiently large. Sufficiently large data has been estimated as the study 
number (n) where that has a ratio of at least 40 data points to each variable 
(477). All three assumptions were met in each of the applications of AIC and 




Non-linear functions for nodes were considered for each of the continuous 
variables. Spline functions with 3, 4, and 5 knots for each variable were created 
and fitted to each in a Cox proportional hazards (semi-parametric) model. The 
linear predictors were saved using the locations recommended in methods 
established by Frank Harrell (478). Plots of functions were visually inspected, 
and model AIC and BIC statistics were calculated. The best fitting cubic spline 
was compared visually to the linear predictor, and used to represent that 




method of model building, even when the final models used are parametric 
because of the proportional hazards assumption not being met. 
 
3.10.6 Objective 2: What are the associations between BP and 
outcomes in this population? 
 
3.10.6.1 Descriptive analysis  
 
The number of events and the crude rates for events were calculated per 100 
person years for all of major adverse cardiovascular events, for all-cause 
mortality and for injurious falls. Event rates were stratified according to category 
of systolic blood pressure and compared. 
 
3.10.6.2 Definitive analysis  
 
The association between systolic BP and all the outcomes measured was 
investigated, adjusted for known cardiovascular risk factors, BP-lowering 
treatment, and frequency of BP measurements at primary care. The hazard risk 
per sBP category for each of the primary and secondary outcomes was 
estimated in an unadjusted model and presented as Kaplan-Meier survival 
curves.  
 
The estimates were then adjusted for known cardiovascular risk, the number of 
BP lowering medications and the frequency of primary care attendance. 




models were presented as forest plots for comparison of associations across 
different sBP categories for the three main outcomes. 
 
3.10.7 Objective 3: Is frailty a relevant prognostic factor in the 
relationship between BP and outcomes? 
 
3.10.7.1 Descriptive analysis 
 
The number of events and the crude rates for events were calculated per 100 
person years for all of primary and secondary outcomes stratified according to 
category of frailty and compared as forest plots. The hazard risk per frailty 
category for each of the primary and secondary outcomes was estimated in an 
unadjusted model and presented as Kaplan-Meier survival curves. 
 
3.10.7.2 Definitive analysis 
 
This study used methods to determine whether frailty is a prognostic factor in 
the management of hypertension. Specifically, it was assessed whether frailty 
presents additional risk in a model which included established risk factors for 
cardiovascular outcomes in the context of hypertension. The additional effect of 
eFI on the cardiovascular model performance was investigated following the 
addition of the eFI as a continuous variable based on improvement in model fit.  
 
Measures of model fit and discrimination were assessed with and without frailty. 




statistic, C-statistic (479) and D-statistic (480) compared using the DeLong 
comparison) and overall (R2 (481)). In the event a parametric model was used, 
model fit was assessed using measures based on likelihood function, employing 
the AIC and BIC measures described earlier. In this analysis, variables in 
QRISK-3 were excluded if duplicated in the eFI (types I and II diabetes mellitus, 
hypertension, rheumatoid, SLE, renal failure). 
 
3.10.8 Objective 4: Is blood pressure an effect modifier in any 
association between frailty and outcomes? 
 
3.10.8.1 Descriptive analysis 
 
The number of events and the crude rates for events were calculated per 100 
person years for primary and secondary outcomes stratified according to 
category of frailty and baseline systolic blood pressure and compared as forest 
plots. The hazard risk per frailty category for each of the primary and secondary 
outcomes was estimated in an unadjusted model and presented as Kaplan-
Meier survival curves. 
 
3.10.8.2 Definitive analysis 
 
The association of sBP and outcomes was measured in the context of frailty. 
Effect modification was assessed using two methods. Firstly, the relative 
hazards were examined for each systolic BP category in different sub-
populations defined by frailty status to assess whether the association varied by 




an interaction parameter to assess whether the effect of frailty is the same 
across different strata of systolic blood pressure. The model was tested with 
and without the interaction term, according to change in AIC and BIC measures 
of fit. 
 
Effect modification was discerned as present: 
- If the inclusion in the model of the interaction term led to a change in the 
point estimate of risk associated with BP; 
- If the interaction term was significantly statistically associated with the 
outcome in the adjusted model; and, 
- If the inclusion of the interaction term improved the model fit, defined by 
a significant Likelihood Ratio Test or a reduction in the AIC/ BIC 
measure.  
 
This process was repeated for an interaction term between frailty and BP and 
frailty and BP-lowering treatment. 
 
Sensitivity analyses were undertaken to assess whether the association of sBP 
and outcomes with different measures of frailty varied depending on 
subpopulation defined by sex. 
 





The number of predictors in the model was estimated to be 55. This includes 
the 43 exposure and confounder variables plus an additional 10 for up to 10 
non-linear terms for continuous variables, and 2 interaction terms on the 
outcome (sBP*frailty; treatment*frailty). To minimise overfitting of the model, a 
uniform heuristic shrinkage factor of >0.9 was estimated, so that overfitting is 
less than 10%. An overall mean risk of cardiovascular disease in this population 
is estimated to be at least 5% per annum (482). The model fit was pre-specified 
as measured by the Cox-Snell R2adj as 0.02193 informed by a recent study 
which tested a baseline cardiovascular model in a similar UK primary care 
population (482). My calculations used methods to estimate sample size for a 
multivariable prediction model for a time to event outcome (R package 
‘pmsampsize’) (483). With an estimated mean follow up of 10 years, for 
estimates of risk at year 10, the minimum sample size was 16,617 participants. 
This corresponded to 11,631.9 person-years of follow-up with 686 outcome 
events per year, assuming an overall MACE event rate of 5.9% (95%CI 5.3%, 
6.2%) estimating an event per predictor rate of 16.71. Given the prevalence of 
hypertension over 65 is estimated at more than 65% (484), I estimated the 





Chapter 4 Results 
4.1 Summary 
 
This chapter will present the results of the retrospective cohort study, the 
methods for which were outlined in Chapter 3. Detail is provided on how this 
study cohort was derived. Characteristics of the cohort are described with 
respect to systolic blood pressure, frailty and key demographic data. Findings 
that address three of this PhD study’s objectives are presented. Firstly, 
associations of systolic blood pressure and outcomes in this routine data set are 
described. Secondly, evidence is presented that the measurement of frailty 
offers prognostic information for important cardiovascular and non-
cardiovascular outcomes, in the context of hypertension management. Finally, it 
is demonstrated that the association of systolic blood pressure and outcomes is 
not significantly different in the context of frailty. Specifically frailty does not 
modify the effect of systolic blood pressure on outcomes. There is evidence 
however that frailty may modify the effect of BP-lowering treatment on 
outcomes. Sensitivity analysis demonstrated that these associations did not 
vary in men and women. 
 
4.2 Study cohort derivation 
 
The original data extract provided by SAIL consisted of 4,340,224 people in 
Wales (Figure 4-1). Following the exclusion of those who were under the age of 
65 years at the start of 2008, this left 815,194 of whom 313,024 (38%) had a 




with an established history of myocardial infarction, heart failure or stroke before 
study start, resulting in an analysis cohort including 200,712 individuals. Of this 
cohort, 73% had had their BP recorded in 2007 in primary care. There were 
56,265 (27%) without a BP recording during this time period, 1,624 (1%) 
patients who had not been registered at their current general practitioner for 
more than 1 year at the time of BP measurement, and 3 patients who had died 
and were incorrectly in the database. Following the exclusion of these three 
groups, the study sample consisted of 145,598 individuals. During ten year 
follow-up: 4,623 (3%) migrated from the general practice to which they were 






Figure 4-1 STROBE flow diagram 
 
Strengthening the Reporting of Observational Studies in Epidemiology 




4.2.1 Missing data 
 
Ethnicity was recorded as one of the 17 NHS Wales ethnicity codes, of which 
94,497 (64.9%) were coded ‘not declared’, and 12,902 (8.9)% were missing in 
this data set. Therefore ethnicity proportions were calculated of those with 
complete data which were available for 38,199 (26.2% of the cohort).  
 
In the study cohort, the highest missing data was in QRISK-3 which was 
missing for 98,323 (69%) (Table 4-1). The QRISK-3 score was calculated from 
the raw derivative variables in the data set. Complete data is required for the 
calculation of a QRISK-3 score. Therefore a missing QRISK-3 is the result of 
missing of any of the 22 constituent factors contributing to the overall QRISK-3 
score. Cholesterol: HDL was missing in 66,534 (46%); 5,409 (4%) had missing 
sBP variability measures; 4,470 (4%) had missing data for postcode meaning 
deprivation and care home residence were not possible to discern. 
 
When stratified by frailty, it is evident that with advancing frailty, proportions with 
missing data were lower (Table 4-1). Those with missing data had lower frailty 
scores (mean eFI 0.13) compared to those with complete data (mean eFI 0.15) 
as shown in Table 4-2. Of those with missing data, fewer had diabetes mellitus 




































































































1,809 (3%) 377 (3%) 39 (3%) 
 
 
Comparison of those with missing data overall and stratified by baseline frailty 
status, per key variable included in the analysis. Presented as raw numbers and 
as percentages of the total number in each sub-group. Abbreviations in the 











Frailty (eFI) Mean (SD) 0.129 (0.07) 0.148 (0.07) 
Age n (%) 75 (7.3) 74 (6.3) 
sBP mean (SD) 147 (17) 145 (16) 
Female n (%) 64,693 (63) 27, 288 (59) 
Townsend score n (%) -0.433 (3.29) -0.189 (3.17) 
Never smoker n (%) 34,417 (34) 14,045 (31) 
Diabetes mellitus II n (%) 10,058 (10) 13,660 (30) 
FH CVD n (%) 20,072 (20) 11,672 (25) 
CKD n (%) 11,691 (11) 6,608 (14) 
BP-lowering treatment n 
(%) 
83,382 (81) 41,860 (91) 
Comparisons between the values of key variables in the sub-population 
with missing data, compared to the sub-population with complete data. 
Abbreviations used in the table: CKD = chronic kidney disease; eFI= 
electronic frailty index; FH CVD = family history of cardiovascular 
disease; n = number; SD = standard deviation;  
 
4.3 Descriptive analysis 
 
The analytic cohort included 145,598 patients who had had their BP recorded 
between 1st January 2007 and 1st January 2008 and were followed up for a 
median follow up period of 10 years. Patients were registered at a total of 502 
GP practices/practice codes, each with median 380 patients per practice (IQR 
94, 695) included in this study cohort. 
 
The mean age was 74.6 years (SD 7.10) (Table 4-3). Average age increased 




(SD 6.36), increasing to those who had severe frailty in whom the mean age 
was 81.5 years (SD 7.15). Overall, 61.9% of the study cohort were female: in 
those who were fit,  56.5% were female; this increased with frailty; in those with 
severe frailty, 81.3% were female. In this cohort, the least deprived quintile was 
not represented as well as in the general population (16.8% compared to 20%). 
However, with advancing frailty, those in the most deprived quintile increased 
as a proportion overall: in those who were fit, 14.1% were in the most deprived 
quintile; and, in those with severe frailty, 18.2% were in the most deprived 
quintile. 
 
Cardiovascular risk was high in this cohort, with a median QRISK-3 score of 
29.3 (IQR 21.1 – 39.1), which is a prediction of a cardiovascular event in that 
individual over the next 10 years. However, it was only possible to measure a 
QRISK-3 score in 47,275 (32.5%) of participants at baseline because of missing 
data among any of the constituent variables. 46,741 (98.9%) of those patients in 
whom a QRISK-3 score was measurable had a QRISK-3 score of higher than 
10%. In the overall cohort the mean BMI was 28.1 kg/m2 which is defined as 
overweight, 31,744 (21.4%) had a family history of cardiovascular disease, 
62,229 (42.7%) were ex-smokers, and 58,038 (39.9%) were prescribed statins 





4.3.1 Characterising systolic blood pressure 
 
Systolic BP recorded in primary care in 2007 demonstrated three patterns 
(Figure 4-2). Of the sBP recordings measured at baseline, 67,204 (46%) ended 
in 0, 80,527 (55%) of readings ended in 0 or 5; 117,861 (81%) end in an even 
number. The distribution of these three sBP patterns remain broadly similar, 
although there is greater asymmetry of numbers ending in even numbers after 
the population BP mean. 
 
Figure 4-2 Frequency historgram of systolic blood pressure readings 
 
Histogram presenting all baseline systolic blood pressure (sBP) readings by 1 
mm Hg intervals: tallest bars represent systolic blood pressure readings ending 
with zero, thereafter readings ending with even numbers or 5 are most frequent. 
 
Average systolic BP (sBP) in the study sample was 146 mm Hg (SD 19.2), and 
diastolic BP (dBP) 81 mm Hg (SD 11.0) (Table 4-4). The majority, 113,129 




targets. On average, each participant was prescribed 2 classes of BP-lowering 
medications: 48% were on an ACEi/ ARB, 26% on beta-blockers, 37% on 
calcium channel blockers, and 52% on diuretics. The median interval between 
BP measures was more than 3 months, 103 days (IQR 28, 211). 
 
4.3.2 Characterising frailty 
 
Summary descriptive characteristics of the patient cohort, which are stratified by 
baseline frailty status, are presented in Table 4-3. In the study cohort as a 
whole, the median eFI was 0.139 (IQR: 0.083 to 0.167), mean 0.135 (SD 0.075, 
range 0 to 0.611), which both represent the equivalent of 5 out of 36 deficits, 
which would be categorised as mild frailty. In women, frailty was higher than 
men on overage: in women, median eFI was 0.139 (IQR, 0.083, 0.194), in men, 
0.111 (0.083, 0.167). The eFI increased by 0.003 (95% CI 0.003 to 0.004) with 
every year older a person was at study baseline. Each 0.05 increase of eFI was 
associated with an increased risk of major adverse cardiovascular events 
(MACE) HR 1.12 (95% CI 1.11,1.13), adjusted HR 1.07 (95%CI 1.05, 1.09); all-
cause mortality, HR 1.31 (95% CI 1.29, 1.33), adjusted HR 1.15 (95% CI 1.12, 
1.17); and, injurious falls HR 1.37 (95% CI 1.34, 1.39), adjusted HR 1.14 (95% 




Table 4-3 Descriptive table stratified by frailty status: demographics 
















Age, mean (SD) 74.6 (7.10) - 72.9 (6.36) 75.7 (7.19) 78.9 (7.47) 81.5 (7.15) 











1) Most n (%) 
2) n (%) 
3) n (%) 
4) n (%) 





















9, 795  
(17%) 
11, 945  
(20%) 




11, 670  
UL(20%) 
2, 321 (18%) 
2, 570 (20%) 
2, 491 (20%) 
2, 555 (20%) 






CH resident, n (%) 2,035 (1%)  278 (<0.5%) 955 (2%) 645 (5%) 157 (11%) 




37,496 (98%) 12,902 (9%) 16,035 (98%) 16,746 (98%) 4,209 (98%) 506 (98%) 




Table 4-4 Descriptive Table stratified by frailty status: blood pressure 
















sBP mm Hg, mean 
(SD) 
146 (19.2) - 148 (19.1) 145 (19.4) 143 (20.4) 141 (20.9) 
dBP mm Hg, mean 
(SD) 
81 (11.0) 529 
(<0.5) 
83 (10.7) 80 (10.8) 78 (11.1) 76 (11.4) 
MAP, mean (SD) 103 (12.0) 104 (11.9) 101 (11.8) 99 (12.3) 98 (12.9) 
PP, mean (SD) 66 (16.1) 66 (15.6) 66 (16.5) 66 (17.3) 65 (17.2) 
























ACEi/ ARB, n (%) 70,234 (48) - 30,076 (41) 31,891 (54) 7,461 (59) 806 (57) 
Beta blockers, n (%) 38,094 (26) - 19,547 (27) 15,339 (26) 2,882 (23) 326 (23) 
CCB, n (%) 53,568 (37) - 24,561 (34) 23,511 (40) 4,969 (39) 527 (38) 
Diuretic, n (%) 75,646 (52) - 34,145 (47) 32,879 (56) 7,734 (61) 888 (63) 
Treatment #, mean 
(SD) 
1.75 (1.13) - 1.58 (1.12) 1.91 (1.11) 1.99 (1.13) 2.01 (1.19) 
BP interval, median 
(IQR) 
103 (28, 211) 2,732 (2) 109 (28, 226) 99 (29, 200) 91 (29, 178) 84 (29, 178) 
# BP in 2yr, median 
(IQR) 
5 (3, 9) - 5 (3, 8) 6 (4, 9) 7 (4, 10) 7 (4, 11) 
 
Abbreviations: ACEi = Angiotensin converting enzyme inhibitor; ARB = angiotensin receptor blocker; BP = blood pressure; 
CCB = calcium channel blocker; dBP = diastolic blood pressure; IQR = inter-quartile range; MAP = mean arterial blood 
pressure; n = number; NICE = National Institute for Health and Care Excellence; PP = pulse pressure; sBP = systolic blood 







Table 4-5 Descriptive table stratified by frailty status: cardiovascular risk 
 Frailty status Overall Missing Fit Mild Moderate Severe 












































Statins, n (%) 58,038 (40) - 25,451 (35) 26,087 (44) 5,838 (46) 662 (47) 














FH of CVD, n (%) 31, 744 (21) - 15,103 (21) 13,074 (22) 2,805 (22) 311 (22) 
Never-smoker, n (%) 
Ex-smoker, n (%) 
Light smoker, n (%) 
Moderate smoker, n 
(%) 
Heavy smoker, n (%) 
55,738 (38)  
15,231 
(10%) 
28,543 (40) 21,972 (37) 4,709 (37) 514 (37) 
62,229 (43) 28,994 (40) 26,530 (45) 6,004 (47) 701 (50) 
3,895 (3) 1,955 (3) 1,546 (3) 355 (3) 39 (3) 
5,204 (4) 2,564 (4) 2,133(4) 464 (4) 43 (3) 
3,301 (2) 1,615 (2) 1,355 (2) 297 (2) 34 (2) 
 
Abbreviations: BMI = body mass index; FH of CVD = family history of cardiovascular disease; Chol: HDL = Cholesterol: high 





When frailty was categorised in the study population: 72,744 (50%) were fit; 
58,747 (40%) had mild frailty; 12,701 (9%) had moderate frailty; and 1,406 (1%) 
had severe frailty. The proportion of the population living in a care home 
increased with greater frailty status (see Table 4-3). In the study cohort as a 
whole, 2,035 (1.4%) were living in a care home: as a proportion, this increased 
from 0.4% in those who were fit; 1.6% in those with mild frailty; 5.1% with 
moderate frailty; and 11.2% with severe frailty. 
 
4.3.3 Baseline systolic blood pressure in the context of baseline 
frailty 
 
In the study population overall, with advancing frailty category, systolic BP was 
lower. There was a 7 mm Hg difference in mean systolic BP and in mean 
diastolic BP between those who were fit and those with severe frailty: in fit, 
mean 148 / 83 mm Hg; in severe frailty, mean 141 / 76 mm Hg (Table 4-4). 
Consistent with these findings, mean arterial pressure fell from a mean, in those 
who were fit, of 104 mm Hg, to a mean in those with severe frailty, of 98 mm 
Hg. There was no difference in pulse pressure between the groups. Variability 
in sBP between readings increased with advancing frailty: median SD 7.07 in 
those who were fit; 7.78 with mild frailty; 8.49 moderate frailty; 9.19 in severe 
frailty.  
 
The treatment count was not different between groups defined by baseline 
frailty. Proportions of participants prescribed ACEi/ ARB and diuretics increased 




channel blockers were less marked in their difference by frailty status. The 
interval between BP measurements was 25 days shorter in those with severe 
frailty (median interval 84 days) compared to those who were fit (median 
interval 109 days). However there was a high degree of variation with wide 
inter-quartile ranges for BP intervals in all categories of baseline frailty. The 
proportion of people on target according to NICE guidelines for their age, 
increased with advancing frailty: from 52,369 (72%) of those who were fit; 
48,459 (82.5%) with mild frailty; 11,037 (86.9%) with moderate frailty; and 1,264 
(89.9%) who had severe frailty. 
 
Cardiovascular risk increased markedly according to frailty category, as 
measured by QRISK-3 (Table 4-3). In those who were fit, median QRISK-3 
score was 24.6%; mild frailty, 31.3%; moderate frailty, 38.5% ; and, severe 
frailty, 43.6%. There were not significant differences between groups conditional 
on baseline frailty in terms of: Cholesterol: HDL ratio, BMI, family history of 
cardiovascular disease and smoking history (Table 4-7). However, statin 
prescription increased with frailty: in those who were fit, 35% were prescribed a 
statin; mild frailty, 44.4%; moderate frailty, 46%; severe frailty 47.1%. 
 
Inclusive of hypertension, 98,381 participants (67.6%) had multi-morbidity, 
where multi-morbidity is defined as having two or more long-term conditions. 
The number of co-morbidities in addition to hypertension ranged between 0-10 
per person (Figure 4-3). Across baseline systolic BP, the median count of 
comorbidities did not vary conditional on sBP category (see Table 4-8). The 




morbidity. The differences with other sBP categories were particularly evident in 
the frequency of type II diabetes, and dementia. The highest proportion of those 
who had moderate or severe frailty was among those with the lowest systolic 
BP: with an sBP < 120 mm Hg: 2,248 (38.3%) were fit; 2,984(46.9%) had mild 
frailty; 984 (15.4%) had moderate frailty; and, 153 (2.4%) had severe frailty. A 
higher proportion of those with sBP < 120 mm Hg were care home residents 
and lived with higher deprivation compared to those with higher baseline sBP 
(see Table 4-6). 
  





Table 4-6 Descriptive table stratified by systolic blood pressure: demographics 
sBP 
category 
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Table 4-7 Descriptive table stratified by systolic blood pressure: cardiovascular risk 
sBP 
category 

























































































































































Abbreviations: BMI = body mass index; Chol: HDL = Cholesterol: high density lipoprotein ratio; IQR = inter-quartile range; n = 






Table 4-8 Descriptive table stratified by systolic blood pressure: frailty and comorbidity 
sBP 
category 

































































3,304 (8) 1,645 (7) 1,197 (7) 650 (7) 769 (8) 
Severe, n 
(%) 




2 (1,3) 2 (2,3) 2 (1,3) 2 (1,3) 2 (1,3) 2 (1,3) 2 (1,3) 2 (1,3) 2 (1,3) 
Abbreviations: n = number; QOF = comorbidity count according to those listed in the quality outcomes framework, * count 




Figure 4-4 Past history of comorbidity according to baseline categorised systolic blood pressure 
 
This histogram demonstrates the baseline prevalence in participants past medical histories of important co-morbidities 
according to baseline systolic blood pressure. Co-morbidities are in order of prevalence for each sBP category with 
numbers representing the count of participants as a proportion of the whole population, n=145,598. Abbreviations: AF = 





4.3.4 Characterising outcomes 
 
Overall in this population over the age of 65 years with hypertension, 41,501 
(28.5%) experienced major adverse cardiovascular events during a median 
follow up time of 1,162,286 person years. In those who sustained a MACE 
event, the event consisted of: 22,394 (15.4%) myocardial infarctions, 16,186 
(11.1%) new diagnoses of heart failure; 9,192 (6.3%) stroke events, and 2,934 
(2.0%) deaths specifically from cardiovascular disease. 
 
Cardiovascular outcomes increased with frailty: of those who were fit, 17,193 
(23.6%) had a MACE event; with mild frailty, 18,775 (32.0%); with moderate 
frailty, 4,940 (38.9%); and, those with severe frailty, 593 (42.2%). These 10 year 
event rates as a proportion of sub-populations defined by frailty status, are 
consistent with the QRISK-3 predictions which were in those who were fit, 
24.6%, with mild frailty, 31.3%; moderate frailty, 38.5%, and severe frailty 
43.6%. 
 
For those developing an outcome during the 10 year period of follow up, median 
age at the time of myocardial infarction, 79 years (IQR 74 to 84 years); first 
stroke, 83 (IQR 77 to 87 years), new heart failure was 83 years (IQR 78 to 88 
years), cardiovascular death, 86 (IQR 82 to 91 years); death of any cause, 85 
years (IQR 79 to 90 years); injurious falls, 84 years (IQR 79 to 88 years), new 





Overall, 57,157( 39.2%) died from any cause (Figure 4-1). Stratified by frailty: 
this included 21,301 (29.3%) deaths among those who were fit; 26,520 (45.1%) 
deaths with mild frailty; 8,227 (64.8%) deaths with moderate frailty; 1,119 
(79.6%) deaths with severe frailty. 
 
Overall, 33,311 (22.9%), sustained falls resulting in admission to hospital. 
Stratified by frailty, this included 12,602 falls (17.3%) among those who were fit; 
15,756 (26.8%), falls with mild frailty; 5,163 (40.7%) falls with moderate frailty; 
and, 557 (39.6%) falls with severe frailty. 
 
Descriptive outcome counts and proportions for the study population overall 
throughout 10 year follow up were as follows:  
 
- 97,635 (67.1%) were admitted to hospital;  
- 22,666 (15.6%) were admitted to hospital with hypotension;  
- 14,969 (10.3%) were admitted to hospital with acute kidney injury;  
- 11,445 (7.9%) were admitted to hospital with electrolyte disturbance. 
- 3,733 (2.6%) had a hospital stay complicated by or because of urinary 
incontinence. 
- 2,139 (1.5%) had delirium as a cause for presentation or developed 
during hospital admission; 
- 16,827 (11.6% ) had a hospital stay indicated by or causing functional 
dependence which required inpatient rehabilitation. 




- 12,528 (8.6%) developed dementia as recorded in primary or secondary 
care;  
 
4.3.5 Model development 
 
In the development of the model, each variable was tested for proportional 
hazards (Figure 4-5). It is evident that the proportional hazards assumption 
could not be met for sBP categories, BP-lowering medications, family history of 
cardiovascular disease; rheumatoid arthritis, SLE, smoking categories and type 
I diabetes mellitus. Given the proportional hazards assumption was not met, 
flexible parametric models were used. Initially the model was developed with 
complete cases only before introducing imputed data into the models. The 
model development was undertaken separately for the primary and each of the 
secondary outcomes. The best fitting model using 3, 4 and 5 degrees of 
freedom, was tested by visual inspection and by comparing the AIC and BIC 
likelihood estimates. Thereafter each continuous variable was included 
individually as a linear and a non-linear term, and as a non-linear term using 
3,4, and 5 restricted cubic splines. Spline functions were plotted and likelihood 
estimates measured and compared to find the best fitting measure of the non-
linear, and three different splines. This was undertaken for all of the continuous 
variables included in the models including: age; systolic BP; weight; height; 
Cholesterol: HDL ratio; number of GP attendances; count of medications; 
systolic BP variability; electronic frailty index; and Townsend score for 





Figure 4-5 Test of each variable to check for proportional hazards 
 
 
AF = atrial fibrillation; Antipsychotics = atypical antipsychotics; sBP categories = 
systolic blood pressure categories; Drug # = BP-lowering medication count ; FH 
CVD = family history of cardiovascular disease; RA = rheumatoid arthritis; Ratio 
= Cholesterol: HDL ratio; Renal F = chronic renal failure; sBP categories = 
systolic BP categories; sBP V = systolic BP variability; Mental H = severe 
mental health illness; SLE = systemic lupus erythematosus; T1 DM = type I 
diabetes mellitus; T2 DM = type II diabetes mellitus; Townsend = Townsend 
score of deprivation; Treated HTN = treated hypertension category; Visits = 






4.4 Objective 2: what are the associations of sBP and outcomes 
in this data set? 
 
4.4.1 Rates of primary outcome events per sBP category 
 
4.4.1.1 Major adverse cardiovascular events (MACE) 
 
In the population overall, the rate per 100 person years of developing a MACE 
outcomes was 4.0 (95% CI 4.0 – 4.0) (Figure 4-6, in red). According to baseline 
sBP, rates demonstrated a U-shaped association: with a peak at sBP < 120 mm 
Hg, 5.0 (95% CI 4.8 – 5.3); nadir at 140 to 159 mm Hg, 3.9 events (95% CI 3.8 
– 4.0); and a second peak at 160 mm Hg, 4.5 events (95% CI 4.3 – 4.6).  
 
The association varied between constituent MACE outcomes. For myocardial 
infarction, the rate per 100  person years in the population overall was 2.1 (95% 
CI 2.1 – 2.1), and the pattern of association stratified by sBP was modestly J-
shaped (Figure 4-7, in red). For new diagnosis of heart failure, the rate per 100 
person years in the population overall was 1.4 (95% CI 1.4 – 1.5), and the 
pattern was more U-shaped with a nadir of risk at sBP 140 – 150 mm Hg 
(Figure 4-7, in blue). For stroke, the rate per 100 person years in the population 
overall was 0.8 (95% CI 0.8 – 0.8), and the pattern according to sBP was more 
modestly U-shaped (Figure 4-7, in green). For cardiovascular death, the rate 
per 100 person years in the population overall was 0.3 (95% CI 0.2 – 0.3), and 





4.4.1.2 All-cause mortality 
 
In the population overall, the rate per 100 person years of dying from any cause 
was 4.9 (95% CI 4.9 – 5.0) (Figure 4-6, in green). Stratified by sBP, the 
association was reverse-tick shaped: first peak at sBP < 120 mm Hg, 8.1 (95% 
CI 7.9, 8.4); nadir at 140 - 149 mm Hg, 4.6 (95% CI 4.5 – 4.6); with a second 





4.4.1.3 Injurious falls 
 
In the population overall, the rate per 100 person years of sustaining an 
injurious fall was 3.1 (95% CI 3.1 – 3.1) (Figure 4-6, in blue). For injurious falls, 
the crude rates varied more modestly conditional on sBP. Stratified by sBP: the 
first peak was at sBP < 120 mm Hg, 4.0 (95%CI 3.8 – 4.2); nadir at 150 to 159 






Figure 4-6 Event rates with 95% confidence intervals for primary and 
secondary outcomes per 100 person years according to baseline 
sBP, n=145,598 
 
Crude event rates with 95% confidence intervals are presented for the primary 
and secondary outcomes: all-cause mortality in green, major adverse 






Figure 4-7 Event rates with 95% confidence intervals for individual MACE 
outcomes per 100 person years according to baseline sBP, n=145,598 
 
Crude event rates with 95% confidence intervals are presented for the  major 
adverse cardiovascular  events (MACE) individually: myocardial infarction (MI in 






4.4.1.4 Descriptive outcomes per sBP category 
 
Overall rate of hospital admissions was 12.2 admission per 100 person years 
(95% CI 12.1 – 12.2) (Figure 4-8). Hospital admissions also demonstrated a 
reverse-tick shaped association: with a first peak at < 120 mm Hg, 17.0 (95% CI 
16.5 – 17.5); nadir at 150 – 159 mm Hg, 11.6 (95% CI 11.4 – 11.7); second 
peak at > 180 mm Hg, 13.6 (95% CI 13.3 – 14.0).  
 
Overall rate of care home admission was 1.2 per 100 person years (95% CI 1.2 
– 1.2) (Figure 4-9) with a peak at < 120 mm Hg, 1.7 (95% CI 1.6 – 1.9); nadir at 
140 – 160 mm Hg, 1.1 (95% CI 1.1 – 1.2); second peak at >180 mm Hg, 1.4 
(95% CI 1.3 – 1.5). 
 
Overall rate of hospital admissions with acute kidney injury was 1.3 per 100 
person years (95% CI 1.3 – 1.3) (Figure 4-10) with a: peak at < 120 mm Hg, 1.7 
(1.6 – 1.8); nadir at 150 – 159 mm Hg, 1.2 (95% CI 1.2 – 1.3); second peak at > 
180 mm Hg, 1.6 (95% CI 1.5 – 1.7). Overall rate of hospital admissions with 
hypotension was 2.0 per 100 person years (95% CI 2.0 – 2.1) with a: first peak 
at sBP < 125 mm Hg, 2.8 (95% CI 2.6 – 3.0); nadir at 160 – 169 mm Hg, 1.9 
(1.8 – 2.0); and second peak at > 180 mm Hg, 2.3 (95% CI 2.2 – 2.4). Overall 
rate of hospital admissions with electrolyte disturbance was 1.0 per 100 person 
years (95% CI 1.0 – 1.0) and there was not a meaningful difference according 





Overall rate of dementia diagnosis was 1.1 per 100 person years (95% CI 1.1 – 
1.1) (Figure 4-10), with a first peak at sBP < 120 mm Hg, 1.5 (95% CI 1.4 – 
1.6); and thereafter little difference above 120 mm Hg. Overall rate of delirium 
was 0.2 events per 100 person years (95% CI 0.2 – 0.2) with no difference in 
rates conditional on baseline sBP. 
 
Overall rate of hospital admission with functional dependence was 1.5 per 100 
person years (95% CI 1.5 – 1.5) (Figure 4-10) with a: peak at sBP < 120 mm 
Hg, 2.0 (95% CI 1.9 – 2.2); nadir at sBP 130 – 159 mm Hg, 1.4 (95% CI 1.4 – 
1.5); and second peak at > 180 mm Hg, 1.9 (95% CI 1.8 – 2.0). Overall rate of 
hospital admissions with urinary incontinence was 0.3 events per 100 person 




Figure 4-8 Event rates for hospital admissions per 100 person years 




Figure 4-9 Event rates of care home admissions per 100 person years 






Figure 4-10 Event rates for descriptive outcomes per 100 person years 
according to baseline systolic blood pressure category, with 95% 






4.4.2 Relative risks of outcomes per sBP category 
 
4.4.2.1 Major adverse cardiovascular events (MACE) 
 
Hazard ratios for the association of sBP category with MACE were estimated in 
a model adjusted for cardiovascular risk and BP-lowering treatment. Risk of 
MACE was higher than the reference category at both upper and lower 
extremes of the range of systolic BP (Figure 4-11). There was evidence of a 
non-linear association between sBP and MACE. Compared to a reference 
category of 130 – 139 mm Hg, a greater hazard was associated with an sBP < 
120 mm Hg (HR 1.16, 95%CI 1.11 – 1.22), and an sBP > 180 mm Hg (HR 1.07, 
95% CI 1.02 – 1.11). There were no significant differences between the 
reference category and sBP between 120 mm Hg and 179 mm Hg. 
 
4.4.2.2 All-cause mortality 
 
Hazard ratios for the association of sBP category with all-cause mortality were 
estimated in a model adjusted for cardiovascular risk and BP-lowering treatment 
(Figure 4-11). Patients with an sBP < 120 mm Hg were associated with a 46% 
increase in risk of all-cause death compared to a reference of patients with sBP 
130-139 mm Hg (HR 1.46, 95% CI 1.40, 1.52)). Patients with an sBP between 
120 – 129 mm Hg were associated with a 13% increase in risk of all-cause 
death compared to reference (HR 1.13, 95%CI 1.09, 1.16)). People with an sBP 
over 140 mm Hg were associated with a reduced risk of mortality compared to 
reference (140-149 mm Hg, HR 0.95, 95% CI 0.93, 0.97; 150 – 159 mm Hg, HR 




179 mm Hg, HR 0.95, 95% CI 0.92, 0.99). However, at an sBP > 180 mm Hg 
hazard risk was not statistically different to the reference range (HR 0.98, 95% 
CI 0.95, 1.02). 
 
4.4.2.3 Injurious falls 
 
 
Hazard ratios for the association of sBP category with injurious falls requiring 
hospitalisation also in a model adjusted for cardiovascular risk and BP-lowering 
treatment (Figure 4-11). In common with the associations reported for all-cause 
mortality, patients with an sBP of < 120 mm Hg were associated with a 21% 
increased risk of sustaining an injurious fall compared to patients with an sBP 
between 130 – 139 mm Hg. People with an sBP > 150 mm Hg were associated 
with a reduced risk of falls compared to reference (150 – 159 mm Hg, HR 0.92, 
95% CI 0.89, 0.96; 160 – 169 mm Hg HR 0.95, 95% CI 0.91, 0.98; 170 – 179 
mm Hg HR 0.93, 95% CI 0.89, 0.98). Also, at an sBP > 180 mm Hg hazard risk 




Figure 4-11 Association of systolic blood pressure with 95% confidence intervals with major adverse cardiovascular 





Adjusted for established cardiovascular risk factors & treatment. Association of systolic blood pressure as a categorical variable with the 
risk of Major Adverse Cardiovascular Event (MACE), all-cause mortality and injurious falls. Hazard ratios of the association between 
systolic blood pressure and risk of MACE (in red), all-cause mortality (green) and injurious falls (blue) with the corresponding 95% 
confidence intervals (black lines) (reference systolic blood pressure: 130 – 139 mmHg). Point estimates were calculated in a flexible 
parametric model with 3 degrees of freedom, using cubic splines for weight and Cholesterol: HDL ratio. HR, hazard ratio; CI, confidence 




4.5 Objective 3: Is frailty a prognostic factor for key outcomes? 
 
4.5.1 Event rates according to baseline frailty status 
 
The crude rate of outcome events increased with advancing frailty status across 
primary and secondary outcomes (Figure 4-12). The rate per 100 person years 
of developing a MACE outcome increased with frailty status: in fit, 3.0 (95% CI 
3.0 – 3.1); mild frailty, 4.8 (95% CI 4.7 to 4.9); moderate frailty, 7.4 (95% CI 7.2 
to 7.6); severe frailty, 9.8 (95% CI 9.0 to 10.6). The rate per 100 person years of 
dying of any cause increased more steeply with frailty status: in fit, 3.4 (95% CI 
3.4 – 3.5); mild frailty, 5.9 (95% CI 5.8 to 6.0); moderate frailty, 10.2 (95% CI 
10.0 to 10.4); severe frailty, 14.9 (95% CI 14.0 to 15.8). The rate per 100 person 
years of being hospitalised with injurious falls also increased with frailty: in fit, 
2.2 (95% CI 2.1 – 2.2); mild frailty, 3.9 (95% CI 3.8 to 4.0); moderate frailty, 6.5 




Figure 4-12 Event rates with 95% confidence intervals for major adverse 
cardiovascular event (MACE), all-cause mortality and injurious falls 






4.5.2 Relative risk according to baseline frailty status 
 
The unadjusted risk for MACE, all-cause mortality, and falls were all increased 
with increasing severity of frailty (see Figure 4-13, Figure 4-14, Figure 4-15). 
The hazard risk for MACE adjusted for known cardiovascular risk factors, BP-
lowering treatment and GP attendance also increased with frailty in comparison 
to those who were fit: mild frailty, HR 1.38, 95% CI 1.35, 1.41; moderate frailty, 
HR 1.84, 95% CI 1.78, 1.91; severe frailty, HR 2.17, 95% CI 2.00, 2.36 (Figure 
4-16). The adjusted risk for all-cause mortality increased with frailty compared 
to those who were fit: mild frailty, HR 1.36, 95% CI 1.33, 1.39; moderate frailty, 
HR 1.86, 95% CI 1.81, 1.91; severe frailty, HR 2.18, 95% CI 2.05, 2.32 (Figure 
4-17). The adjusted risk of injurious falls increased in comparison to fit: mild 
frailty, HR 1.44, 95% CI 1.41, 1.48; moderate frailty, HR 1.93, 95% CI 1.86, 
























Figure 4-16 Association between frailty status at baseline and major adverse cardiovascular events (MACE), 






Figure 4-17 Association between frailty status at baseline and all-cause mortality, unadjusted (grey), adjusted (black) 






Figure 4-18 Association between frailty status at baseline and injurious falls, unadjusted (grey), adjusted (black) 





4.5.3 Change in model fit with adjustment for frailty  
 
The model fit with and without frailty as a continuous term was tested (Table 
4-9). For all outcomes both the AIC and BIC reduced with the addition of frailty 
to the model. For MACE, the best current model had an AIC of 248,829 and BIC 
of 249,023. With frailty this reduced to an AIC of 247,409 and BIC of 247,579. 
For all primary outcomes therefore, these are consistent with an improvement of 
model fit with the addition of frailty. For all-cause mortality, the best current 
model had an AIC of 260,202 and BIC of 260,396. The addition of frailty 
reduced the AIC to 259,252 and BIC to 259,422. For injurious falls, the best 
current model had an AIC of 183,481 and BIC of 183,675. There were similar 
reductions of AIC to 182,276 and BIC to 182,446. 
 
Table 4-9 Survival models with and without the addition of frailty as a 
prognostic factor, adjusted for cardiovascular risk, BP-lowering 
treatment and GP attendance, for primary and secondary outcomes 
Outcome Prognostic factor AIC BIC 
MACE Without frailty 248,828.6 249,023 
 With frailty 247,409.3 247,578.8 
All-cause mortality Without frailty 260,201.6 260,396 
 With frailty 259,252.3 259,421.8 
Injurious falls Without frailty 183,480.9 183,675.3 
 With frailty 182,276 182,445.5 
AIC = Akaike Information Criterion; BIC = Bayesian Information Criterion; MACE 





4.6 Objective 4: Does frailty modify the association between 
blood pressure and outcomes?  
 
4.6.1 Event rates according to systolic blood pressure in sub-
population defined by frailty status 
 
4.6.1.1 Major adverse cardiovascular events (MACE) 
 
The differential rate of MACE according to baseline sBP varied in pattern in 
different sub-populations defined by frailty status. MACE crude rates in fit and 
mild frailty groups were modestly U-shaped (Figure 4-19). In fit people, the 
crude rate was highest at <120 mm Hg, at 3.6 events per 1000 person years 
(95% CI 3.3 – 3.9) and at > 180 mm Hg, at 3.5 events (95% CI 3.3 – 3.6), and 
lower in-between. In mild frailty, the pattern was similar, with crude rates highest 
at < 120 mm Hg (5.6 (95% CI 5.2 – 6.0), lowest rate at 130 – 139 mm Hg (4.5 
(95% CI 4.3 – 4.6), but a more gradual increase with increasing sBP thereafter 
until > 180 mm Hg, at 5.6 (95% CI 5.3 – 5.9).  
 
However in populations defined by moderate and severe frailty, associations 
between sBP and MACE are broadly indifferent across sBP. Conversely among 
those with moderate frailty the crude rate varied only between 7 and 8 events 
per 1000 person years at all sBPs. In people with severe frailty crude rates 





4.6.1.2 All-cause mortality 
 
The crude mortality rate associated with sBP also varied in pattern according to 
frailty status but in a different manner to MACE. The pattern throughout was 
shaped as an inverted J, and this became more pronounced with advancing 
frailty (Figure 4-20). In fit people, crude death rates were not grossly different 
across sBP categories, ranging from highest rate at < 120 mm Hg, 4.7 (95%CI 
4.4 – 5.1), to lowest rate at 130 – 139 mm Hg, 3.2 (95% CI 3.1 – 3.3), rising 
again at > 180 mm Hg, 4.2 (95% CI 4 – 4.4). The J shape becomes more 
pronounced in mild frailty, ranging from highest at < 120 mm Hg , 8.9 (95% CI 
8.5 – 9.4) to a nadir at 140 – 149 mm Hg, 5.5 (5% CI 5.3 – 5.6), rising thereafter 
up to > 180 mm Hg, 6.9 (95% CI 6.6 – 7.3). In moderate frailty, rates were 
highest < 120 mm Hg 15.6 (95% CI 14.5 – 16.8), lowest at 150 – 159 mm Hg, 
9.3 (95% CI 8.7 – 9.9), rising to > 180 mm Hg, at 11.1 (95% CI 10.1 – 12.1). In 
severe frailty, rates peaked at < 120 mm Hg, 21.2 (95% CI 17.8 – 25.1), then 





The pattern in the crude risk of falls remained U shaped in those who were fit or 
who had mild frailty (Figure 4-21). However in those with moderate frailty, and 
particularly in those with severe frailty, the sBP-falls association became more 
of the conventional J-shaped association. In those who are fit, crude rate of falls 
was high < 120 mm Hg, 2.6 (95% CI 2.4 – 2.9) and again > 180 mm Hg, 2.7 




frailty, similarly, rates were highest < 120 mm Hg, 4.4 (95% CI 4.1 – 4.7) and > 
180 mm Hg 4.5 (95% CI 4.2 – 4.8) , and in-between rates were between 3.6 
and 4.0. In moderate frailty, also, highest < 120 mm Hg at 7.2 (95% CI 6.4 – 
8.0), and > 180 mm Hg, at 8 (95% CI 7.1 – 8.9), an in-between 6.1 and 6.5. In 
severe frailty, a J-shaped association was more evident, with rates highest < 
120 mm Hg, 11.2 (95% CI 8.5 – 14.5), lowest at 120 – 129 mm Hg, 7.9 (95% CI 





Figure 4-19 Event rates with 95% confidence intervals for major adverse 
cardiovascular events (MACE) according to frailty status and systolic 





Figure 4-20 Event rates with 95% confidence intervals for all-cause 









Figure 4-21 Event rates with 95% confidence intervals for injurious falls 








4.6.2 Relative risk according to systolic blood pressure in sub-
populations defined by frailty  
 
Analyses were adjusted for cardiovascular risk, BP-lowering treatment count 
and number of visits to the GP. 
 
4.6.2.1 Major adverse cardiovascular events (MACE) 
 
Overall, there was a greater relative hazard for MACE at the extremes of 
systolic BP (Figure 4-22), and this pattern was maintained in people who were 
fit or had mild frailty. In people who were fit, an sBP <120 mm Hg was 
associated with 13% higher risk of developing MACE, compared to those with 
sBP 130 – 139 mm Hg, HR 1.13 (95% CI 1.03, 1.23). Patients with an sBP 
>180 mm Hg were associated with 11% higher risk of developing MACE 
compared to reference range, HR 1.11 (95% CI 1.04, 1.19). In people with mild 
frailty, sBP < 120 mm Hg was associated with 18% increase in risk of MACE 
compared to reference (HR 1.18 (95% CI 1.10, 1.27), and sBP > 180 mm Hg 
13% increase risk of MACE, HR 1.13 (95% CI 1.06, 1.21). In people who were 
fit or had mild frailty, sBPs running in-between 120 and 180 mm Hg were not 
associated with higher relative hazard. In people with moderate or severe frailty, 





4.6.2.2 All-cause mortality 
 
Overall there highest risk of death from any cause was at low sBPs, and this 
pattern was maintained in all frailty subgroups except for severe frailty (Figure 
4-23). For patients who were fit, compared to sBP 130 – 139 mm Hg, an sBP < 
120 mm Hg was associated with 42% increased risk of death, HR 1.42 (95% CI 
1.32, 1.54), an sBP 120-129 mm Hg had 13% higher risk, HR 1.13 (95% CI 
1.07, 1.20), and sBP > 180 mm Hg, 12% higher risk, HR 1.12 (95% CI 1.03, 
1.20). In mild frailty, sBP < 120 mm Hg was associated with a HR 1.42 (95% CI 
1.35, 1.50), and, 120 – 129 mm Hg, a HR 1.10 (95% CI 1.05, 1.15). For patients 
with mild frailty sBP above 140 mm Hg was associated with lower risk of death 
up to a sBP of 170 mmHg. In moderate frailty, sBP < 120 mm Hg was 
associated with a HR 1.40 (95%CI 1.28, 1.52), 120 – 129 mm Hg with HR 1.10 
(95%CI 1.01, 1.18). In people with severe frailty, there was no clear association 
that was conditional on sBP.  
 
4.6.2.3 Injurious falls 
 
In fit patients, hazard risk of injurious falls was highest at very low sBP and very 
high sBP (Figure 4-24). For people who were fit, compared to a reference of 
130 – 139 mm Hg, the hazard risk of falling was 29% higher with an sBP < 120 
mm Hg, HR 1.29 (95% CI 1.16, 1.43), 8% higher with an sBP 120-129 mm Hg, 
and 12 % higher with an sBP > 180 mm Hg, HR 1.12 (95%CI 1.3, 1.20). In 




to reference, in mild frailty, sBP < 120 mm Hg was associated with a 14% 
increase in risk of death, HR 1.14 (95%CI 1.05, 1.23). In moderate or severe 




Figure 4-22 Associations between systolic blood pressure and major adverse cardiovascular event stratified by 






Figure 4-23 Associations between systolic blood pressure and all-cause mortality stratified by baseline frailty status, 





Figure 4-24Associations between systolic blood pressure and injurious falls stratified by baseline frailty status, with 




4.6.3 Frailty modification of the effect of systolic blood pressure on 
outcomes 
 
The model with and without an interaction term between frailty as a continuous 
term and sBP as a cubic spline was tested for each of the three main outcomes. 
The initial model was fully adjusted for cardiovascular risk, BP-lowering 
treatment and GP attendance. 
 
4.6.3.1 Major adverse cardiovascular events (MACE) 
 
The association of categorised sBP and the hazard of a MACE event was not 
significantly altered by the inclusion of frailty (Model 2), or an interaction 
between sBP and frailty (Model 3) (Table 4-10). The interaction term in the 
model itself did not have a statistically significant association with MACE (p-
values for interaction with sBP splines 1 and 2: p=0.419, p=0.658). In terms of 
improving model fit, the addition of the interaction term (sBP with frailty) had 
equivocal effects on the AIC and BIC measures. The AIC of model 2 was 
247,409 which reduced in model 3 to an AIC of 247,404. The BIC of model 2 
was 247,579 which increased in model 3 to a BIC of 247,583. Overall then there 
was no evidence of effect modification by frailty of the association between sBP 
and MACE. 
 





The association of categorised sBP and the hazard of death was not 
significantly altered by the inclusion of frailty (Model 2), or an interaction term 
between frailty and sBP (Model 3) (Table 4-11). The interaction term in the 
model itself did have a statistically significant association with all-cause 
mortality (p-values for interaction with sBP splines 1 and 2 within interaction: 
p<0.001, p=0.020). The AIC of model 2, for all-cause mortality was 259,252 
which reduced in model 3 to an AIC of 259,241. The BIC of model 2, for all-
cause mortality was 259,422 which reduced in model 3 to a BIC of 259,420. 
Therefore there is mixed evidence of modest improvement in model fit with the 
inclusion of an interaction term between frailty and sBP on all-cause mortality. 
 
4.6.3.3 Injurious falls 
 
The association of categorised sBP and the hazard of injurious falls was not 
altered by the inclusion of frailty (Model 2), or the inclusion of an interaction 
term between frailty and sBP (Model 3) (Table 4-12). The interaction term in the 
model did not have a statistically significant association with injurious falls (p-
values for interaction with sBP splines 1 and 2 within interaction respectively: 
p=0.868; p=0.420). For injurious falls, the AIC of model 2 was 182,276, which 
reduced in model 3 to an AIC of 182,273. The BIC of model 2 was 182,446 
which increased to a BIC of 182,452 in model 3. Overall then there was no 





Table 4-10 Association between systolic blood pressure and major adverse cardiovascular events (MACE) and 
estimates of model fit according to pre-specified model adjustment sets 
 HR associated with systolic blood pressure category AIC BIC 
Model 1 Adjusted for established cardiovascular risk factors & treatment 248,82
9 
249,023 
 <120 120-129 Re
f 
























Model 2 Model 1 + addition of frailty 247,40
9 
247,579 
 <120 120-129 Re
f 
























Model 3 Model 2 + addition of interaction between frailty and sBP,  247,40
4 
247,583 
 <120 120-129 Re
f 
























Model 4 Model 2 + addition of interaction between frailty and treatment 247,39
3 
247,567 
 <120 120-129 Re
f 





























Table 4-11 Association between systolic blood pressure and all-cause mortality and estimates of model fit according 
to pre-specified model adjustment sets 
 HR associated with systolic blood pressure category AIC BIC 
Model 1 Adjusted for established cardiovascular risk factors & treatment 260,20
2 
260,396  
 <120 120-129 Re
f 
























Model 2 Model 1 + addition of frailty 259,25
2 
259,422 
 <120 120-129 Re
f 
























Model 3 Model 2 + addition of interaction between frailty and sBP,  259,24
1 
259,420 
 <120 120-129 Re
f 
























Model 4 Model 2 + addition of interaction between frailty and treatment 259,24
9 
259,423 
 <120 120-129 Re
f 




























Table 4-12 Association between systolic blood pressure and injurious falls and estimates of model fit according to 
pre-specified model adjustment sets 
 HR associated with systolic blood pressure category AIC BIC 
Model 1 Adjusted for established cardiovascular risk factors & treatment 184,15
8 
184,322 
 <120 120-129 Re
f 
























Model 2 Model 1 + addition of frailty 182,27
6 
182,446 
 <120 120-129 Re
f 
























Model 3 Model 2 + addition of interaction between frailty and sBP,  182,27
3 
182,452 
 <120 120-129 Re
f 























Model 4 Model 2 + addition of interaction between frailty and treatment 182,26
6 
182,440 
 <120 120-129 Re
f 




























4.6.4 Frailty modification of the effect of BP-lowering treatment on 
outcomes 
 
The model with and without an interaction term between frailty as a continuous 
term and BP-lowering treatment as a continuous measure was tested for each 
of the three main outcomes. The initial model was fully adjusted for 
cardiovascular risk and GP attendance. 
 
4.6.4.1 Major adverse cardiovascular events (MACE) 
 
The association of categorised sBP and the hazard of a MACE event was not 
significantly altered by the inclusion of an interaction term involving frailty and 
BP-lowering treatment (Model 4) (Table 4-10). The interaction term in the model 
itself did have a statistically significant association with MACE (p-values for 
interaction: p<0.001). With the addition of a frailty-treatment interaction term, 
the AIC changed from 247,409 in model 2 to 247, 393 in model 3, and BIC 
changed from 247,579 in model 2 to 247,567 in model 3. This reduction in AIC 
and BIC is consistent with evidence of effect modification by frailty of the 
association of BP-lowering treatment and MACE. 
 
4.6.4.2 All-cause mortality 
 
There was no meaningful difference in the pattern of association of sBP and all-




lowering treatment and frailty (Model 4) (Table 4-11).The interaction term in the 
model itself did have a statistically significant association with all-cause 
mortality (p=0.020). The AIC in model 2 was 259,252, which reduced in model 3 
to an AIC of 259,249. The BIC in model 2 was 259,442 which increased in 
model 3 to a BIC of 259,423. Therefore there is no clear evidence of effect 
modification by frailty on the association of BP-lowering treatment and all-cause 
mortality. 
 
4.6.4.3 Injurious falls 
 
There was no clear difference in the pattern of association of sBP and injurious 
falls in the presence of an interaction term between frailty and BP-lowering 
treatment (Model 4) (Table 4-12). The interaction term in the model itself did 
have a statistically significant association with injurious fall events (p=0.001). 
The addition of this interaction term changed the AIC of 182,276 in model 2 to 
an AIC of 182,266 in model 3 and BIC of 182,446 in model 2 to a BIC of 
182,440 in model 3. This demonstrates that frailty may modify the effect of BP-
lowering treatment on the risk of injurious falls. 
 
4.7 Sensitivity analyses 
 
Sensitivity analyses were undertaken to determine whether there was a 
difference conditional on sex in the association between systolic BP and major 
cardiovascular events (see Table 4-13 and Table 4-14). Models adjusted for 




addition of frailty and with the addition of an interaction term between frailty and 
systolic blood pressure. There were no significant differences in the 




Table 4-13 Association between systolic blood pressure and major adverse cardiovascular events (MACE) in men, n=55,545 
 HR associated with systolic blood pressure category 
Model 1 Adjusted for established cardiovascular risk factors & treatment 
 <120 120-129 Re
f 






















Model 2 Model 1 + addition of frailty 
 <120 120-129 Re
f 
























Model 3 Model 2 + addition of interaction between frailty and sBP,  
 <120 120-129 Re
f 
































Table 4-14 Association between systolic blood pressure and major adverse cardiovascular events (MACE) in women, n=90,053 
 HR associated with systolic blood pressure category 
Model 1 Adjusted for established cardiovascular risk factors & treatment 
 <120 120-129 Re
f 
























Model 2 Model 1 + addition of frailty 
 <120 120-129 Re
f 
























Model 3 Model 2 + addition of interaction between frailty and sBP,  
 <120 120-129 Re
f 































The associations of systolic blood pressure with a range of cardiovascular and 
non-cardiovascular outcomes were modest and non-linear. Highest risk of 
adverse outcomes was associated with lowest systolic blood pressure. Findings 
presented in this chapter provide the first population-based evidence of frailty as 
a useful prognostic factor in a cohort of patients with hypertension for treatment 
as primary prevention of cardiovascular outcomes through the use of routine 
primary care data linked to routinely collected inpatient data and mortality data. 
The associations between systolic blood pressure and outcomes were not 
evident in sub-populations defined by moderate and severe frailty. This study 
found no clear evidence of effect modification by frailty of associations of 
systolic blood pressure with primary and secondary outcomes. However, 
findings demonstrate evidence of possible effect modification by frailty on the 




Chapter 5 Biographical interviews 
5.1 Summary 
This chapter presents the methods and findings of ten biographical interviews. 
Here I will address the final objective of this PhD which is to explore the 
patient’s perspective using a series of narrative interviews to reveal how the 
concept of frailty can inform shared decision making in older people with 
hypertension. This study was undertaken to complement the interpretation of 
routine data findings presented in Chapter 4 with the perspective of those who 
live with hypertension and frailty. Three themes emanated from the analysis: 





In the context of the uncertainty of how current evidence applies to older people 
with frailty, international guidelines recommend a more personalised approach 
to the management of hypertension in later life by using shared-decision 
making. Guidelines specifically recommend that the clinician considers: a 
person’s competing health concerns (323); overall clinical condition; and, 
concomitant medications (322). Guidelines recommend involving the patient to 
identify whether the balance of benefits and risks related to BP-lowering are in 





To do this requires an understanding of how people make choices about 
different outcomes related to hypertension, as this may be different in the 
context of ageing and competing risks. Currently, there is a lack of evidence as 
to what is important to older people and whether this is different in the context of 
frailty. As such, there is a need to understand more about the lives of older 
people with hypertension, to appreciate how hypertension and the 
consequences of treatment / non treatment may impact them. This study 
explores the perspective of older adults living with frailty on what is important 
from their own perspective, to determine which outcomes might be prioritised in 
the management of hypertension.  
 
5.3 Research Question 
 
Is frailty a useful measure to inform management of hypertension from the 
perspective of patients themselves? 
 
5.4 Objective 5 
 
To explore the patient’s perspective using a series of narrative interviews to 
reveal how the concept frailty can inform shared decision making in older 





5.5 Methods  
This study will be reported according to Consolidated Criteria for Recording of 
Qualitative Research (COREQ) guidelines (485). Ethical approval was granted 
by the East Midlands Research Ethics Committee (REC) 18/WM/0011 and 
written consent sought from all participants.  
 
5.5.1 Research team and reflexivity 
 
5.5.1.1 Personal characteristics of interviewer and team 
 
The interviewer throughout was the PhD student (OT). The interviewer is male, 
mixed white ethnicity, brought up in Cardiff, but had lived 2 years in the 
Bradford district where the interview participants lived. At the time of interviews, 
OT was aged in his early thirties, and a clinician with 9 years of clinical 
experience in London, Edinburgh, Bielefeld (Germany), and Katete (Zambia) 
following qualification. Currently, he was in post as a geriatrics registrar at 
Bradford Royal Infirmary. OT has experience of working with older people and 
was sensitive to those with frailty and the nature of mental capacity within this 
group.  
 
OT was supervised by a qualitative methods researcher, Mary Godfrey who has 
significant expertise in qualitative research methods, particularly in the context 
of frail older people. MG has worked on multiple qualitative research studies in 




OT’s interview methods and oversaw his development as an interviewer, using 
his experience of interviewing in clinical history-taking as a base. 
 
5.5.1.2 Relationship with participants 
 
5.5.1.2.1 Relationship established  
 
All of the CARE 75+ study cohort participants who were approached gave their 
consent for their contact details to be provided to the researchers seeking their 
participation in related future studies. The researcher (OT) first made contact 
three to four weeks prior to the first interview with a personal letter inviting the 
person’s participation in this study. The information sheet accompanying this 
letter explained who we were, together with photos of and contact details for the 
principle investigator (OT) and the qualitative PhD supervisor (MG). Shortly 
after the letters were sent, the interviewer (OT) called the participant to enquire 
whether the letter had been received and whether the person had any 
questions. All interviews were undertaken by one person (OT), who at the 
beginning of the first interview went through the participant consent process 
with each interviewee, and made an assessment of the mental capacity of the 
participant. 
 
5.5.1.2.2 Participant knowledge of the interviewer 
 
In an attempt to enable a more candid discussion of what can otherwise seem 
clinically prescribed concepts, OT introduced himself to participants in his 




written by the interviewer who was introduced as the researcher on the Study of 
blood pressure: What matters in Later Life? (SWaLLow) project. The purpose of 
the study was described in the information sheet as research ‘to understand 
from a patient’s perspective what matters in later life with regards blood 
pressure, so we will be able to understand how to better treat blood pressure in 
later life’. 
 
5.5.1.2.3 Interviewer assumptions 
 
The interviewer had a medical training, so his occupation, interests, cohort and 
background will be factors which shaped his interviewing style and analysis of 
the data. The interviewer was motivated to include a patient voice in this PhD 
study to balance the weight given to routine data,and  to inform how frailty may 
inform the clinical management of hypertension. Assumptions made early on in 
the conception of this study included that: outcomes of interest for older people 
with frailty may be different from those without frailty; and that, a person’s focus 
in later life may be more on the quality of life rather than longevity. It was also 
assumed that patients knew they had hypertension and may have had some 
experience of sharing decision making regarding BP-lowering treatment. 
Another assumption was that the language of priorities or choice of outcomes 
may be salient, as is the case in other patient groups. 
 





5.5.2.1 Methodological approach  
 
This study took an exploratory qualitative approach, employing interviews to 
elicit narratives and undertaking open biographical interviews, supported by a 
broad topic guide, among community-dwelling older participants. The choice of 
biographical approach was based on the following considerations: 
 
1. Experience of older age is shaped by structural and relational factors 
formed across the course of one’s life and therefore not something that 
can be considered separately from what has gone before. 
2. Lives, relationships and experiences change through time as does the 
way in which participants frame values and their sense of self. Within this 
there are cohort and cumulative dimensions to consider. The times a 
person has lived through as well as their chronological age will contribute 
to a person’s perceptions and values. 
3. Frailty and hypertension may appear medicalised concepts, so eliciting 
stories represents a means of empowering the narrator to speak on their 
own terms and represents a socially normative way of navigating 
subjects that may be intimate or sensitive such as ageing and death. 
Narratives are often rehearsed over time, reflecting enduring values, and 
can represent a means of communication that is still accessible for those 
developing cognitive impairment. 
4. Story-telling is a culturally normative means of communicating between 
older and younger people. Their currency may well help develop a 




and the interviewee. The potential for humour and metaphor in stories 





5.5.2.2 Patient Representative 
 
Mrs Dorothy Jones (DJ) was recruited as a patient representative. DJ is also 
older than 75 years old, has hypertension and has clinical features of frailty: 
having experienced multiple falls over the year prior to the study. A pilot 
interview was conducted with her to refine the topic guide. Mrs Jones also 
reviewed the invitation letter and information sheet for readability. 
 
5.5.2.3 Participant selection 
 
5.5.2.3.1 Sampling method 
 
A purposive sampling approach was adopted. Purposive sampling is a method 
of sampling that is common in qualitative research (486). This sampling method 
seeks to identify and select informative cases (487) by identifying and selecting 
groups who are willing to engage, and can communicate these experiences in a 
reflective manner (488).  
 
The aim of the study was to better understand the impact of one’s experience of 
ageing on hypertension management. Many characteristics are known to shape 
the ageing experience. The purposive sampling strategy in this study was 
based on key factors involved in ageing which are measurable: age; sex; level 
of frailty; and, whether prospective participants were living alone, with a partner, 





5.5.2.3.2 Sample size 
 
The aim was to recruit ten people. The sample size was chosen a priori, to 
achieve enough data for the purpose of this research which was: 
 
1. To explore a patient’s voice to complement a large routine data study 
which had a more generalisable study sample; 
2. To get as full a picture as possible within the limitations of this study, this 
being part of a research training fellowship whose dual aim was to 
introduce and train the investigator in qualitative research methods. 
 
This was planned as a small study which of itself was not intended to be 
representative of the whole population nor definitive in its findings. A sample 
size of ten patients was felt to be appropriate for the methodological approach 
employed, the purpose of which was to discover meaning, and to explore what 
is said and unsaid in sufficient depth and detail (489). The choice of sample size 








The recruitment process is presented in (Figure 5-1). Participants were 
recruited from the Community Ageing Research (CARE75+) cohort study (1,106 
participants recruited nationally at that time). CARE75+ participants are 
community dwelling older people aged >75 years. Care home residents, people 
living at home who were bedbound, and people in the terminal stage of life were 
excluded from the study (490). The CARE 75+ cohort has been profiled in 
published literature where cohort inclusion and exclusion criteria are also 
detailed (490). 86% of the CARE 75+ study cohort have given consent for their 
contact details to be provided to researchers seeking their participation in 
related future studies. Only those who had volunteered to be contacted to take 
part in future research studies were approached. Of these participants, the 
CARE 75+ cohort Project Manager was asked to provide a list of potential 
participants meeting all the inclusion criteria to the study researcher. 
 








All participants of this study were required to be: 
 
1. Participants of the CARE 75+ cohort study who have consented to be 
contacted about future studies; 
2. People identified as having frailty according to both the phenotype model 
and the electronic frailty index (both of which are defined in Section 
1.7.1).  
3. People with a diagnosis of hypertension on their GP record. 




This study excluded: 
 
1. People who are deemed to lack mental capacity and cannot consent to 
participating in this study; 
2. People who are not fluent in the English language.  
 
Participants with cognitive impairment who had capacity to consent were not 
excluded. An open invitation was made for a friend or close relative to attend, 
particularly where there were concerns from the investigator or family member 
that whilst the patient had capacity to consent, because of cognitive impairment, 





Given that the study was funded as a research training fellowship, interviews 
were undertaken in the interviewer’s first language only. As a result, 
participation in the study was limited to those who could understand verbal or 
written English.  
 
The researcher (OT) sent a letter inviting participation in the study by post to the 
identified potential participants. An information sheet accompanied this, 
explaining the study. This information sheet was co-written with the patient 
representative (DJ) to include contact details and photos of both the study 
investigator (OT) and supervisor (MG). The information sheet detailed: the 
study purpose; why the person had been approached; what taking part would 
involve; possible benefits and disadvantages of participation; and, what would 
happen to the results of the study. The letter clearly stated the plan to follow up 
with a telephone call to discuss the study in more detail. Those who did not 
want to discuss participation could call the team directly (i.e. an opt out 
process).  
 
To provide ample time to read the information sheets, the researcher 
telephoned potential participants a minimum of 5 days after sending the 
invitation letter and the information sheet. If the participant was eligible and 
interested in taking part, the researcher organised a time and place to meet. 
 
During the visit, the researcher first discussed and answered any questions 
about the study. It was made clear that the choice of whether to participate in 




way. If the person was willing and had capacity to consent, they were asked to 
complete the study consent form, and proceed to the initial interview.  
 
Capacity to consent was assessed by the researcher using the framework of 
the Mental Capacity Act (491). This assessment continued over the course of 
the telephone conversations and during the initial visit to explain the study, and 
also when going through the Consent Form. A copy of the consent form was 
given to the participants, and the original is stored centrally at the Academic 
Unit of Ageing and Stroke Research (ASR) at the Bradford Institute for Health 
Research.  
 
If consent was not given, the researcher left without conducting data collection, 
and any information held about the person by the research team was 
confidentially destroyed. The right of potential participants to refuse consent 
without giving reasons was respected. Participants who gave consent were free 
to withdraw from the study at any time without giving reasons, but the data 
recorded until that point were retained and this was explained both at the time 
of consent and time of withdrawal. 
 
For those who were unable to read but had capacity to consent, large print 
information sheets and consent forms were provided. Consent was also audio-
recorded. For those with hearing impairment, corrective devices were sought, 







The data manager of the CARE75+ study (490) provided a list of 42 participants 
who met the inclusion criteria for the study. Participants were approached in two 
waves to allow a period of time for people to decline and allow purposive 
sampling. A flow chart describes participation and reasons for rejection at each 
stage (Figure 5-2). The first patient was recruited on 9th April 2018, and the last 
patient was recruited on 18th May 2018. All patient recruitment was recorded 




Figure 5-2 Participant Flow Chart 
  
Figure description: The patient list provided by the CARE75+ data manager was an encrypted list, which was purposively sampled in 






5.5.2.4.1 Setting of interviews 
 
Once the consent form had been obtained and signed the researcher 
proceeded with the initial interview. Interviews took place at a time and location 
convenient for the participants and their carers, preferably at their own home. 
Participants were invited to have a member of their family, friend or carer 
present during the interview. The accompanying person was not actively 
involved in the interview. The interview was carried out in two parts, 
approximately one week apart. 
 
5.5.2.4.2 Sample characteristics 
 
The sample was balanced on age, sex, frailty score and living circumstances 









Participants were allocated a pseudonym in the data analysis. The choice of a 
pseudonym over a study number was a purposeful decision. Although both are 
of equivalent anonymity, the use of pseudonym may be more appropriate for a 
study using qualitative methods that aims at understanding the person in their 
social and biographical context. From a research practice perspective, 
assigning a pseudonym from the outset means that the researcher maintains a 
picture of the interviewee in terms of their pseudonym. It avoids the 
reductionism implicit in using a study number and for this type of study 
represents a more personalised approach whilst retaining anonymity. 
 
5.5.2.5 Data collection 
 





A two stage interview sequence was chosen to: lessen interviewee fatigue; give 
time to develop rapport; allow reflection by both interviewer and interviewee 
upon the issues discussed; and, for the interviewer to use the second interview 
to test out developing theories and explore emerging topics not covered in 
sufficient depth in the initial interview.  
 
Interviews were semi-structured, and based on a topic guide (see Appendix E). 
The first interview focused on the person’s identity, who they were, who they 
had become and what was important in defining a good life. The second 
interview was set in the context of what shaped the person over time, to explore 
more direct questions about: the process and meaning of older age; the 
concepts of frailty; hypertension; their own priorities; and, the concept of sharing 
decision making in the management of hypertension. 
 
5.5.2.5.2 Development of topic guide 
 
The interviewer used open methods of inquiry to invite the interviewee to tell 
their story. Prompted initially by the SWaLLow study topic guide, the interview 
was adapted to the needs of the individual participant. The topic guide was 
informed by a review of the evidence presented in Chapter 1 and Chapter 2, 
and was developed together with the patient representative DJ.  The topic guide 





1) Life events - health and illness experience, quality of life and 
wellbeing: 
 Briefly explore the person’s own biography – place of birth and growing 
up, family and occupation 
 Focus on any recent experience of changing health and illness, transition 
points, times of crisis and improvement (‘good days, bad days’)  
 
2) High blood pressure - personal experience of its diagnosis, treatment, 
and consequences: 
 Understanding of the diagnosis and implications of high blood pressure 
 Perception of blood pressure monitoring as a burden or an opportunity 
 
3) What is important for a good life - priorities in later life: 
 What it is important to them in terms of quality of life and wellbeing 
o Main fears and anxieties day to day 
 Priorities with respect to balancing short and long term goals. 
o Does perception change with changing overall health? 
 
5.5.2.5.3 Data recording 
 
Basic demographic data were extracted from the CARE75+ records. Interviews 
were audio-recoded and professionally transcribed in full. Field notes 
documented characteristics of the interviewee and home situation, reflective 
observations and impressions at the time. Key events in each person’s 







Interviews were planned to last approximately 45 minutes.  
 
5.5.2.5.5 Data saturation 
 
Once evolving concepts were fully accounted for across the data, the variability 
between concepts and participants was explained and relations between 
concepts were tested so that a theory emerged, and at this stage it could be 
verified that data saturation was attained (493). Data saturation is a concept 
where planned methods of analysis draw from a grounded theoretical approach, 
as did the comparative methods detailed below, where the aim was to develop 
an explanation of social processes in the context in which they take place (494, 
495).  
 
5.5.3 Data analysis  
 
5.5.3.1 Analytic techniques  
 
Narrative techniques of interviewing shaped the character of the data that 
emerged. A variety of techniques were explored to find meaning and to develop 
themes including narrative analysis and constant comparison (from grounded 
theory). Time-lines, matrices and coding were used to support the application of 





Transcripts were revisited to establish a person’s narrative or story. In 
particular, focus was given to how descriptions of self-identity might relate to 
changing experience of symptoms of ill-health over time and impact on current 
well-being. Both content and form were considered, and methods of inductive 
analysis were used, working from a reflexive stance.  
 
Key points of the analysis included the following: 
 
1. I sought to identify an individual’s trajectory over time by drawing 
timelines to identify correlation between changes in health status 
alongside major landmark life events.  
2. The data were analysed in an open manner.  
3. Stories were identified and each of them assessed with regards to 
structure (i.e. how the story is developed, conducted and told), and 
content (what the story means(496)). In particular, I looked for 
coherence: of the story within itself; of the story with other stories (497) 
and, of the story within an individual’s world (498). Matrices were 
developed that combined patterns of themes, relationships and 
trajectories over time around the three concepts introduced in the topic 
guide: ageing, high blood pressure and priorities in later life. 
4. I wanted to assess in what light the person presents themselves in the 
context of friends, family, and society (499, 500). A reflexive diary (501) 
was recorded to analyse findings in the context of the standpoint as an 
observer, and to iterate the method of inquiry and questioning.  




applied to identify broad themes as well as the manner of their telling, 
the attitudes that they expressed, what was said and what was left 
unsaid. Incidents that are conceptually similar were grouped together 
(502). Areas of dissonance were explored as representing potential 
uncertainty (503). Interviews were compared and contrasted and 
critically assessed for key themes.  
 





5.5.3.2 Participant checking 
 
Emerging findings were discussed with the Study Management Group, with the 
lay researcher (DJ), and with Patient and Public Involvement representatives on 
the Frailty Oversight Group which oversees projects involving the CARE 75+ 
study. At the end of the study, the findings were presented at an event to thank 
participants and their carers for their involvement, and feedback was sought 
from participants on the emerging themes identified. Findings were also 
presented to the Halifax Rugby Union Club Men United group and a discussion 
followed to determine whether the themes evolving from analyses were salient 




Standard approaches to demonstrating trustworthiness and quality in qualitative 
research were used, including: clear documentation of the research process 
(methods, analysis, any problems encountered and solutions found); 
transparency of the development of interview topic guides; documentation of the 
contextual features in which the research was carried out; the exploration of 
deviant cases and alternative explanations; discussions of emerging findings 







Twenty interviews with ten participants took place between March and May 
2018 (Table 5-1), lasting an average of 52 minutes (range 38 to 80 minutes). 
Six interviews involved family members. Participant mean age was 86 years 
(range 77 to 94). Half were women; half were men. The average frailty index in 
the cohort was 0.364 which is the equivalent of severe frailty, with a median 
phenotype frailty score of 3.5. Seven lived alone, two with their spouses, one 
with family. Hypertension had been diagnosed at different points in the life 
course: 2 during pregnancy, 3 following a stroke, 1 following a fall, 3 on 
screening. 
 
In terms of their biography, they were mostly born to large families, but had 
smaller families of their own (Table 5-2). Most had experienced upward social 
mobility. Half remembered regularly going hungry as children, now seven out of 
ten owned their own homes.  
 
Stories about biography focused on: overcoming constraints of the time (Table 
5-3) about the times they lived through; and, their relationships with others. The 
major and minor findings are grouped in three themes: how ageing is 
















Table 5-3 Characteristics of participants according to subjects of narrative across the life-course 
 




5.6.1 How is ageing conceived? 
 
5.6.1.1 Points of agreement 
 
There were several overarching themes in defining what ageing looked like in 
terms of the older people themselves. Ageing was often described as a gradual 
process made evident by external events, illnesses, or in other terms personal 
to that individual. Ageing was more visible in others than in oneself. Most did 
not identify as frail and described the term in negative and value laden terms. 
 
In their stories, participants used different markers to identify transitions across 
the life-course. Most often these markers represented changes of role, rather 
than age, and variably used children’s birthdays, a new job, moving house, 
one’s own illness, or more often, the illness of others. Several interviewees 
recalled childhoods in the inter-war years moving house or city in search of 
work, and went on to describe periods of their life by where they lived. Betty 
called the sheltered housing she moved into after her husband’s death “God’s 
waiting rooms”. Women including Margaret and Mary used the birthdays of 
children and grandchildren to charter their timelines. Men including Glen, 
Trevor, and Charlie referred to jobs, or associations with clubs.  
 
Ageing was variably described by it’s associated limitations, with the struggle to 
overcome these limitations, and with loss. For Betty, it was the limitations 
imposed by illness, she said “I walk slowly now”, “I think I’m tired, I must be tired 
at 94”, “I'm breathless all the time”. For Margaret it was a struggle that was 




most things for myself but I do struggle. I don’t always tell [my Daughter in Law, 
present]”. Indeed at each of Margaret’s losses: her husband’s death, her 
developing breathlessness, her delirium, she described how she had to find a 
new way to adjust and now life was “in slow motion. I mean I can’t shower every 
day else I’d never be out of it. I have to prepare me self every step of the way 
that I’m doing because it takes me so long to do everything”. Since her 
experience of post-operative delirium, Margaret felt more insecure about her 
memory, and she had taken measures to keep records, lists and plan the 
following day beforehand: she said, that now “there are a lot more things to 
remember”.  
 
Ron, engineer by profession, and do-it-yourself man in retirement, similarly 
characterised himself by his adaptations to overcome the effects of ageing. 
When Ron was asked whether he identified himself as frail, his son who was 
present, refined the question: 
Son: “A jar opened and it was really stiff, that’s a sign of frailty if you’re not 
able to twist the jar open, or something like that…” 
Ron: “Well, I’ve got a gadget…” 
 
5.6.1.2 Points of divergence 
 
There were differences in how people characterised their attitude to ageing and 
how much the ageing process was perceived to be in one’s own hands. On one 
hand, for many, there was an explicit acceptance that life would not go on for 




had become a carer in her later years. Her attitude to old age was “I've had my 
life, get off home lad”. On the other hand, ‘keeping doing’ was a major theme, 
and a strong identity as ‘survivors’ was expressed by various interviewees. 
Patricia, herself a soroptomist and strong believer in the importance of 
education, spoke of how the role of the older person had changed, and how 
people were themselves agents of that change. Patricia described ageing as a 
state of mind: “age is just a number isn’t it” and, “there’s no point just sitting in 
the corner with a shawl around your shoulders is there?” 
 
This related in part to where someone was on their own trajectory of ageing. For 
some, particularly where time had elapsed since, acute health events were 
associated with a permanent loss that had changed their landscape. This was 
the case both for illnesses of their own, and (more often), illnesses affecting 
their spouse. Ali said that “since my wife got cancer, then, I changed myself.. a 
lot of things happened”, he became much more focused on his faith and 
maintaining a healthy lifestyle. 
 
In others, one could sense a current tension, as their recognition of themselves 
ageing, seemed to be in transition. For Gertrude whose situation was changing, 
the effects of ageing were characterised as a (hopefully) temporary 
phenomenon. Gertrude said of the changes of aging “you just ignore them don’t 
you”, and seemed aware that her current way of life was under threat from 
increasing instability and falls, but pointed to different hobbies and tasks about 
the house, even hanging the washing on the line during the second interview. 









Most did not identify as frail and there was a resistance to accept the label for 
oneself. Ali said “I think I didn’t want.. to say I was frail, no, but weak … 
Sometimes weak, you know, I mean but it’s very rare I feel frail”. Frailty was 
often characterised in others rather than oneself. Frailty was differently defined 
but perceived generally in negative terms, and as something to avoid.  
 
Falls or rather the fear of falls defined frailty for Trevor who characterised frailty 
by decribing a relative: “she's perfectly capable of walking but she's frightened 
of falling again so she can't walk unaided”. Patricia said of her own fear “I didn’t 
trust meself”, “a matter of not being stupid, not doing something stupid to bring 
about [a fall]”. For others it was physical weakness. Mary described someone 
she had met at a community group “a lady there who was on crutches and she 
can’t come anymore because she can’t get out of her house, she must’ve 
twisted her ankle”, or another with memory problems: “she didn’t know where 
the heck she were, I know she couldn’t help it and it was pitiful”.  
 
For Charlie the image of frailty was of death itself, an image he had from a 
childhood memory when he was delivering papers “I went back to the shop and 
I said, “She’s not in,” “She is, get on and see, she takes a long while to get to 




me life, like a bloody skeleton, face were all eyeballs, you know, all there”. 
Margaret described frailty as complete dependence – as a pitiable state: “just a 
weakling and needing other people, needing help”.  
 
The fear of loneliness was profound. For Charlie, himself a soldier in world war 
2, survivorship came to him as much as a sense of duty as a matter of choice – 
he was “on the last bit” and it could be a “very lonely life in’t it, same with the 
watching telly like, and that’s bloody rubbish”. 
 
5.6.2 What is valued in life now? 
 
5.6.2.1 Points of agreement 
 
Narratives were focused on maintaining identity and finding meaning. Stories 
championed: survivorship in the face of adversity; inter-relatedness; and, 
keeping going. In contrast, giving up or being given up on characterised chief 
fears. 
 
Participants presented themselves as survivors, with an emphasis on defiance 
in the face of adversity. Participants were born between 1924 and 1941, so 
early life was characterised by living with the effects of world war one (WW1), 
the depression and world war two (WW2). Stories of ageing and disability were 
not confined to later life. Stories of youth, particularly for women, commonly 
involved caring for prematurely ill fathers: three of whom returned disabled from 




Identity was forged through experience of hardship and disability. After the 
death of Betty’s father whilst she was still a child, her mother and six siblings 
were left in poverty, “but she always fed us, you know, we never went hungry, 
[despite] being very poor”.  
 
‘Keeping going’, whatever the circumstance was a means of dealing with 
challenges of old age too. In later life, Glen, who had two jobs and kept working 
a 14 hour day until he was 75 said, “you’re better keeping work because once 
you stop you lose it and you can’t do it and if you stop you’re up the creek”. 
Surviving against the odds was esteemed in others. Betty revered her 
neighbour: “He’ll be 86 this time, I’m sure he is, he wants to see 100. But, there 
isn’t a lot like [him], is there, I mean, I see how he walks, he goes, he lives 
downstairs and he walks round”.  
 
Giving up the will or being given up on was a fear expressed in stories 
comparing themselves to peers. Glen described his younger neighbour who 
was ageing before his time as if a moral failure: “I know there’s a chap up [the 
road, and when I last visited, I asked] ’Where’s Len?’, I said ‘It’s dinner time, 
where’s Len, I’ve been looking for him?’, [his wife replied] ‘Oh, he hasn’t got out 
of his bed yet’, I said, ‘It’s bloody one o’clock’, ‘Oh, well he doesn’t get up if he’s 
nowt to get up for’”.  
 
How people justified themselves as not being frail also revealed values 




and dinner, and, being able to shave himself. These were functions he had 
previously lost whilst sick in hospital.  
 
Daughter: “He isn’t frail if he can do that is he, he isn’t frail if he can sit and have 
his drinks and have his dinner, no, I think you’re doing alright dad”.  
Charlie: “I’m not going to say ‘owt about that love”.  
[Both laughed] 
 
Betty resisted that she was frail because she is still going out, even if it was just 
once a week. Betty asked her daughter whether she was frail: 
 
Betty: “Am I frail love?”  
Daughter: “You’re frail now, yeah” 
Betty: “Yes, I am frail, yeah. “But I go out, we go out you see, a lot”  
 
Engaging with others was valued highly. Patricia described her friend talking 
about another from church “You’re the oldest of the lot of us”, she says, “and 
you’re organising us all!”. She got that straight, to keep going and want to be the 
organiser. So [...] it’s only a matter of a number on a book isn’t it, you know, 
age, it’s as you feel” . 
 





Differences in values were expressed in how they related to the individual, to 
family, or, to the community. Women often valued family and community more 
explicitly in the stories they told. 
 
Stories characterised their narrators by group identity, whether that was: as a 
couple; as a family; or, in their local community. Early in life, Betty developed 
tuberculosis for which she was moved to a sanatorium for more than a year, 
and her mother was left to bring up her new-born child. Explaining how this 
worked, Betty said “we got by, stuck together”.  
 
The post-war years were associated with a celebration of communal spirit, 
Margaret recollected the street parties in Keighley at the end of WW 2. Gertrude 
described in vivid detail the kindness of strangers who, 50 years ago, looked 
after her other children when she had to accompany her eldest daughter to 
hospital.  
 
In later life, inter-dependence emerged as a means of dealing with sickness. All 
five women married older men. When describing her husband suffering three 
life-threatening illnesses, and each time going to intensive care, Patricia spoke 
as if she and her husband went through it together. Patricia said “we went 
through intensive care and we got him through absolutely fine”.  
 
Sharing the burdens of family did not abate with age, even in the context of 




her own, Mary organised a family holiday for her son who had cancer, and was 
busy supporting her daughter through a difficult divorce.  
 
Existing without one’s family could be difficult to imagine. About the future, Ali 
said regarding his niece who planned to move out of their shared house “I think 
when she will go out [moves out], God knows what happen[s then]”. 
 
The role of inter-dependence in identity appeared particularly prominent for 
those for whom memory loss was a problem. This was evident in the exchanges 
enabled by the dyadic interviews (listed with * in Table 5-2). The interviewee 
seemed more comfortable in the presence of the son/ daughter. In different 
ways the son/ daughter helped craft a scaffold for which the interviewee’s 
fledgling memory could transmit a fuller sense of themselves. For example, in 
an exchange between Betty and her daughter, they describe Betty’s excitement 
about pension day, which is celebrated with tea at the supermarket:  
 
Daughter: “Every day she’ll say ‘Is it Thursday?’, No, it’s not pension day, mum” 
Betty: laughs 
Daughter: “It’s Saturday. She’ll say “What day is it? Oh, I thought it was 
Thursday” 
Betty: Is it Thursday today? “ 
Daughter: “No, it isn’t Thursday today, no. And when it’s Thursday, it’s “Is it 
Monday?” 





The daughter recounts the significance of Thursdays for her mother as a 
celebratory event, but the exchange does not suggest embarassement at her 
mother always asking ‘is it Thursday?’. This exchange reveals the manner in 
which Betty’s daughter supports her recall without challenging her competence, 





5.6.3 How is hypertension perceived? 
 
5.6.3.1 Points of agreement  
 
Hypertension was a peripheral matter, abstract, medicalised and difficult to 
relate to in its impact on one’s day to day life. This contrasted with discussions 
among participants about other health matters, falls for example. Hypertension 
was difficult to characterise as having an impact in a way that one could tell 
stories about. Margaret said “I’ve never had high blood pressure before, till that 
last time they said I had it!”. The relevance of hypertension to participants lives 
was evident by what was not said about hypertension. Glen said “I wouldn't 
know that I've got blood pressure except they tell me”. Gertrude said of her 
hypertension: “Yes, it did worry me but it didn’t alter me”. However, there was 
more of a sense of the dangers of high blood pressure, than the dangers of low 
blood pressure. Trevor said his BP varied a lot: “it can vary from reasonable to 
oh my God I’m glad to know I’m still here, so”. 
 
There was a sense that hypertension is something for which care could be 
delegated to others, not only doctors. Patricia was not worried about her own 
hypertension but when describing a visit to her friend in hospital, she said she 
asked the nurse “have you checked [his BP]... and [the nurse] showed me the 
chart… I said, ‘that’s better than mine’”. Similarly Glen said of his own 
hypertension: “it's made no difference to me, you know, that's why I said I can't 
really tell you much about blood [pressure], because it hasn't actually affected 





5.6.3.2 Points of divergence 
 
There was variation in the degree to which participants were engaged with the 
concept of hypertension, and how much they were actively involved in shared 
decision making regarding its management.  
 
Hypertension mattered where it’s outcomes were tangible, such as in 
pregnancy. Gertrude said “I knew more about it then than I do now really, but 
there was not as much you could do about it”. Or, after Ali’s stroke “but after the 
stroke I worried about it, yeah, after the stroke, everything went wrong with it 
anyway”. Ali remained clearly aware of blood pressure targets. Ali: “so I hope 
that [my BP] will come down again, you know? Hope it’s 140 at least, or 145. So 
I was thinking you will take the blood pressure”. 
 
Hypertension management decisions were contested by those who were more 
able to engage with their GPs. Trevor, who knew his GP socially, told him “ ‘I 
haven’t had one of your bloody pills for a month’. So [GP] said ‘you could have 
killed yourself; and I said ‘ well that would be my choice not yours”.  
 
Others experienced blood pressure management as outside of their control, 
particularly in how treatment changed over time. Charlie said “Some of them 
[tablets] have changed, you know, they [doctors] know you better”. Gertrude 




influenced by the importance that their own doctor had placed on their 
hypertension. Mary was aware of the uncertainty of the interpretation of BP 
measurement: “my blood pressure was always high there [at one GP], ..I 
finished up taking about seven different tablets, ..and as soon as I came over.., 
it was normal on the pump up one [sphygmomanometer]…we stopped them all. 
Apart from three.” 
 
5.6.4 Reflexive analysis 
 
Using narrative empowered the participants to take the floor, to speak on their 
terms. Narrative as a means of communication was something the participants 
felt at ease with and enjoyed. With it they used humour to navigate topics that 
were intimate including uncertainty about the future, their fears and threats to 
health. Narratives provided a rich picture of the complexity of ageing and it’s 
multifaceted aspects. Stories also communicated a person’s identity as more 
than their current condition, and the sum of all they were across their life-
course.  
 
A motivation for this study was to understand how people described their ageing 
trajectories and how priorities may change over time. Trajectories were difficult 
to discern because each person sees themselves as they are now and it is 
difficult to separate oneself from that to think about yourself in younger years. 
 
These stories revealed ageing on a person’s own terms. It became evident that 




cohorts of older people are the same. The social, economic and cultural context 
in which a cohort has grown up in forms who they are and what they value. The 
people interviewed in this study are part of a generation that are trail-blazers – 
ahead of the curve of a demographic shift to an ageing society, and the first 
generation for whom living to advanced old age is normal. They had defied 
odds that would have applied to earlier generations. Similarly, some of them 
lived through two world wars, tuberculosis, many illnesses that the past half 
century has found cures for. So they have experience of living with uncertainty 
that is beyond what someone in a much younger generation could understand. 
Perhaps related to this, the language of choices, priorities or outcomes do not 
translate well to this group. Similarly, sharing decision making may be a difficult 
concept for a generation for whom the same family doctor may have looked 
after people from ‘cradle to grave’, and social class was less transferable 
making doctors separate beings to be treated differently. 
 
One’s sense of age was a subject of tension in the stories. Ageing was 
estimated differently in others to oneself, and sometimes was presented in 
moral terms. Grounding approaches to shared decision making on an external 
measure of someone’s biological age may therefore prove challenging, 
particularly where it diverges from a person’s own sense of their age.  
 
The impression gained was that the way the doctor thought about their 
hypertension may have influenced how the patient thinks about hypertension. 
The way clinicians talk about medical problems influences the way the patient 




than the manner and attitude respected to a person’s blood pressure. If BP is 
checked routinely, and seen to be interpreted in a varied manner, it could be 
interpreted as indifference, and this could be projected onto patients.  
 
Experience as a doctor motivated the original research enquiry, and formed the 
basis of the heuristic technique of medical history taking which I was able to 
develop into a method of qualitative interviewing. However medical experience 
also will have shaped my interpretation of the data. Hypertension was not focal 
to these people, as I had expected it to be. Indeed medical conditions were not 
focal to their description of themselves. The personhood that emerged from 
these stories dwarfed the patient identity that electronic health records could 
ever capture, and witnessing this was rich and enlightening. From these stories 
emerged a person redefined not only as an individual but also in terms of their 
spouse and their community, with a high degree of interdependence.  
 
Frailty has social meaning separate from its academic definition. Language in 
society is not determined by academic health papers, denial of which could lead 
to harm, because current terminology has the potential to appear nihilistic or 
pejorative. 
 
Finally, from an ethical standpoint there are categorical imperative and utilitarian 
duties of a doctor. Blood pressure management is generally considered a 
matter of public health. On an individual level, population risk is difficult to 
translate. The language of shared decision making then in interventions of 




cohort, recognised the role of the doctor in balancing these risks, and that this 




5.7.1 Key findings 
 
1. Summary of key results according to objectives 
 
This study set out to explore what older people with frailty value and to 
determine whether or not frailty may be a useful measure to guide management 
of hypertension for patients on their own terms. Emerging from these interviews 
are three key factors impacting on shared decision making in the management 
of hypertension: their sense of ageing; ‘what matters’; and, hypertension itself. 
 
First, in relation to ageing, narratives revealed the agency of older people to 
adapt to maintain a good life despite the constraints of increasing disability and 
illness. The interviewees did not define themselves as frail, but rather by who 
they were in spite of their frailty. Frailty was characterised in reference to 
physical or cognitive impairments, or to the sense of ‘giving up’, and frailty was 
described generally in negative and value laden terms.  
 
Second, with regards to what matters, keeping going and maintaining identity 




feared. The role of the spouse, family and community were important to 
maintaining identity, as a scaffold for what matters, especially where a person’s 
identity was under threat, e.g. with cognitive impairment. 
 
Third, participants were engaged with the concept of hypertension where the 
outcomes were tangible (i.e. in secondary prevention) and the impact was 
evident in their everyday lives. In the absence of these factors, and in contrast 
with competing problems such as falls and obstacles to getting around, 




The individuals interviewed all lived in the Bradford district, they had grown up 
and lived with the shared social and cultural influences of a particular period of 
time; and only one of the ten was born outside the UK. This cohort had 
experienced a particular world in their upbringing which will have defined who 
they were. They held values such as keeping going and resilience and 
respected the social status given to doctors. These factors may have influenced 
how a person approaches shared decision making, and may not generalise: to 
other older people from younger cohorts; to those in different cultural settings 
across the UK; or, to those of different ethnic origin.  
 
The life course methods chosen in this study enabled a rich exploration of the 
topics relevant to the research question. Maybe as a result of the choice of 




the intention of the study design. Limitations included the primary assumption 
on which this study was based, i.e. what matters to someone is evident in the 
stories they tell, but there are likely to be additional implicit values that are not 
easy to articulate in narrative. How one presents oneself in an interview does 
not necessarily represent how one sees oneself, although this gap may have 
been addressed in small part by returning for a second interview. 
 
Participants were not forthcoming on the topic of hypertension. It seems 
possible that while clinical aspects of hypertension are more difficult to tell 
stories about, hypertension is not necessarily less pertinent to a person. In this 
study sample there was a minority of people who seemed to have engaged with 
sharing decision making on hypertension management, the majority had not. 
Subsequent presentation of the findings to a Patient and Public Involvement 
group (PPI) revealed a much more engaged approach to hypertension 
management among panel members. The purposive selection of older people 
with more active engagement in their hypertension management may provide a 
useful extension of the study to explore more divergent views.  
 
5.7.3 Cautious interpretation of results 
 
1. Concept of the ageing process and utility of frailty 
A rich picture emerged of ageing across the life course, of cohort effects, and of 
the role of spouse and community. The life course approach highlighted stories 
of agency, in the face of adversity, be that: war and poverty; the consequences 




ageing of their own. Frailty was defined by its impairments and by the negative 
stereotypes which may represent stereotypes of ageing itself. However, frailty 
did open up conversations about what matters, and it facilitated discussions on 
how social and psychological factors may impact upon people’s lives. 
 
2. Hypertension and shared decision making 
 
Agency was a key theme in the stories that described ageing, and in values in 
later life. Shared decision making is of course an exercise in empowering a 
patient to be an agent in their medical care. However, to have meaning, shared 
decision making must engage issues that are tangible or salient with the 
person. For a minority of those interviewed, this may include hypertension. For 
example for Ali, for whom hypertension was diagnosed after a life changing 
stroke, and the management of hypertension was in the secondary prevention 
of a future recurrent stroke. For others, where hypertension was less pertinent, 
shared decision making might better focus on matters that are salient. For 
many, falls or ability to move around were highly relevant to their day to day. 
The management of BP and its impact maybe relevant then in the context of 
these goals, rather than to manage hypertension per se. 
 
Therefore, rather than focus on greater guidance for shared decision making in 
hypertension, tools for discussing BP lowering should be applicable to a range 





5.7.4 Generalisability - considering the literature 
 
In the qualitative literature, there are two major themes in research involving the 
concept of frailty. Firstly, those with frailty do not regard themselves as frail, and 
they tend to distance themselves from the label of frailty. Secondly, people who 
have frailty, and may not consider themselves to be frail, are very resilient and 
highly adaptive in managing to adapt to changes brought on by frailty in ways 
that may not be evident if seeing them only through a medical lens. 
 
With regard to the first, it was apparent from these interviews, that people with 
frailty had a different perception of frailty to how clinicians may perceive people 
with frailty, which may also be different to the clinical concept of frailty (504, 
505). Negative outcomes or fears or being ‘given up on’ or ‘giving up’ oneself 
(506), were revealed through techniques of ‘othering’ of frailty (507). Othering 
describes a process taken by individuals to identify those who are classified in a 
negative way and distinct from oneself. Othering can reveal the biomedical and 
cultural notions of what it means to have frailty. Warmoth et al describe the 
resistance to the label of frailty as representing an identity that can be 
stigmatising and disempowering (504). Nicholson described frailty as perceived 
by patients, as assuming a moral character or denoting a lack of agency (505).  
 
Secondly, people who have frailty, and may not consider themselves to be frail, 
are very resilient and highly adaptive in managing to adapt to changes brought 




the limitations on these people’s lives that are brought upon by ageing as 
affected by loss, disability, and illness. However, as Ron described when he 
could not open a jar by himself, but he could with the aid of a gadget, not being 
able to do things, forced people to do things differently. This adaptive capacity 
is described elsewhere and may represent the features of successful ageing 
(508); ageing characterised not by the absence of health problems but by the 
adjustment to health problems – and in that adjustment a sense of self growth 
through loss.  
 
The value of maintaining identity in spite of illness, described in these stories, 
correlates with the description of ‘work as illness’ (509). Corbin and Strauss 
describe the trajectory of living with illness, as a combination of the 
physiological unfolding of disease, medical treatments given, and the inter-
related work of both the person who is ill and those around them, to live, adapt 
to, and manage illness.  
 
The work of illness was not evident with respect to hypertension as much as it 
was in relation to other problems such as falls or mobility. However, this is 
perhaps unsurprising because for most individuals interviewed, hypertension 
was not evident in their narratives. Hypertension hadn’t caused disruption in 
their biographies. The BP-lowering medication routine did not stand out as 
being particularly meaningful or unusual for any of the interviewees. The side 
effects or burden of medications did not, as far as they were aware, threaten 
their identity. This may relate to limitations of the methodological approach, 




hypertension, particularly as primary prevention is not a salient issue among 
this cohort. This may relate to the lack of association with impact on their daily 
life, or relate to a perceived lack of importance placed on hypertension by their 
clinicians.  
 
The utility of frailty given the different understandings of the term between 
clinicians and patients pose questions for the use of ‘frailty’ in prompting shared 
decision making in hypertension. On reflection, the narratives around frailty in 
these interviews themselves framed discussions about coping strategies and 
what matters to an individual. As a clinical concept, frailty does at least open up 
the impact of social and psychological factors (510, 511) and aspects of agency 
(512) upon the ageing process. These discussions, sometimes enabled by the 
presence of a care-giver or family member, may help to reveal the sense of a 
person through a non-medical lens – out with their identity as a patient. This 
was evident from the exchanges between Betty and her daughter which was full 
of humour, that their relationship was bidirectional, each gained from the 
another, and they were inter-dependent (513). 
 
5.8 Conclusions  
 
The conception of frailty emerging from the perspectives of patients with 
hypertension is different to how clinicians may routinely consider the concept of 
frailty. Understanding how a person conceives of frailty offer a means to 




value and what they fear. Shared decision making in hypertension was engaged 
in where the outcomes relating to treatment were tangible and relevant. 
Therefore, guides and tools for shared decision making about BP-lowering 
should have application to a range of patient concerns. Involving a close family 




Chapter 6 Discussion 
 
6.1 Introduction  
 
Cardiovascular disease is the leading cause of death worldwide (514) and 
hypertension is its most common risk factor (5). Hypertension is the most 
frequent lifelong condition (9), and its prevalence increases steadily with age 
(23). However, guidelines for the management of hypertension for older people 
remain based on expert opinion (320, 322, 323) due to the absence of a good 
quality evidence base. 
 
This study set out to address an important knowledge gap in the current 
understanding of the association of BP with outcomes for older people with 
frailty. The research was motivated by new advances in the field of vascular 
ageing and the aim of this work was to ascertain the application of knowledge 
gained through ‘bench’ science to ‘bedside’ clinical hypertension care.  
 
The research presented in this thesis is a thorough investigation of BP and 
outcomes in older people according to their frailty status. This is the first study 
of its kind to do so in a large scale generalisable population which has direct 
application to a specific clinical setting, namely those with hypertension that is 
managed for primary prevention of cardiovascular risk in primary care. This 
study is novel in distinguishing distinct questions of prognosis and causal 




research by applying more rigorous statistical methods to account for the 
complexity of this real world data. These methods included the use of 
parametric models to address non-proportional hazards; adjustment for the 
most up-to-date profile of established cardiovascular risk (QRISK-3); 
investigation of non-cardiovascular and non-fatal outcomes; and, data 
imputation to mitigate bias resulting from missing data. Moreover, the research 
presented in this thesis pioneers the use of mixed methods to explore the 
perspectives of patients in the interpretation of data findings; and in the use of 
narrative methods to understand the perspectives of older people on priorities in 
hypertension management.  
 
The empirical and novel findings which have arisen from this thesis are 
summarised below. A synthesis and a detailed discussion of these results are 
given in Section 6.2.1, Section 6.2.2, Section 6.2.3 and Section 6.3. All 
findings are placed in the context of an up to date literature review assessing a 
broad set of relevant prior research. Strengths and limitations of the 
methodological approaches used throughout the PhD research study are 
discussed. This will be followed by an examination of various sources of 
potential bias which may impact on the interpretation of findings. The chapter 
concludes with a comprehensive set of study implications, recommendations for 
clinical management, healthcare policy and future research before reaching an 
overall conclusion. 
 




1. In the systematic review and meta-analysis, I summarised evidence from 
traditional cohort studies, identifying that lower systolic BP is associated 
with reduced all-cause mortality in those without frailty, but that there is 
no association in those with frailty.  
2. In the large routine data study, I identified that frailty represents an 
important prognostic factor for cardiovascular and non-cardiovascular 
outcomes, in addition to measures of established cardiovascular risk. 
3. In the large routine data study, I found no evidence that the effect of 
systolic BP on outcomes is different in older people according their frailty 
status. However, I did find evidence that the effect of BP-lowering 
treatment on outcomes was different in older people according to their 
frailty status. 
4. My interviews with people living with frailty and hypertension reveal that 
engaging patients in the management of their hypertension is possible 
when the outcomes relating to treatment are tangible and relevant to that 
person. Identifying how a person conceives frailty may itself offer a 
means to understand that person on their terms: how they identify 
themselves; what they value; and, what they fear. 
 
6.2 Summary of key findings 





Evidence from existing observational studies found no statistical difference in 
risk of all-cause mortality for older people with frailty whose systolic BP is <140 
mm Hg, compared to those with a systolic BP >140 mm Hg. 
In these nine studies, there were both general limitations due to the use of 
traditional cohort studies, and specific limitations relating to the design of these 
particular cohort studies. A key constraint of the use of traditional cohort studies 
in comparison to routine data is the lack of external validity (as discussed in 
Section 3.5.3.1). Concerning the particular design of the nine included studies: 
the study numbers were small; BP was categorised according to various 
classifications that do not relate to hypertension guideline categorisations; 
cardiovascular risk was measured without using established cardiovascular risk 
scores, and frailty without using frailty measures that are commonly used in 
clinical practice. More specifically, none of the included studies distinguished 
between older people in their study sample who had hypertension and those 
without hypertension, or hypertension management for primary prevention with 
that for secondary prevention. Only five out of the nine included studies 
reported the overall risk of outcomes in the study population as a whole before 
stratifying by frailty (318, 351, 354-356). In all of these five studies, risk of 
outcome was decreased in association with higher BPs.  
 
The methods and designs of these studies were not distinguished as either 
prognostic, or causal inference studies, although doing so would have also 
aided the interpretation of their results. The absence of methods to address 




were therefore difficult to extrapolate to a particular clinical setting, with limited 
ability therefore to impact upon clinical practice. 
 
6.2.2 Association between systolic BP and outcomes in 145,598 
people over the age of 65 years 
 
The analysis of primary healthcare records of people older than 65 years who 
had hypertension but no previous history of cardiovascular disease, revealed 
that there was a higher risk of outcomes associated with low systolic BP over 10 
year follow-up. Findings indicate that despite adjustment, the risk of death from 
any cause is 46% higher in those with a systolic BP < 120 mm Hg compared to 
a systolic BP between 130-139 mm Hg; injurious falls are 21% higher, and 
MACE 16% higher. Risk of high BP was only evident with respect to MACE at a 
systolic BP > 180 mm Hg which is associated with a 7% increased risk of MACE 
compared to a systolic BP between 130-139 mm Hg (see Section 4.4.2). 
 
6.2.3 Investigation of frailty as a prognostic factor in the 
management of hypertension 
 
Older people with higher degrees of frailty had lower average systolic and 
diastolic BP recordings and variability of systolic BP increased. Despite 
adjustment for known cardiovascular risk factors, patients were at higher risk of 
MACE with advancing frailty. Compared to those who were fit, mild frailty was 
associated with a 38% increased risk of MACE; moderate frailty; 84% increased 
risk; and, severe frailty, 117% increased risk (see Section 4.5.2). Greater 




and sustaining injurious falls. The addition of frailty improved model fit 
significantly above that using cardiovascular risk factors alone (see Section 
4.5.3). This is evidence that frailty is a useful prognostic factor for 
cardiovascular and non-cardiovascular adverse events in the context of 
hypertension management. 
 
6.2.4 Epidemiological investigation of associations between BP and 
outcomes in the context of frailty  
 
The findings of the PhD study indicate that extremes of low and high systolic BP 
are associated with higher risk of cardiovascular and non-cardiovascular 
outcomes in older people without frailty, and in people with mild frailty. 
However, in people with moderate and severe frailty, the results indicate no 
difference conditional on systolic BP with respect to cardiovascular and non-
cardiovascular outcomes measured (see Section 4.6.2).  
 
The association of systolic BP and outcomes was not different in the context of 
frailty. Specifically, three pre-specified tests of effect modification returned 
equivocal results. This indicates that the effect of systolic BP on outcomes was 
not meaningfully different on condition of baseline frailty (see Section 4.6.3). 
However, the PhD study did find evidence of a differential effect of BP-lowering 
medication on outcomes in the context of frailty (see Section 4.6.4). This may 
suggest that the modifying effect of frailty in the context of hypertension 




adverse effects of BP-lowering treatment. This is an important finding and one 
deserving of further investigation. 
 
6.2.5 Personal perspectives of older people treated for hypertension 
 
The personal perspectives of people who are in receipt of care for hypertension, 
and have features of frailty was informative. In the stories reported in Chapter 5, 
ageing was presented in terms that challenged established negative 
stereotypes of ageing. Stories championed the concept of agency, as defined 
as the capacity of an individual to act independently and make free choices 
(515). In the context of this more holistic depiction of an older person’s life, 
hypertension management appeared abstract, medicalised and peripheral to 
what mattered to the people interviewed. Only a minority recalled being 
engaged with the management of their hypertension. For this minority, this 
engagement was in a context where outcomes were tangible, personal and 
salient to them. Although this study was small and exploratory in nature, it may 
inform the interpretation of the data findings to clinical care and future research. 
 
6.3 Data findings in the context of previous research 
 
6.3.1 Investigation of associations of systolic BP and outcomes 
 
First, the association between systolic BP and outcomes was non-linear and the 





The PhD study finding of a U-shaped association between systolic BP and 
outcomes is consistent with the findings of many small traditional cohort studies 
which were presented in Table 1.4. In addition, the PhD findings are consistent 
with those five studies included in the meta-analysis which reported BP-
outcome associations in their study populations overall (318, 351, 354-356). 
Other studies also investigating associations of BP and outcome in the context 
of frailty, using routine data from primary care records, did not report overall 
population associations before stratifying by frailty (365, 366). 
 
However, the findings of the PhD study are inconsistent with data from trials 
which, despite the caveats discussed in Section 1.6.1, demonstrate evidence of 
a positive dose-response relationship between systolic BP and outcomes. The 
associations demonstrated between BP and outcomes in the PhD study are 
also inconsistent with the findings of other large epidemiological research 
studies that demonstrate a linear association between BP and cardiovascular 
outcomes. The Prospective Studies Collaborative (PSC) undertook an individual 
patient data (IPD) meta-analysis, including 958,074 participants in 61 studies in 
America, Asia, and Europe published in 2001 (367). This large meta-analysis 
demonstrated that above a systolic BP of 115 mm Hg, there is a continuous 
association between systolic BP and cardiovascular risk (367).  
 
The finding of the PhD study, that the association between BP and outcomes 
was only modestly increased with higher BP is also contrary to the findings of 
the Prospective Studies Collaborative (PSC). In the PSC meta-analysis, a 20 




aged 60 – 69 years, by 57% (HR 0.43 (95% CI 0.41 – 0.45); in those aged 70-
79 years, by 50% (HR 0.50 (95% CI 0.48 – 0.52); and in those aged 80- 89 
years, by 33% (HR 0.67 (95% CI 0.63 – 0.71) (367). Risk reduction for incident 
ischaemic heart disease and other vascular events were similarly marked, and 
remained significant in older age groups.  
 
There are two major differences in study design between the PhD study and 
both the PSC meta-analysis and the trial data: in relation to disease burden in 
the study population; and, in relation to the method of BP measurement. I will 
discuss each in turn. 
 
Firstly, considering study population, the PhD study involved a relatively current 
and broadly generalisable population representative of clinical practice, i.e. a 
cohort with a disease burden representative of older people with hypertension. 
Of the whole PhD study cohort, 1.4% were care home residents. The median 
number of co-morbidities in this study population was three (inclusive of 
hypertension), and 67.5% had multi-morbidity (defined as two or more long-term 
conditions), which is consistent with proportions reported in a recent large scale 
community UK cohort study (340). In contrast, trial populations represented 
selective, healthy populations, as discussed in Section 1.6.1(277).  
 
Examining the studies included in Lewington’s PSC meta-analysis, whilst they 
included people of older age, these participants had a low burden of non-
cardiovascular disease. The study cohorts included in the pooled analysis had 




management changes with time (516) and will have been markedly different in 
the time of the PSC study period compared to the PhD study period. Also, the 
population of older people at that time had a lower level of chronic disease than 
the population of older people in 2007, as the prevalence of living with chronic 
disability has been increasing over time in the UK (517). Fewer people at the 
time of the PSC study would have been on BP-lowering treatment. Indeed 
adjustment in the synthesis was made for age and sex only, not for BP-lowering 
treatment or other cardiovascular risk factors. Furthermore, there was no 
analysis of the risk of bias in included studies or of the representativeness of 
study populations. 
 
Secondly, a major difference between the PhD study, relevant trials such as 
SPRINT (275) and HYVET (267), and epidemiological studies such as included 
in the PSC meta-analysis (367), is in the method of BP measurement. BP 
measurement in a trial setting is typically more precise and time consuming, 
and for those reasons maybe closer to a person’s true BP than BPs measured 
in routine clinical practice (518). In the PSC study, whilst the practice of BP 
measurement was not necessarily more precise, methods of correction of time-
dependent regression dilution used sequential BPs to address the imprecision 
of single BP measures. Bias because of regression dilution will be discussed in 
greater detail in Section 6.6.4. 
 
The more modest point estimate of cardiovascular risk associated with systolic 
BP in the PhD is consistent with other recent studies in the UK that also use 




and BP-lowering treatment. In the development of the QRISK-3 cardiovascular 
score using the QRESEARCH database (profiled in Table 3-1), a 1 mm Hg 
increase in systolic BP was associated with an 0.5% increase in cardiovascular 
outcomes, HR 1.005 (95% CI 1.004 – 1.005) (446). Like SAIL, QRESEARCH, is 
representative of clinical practice where high BPs are treated and therefore their 
associated clinical risk is mitigated.  
 
Another study also using routine data with single BP measures is work 
published by Rapsomaniki et al in 2014 using UK primary care data from CPRD 
(also profiled in Table 3-1) to examine the association between systolic BP and 
12 cardiovascular outcomes in a population of 1,258,006 adults over the age of 
30 years (519). The Rapsomaniki study found associations between BP and 12 
cardiovascular outcomes in the age group 60 – 79 years remained linear. 
However, the authors reported that associations were more modest in the 
oldest age sub-population (>80 years), and that the association of increased 
outcomes with increasing BP was not significantly different for unstable angina, 
stroke or abdominal aortic aneurysm. For incidence of myocardial infarction, 
new diagnosis of heart failure, peripheral arterial disease and stable angina, risk 
with increased systolic BP was only evident above a systolic BP of 160 mm Hg. 
Associations were U-shaped only for those with unheralded coronary death and 
cardiac arrest, but in these cases, systolic BP hazard ratios were not statistically 
different at any systolic BP.  
 
Important differences with the PhD study include that the study population in the 




CPRD study cohort had BP > 140/90 mm Hg, and only 21% were prescribed 
BP-lowering drugs at baseline. This is in contrast with the PhD study in which all 
of the patients had either a diagnosis of hypertension or a BP measure which 
was above NICE guideline diagnostic criteria for hypertension, and 87% of 
whom were on BP-lowering drugs at baseline. Adjustment of the CPRD data 
was made for age and sex only, rather than the full profile of cardiovascular risk 
and BP-lowering treatment.  
 
In a similarly large prospective cohort study involving 512,891 adults living in 
China who were between the ages of 30 and 79 years, followed up for a median 
period of 9 years, Lacey et al demonstrated linear associations of systolic BP 
with cardiovascular outcomes (520). In this study every 10 mm Hg increase in 
systolic BP was associated with a 31% increase in ischaemic heart disease (HR 
1.31 (95% CI 1.28 – 1.34)), and a 30% increase in stroke (HR 1.30 (95% CI 
1.29 – 1.34)). However, it was estimated that in this same study population only 
5% had been diagnosed with hypertension and were prescribed BP-lowering 
medication (521). 
 
In summary, before discussing whether there is a differential association 
between systolic BP and outcomes relative to levels of frailty, it has been 
important to examine the generalisability of BP-outcome associations in the 
PhD study compared to other major studies in the field. The findings of current 
evidence are conflicting: with some studies demonstrating a U-shaped or J–
shaped non-linear association between systolic BP and outcomes, and others 




variation in the existing evidence base may relate not so much to study design 
(i.e. whether a study is interventional or epidemiological) as to the burden of 
disease in the population studied (and related to this, the level of BP-lowering 





6.3.2 Investigation of frailty as a prognostic factor in the 
management of hypertension 
 
This study has found that advancing frailty is associated with increased 
variability in systolic BP and that average systolic and diastolic BP fall with 
advancing frailty. However, there was no difference in pulse pressure 
conditional on frailty. The finding that systolic BP variability increases with 
increasing arterial stiffness was demonstrated by early studies of the elasticity 
of the human aorta (66). Falling BP in the 20 years ahead of death has also 
been shown in another large population study using CPRD data (32).  
 
The finding of the PhD study, that the measurement of frailty has prognostic 
utility in hypertension, is a confirmation of findings of other studies. The role of 
frailty alongside other measures of traditional cardiovascular risk factors for 
cardiovascular outcomes has been investigated in a Canadian health records 
data set (522). This comparatively small study analysed population-based 
medical records with a ten year follow up where the outcomes included 
coronary heart disease (CHD) hospitalisation and coronary heart disease (CHD) 
mortality in a study population with an average age of 47 years. None of the 
participants in the Canadian study were care home residents and none had a 
history of coronary heart disease. Those with missing data were excluded. The 
study investigated the value of non-traditional risk factors for the prediction of 
cardiovascular events. Only 8% of the population went on to sustain a 
cardiovascular event. The study found non-traditional risk factors were 
associated with increased risk of future cardiovascular events despite 




traditional cardiovascular risk factors and incident CHD events was also 
significant after controlling for all of the traditional cardiovascular risk factors 
(adjusted HR = 1.31, 95% CI 1.14 – 1.51, p = 0.001), and the estimate associated 
with a frailty index that combined cardiovascular and non-cardiovascular risk 
factors was further from the null. (adj. HR = 1.61, 95% CI 1.40 – 1.85) (522). 
 
The findings of the PhD also are consistent with a recent post-hoc analysis of 
13 randomised control trial populations involving a variety of cardiovascular 
interventions (including the HOPE-3 trial (276) profiled in Table 1-2) (523). In a 
total population of 154,696 individuals, frailty (defined as an FI > 0.21) added 
prognostic value to a Framingham cardiovascular risk model in predicting 
cardiovascular morbidity and mortality (C statistic improved from 0.58 to 0.60). 
The PhD builds on the work of Farooqi: by using a measure of frailty that is 
gradable rather than dichotomised; to extend the role of frailty to a particular 
application in the management of hypertension for primary prevention; and to a 
study population which has greater external validity that trial populations can 
afford. 
 
6.3.3 Epidemiological investigation of associations between systolic 
BP and outcomes in the context of frailty  
 
The findings of the PhD routine data study are in parts both consistent and 
inconsistent with the pooled synthesis of the meta-analysis presented in 
Chapter 2. Consistent with the meta-analysis, the PhD routine data study found 




person’s systolic BP, but in the presence of frailty, there is no association 
between systolic BP and all-cause mortality. The routine data study extended 
this finding to a broader range of outcomes to include major adverse 
cardiovascular events and injurious falls.  
 
In contrast with the findings of the meta-analysis, the PhD routine data study 
demonstrates systolic BP < 120 mm Hg was associated with a higher risk of all 
outcomes in participants who were fit or had mild frailty. Results of the meta-
analysis demonstrated that in participants without frailty, systolic BP < 140 mm 
Hg was associated with lower mortality. However, as discussed in Section 
6.3.1, it seems plausible that these differences relate to variation in population 
characteristics or in the method of BP measurement between the PhD data 
study and the traditional cohort studies included in the meta-analysis.  
  
6.3.3.1 No evidence that frailty causes an effect modification of the 
association between systolic BP and outcomes 
 
The PhD routine data study found no evidence that frailty causes an effect 
modification of the association between systolic BP and outcomes. This is in 
keeping with five of the six cohort studies included in the meta-analysis that 
tested for an interaction term between BP and outcome in an adjusted model 
(351, 354-357), as discussed in Section 2.4.7. In the single study reporting a 
significant role of frailty as effect modifier of the association of systolic BP with 
outcomes (318), frailty was measured using a phenotype measure of frailty 




Other differences included: the population ethnicity (Lv study was located in 
China); and the proportion of the population prescribed BP-lowering treatment 
(59% in Lv et al study; 87% in the PhD study). Furthermore, it was unclear in 
the Lv study’s reporting whether the interaction term had been tested within a 
model already adjusted for cardiovascular risk. The method of testing for the 
interaction term was not detailed in the Lv study. Finally, the interaction term 
with frailty was one of eight interaction terms tested in the Lv study, raising the 
risk that multiple testing may have led to a false positive finding (524). 
 
6.3.3.2 Evidence frailty causes effect modification of the association 
between BP-lowering treatment and outcomes 
 
This study found evidence that frailty modified the effect of BP-lowering 
treatment on outcomes. The number of BP-lowering treatments was not 
different conditional on frailty in this study population, so it seems less plausible 
that the effect modification represents different prescribing practice. This may 
suggest that the modifying effect of frailty in the context of hypertension 
management, is in the degree to which someone suffers adverse effects or 
gains benefit from BP-lowering treatment. This is an important finding, as it may 
be consistent with the evidence that older people with frailty are more at risk of 
adverse effects from treatment (Section 1.6.2.2.1). From this study alone, given 
its observational nature, it is not possible to infer any causal relationship from 





Importantly, this observation, of the association of BP-lowering treatment 
exposure on outcomes was exploratory in nature: it was not pre-specified in the 
protocol; and, the size of effect was not measured. The interaction between 
measured BP and outcomes stratified by frailty and treatment has previously 
been investigated in electronic health records (365), but in this study, like the 
pre-specified analysis of this PhD, the exposure was BP not BP-lowering 
treatment.  
 
These exploratory findings are inconsistent with both analyses of randomised 
control trials in the management of hypertension that have been retrospectively 
analysed with a post-hoc frailty index (359, 362). Both analyses demonstrated 
no evidence of effect modification by frailty on the effect of treatment on 
cardiovascular outcomes. As discussed in Section 2.5.2.1, there were 
particular limitations about the retrospective measurement of frailty, the over-
representation of cardiovascular risk factors in those frailty indices and the lack 
of statistical power of these analyses for them to be definitive. 
 
The exploratory findings are consistent with those of the Predictive Values of 
BP and Arterial Stiffness in Institutionalised Very Aged Population (PARTAGE) 
study undertaken among 1,127 nursing home residents over the age of 80 
years in France and Italy with 2 year follow up (525). The PARTAGE study 
demonstrated that those with a systolic BP of less than 130 mm Hg, on > 2 BP-
lowering medications had a higher risk of all-cause mortality (HR 1.78, 95% CI 
1.34 - 2.37) compared to other patients. This finding remained fit in three 




cardiovascular risk; and, the authors also tested their findings by repeating 
analyses limited only to those people who had a diagnosis of hypertension and 
were prescribed BP-lowering medication.  
 
The PhD study findings are also consistent with one of the few studies 
examining the association between BP and falls. The Tinetti study in the USA 
included 4,961 Medicare participants enrolled between 2004-2007 who were 
over the age of 70 years old. The study followed up participants for 3 years to 
record serious fall injuries including hip and other major fractures, traumatic 
brain injuries and joint dislocations. 85.9% of study participants were prescribed 
BP-lowering medications. BP-lowering medications were categorised as low, 
moderate or high intensity corresponding to the patient’s defined daily dose of 
relevant classes of BP-lowering medication. The adjusted risk of a fall with 
serious injury was HR 1.4 (95% CI 1.03 – 1.90) in moderate intensity, and HR 
1.29 (95% CI 0.91 – 1.80) in the high intensity groups (526). 
 
The rates of descriptive outcomes in the PhD study were too low to enable a 
more granular investigation of drug side effects which may underlie the 
association between low BP and higher all-cause mortality. Relevant are the 
findings from another CPRD study which included 570,445 adults of all ages, 
with records on the database between 1997 and 2014 and a mean follow up of 
4.1 years. The primary outcome was acute kidney injury. The exposure was 
time on treatment where treatment was an Angiotensin-converting enzyme 
inhibitor (ACEi) or an Angiotensin Receptor Blocker (ARB) and time without 




associated with a higher risk of acute kidney injury (HR 1.12, 95% CI 1.07 - 
1.17). Risk of acute kidney injury varied per patient: those at highest absolute 
risk of acute kidney injury experienced little relative risk difference on or off an 
ACE/ ARB. On the other hand, those at low absolute risk of acute kidney injury 
experienced statistically significant difference in the relative risk on and off ACE/ 
ARB (527). These findings are consistent with the PhD study findings of 
significant associations of systolic BP and outcome in people with low levels of 
frailty, but insignificant associations of systolic BP and outcomes in the context 
of high levels of frailty.  
 
6.4 Data findings in the context of the patient perspective 
 
Major hypertension guidelines recommend considering a person’s frailty in 
shared decision making around hypertension management  (Table 1-5). The 
PhD study has shown that frailty predicts an increased risk of cardiovascular 
and non-cardiovascular outcomes in hypertension management in the routine 
data. However, participants in the narrative interviews (Section 5.7.1) did not 
define themselves as frail but rather by how they faced or managed frailty. The 
agency demonstrated in the stories told challenged the stereotypes of 
frailty/ageing which are often passive and dependent. The tensions around the 
concept of frailty are perhaps inevitable of any measure of ageing. As a 
prognostic factor, frailty may usefully identify a sub-population of older adults 
who are at higher risk of cardiovascular and non-cardiovascular outcomes, for 






The outcomes measured in the routine data study (Section 3.8.4) were not 
mentioned in the stories told in Chapter 5, except among participants for whom 
hypertension was diagnosed in the context of a stroke. Medical conditions 
generally received little mention in the narratives. Instead, stories focused on 
everyday challenges: getting up; moving around; dressing; washing oneself; 
and, being able to get out and about. These aspects of life are not measured or 
recorded well in routine healthcare records, preventing their inclusion in the 
analysis. Physical function, disability or cognitive function are clearly important 
in their impact on quality of life, but they are not recorded or are under-recorded 
in routine data. However, there are moves towards developing core outcome 
sets relevant to older people with frailty designed in conjunction with older 
patients themselves (528). There is also recent progress in developing patient 
reported outcomes for older people (529, 530) that could be recorded in routine 
data. In the more immediate future, including a broader range of outcomes in 
trials and epidemiological studies is important to better understand the relative 
risks of treatment in the context of an individual patient.  
 
Self-management and shared decision making (SDM) in the management of 
hypertension have been studied predominantly in populations whose primary 
and single problem is hypertension(531). A recent review highlighted a lack of 
research in how to undertake SDM in hypertension in a wider context(531). 
Ways of empowering patients in making choices need to start by including and 





It is plausible that clinical equipoise experienced by clinicians in the context of 
frailty is reflected in the overall indifference expressed by participants in the 
narrative interviews to the concept of hypertension. Indeed a recent survey of 
clinicians (which I co-authored) demonstrates significant uncertainty among 
practitioners who manage hypertension around BP targets and at which target 
BP a new trial is needed (532). Alternatively the lack of relevance attributed to 
hypertension may simply reflect that older people place less emphasis on 
medical problems than healthcare professionals think they do.  
 
6.5 Strengths and limitations 
 
Strengths and limitations of the PhD study will be considered with respect to 
various aspects of the study design: in relation to routine data in general; in 
relation to the SAIL data set; and, in relation to the methods adopted.  
 
6.5.1 Study population 
 
The study population included in the PhD study appears to be broadly 
representative of older people in the UK. In terms of frailty, the distribution in the 
PhD study cohort was categorised as: 50% fit, 40% with mild frailty, 9% with 
moderate frailty, and, 1% with severe frailty. These proportions are subtly 
different from those reported in ResearchOne and THIN data sets (50% fit; 35% 
mild frailty; 12% moderate frailty; 3% severe frailty) (341) and in other extracts 
from the SAIL data set (52% fit; 33% mild frailty; 12% moderate frailty; 3% 




well represented in the PhD study cohort. This may relate to the exclusion of 
participants with established cardiovascular disease from the study population.  
 
The proportion of the PhD study population who reside in care homes at study 
baseline was 1.5% of the total study population. This is likely to be an 
underestimation of the true care home population in Wales in 2007. In the UK 
overall a survey has shown that 4% of people over the age of 65 lived in a care 
home in 2018 (533). This does not account for differences across the devolved 
nations which may be present. However, there are limitations in identifying care 
home residence in the SAIL data. The care home registry available to identify 
care homes within the SAIL databank was created using a list of care homes 
defined by the Care Inspectorate Wales (408). This care home list was created 
in 2018 and is therefore not contemporaneous to the time of study start in 2007. 
This is a limitation as care homes will have opened and closed over time, 
resulting in the list being incomplete between 2007 and 2018 which represented 
the duration of follow-up in the PhD study.  
 
The geographic representation of a whole UK nation is unique to SAIL, in 
comparison to other UK routine data sets that have been established (the 
exception being SPIRE in Scotland which is still in development). In England, 
there is a clustering of ‘research’ GP practices in the South of England. This is 
largely as a result of changes in market share of the companies responsible for 
the respective computer systems. The Vision primary care electronic health 
record system is the source of the main routine primary care data sets (CPRD-




However, the geographical coverage of Vision is concentrated in only three 
urban conurbations throughout England, and in the south of England (385). 
Cross sectional analysis of the spatial distributions of primary care clinical 
computer systems in 2016 also revealed that SystmOne (the system underlying 
ResearchOne) does not include the North West, West Midlands, London and 
South East. In contrast, QRESEARCH which is relatively under-represented in 
published research literature, is the most nationally representative single 
database across England (385). 
 
Although representative of the Welsh population, the study population’s ethnic 
diversity was not generalisable to many other UK settings. Across England and 
Wales, the ethnic mix of the population over the age of 65 years was: 95.5% 
White; 2.6% Asian/ Asian British; 1.3% Black; 0.4% Mixed; 0.3% Other (534). In 
Wales alone the population over 65 years is 98.9% White, 0.5% Asian; 0.3% 
Mixed; 0.17% Black ethnicity (535).  
 
In the study cohort, non-White ethnicity represented 1.8% of the SAIL cohort, 
which is higher than that reported (1.1%) in the Census data for Wales. The 
ethnicity data in the PhD study data set were extracted from hospital data 
because primary care ethnicity data were not available in SAIL at the time of 
extraction. Ethnicity data were only present for 26.2% of the PhD study’s 
participants. Other primary care data bases have similar levels of completeness 
of ethnicity data (CPRD – 29.3%, QRESEARCH – 33.5%, THIN – 23.1%) (536). 
As for SAIL hospital ethnicity, GP coded ethnicity also seems to be broadly 





It is planned for ethnicity data recorded in the Welsh Demographic Service Data 
(WDSD) sets to be uploaded to SAIL within the next year to address this lack of 
comprehensive ethnicity data. Secondly, ethnicity coding has been incentivised 
by the Quality Outcomes Framework in 2006/2007 and 2011/2012, and ethnicity 
coding in general practice has been shown to improve since (536, 537). 
 
Deprivation measures, according to Townsend quintiles were broadly 
representative of the overall UK population although proportionally the most 
deprived were less well represented (16.8% were in the poorest quintile). 
Evidence from the King’s Fund using ResearchOne data demonstrated that 
people living in high deprivation areas were more likely to attend medical 
services (538). Frequency of attendance to general practice was not measured 
in the PhD study data, only the attendances when BP was measured. It is not 
possible therefore, to infer whether the differences in deprivation profile relate to 
those who are poor accessing GP services less often for hypertension 
management, or that, despite accessing services, those who are poor are less 
likely to have their BP checked by their GP as frequently. This is a research 
question that requires further investigation. 
 
6.5.2 Study design 
 
There was a balance to be struck in the design of this study, between what is 
precise and is true of the underlying biology described in Chapter 1, and what 




measured in a research setting have been criticised for not being generalisable 
to clinical practice (539), although they are likely to be more representative of 
that person’s true resting BP. On the other hand, clinical BP measures, whilst 
more likely to be representative of clinical practice, are less likely to be indicate 
a person’s true BP, and therefore any association with the true biology may be 
diluted (235). An office reading is not a good representation of a person’s true 
BP because it may instead represent masked or white coat hypertension. 
 
Informed by the qualitative study, it is evident the context in which a BP is 
measured is important. A significant unknown in this study is the context in 
which each BP was measured in primary care, whether it was undertaken as: 
an opportunistic screening measure; because of concern a person’s BP was too 
low; because the patient was unwell, and may need to attend hospital; or, 
whether it was to inform titration of BP-lowering therapy. In the future, 
contextual information should be extracted alongside a BP measure to indicate 
the purpose of the recording, such as by using hypertension review codes. 
Even if this contextual information is only available for a minority of BP 
measures, a sensitivity analysis comparing the use of these codes with BP 
codes more generally could reveal potential bias in the main analysis. 
 
6.5.3 Choice of exposure 
 
Blood pressure was chosen as the primary exposure for this study, informed by 
the biological considerations outlined in Chapter 1, and the uncertainty arising 




hypertension in older people. An alternative exposure would have been BP-
lowering therapy, and this was highlighted in the exploratory analysis (Section 
6.3.3.2). The choice of BP-lowering treatment as exposure has advantages: 
treatment represents the reversible factor and an interventional study could 
determine whether this is causal; and, treatment is easier to measure than BP. 
However, the prescription data available in electronic health records does not 
represent what the patient actually takes; and important information on dose 
was not available in the SAIL data set during the study time period chosen.  
 
6.5.4 Definition of BP 
 
In considering the measurement of BP in this study, there is the potential for 
bias at various points: at the point of measurement; at data entry; at data 
cleaning; at data analysis; and at the point of model development. 
 
At BP measurement, there are multiple reasons to question the accuracy of a 
single reading to be a true representation of a person’s BP. From a biological 
perspective, BP will vary, in an individual: within seconds to minutes, conditional 
on activity and psychological stress; and, within hours, according to a circadian 
pattern (see Section 1.5.5). In addition, measurement error exists in the 
recording device and the method of taking a person’s BP. Unlike in trials, there 
is no quality control undertaken on how BP is measured in routine data. The 
challenges involved in the extraction of systolic BP < 100 mm Hg from 7 digit 
rather than 8 digit strings (see Section 3.9.2.1) may have unequally affected 





At the start point of the PhD study, in 2007, it is likely there were many manual 
sphygmomanometers still in use when readings were often rounded to the 
nearest 5 or 10 mm Hg (540). As such, a greater tendency to round up or round 
down may have led to bias of BP entry. However, the histogram of BP results 
shows that the three patterns of BP results are more or less in keeping with one 
another which is partly reassuring (Figure 4-2). 
 
Data entry in electronic health records is undertaken at the time of the clinical 
care interaction or is entered subsequently from medical notes. The primary 
focus of the person inputting the data will be to record the clinical encounter and 
the delivery of care as opposed to recording data for research purposes. The 
data from all GP practices are included in SAIL. This is not the case in other 
data sets, for example, in CPRD, data is extracted only from practices that meet 
data quality criteria (395). In SAIL the processes assuring quality of data entry 
and maintenance are less clear.  
 
There is evidence GPs generally follow hypertension guidelines (Section 1.6.3) 
– they record the first reading where this is normal, and when it is too high they 
then record the lowest reading (541). This recording bias may dilute the effect of 
BP on outcomes as described in greater detail in Section 6.6.4. 
 
During data cleaning certain assumptions were made to determine which 
readings were likely to be outliers, to exclude a small minority of anomalous or 




decisions that may have influenced the data entered, although the transparent 
presentation of the decisions made do subject them to scrutiny.  
 
When carrying out data analysis, the minimum BP recorded on a particular day 
was used. This measure was chosen to represent BP because it is this 
measure that is recommended in the guidelines used to inform treatment (320). 
This method has particular application to the prognostic factor study 
(addressing Objective 3). However it is conceivable that for the causal 
inference research question (addressing Objective 4), one of the alternative 
methods presented in Table 3-5 would have provided greater precision in 
estimates of a person’s true BP and therefore greater precision in detecting the 
true relationship between BP and outcomes. 
 
There are significant discrepancies in a person’s BP measured at home and in 
the clinic or practice. In this study, we have used BP recorded by GPs, without 
specifying whether they were home, office or ambulatory measures. It is likely 
therefore that a proportion of the BP measurements are not true readings for 
those individuals and will include both white coat effect, and masked 
hypertension (Section 1.6.1). Home BP measurements were not specified in 
the NICE guidelines in 2006 (Table 3-8), at the time of study start, and therefore 
it was not possible to undertake a sensitivity analysis to determine whether the 
association with home readings was different to those with clinic readings. 
Since 2011, NICE guidelines have increasingly recommended the use of home 
BP readings for the diagnosis and follow-up of BP. Sensitivity analyses using 





There is evidence from electronic health records that BP decreases more 
steeply towards the end of life in the context of frailty (32). The inclusion of BP 
trajectories as a covariate was not undertaken in the prognostic study whose 
aim was to investigate the role of frailty in addition to current hypertension 
management; the measurement of BP trajectories is not part of current 
hypertension management. Indeed, the inclusion of BP trajectories as a 
covariate in the epidemiological study may have better characterised the true 
relationship between BP and outcomes. However, the inclusion of a frailty index 
as a covariate would be methodologically challenging. The measurement of the 
frailty index would have to be prior to the series of BP readings or else the eFI 
could represent a mediator of the association of BP and outcomes, thereby 
introducing collider bias (Section 6.6.1). This may be possible using joint 
longitudinal modelling techniques. Whilst these methods are outside of the 
scope of this PhD, they may represent a potential avenue for future research 
(Section 6.7.3). 
 
During model development- BP recordings were ultimately categorised to allow 
for the non-linear association with outcomes observed elsewhere. However, 
methods more closely aligned to the true association would have been more 
ideal. For example, rather than superimpose guideline BP categories, cubic 
splines or fractional polynomials could have been employed (519), or categories 
informed by the data distribution around the median value (542). Such methods, 




power and precision of the analysis. These methods were outside the scope of 
the PhD but ones that are important for future investigation. 
 
6.5.5 Definition of frailty 
 
Frailty in this study was measured using a method accessible to the majority of 
general practitioners in the UK (543), and this improves the external validity of 
PhD study findings. However, whilst the frailty phenotype and frailty index (FI) 
measures often indicate similar proportions of a population as having frailty, 
they do not correlate exactly (544). Previous research using the CARE75 cohort 
from which the narrative interview study recruited patients (Section 5.5.2.3.3), 
reported that the electronic frailty index (eFI) has a correlation coefficient of 0.68 
(95% CI 0.62 - 0.74) with a research standard FI in the same population (545). 
When comparison is made between the eFI and the phenotype model of frailty 
the Spearman’s coefficient, was lower still, - ρ = 0.59 (95% CI 0.49–0.65) (545). 
As the authors discuss, this may be because functional deficits are not as well 
coded in routine primary care data as is the case in an epidemiological cohort 
study (545). Whilst these coefficients represent moderate-to-good agreement in 
terms of test coefficients, the degree of discordance would have significant 
impact on an individual’s classification as frail or not frail (546). 
 
With hindsight, it is evident from the findings of this PhD that the concept of 
frailty may be too broad to be helpful in personalising hypertension 
management for older people. The global measure of frailty combines patients 




disease, but at high risk of falls. Whilst the former group may conceivably 
benefit from low BP, the latter may be at risk of harm from low BP. However, 
dissecting the different parts of the frailty index would jeopardise the clinical 
utility of the frailty measure as a whole. Instead, an alternative potential 
approach for future research would be to investigate from first principles, which 
are risk factors for harm from BP-lowering treatment in older people. 
 
6.5.6 Choice of covariates 
 
The choice of covariates to be included in this study was made to represent the 
optimal prognostic model currently in clinical use, so as to best investigate the 
additive value of frailty. The decision to use QRISK-3 as a measure of 
cardiovascular risk was made because of its recommended and widespread 
use in UK primary care, and thus is in line with the aim of the PhD to be 
generalisable to current practice. However, there are limitations to the choice of 
QRISK-3. The QRISK-3 used was not developed at the time of the study, so it 
has been calculated retrospectively. Clinical practice guidelines stipulate a 
measure of cardiovascular risk should be measured in the management of 
hypertension, but this is at the time of diagnosis of hypertension. Given the 
focus of this study was the long-term management of hypertension, and most 
patients were not captured at the time of hypertension diagnosis, this may 
explain the high proportion of missing data on cardiovascular risk factors for the 
majority of included patients. Hence, the PhD study does not fully mimic clinical 
decisions made in 2007. The analysis followed the pre-analytic protocol, and 




missing data on cardiovascular risk. This means that whilst confounding bias 
has been minimised, the risk of bias from missing data is likely to be high, 
although this is difficult to estimate. In future research investigating important 
predictors involved in hypertension management at follow up, the choice of 
confounders should be more targeted specifically to the context of follow up and 
based on theoretical grounds. 
 
Furthermore there are limitations specific to the QRISK score itself. The QRISK-
3 Score is not validated over the age of 84 years and the algorithm applies a 
ceiling of risk at this age limit. QRISK-3 was not developed to account for 
competing risks, and so the cardiovascular risk prediction for this group may 
theoretically have been over-inflated.  
 
There are multiple cardiovascular prediction models (319). The majority have 
been developed for adults in middle age and there is evidence these have poor 
predictive value in adults who are older (547). Several studies have 
demonstrated that the association between traditional cardiovascular risk 
factors and cardiovascular outcomes weakens with age (548), and other risk 
factors may become important, for example, measures of inflammation (549), 
apathy (550), and polypharmacy. A minority of cardiovascular risk models have 
recently been developed specifically for older people (551, 552). One of these 
uses a competing risks framework, in a post-hoc analysis of data from 1,811 
participants of the Prevention of Dementia – Intensive Vascular care (Pre-DIVA) 




in common use in UK primary care or recommended in clinical guidelines (320). 
This is an area requiring future research. 
 
Despite these caveats, using the algorithm to calculate the QRISK in those with 
complete observational data in the PhD study estimated a 10 year 
cardiovascular risk of 29.3% which compared to the observed cardiovascular 
event rate of 28.5% suggests good calibration in this cohort. It is also important 
to note that in the survival model used to test frailty as a prognostic factor, 
cardiovascular risk was defined by variables included in the QRISK-3 but not 
the QRISK-3 algorithm itself. Separately, the QRISK-3 algorithm, as a complete 
score, was run in a minority of patients for whom the component data were 
complete. In this minority of the study population, the QRISK-3 prediction of 10 
year cardiovascular risk was highly consistent with the observed associations 
with cardiovascular disease in the whole data set, and the predictive ability of 
QRISK-3 was maintained in sub-groups defined by frailty (see Section 4.3.4). 
 
6.5.7 Definition of treatment 
 
Adjustment for the treatment effect in this research may have been insufficient. 
Treatment was measured by the number of BP-lowering medications by class 
recorded in a patient record whereas number of prescribed medications, drug 
adherence and frequency of prescription all influence the degree to which a 
person’s BP is treated. Furthermore, a far greater degree of granularity may 
have been necessary given the central role of treatment in influencing any effect 




was chosen as the PhD study’s start date, and the BP recorded will have 




Outcomes are typically less well recorded in routine data compared with registry 
data, and there is evidence that the lack of linking to registry data may lead to 
missed outcome records (554). Code lists for disease phenotypes that are 
widely accessible and developed by consensus were used where they were 
available, that is for cardiovascular disease. However, equivalent code lists 
were not available for outcomes which relate more closely to the diseases of 
ageing. These limitations exists because these phenotype code lists have not 
been developed, but also because diseases of ageing are not well coded in 
routine primary and secondary care data. 
 
Mortality rates reported in the PhD study are consistent with other routine data 
studies. In the PhD study 39.2% of participants died during 10 year follow up. 
This rate was higher than: the Masoli study population who were over 75 years 
and had a mortality rate overall of 33% (366); and the Ravindrarajah study 
population who were over the age of 80 years and had a mortality rate of 36% 
(365). Differences in mortality rates between this study and the other two may 
relate to: the PhD study’s selection of people with hypertension in whom 
mortality is known to be higher; and PhD study’s use of ONS linked data 
records which represents a more robust method of death identification than 





The choice of MACE as the primary outcome was justified in the study design 
by its use as a primary outcome in trials and observational data in hypertension 
research. The choice of MACE as primary outcome was pre-specified and 
informed the sample size calculation in Chapter 3. The crude rates per 100 
person years varied between the individual MACE outcomes. Greater depth of 
analysis may have revealed variation between individual MACE outcomes in 
their associations with BP and frailty. However, these analyses were not pre-
specified and therefore not undertaken. The qualitative study highlighted the 
importance of specific outcomes to patients and their day-to-day lives. 
Composite outcomes may therefore be of unclear relevance to patient-centred 
or shared decision making. Future research would be better powered to 
investigate individual outcomes and involve patients in their study design. 
 
The PhD study data set benefited from linkage to hospital record data in the 
ascertainment of outcomes, and this is particularly evident in the descriptive 
outcomes. Proportions admitted to hospital with symptoms that may represent 
side effects of BP-lowering treatment ranged between 7.9% for electrolyte 
disturbances to 15.6% for hypotension over the 10 year follow up period. 
However, ageing related conditions including urinary incontinence and delirium 
were uncommonly reported. The rate of delirium was 1.5% over 10 years for a 
population 67.1% of whom was admitted to hospital in that same time period. 
This suggests significant under-reporting of delirium in this study sample given 
that prevalence of delirium is estimated between 10-31% of inpatients over the 




diseases was the incidence of dementia. Incidence rates of dementia over the 
age of 65 years in the PhD study were calculated using records from primary 
and secondary care and incidence was estimated at 15 per 1,000 person years, 
which is consistent with rates reported in a definitive cohort study characterising 
dementia – the Cognitive Function and Ageing Study (CFAS) where it was 
reported as 20.0 (95% CI: 16.9–23.8) per 1,000 person years in CFAS I, and 
17.7 (95% CI: 15.2–20.9) in the CFAS II study (556). 
 
The difficulty recording ageing related problems, such as delirium and urinary 
incontinence in not unique to SAIL, it is true of all routine data sets. Electronic 
health records only include data items relevant to the particular clinical or 
administrative process, rather than what is relevant to an individual research 
question. The loss of higher-order function (cognition, mobility or continence) 
featured heavily in the narratives told in Chapter 5. In routine data, these higher 
function losses are most often represented by codes for the easiest attributable 
cause (e.g. urinary tract infection instead of delirium), whether accurate or not. 
Indeed the use of codes in recording symptoms may be insufficient to represent 
the complex interaction of multiple pre-disposing and precipitating factors 
involved in a geriatric syndrome. Where the dominant symptom is the only one 
recorded, the accompanying symptoms are missing. In such cases, the content 
of free text may be informative. The analysis of narrative text using Artificial 
Intelligence (AI) techniques, such as natural language processing algorithms is 





Arising from the PhD I have established, together with other researchers across 
the UK, an Ageing Data Research Collaborative (@geridata) with the support of 
the British Geriatrics Society (BGS) (557). This community has been developed 
to foster peer support among researchers and encourage sharing of pre-
analytic protocols, code lists for conditions relevant to geriatric medicine and 
gerontology, methods of data cleaning and analysis. 
 
6.5.9 Missing data 
 
Important information was missing in this study. Data were missing in different 
ways. Some data were missing when they should have been recorded, such as 
the Cholesterol: HDL ratio and smoking status, given cardiovascular risk 
assessment is a necessary part of hypertension management and treatment. 
This was assumed to be data ‘missing at random’. However, this missing data 
may affect some people more than others because some people will have had 
fewer opportunities to have their data recorded, because they used healthcare 
services less. On the other hand, there is the problem of informed presence 
bias which will be examined in more detail in Section 6.6.2.  
 
Data may have also been missing because of the design of routine data 
records. Routine data is produced by positive recording, so: the absence of a 
recording of a particular diagnosis is assumed to represent the absence of 
diagnosis. Codes represent disease as being either present or absent. 
Therefore, the grade or severity of disease is difficult to account for in routine 




care or are under recorded (e.g. delirium and incontinence) and the omission or 
undercounting of such information could lead to spurious research findings.  
 
6.5.10 Period of study 
 
The availability of data on outcomes, covariates, and BP recordings is 
predetermined by what was measured in routine care in 2007 and in the ten 
years of follow up. Over the period of follow up (from 2007 until 2018) a number 
of guidelines for hypertension management changed significantly. NICE revised 
the initial 2004 guidelines in 2011 (559). Also, the NHS Health Check 
cardiovascular screening was launched in 2009 (560) and impacted on pay-for-
performance targets for GPs, according to the Quality and Outcomes 
Framework (QOF) for BP in 2013 (380). These factors and other guideline 
changes from the American and European societies may have influenced 
clinical decisions made during the period of study. The PhD study could have 
been improved by including a longer time period of index dates and adjusting 




Given the observational nature of this study, no causal inference can be made 
from the findings. The interpretation of observational studies must account for 
their higher risk of reverse causality and residual confounding. There are 
several aspects to this study which may have caused bias to influence study 





6.6.1 Reversal paradox 
 
A key limitation of observational research is confounding bias. Confounding is 
the effect on the association between an exposure and an outcome by a 
common cause. By conditioning on a confounder, we close off an alternative 
causal pathway from exposure to outcome. Methods to address conditioning 
include: restriction; confounder adjustment; stratification; and, matching. 
However, problems can arise if the variable conditioned upon is a mediator, as 
conditioning for a mediator may block the causal path. Conditioning on a 
mediator can also introduce collider bias (561). A collider represents a variable 
which is affected by two or more other variables in a causal path (562). 
 
Conditioning on mediators can bias the results so much to cause a reversal of 
the overall effect. This has been described as the reversal paradox or 
Simpson’s paradox (563). This was best described in the context of smoking 
and infant death, stratified by ethnicity and birthweight. In a series of studies 
analysing infant death in low birthweight infants, maternal ethnicity and smoking 
status were adjusted for. The surprising findings were that infant deaths in low 
birthweight babies were lower if the mother had smoked (564). Hernan and 
colleagues dissected the birth weight paradox by explaining that birthweight is a 
collider for unobserved causes of infant death (such as congenital disorders) 
and conditioning on it may well have led to a reversal of the association 





Figure 6-1 Directed acyclic graph demonstrating Simpson's paradox 
 
This schematic describes a simplified directed acyclic graph(566) illustrating Simpson’s 
paradox with respect to investigations into low birthweight and infant death. This 
schematic is developed from discussions in Porta et al (375): low birth weight 
represents the collider in this graph because it is acted on by both smoking and 
unmeasured confounding (e.g. congenital disorders). Conditioning (e.g. adjusting or 
stratifying) for this collider opens up other causal pathways of unmeasured confounding 
Abbreviations: u – unmeasured confounder.  
 
 
The frailty index represents a prognostic model, not a causal construct. This 
thesis demonstrates that frailty has a role in predicting future cardiovascular and 
non-cardiovascular outcomes in the context of hypertension. However, the 
question of how to intervene on BP differently in the context of frailty is an 
epidemiological question that requires causal methodology. Drawing a directed 
acyclic graph is a recognised method to identifying potential mediator and 
confounder relationships to reduce bias of the sort described by Simpson’s 
paradox (567).  
 
If frailty had a mediating role in the association between BP and cardiovascular 
outcomes this would theoretically introduce collider bias (Figure 6-2). In such a 
case, stratification on frailty sub-group, as has been undertaken in the PhD 
study, could lead to overall findings being influenced by un-observed factors. 




factors, for example, endothelial dysfunction which relates both to 
cardiovascular risk and to frailty (see Section 1.5.4).  
Figure 6-2 Simplified directed acyclic graph for Frailty as a mediator 
 
This schematic describes a simplified directed acyclic graph demonstrated the potential 
challenges of collider bias if frailty is a mediator in the association between BP (BP) 
and major adverse cardiovascular events (MACE) making the findings vulnerable to the 
effects of unmeasured confounding (U). 
 
As a multicomponent variable, frailty has constituent deficits, some of which 
may have a mediating role on the causal pathway from BP to cardiovascular 
outcomes, some of which may have a confounding role. The different 
relationships of the deficits within the eFI will vary according to the causal 
framework in which the eFI is being examined. This limitation is not specific to 
the eFI, and would similarly present a problem for the causal investigation of 
other measures of frailty, such as gait speed, grip strength or the Fried 
phenotype model, because all represent global proxy measures of an 
individual’s overall health. Indeed, the problem is more explicit with a frailty 
measure that lists its constituent parts. However, dissecting frailty into mediator 
and confounder parts, as required by a causal inference study, would mean 
developing a different version of frailty from what is currently used across 




hypertension management would undermine the universality and global utility of 
the eFI. 
 
6.6.2 Informed presence bias 
 
As a consequence of using a positive recording database, inclusion in this 
cohort is reliant on a person’s attendance to medical services. More frequent 
attenders will be better represented in routine data. This phenomenon is called 
informed presence bias (introduced in Section 3.5.3.3). The frailty index is 
highly correlated with use of healthcare services (568), so the analysis was 
adjusted for frequency of attendances where BP was measured to adjust for 
informed presence bias. Nevertheless it is likely to have been insufficient. 
 
6.6.3 Confounding by indication 
 
Making a causal interpretation of observational data on treatment is of limited 
value because treatments have not been randomised. The level of treatment in 
an effective healthcare system, will relate to the indication for treatment. Applied 
to BP, the more persistent someone presents with high BP whilst adhering to 
prescribed therapy, the more that person will be in receipt of treatment. This 
describes the concept of confounding by indication, where the comparison of 
medication users to medication non-users may lead to bias or difficulty in 
interpreting findings (569). There is a variety of methods to address this, all 
share the aim of emulating a clinical trial using observational data (570). These 
include propensity score matching (369). Where there are repeated events (as 




made for the estimate of the outcome during a prior treatment-free window 
(571). This is called the ‘difference-in-differences’ approach (572). 
 
6.6.4 Regression dilution 
 
Regression dilution may also have contributed to a more modest association 
between BP and cardiovascular outcomes in the PhD study and in 
QRESEARCH data (368). Regression dilution illustrates bias as a result of the 
factors which make the single measure of BP as an exposure unreliable. These 
factors are described with regard to BP measurement in Section 6.5.3. An 
alternative approach could have been to take an average of serial measures, 
but as presented in Table 3-5 this method also has the disadvantage that it 
leads to a regression to the mean. Another possibility would have been to use a 
method of time-dependent correction for regression dilution (367) whereby 
repeat BP measures during follow up time are used to correct for random 
measurement and short-term BP variability (368). This method was not used 
because the chief aim when designing this study was to imitate the clinical 
encounter a GP faces. As a result, residual bias of regression dilution may well 
have acted to underestimate the strength of association between BP and 
outcomes. 
 
6.6.5 Unmeasured confounding  
 
In retrospective analyses of routine data, the choice of confounders is 




biologically relevant (572). As a consequence, unmeasured confounding may 
have significant consequences on study findings. In the PhD study, these 
unobserved factors may include GP practitioner effects, i.e. the degree to which 
clinicians varied in the way they managed a person’s BP, and the degree to 
which treatment was not sufficiently accounted for. 
 
The E-value represents a method of assessing the impact of unmeasured 
confounding. It is a measure of the minimum strength of association that 
unmeasured confounding needs to have to explain the exposure- outcome 
relationship (573). A sensitivity analysis or E-value estimate of the impact of 
potential unmeasured confounding is a recommended means of estimating the 
robustness of the effect size if it is determined without information on these 
factors. 
  
For the prognostic factor study, the adjusted hazard ratio (HR) of MACE 
associated with mild frailty compared to those who were fit was reported as HR 
1.38 (95% CI 1.35 to 1.41) (see Section 4.5.2). Using an E-value calculator, an 
adjusted HR of 1.38 could be explained by an unmeasured confounder that was 
associated with both frailty and the cardiovascular outcome by a risk ratio of 
1.81-fold each, above and beyond the measured confounders. An unmeasured 
confounding effect of this magnitude may therefore be conceivable, and the 
estimated effect size reported in association with mild frailty may purely 





Measurement error was a key concern in this analysis. Many of the continuous 
variables included in my analyses will have been associated with measurement 
error. One way of addressing this is to take repeated measures, to ensure that 
the variability can be accounted for, as was undertaken by including a measure 
of standard deviation of BP recordings. However the same was not undertaken 
for other continuous variables, including the eFI. Where variation is large (e.g. in 
severe frailty), prognostic factor effects may be too conservative (closer to 1) or 
too precise (having narrow confidence intervals), when measurement error is 
not accounted for (574). 
 
6.6.6 Misclassification bias 
 
Whilst an attempt was made to use best methods to measure outcomes in a 
way that is robust and valid, particularly for non-cardiovascular outcomes, 
where there are no consensus code lists available, outcome recording may 
have been misclassified or missed. Code lists have been included (Appendix C 
and Appendix D), as recommended by RECORD guidelines (575), to improve 
transparency. However, in an ideal scenario the CTV codes used for this study 
would have included code phenotypes for all outcomes and covariates, which 
have been validated against data from other sources to reduce the risk of bias 
at the level of code entry (see Section 3.6.5) Where code phenotypes are not 
developed (i.e. in non-cardiovascular disease) code lists were relied upon which 
were drawn from other published studies which reported disease prevalence 





In future, work involving diseases of ageing needs to develop code phenotypes 
to combine EHR information from a variety of complementary sources (primary 
and secondary care) to improve case detection. There is a validated process of 
creating EHR phenotypes that has been undertaken in cardiovascular diseases 
(576), which could be pursued for conditions of ageing also. This process 
involves the assembly of terms through research and consensus work, 
implementation and validation procedures to ensure that these phenotypes are 
reproducible (577).  
 
In routine data, patients may be misclassified as having a disease when they 
previously had a disease which has since resolved with treatment, cancer for 
example. This is relevant to the measurement of frailty where the frailty index 
includes symptoms and disabilities which may resolve with treatment or 
therapy. Whilst levels of frailty and comorbidity in the PhD study population are 
consistent with studies of similar cohorts, it is conceivable that the average 
comorbidity count, frailty and past medical history were inflated. Methods to 
address this include running sensitivity analyses : 
-  using code lists for conditions that prioritise specificity over sensitivity of 
diagnostic capture.  
- using codes with allied information, for example, not include AF in the 
context of a concurrent illness, where the AF may therefore be 
reasonably assumed to have a reversible cause. 
- Using codes for conditions that include temporal parameters –e.g. 







My interpretation of the key findings in the PhD are as follows: 
 
1.  Frailty does not identify a population of older people with 
hypertension in whom the associations of BP and outcomes are 
meaningfully different 
 
The PhD study was designed primarily to test the hypothesis that frailty 
may usefully distinguish a population in whom the association of BP and 
outcomes is non-linear as distinct from a population in whom the 
association of BP and outcomes is linear. This study has found no 
evidence to support this hypothesis and this is an important negative 
finding of the PhD.  
 
Furthermore this negative finding is evidenced by the lack of significant 
interaction between frailty and BP and outcomes. As discussed in this 
chapter there are aspects of the study design which may have influenced 
distorted these findings. Considered in the context of the wider literature, 
it is proposed that the difference in populations in whom the association 
of BP and outcomes is non-linear to populations in whom the association 
is linear may instead relate to two factors: 
a. the degree of cardiovascular disease burden and/ level of BP-
lowering treatment, and 





2. Frailty has a mediating role in the association between BP and 
outcomes 
The PhD found clear evidence that frailty is a prognostic factor which is 
relevant to the prediction of cardiovascular outcomes in addition to 
established cardiovascular risk factors. The finding that frailty improves 
model fit in addition to the components of QRISK-3, and that separately, 
the QRISK-3 model when run in its entirety, has a high level of accuracy 
in predicting cardiovascular risk in this population, are together 
suggestive that frailty has a mediating role in the cardiovascular risk 
measured by the QRISK-3 algorithm.  
 
Frailty as a mediator in the association between BP and outcomes would 
also be consistent with another key finding of the PhD. The associations 
between systolic BP and outcomes were not evident in sub-populations 
defined by more advanced frailty. By conditioning on the mediator 
(frailty), the association between BP and outcomes is no longer evident. 
This is in keeping with the concept of the reversal paradox, and having 
conditioned on a mediator in this analysis, unobserved confounding has 
been allowed to influence the findings.  
 
The implications of considering frailty as a mediator of cardiovascular risk 
are manifold. They include the need to consider frailty as a prognostic 
factor in prognostic models to predict cardiovascular risk in relation to 




ageing processes should also be tested on cardiovascular events. A 
similarly less parochial approach to prediction and intervention in 
cardiovascular disease in the context of ageing, has been proposed in 
relation to heart failure with preserved ejection fraction (578).  
 
3. Frailty modifies the association of BP-lowering treatment and 
outcomes in older people with hypertension 
 
The PhD found evidence that frailty modified the effect of BP-lowering 
treatment on cardiovascular and non-cardiovascular outcomes. There at 
least three possible explanations for this, which will be considered in 
turn: 
 
1. Frailty alters the benefit from BP-lowering treatment. This explanation 
would be consistent with evidence presented in Chapter 1 indicating 
that ageing is central to the aetiology of hypertension in old age, and 
that therefore the targets and the effectiveness of BP-lowering 
treatment could conceivably be altered in the context of ageing. 
 
2. The modifying effect of frailty in the context of hypertension 
management, is in the degree to which someone suffers adverse 
effects from BP-lowering treatment. This explanation would be 
consistent with clinical conception of frailty as increasing vulnerability 
to adverse effects of medication, and the research findings elsewhere 
associating BP-lowering treatment: at low BP with higher mortality 






3. Frailty alters prescription of BP-lowering medications in older people. 
Whilst the GP at the index encounter in 2007 would not have had 
access to an eFI of the patient, it is likely that if the eFI suggests 
frailty the GP would have been aware of the patient’s frailty through 
other clinical features, such as multi-morbidity or disability. However, 
the number of treatment (by BP-lowering class) was the same in all 
frailty sub-groups. Another possibility is that adherence to BP-
lowering therapy is different in the context of frailty. For example, 
adherence may be higher in people who have carers every morning 
attending to give medications, either visiting their home or within a 
care home setting. 
  
6.7.1 Implications for clinical practice 
 
The clinical implications of the PhD findings are: 
 
1. Precision of BP measurement in older people is important, and where 
possible office readings should not direct BP-lowering treatment. The 
PhD study findings demonstrated increased variability of systolic BP with 
advancing frailty. The use of home readings or 24 h ambulatory readings 
have been shown to be more accurate in their representation of a 
person’s true BP, and can better predict cardiovascular risk in 





2. Frailty as measured by the eFI can identify people who are at high 
cardiovascular risk and high risk of non-cardiovascular outcomes related 
to hypertension management including death and injurious falls. Frailty 
can identify a sub-population of older people for whom a different 
approach to treatment may be necessary.  
 
 
3. This study found no evidence that justifies the use of an eFI in clinical 
practice, to identify an alternative BP for an older person with 
hypertension. 
 
4. The PhD findings indicate a possible modifying effect of frailty in the 
context of hypertension management, in the degree to which someone 
suffers adverse effects from BP-lowering treatment. In this context, 
potential side effects related to BP-lowering medication should be kept 
under regular review in older people with frailty who have hypertension. 
 
6.7.2 Implications for policy 
 
The findings of the PhD routine data study support international consensus 
hypertension guidelines which recommend the measurement of frailty in old age 
(320, 322) to inform approach to hypertension management. The exploration of 
the patient’s perspective highlighted the necessity for shared decision making to 
address what matters to the individual in terms of outcomes that are tangible 





Shared decision making strategies may need to be varied according to whether 
hypertension management is in the context of either primary or secondary 
prevention of cardiovascular disease. Consideration to whether this decision 
making is best placed in the context of hypertension review, or as part of a 
comprehensive geriatric assessment that involves anticipatory planning around 
frailty. This needs serious consideration with patient representatives. In the 
future, investigations into different methods of SDM could inform a step-by-step 
approach to guide clinicians on how to do this effectively and in a patient 
centred way.  
 
A more holistic approach to hypertension treatment review in the context of 
frailty may be enabled by a more integrated approach from national guidelines. 
There are calls to better adapt UK single disease guidelines to the care of 
patients multi-morbidity by cross-referencing guidelines which are applicable to 
the same patient (580). In the case of NICE hypertension guidelines for older 
people with frailty, this could involve NICE guidelines on multi-morbidity (581) 
and the ‘Fit for Frailty’ guideline on the identification and management of frailty 
(582).  
 
6.7.3 Future research 
 





1. Which risk factors predict adverse effects of BP-lowering 
treatment in older people? 
 
The primary exposure would be BP lowering treatment given this 
is the potentially reversible factor which a trial could proceed to 
investigate. The choice of covariates would be informed by 
systematic review of risk factors relating to ageing that do interact 
with BP treatment to cause different associations with outcomes. 
Consideration would be given to characterising BP in greater 
granularity, including: 
 
1. Between visit BP variability, short and long term; 
2. BP trajectory, using join modelling techniques; 
3. Home or ambulatory BP readings. 
 
Prognostic models would be developed in a competing risks 
framework, according to PROGRESS-III consensus methods of 
prognostic model development (374). Prediction scores for 
treatment harm on a range of outcomes could inform shared 
decision making with patients and identify populations of older 
people who may be candidates for a BP-lowering treatment de-
escalation trial. 
 
2. Randomised control trial to investigate the role of BP-
lowering treatment withdrawal in patients who are at high risk 





To adequately address the limitations identified with confounding 
and other sources or bias, a randomised control trial is required. 
Using a prognostic model developed from the study above, a trial 
would target a population of older adults at high risk from 
treatment harm. Two levels of treatment arms would potentially 
align with different treatment strategies as set out by international 
guideline systolic BP treatment thresholds, e.g. American Family 
Physicians (AFP) target of <150 mm Hg; European Society of 
Cardiology (ESC) target of < 140 mm Hg, and > 130 mm Hg. 
Precise measurement of BP will be necessary in this trial, using 
methods that are replicable in routine daily care such as 
ambulatory or home BP measurement. A range of cardiovascular 
and non-cardiovascular outcomes would be measured, and 
patient representatives would need to be involved early in the 





6.8 Conclusions  
 
The research presented in this thesis is a thorough investigation of BP and 
outcomes in older people according to their frailty status. This is the first 
study in a population which has direct application to a specific clinical 
setting, namely those with hypertension managed for primary cardiovascular 
prevention. This is the first study to use mixed methods to explore the 
perspectives of patients in the interpretation of data findings. The study 
population was over 65 years old, large in scale (145,598), and 
generalizable to routine clinical care: 67.5% had multi-morbidity, and, 87% 
were prescribed BP-lowering treatment. The study used linked data sets to 
ascertain primary and secondary outcomes including 57,157( 39.2%) deaths 
from any cause. 
 
There is strong evidence frailty is a prognostic factor that identifies older 
people who are at high risk of cardiovascular and non-cardiovascular 
outcomes in the management of hypertension. Frailty may therefore identify 
patients for whom a different approach to shared decision making is 
indicated. From a patient’s perspective, this could include understanding 
how a person conceives of frailty as a means to understand what they value 
to engage them in shared decision making regarding BP-lowering treatment. 
The finding of a significant interaction between frailty and BP-lowering 
treatment may suggest that the modifying effect of frailty in the context of 
hypertension management, is in the degree to which someone suffers 




an epidemiological study using more precise measures of BP and BP-
lowering treatment. Ultimately a randomised control trial is needed to 
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Review Search Strategy 
 
Database: Ovid MEDLINE(R) Epub Ahead of Print, In-Process & Other Non-




1     late* life.tw. (16019) 
2     age factors/ (452959) 
3     (frail* or sarcop?eni* or prefrailty).mp. (26267) 
4     Sarcopenia/ (2686) 
5     function* status.tw. (24184) 
6     activities of daily living.tw. (23276) 
7     "activities of daily living"/ (63462) 
8     (physical adj3 function).tw. (14334) 
9     Hypertension/ (238653) 
10     ((high or elevat*or rais*) adj2 blood pressure).tw. (16209) 
11     (blood pressure adj6 goal?).mp. (2028) 
12     Blood Pressure Determination/ (27584) 
13     epidemiologic studies/ (8301) 




15     exp cohort studies/ (1905682) 
16     case control.tw. (116518) 
17     (cohort adj (study or studies)).tw. (164282) 
18     cohort analy*.tw. (6584) 
19     (follow up adj (study or studies)).tw. (48680) 
20     (observational adj (study or studies)).tw. (85828) 
21     Longitudinal.tw. (219409) 
22     retrospective.tw. (451275) 
23     cross sectional.tw. (291356) 
24     cross-sectional studies/ (283885) 
25     survey.tw. (466607) 
26     survey/ (429354) 
27     or/13-26 [epidemiology filter] (3317120) 
28     or/9-12 (264635) 
29     or/1-8 (587455) 





Method of Extraction for Meta-Analyses 
 
Comparison to a standard reference: 
 
Where we have two hazard ratios comparing groups B and C to group A, and 
we want a hazard ratio comparing group C to group B: 
 A B C 
HR (95% CI) 1 0.89 (0.62, 1.28) 0.94(0.65,1.35) 
 
We will find HRs and SEs, then find SE for log difference, C − B 
First we switch A & B: 
log(0.89) = −0.11653382 
log(0.62) = −0.4780358 
log(1.28) = 0.24686008 
 
Switching the signs of these gives the ratio for the log HR for A with B as 
standard. 
Now find the standard error: 





Note that “*” means “multiply”.  Later, “^2” means “raised to the power 2” or 
“squared” and “sqrt” means “square root”. 
 
Convert back to natural scale and find the confidence interval:  
exp(−log(0.89) − 1.96*(log(1.28) − log(0.62)) /(2*1.96)) = 0.78198938 
exp(−log(0.89) + 1.96*(log(1.28) − log(0.62)) /(2*1.96)) = 1.6144297 
Hence the estimate is 1.12 and the 95% confidence interval is 0.78 to 1.61. 
 
Now for C with B as standard, which is more difficult. The problem is that we 
need to combine both HRs. 
 
log(0.94) = −0.0618754 
log(0.65) = −0.43078292 
log(1.35) = 0.30010459 
 
SE: (log(1.35) − log(0.65))/(2*1.96) = 0.1864509 
 
Difference, C – B:  
log(HR) = log(0.94) − log(0.89) = 0.05465841 





Now, we can calculate the SE for the difference, by taking the square root of the 
sum of the squares of the two SEs. However, there is an assumption, that the 
estimates for B/A and C/A are independent, which is clearly false.  
 
SE(difference) = sqrt( ((log(1.35) − log(0.65))/(2*1.96))^2 + ((log(1.28) − 
log(0.62)) /(2*1.96))^2) = 0.26260281 
 
Transform back and get 95% CI: 
exp( log(0.94) − log(0.89) − 1.96*sqrt( ((log(1.35) − log(0.65))/(2*1.96))^2 + 
((log(1.28) − log(0.62)) /(2*1.96))^2)) = 0.63125644 
exp( log(0.94) − log(0.89) + 1.96*sqrt( ((log(1.35) − log(0.65))/(2*1.96))^2 + 
((log(1.28) − log(0.62)) /(2*1.96))^2)) = 1.7671356 
 
The estimated 95% CI for the HR is 0.631 to 1.767. 
This is plausible, in that it contains the estimate 1.056 comfortably. It looks 
wide, compare to the CIs for B/A and C/A. This is because of the false 
assumption of independence. If we had all the data, we could allow for the 
dependence and obtain a smaller SE and narrower confidence interval. 
However, we don’t. So we would use this as an approximation, with the caveat 
that the standard error may be too big, which may slightly reduce the 





Source of code lists per study variable 
 
Variable Reference Code source Code 
type 











BNF Manual Review of TRUD (see below) CTV2 
    
Cardiovascular risk factors measured before or at start of study 















































































































eFI validation in SAIL(407) CTV2 
Comorbidities measured before or at start of study 
















































































































































































































AKI= acute kidney injury; BMI = body mass index; BNF = British National 
Formulary; BP= blood pressure; CALIBER = Cardiovascular disease research 




Version 2 codes; DISCO = Discovery of Symptomatic Cancer Optimally team; 
eFI = electronic Frailty Index; HFS = Hospital Frailty Score; ICD-10 = 
International Classification of Disease manual, 10th editionˑ NOS = Not 
Otherwise Specified; QOF = Quality Outcomes Framework; SAIL = Secure 





Code lists for BP-lowering medications 
6.9 Alpha blockers 
2.5.4 Alpha-adrenoceptor blocking drugs 
Bethanidine BETHANIDINE SULPHATE bg1.. 
BETANIDINE 10mg tablets bg11. 
*BETHANIDINE 50mg tablets bg12. 
*BENDOGEN 10mg tablets bg13. 
*BENDOGEN 50mg tablets bg14. 
*ESBATAL 10mg tablets bg15. 
*ESBATAL 50mg tablets bg16. 
BETANIDINE SULPHATE 10mg tablets bg1y. 
BETANIDINE SULPHATE 50mg tablets bg1z. 
Clonidine CLONIDINE HYDROCHLORIDE 
[ANTIHYPERTENSIVE] 
bf1.. 
CATAPRES 100micrograms tablets bf11. 
CATAPRES 300micrograms tablets bf12. 
CATAPRES PERLONGETS 250microgram 
m/r capsules 
bf13. 
CATAPRES 150micrograms/mL injection bf14. 
CLONIDINE 100microgram tablets bf1w. 
CLONIDINE 300micrograms tablets bf1x. 
CLONIDINE 250microgram m/r capsules bf1y. 
CLONIDINE 150microgram/mL injection bf1z. 
Desbrisoquine DEBRISOQUINE bg2.. 
*DECLINAX 10mg tablets bg21. 
*DECLINAX 20mg tablets bg22. 
*DEBRISOQUINE 10mg tablets bg2y. 
*DEBRISOQUINE 20mg tablets bg2z. 
Doxazosin DOXAZOSIN bh6.. 
DOXAZOSIN 1mg tablets bh61. 
DOXAZOSIN 2mg tablets bh62. 
DOXAZOSIN 4mg tablets bh63. 
CARDURA 1mg tablets bh64. 
CARDURA 2mg tablets bh65. 
*CARDURA 4mg tablets bh66. 
CARDURA XL 4mg m/r tablets bh67. 
CARDURA XL 8mg m/r tablets bh68. 
*CASCOR 2mg tablets bh69. 
*CASCOR 4mg tablets bh6A. 
DOXADURA 1mg tablets bh6B. 
DOXADURA 2mg tablets bh6C. 
DOXADURA 4mg tablets bh6D. 
SLOCINX XL 4mg m/r tablets bh6E. 




OXANDOSIN XL 4mg m/r tablets bh6G. 
RAPORSIN XL 4mg m/r tablets bh6H. 
DOXAZOSIN 8mg m/r tablets bh6y. 
DOXAZOSIN 4mg m/r tablets bh6z. 
Indoramin INDORAMIN bh1.. 
*BARATOL 25mg tablets bh11. 
*BARATOL 50mg tablets bh12. 
DORALESE TILTAB 20mg tablets bh13. 
INDORAMIN 20mg tablets bh14. 
INDORAMIN 25mg tablets bh1y. 
INDORAMIN 50mg tablets bh1z. 
Methyldopa METHYLDOPA bf2.. 
METHYLDOPA 125mg tablets bf21. 
METHYLDOPA 250mg tablets bf22. 
METHYLDOPA 500mg tablets bf23. 
*ALDOMET 125mg tablets bf24. 
ALDOMET 250mg tablets bf25. 
ALDOMET 500mg tablets bf26. 
ALDOMET 250mg/5mL oral mixture bf27. 
*ALDOMET 250mg/5mL injection bf28. 
*DOPAMET 125mg tablets bf29. 
*DOPAMET 250mg tablets bf2a. 
*DOPAMET 500mg tablets bf2b. 
MEDOMET 250mg capsules bf2c. 
MEDOMET 250mg tablets bf2d. 
MEDOMET 500mg tablets bf2e. 
*HYDROMET tablets bf2f. 
*METALPHA 250mg tablets bf2g. 








METHYLDOPA 250mg capsules bf2z. 
Metirosine METIROSINE bk1.. 
*DEMSER 250mg capsules bk11. 
*METIROSINE 250mg capsules bk1z. 







DIBENYLINE [CVS] 10mg capsules bh21. 
DIBENYLINE 100mg/2mL injection bh22. 
Prazosin PRAZOSIN HYDROCHLORIDE bh4.. 
HYPOVASE 500micrograms tablets bh41. 
HYPOVASE 1mg tablets bh42. 
*HYPOVASE 2mg tablets bh43. 




HYPOVASE BD STARTER PACK tablets bh45. 
ALPHAVASE 500micrograms tablets bh46. 
*ALPHAVASE 1mg tablets bh47. 
*ALPHAVASE 2mg tablets bh48. 
*ALPHAVASE 5mg tablets bh49. 
KENTOVACE 500micrograms tablets bh4A. 
KENTOVACE 1mg tablets bh4B. 
KENTOVACE 2mg tablets bh4C. 
KENTOVACE 5mg tablets bh4D. 
PRAZOSIN HYDROCHLORIDE STARTER 





PRAZOSIN HYDROCHLORIDE 1mg tablets bh4x. 
PRAZOSIN HYDROCHLORIDE 2mg tablets bh4y. 
PRAZOSIN HYDROCHLORIDE 5mg tablets bh4z. 
Terazosin TERAZOSIN 1mg tablets bh5x. 
TERAZOSIN 2mg tablets bh5z. 
TERAZOSIN 5mg tablets bh55. 
TERAZOSIN 10mg tablets bh56. 
TERAZOSIN HYDROCHLORIDE bh5.. 
HYTRIN 2mg tablets bh51. 
HYTRIN 5mg tablets bh52. 
HYTRIN 10mg tablets bh53. 
HYTRIN STARTER PACK tablets bh54. 
TERAZOSIN 5mg tablets bh55. 
TERAZOSIN 10mg tablets bh56. 
HYTRIN 1mg tablets bh57. 
TERAZOSIN 1mg tablets bh5x. 
TERAZOSIN STARTER PACK 1mg+2mg 
tablets 
bh5y. 
TERAZOSIN 1mg+2mg+5mg tablets starter 
pack 
gc5z. 
TERAZOSIN HYDROCHLORIDE [see chap 
b for generic preps] 
gc5.. 
HYTRIN BPH STARTER PACK tablets gc51. 
HYTRIN BPH 2mg tablets gc52. 
HYTRIN BPH 5mg tablets gc53. 
HYTRIN BPH 10mg tablets gc54. 
HYTRIN BPH 1mg tablets gc55. 
 
6.10 Angiotensin Converting Enzyme inhibitors (ACEi) 
 
2.5.5 Renin-Angiotensin System Drugs 
(a) ACEi 
Captopril CAPTOPRIL bi1.. 




ACEPRIL 25mg tablets bi12. 
ACEPRIL 25mg tablets x56 bi13. 
ACEPRIL 50mg tablets bi14. 
ACEPRIL 50mg tablets x56 bi15. 
*CAPOTEN 12.5mg tablets bi16. 
CAPOTEN 25mg tablets bi17. 
CAPOTEN 25mg tablets x56 bi18. 
CAPOTEN 50mg tablets bi19. 
*HYPAPRIL 12.5mg tablets bi1A. 
*HYPAPRIL 25mg tablets bi1B. 
*HYPAPRIL 50mg tablets bi1C. 
*CAPTO-CO 25mg/12.5mg tablets bi1D. 
*CAPTO-CO 50mg/25mg tablets bi1E. 
CO-ZIDOCAPT 25mg/12.5mg tablet bi1F. 
*CO-ZIDOCAPT 50mg/25mg tablets bi1G. 
NOYADA 5mg/5mL oral solution bi1H. 
CAPTOPRIL 5mg/5mL oral solution bi1I. 
NOYADA 25mg/5mL oral solution bi1J. 
CAPTOPRIL 25mg/5mL oral solution bi1K. 
CAPOTEN 50mg tablets x56 bi1a. 
ACEZIDE 50mg tablets x56 bi1b. 
*CAPOZIDE 50mg tablets x28 bi1c. 







ECOPACE 12.5mg tablets bi1g. 
ECOPACE 25mg tablets bi1h. 
ECOPACE 50mg tablets bi1i. 
*KAPLON 12.5mg tablets bi1j. 
*KAPLON 25mg tablets bi1k. 
*KAPLON 50mg tablets bi1l. 
*HYTENEZE 12.5 tablets bi1m. 
*HYTENEZE 25 tablets bi1n. 
*HYTENEZE 50 tablets bi1o. 
*TENSOPRIL 12.5mg tablets bi1p. 
*TENSOPRIL 25mg tablets bi1q. 
*TENSOPRIL 50mg tablets bi1r. 
CAPOZIDE 50mg/25mg tablets bi1s. 
CAPTOPRIL 12.5mg tablets bi1v. 
CAPTOPRIL 25mg tablets bi1w. 
CAPTOPRIL 25mg tablets x56 bi1x. 
CAPTOPRIL 50mg tablets x56 bi1y. 
CAPTOPRIL 50mg tablets bi1z. 
Cilazapril CILAZAPRIL bi8.. 
CILAZAPRIL 250micrograms tablets bi81. 
CILAZAPRIL 500micrograms tablets bi82. 
*CILAZAPRIL 1mg tablets bi83. 




*VASCACE 250micrograms tablets bi85. 
*VASCACE 500micrograms tablets bi86. 
*VASCACE 1mg tablets bi87. 
*VASCACE 2.5mg tablets bi88. 
*VASCACE 5mg tablets bi89. 
CILAZAPRIL 5mg tablets bi8a. 
Enalapril ENALAPRIL MALEATE bi2.. 
INNOVACE 2.5mg tablets bi21. 
INNOVACE 5mg tablets bi22. 
INNOVACE 5mg tablets x28 bi23. 
INNOVACE 10mg tablets bi24. 
INNOVACE 10mg tablets x28 bi25. 
INNOVACE 20mg tablets bi26. 
INNOVACE 20mg tablets x28 bi27. 
INNOZIDE 20/12.5mg tablets bi28. 
INNOVACE tablets titration pack bi29. 
*ENALAPRIL MALEATE 2.5mg wafer bi2A. 
*ENALAPRIL MALEATE 5mg wafer bi2B. 
*ENALAPRIL MALEATE 10mg wafer bi2C. 
*ENALAPRIL MALEATE 20mg wafer bi2D. 
*INNOVACE MELT 2.5mg wafer bi2E. 
*INNOVACE MELT 5mg wafer bi2F. 
*INNOVACE MELT 10mg wafer bi2G. 
*INNOVACE MELT 20mg wafer bi2H. 
*PRALENAL 2.5mg tablets bi2J. 
*PRALENAL 5mg tablets bi2K. 
*PRALENAL 10mg tablets bi2L. 
*PRALENAL 20mg tablets bi2M. 







ENALAPRIL MALEATE 2.5mg tablets bi2t. 
ENALAPRIL MALEATE 5mg tablets bi2u. 
ENALAPRIL MALEATE 5mg tablets x28 bi2v. 
ENALAPRIL MALEATE 10mg tablets bi2w. 
ENALAPRIL MALEATE 10mg tablets x28 bi2x. 
ENALAPRIL MALEATE 20mg tablets bi2y. 
ENALAPRIL MALEATE 20mg tablets x28 bi2z. 
Sodium Fosinopril SODIUM FOSINOPRIL bi7.. 
FOSINOPRIL 10mg tablets bi71. 
FOSINOPRIL 20mg tablets bi72. 
*STARIL 10mg tablets bi73. 
*STARIL 20mg tablets bi74. 
Imidapril IMIDAPRIL HYDROCHLORIDE biB.. 
TANATRIL 5mg tablets biB1. 
TANATRIL 10mg tablets biB2. 
TANATRIL 20mg tablets biB3. 





IMIDAPRIL HYDROCHLORIDE 5mg 
tablets 
biBy. 
IMIDAPRIL HYDROCHLORIDE 10mg 
tablets 
biBz. 
Lisinopril LISINOPRIL bi3.. 
LISINOPRIL 2.5mg tablets bi31. 
LISINOPRIL 5mg tablets bi32. 
LISINOPRIL 10mg tablets bi33. 
LISINOPRIL 20mg tablets bi34. 
*CARACE 2.5mg tablets bi35. 
*CARACE 5mg tablets 28CP bi36. 
*CARACE 5mg tablets bi37. 
*CARACE 10mg tablets 28CP bi38. 
*CARACE 10mg tablets bi39. 
*CARACE 20mg tablets 28CP bi3a. 
*CARACE 20mg tablets bi3b. 
*ZESTRIL 2.5mg tablets 28CP bi3c. 
*ZESTRIL 2.5mg tablets bi3d. 
ZESTRIL 5mg tablets 28CP bi3e. 
ZESTRIL 5mg tablets bi3f. 
ZESTRIL 10mg tablets 28CP bi3g. 
ZESTRIL 10mg tablets bi3h. 
ZESTRIL 20mg tablets 28CP bi3i. 
ZESTRIL 20mg tablets bi3j. 
CARACE 20 PLUS tablets bi3k. 
*CARACE 10 PLUS tablets bi3l. 
*ZESTORETIC tablets 28CP bi3m. 




*ZESTRIL 2.5mg starter pack bi3q. 
LISINOPRIL 2.5mg tablets starter pack bi3r. 




*CARALPHA 10/12.5mg tablets bi3u. 
*CARALPHA 20/12.5mg tablets bi3v. 
LISICOSTAD HCT 20/12.5mg tablets bi3w. 
LISICOSTAD HCT 10/12.5mg tablets bi3x. 
Moexipril MOEXIPRIL biA.. 
MOEXIPRIL HYDROCHLORIDE 7.5mg 
tablets 
biA1. 
MOEXIPRIL HYDROCHLORIDE 15mg 
tablets 
biA2. 
PERDIX 7.5mg tablets biA3. 
PERDIX 15mg tablets biA4. 
Perindopril Arginine PERINDOPRIL ARGININE biC.. 
COVERSYL ARGININE 2.5mg tablets biC1. 




COVERSYL ARGININE 5mg tablets biC3. 
PERINDOPRIL ARGININE 5mg tablets biC4. 
COVERSYL ARGININE 10mg tablets biC5. 
PERINDOPRIL ARGININE 10mg tablets biC6. 






PERINDOPRIL ERBUMINE bi5.. 
PERINDOPRIL ERBUMINE 2mg tablets bi51. 
PERINDOPRIL ERBUMINE 4mg tablets bi52. 
*COVERSYL 2mg tablets bi53. 




COVERSYL PLUS 4mg/1.25mg tablets bi56. 
PERINDOPRIL ERBUMINE 8mg tablets bi57. 
*COVERSYL 8mg tablets bi58. 
PERINDOPRIL TERT-BUTYLAMINE bi5.. 
PERINDOPRIL ERBUMINE 2mg tablets bi51. 
PERINDOPRIL ERBUMINE 4mg tablets bi52. 
*COVERSYL 2mg tablets bi53. 




COVERSYL PLUS 4mg/1.25mg tablets bi56. 
PERINDOPRIL ERBUMINE 8mg tablets bi57. 
*COVERSYL 8mg tablets bi58. 
Quinapril QUINAPRIL bi4.. 
QUINAPRIL 5mg tablets bi41. 
QUINAPRIL 10mg tablets bi42. 
QUINAPRIL 20mg tablets bi43. 
ACCUPRO 5mg tablets 28CP bi44. 
ACCUPRO 10mg tablets 28CP bi45. 
ACCUPRO 20mg tablets 28CP bi46. 




ACCUPRO 40mg tablets bi49. 
QUINAPRIL 40mg tablets bi4A. 
QUINIL 5mg tablets bi4B. 
QUINIL 10mg tablets bi4C. 
QUINIL 20mg tablets bi4D. 
QUINIL 40mg tablets bi4E. 
Ramipril RAMIPRIL bi6.. 
RAMIPRIL 1.25mg tablets bi6B. 
TRITACE 1.25mg tablets bi6z. 
RAMIPRIL 2.5mg tablets bi6C. 
TRITACE 2.5mg tablets bi6y. 




TRITACE 5mg tablets bi6x. 
RAMIPRIL 10mg tablets bi6E. 
TRITACE 10mg tablets bi6w. 
RAMIPRIL 1.25mg capsules bi61. 
*RANACE 1.25mg capsules bi6s. 
*TRITACE 1.25mg capsules bi64. 
RAMIPRIL 2.5mg capsules bi62. 
*LOPACE 2.5mg capsules bi6t. 
*RANACE 2.5mg capsules bi6r. 
*TRITACE 2.5mg capsules bi65. 
RAMIPRIL 5mg capsules bi63. 
*LOPACE 5mg capsules bi6u. 
*RANACE 5mg capsules bi6q. 
RAMIPRIL 10mg capsules bi67. 
RAMIPRIL 10mg capsules bi67. 
*LOPACE 10mg capsules bi6v. 
*RANACE 10mg capsules bi6p. 
*TRITACE 10mg capsules bi68. 
RAMIPRIL 2.5mg+5mg+10mg capsules 
titration pack 
bi69. 
TRITACE Titration Pack capsules bi6A. 





TRIAPIN MITE 2.5mg/2.5mg tablets bA11. 
FELODIPINE+RAMIPRIL 5mg/5mg tablets bA1z. 
TRIAPIN 5mg/5mg tablets bA12. 
RAMIPRIL 2.5mg+5mg+10mg tablets 
titration pack 
bi6F. 
TRITACE Titration Pack tablets bi6o. 
Trandolapril TRANDOLAPRIL bi9.. 
TRANDOLAPRIL 500micrograms capsules bi91. 
TRANDOLAPRIL 1mg capsules bi92. 
TRANDOLAPRIL 2mg capsules bi93. 
*GOPTEN 500micrograms capsules bi94. 
*GOPTEN 1mg capsules bi95. 
*GOPTEN 2mg capsules bi96. 
*ODRIK 500micrograms capsules bi97. 
*ODRIK 1mg capsules bi98. 
*ODRIK 2mg capsules bi99. 
*GOPTEN 4mg capsules bi9A. 





HYDROCHLORIDE 2mg/180mg m/r 
capsules 
bk61. 





6.11 Angiotensin Receptor Blockers (ARBs) 
 
(b) Angiotensin Receptor Blockers 
Azilsartan AZILSARTAN bkJ.. 
EDARBI 20mg tablets bkJ1. 
AZILSARTAN MEDOXOMIL 20mg tablets bkJ2. 
EDARBI 40mg tablets bkJ3. 
AZILSARTAN MEDOXOMIL 40mg tablets bkJ4. 
EDARBI 80mg tablets bkJ5. 




CANDESARTAN CILEXETIL 2mg tablets bk71. 
CANDESARTAN CILEXETIL 4mg tablets bk72. 
CANDESARTAN CILEXETIL 8mg tablets bk73. 
CANDESARTAN CILEXETIL 16mg tablets bk74. 
AMIAS 2mg tablets bk75. 
AMIAS 4mg tablets bk76. 
AMIAS 8mg tablets bk77. 
AMIAS 16mg tablets bk78. 
AMIAS 32mg tablets bk79. 
CANDESARTAN CILEXETIL 32mg tablets bk7z. 
Eprosartan EPROSARTAN bk9.. 
TEVETEN 300mg tablets bk91. 
*TEVETEN 400mg tablets bk92. 
TEVETEN 600mg tablets bk93. 
EPROSARTAN 300mg tablets bk9x. 
EPROSARTAN 400mg tablets bk9y. 
EPROSARTAN 600mg tablets bk9z. 
Irbesartan IRBESARTAN bk5.. 
IRBESARTAN 75mg tablets bk51. 
IRBESARTAN 150mg tablets bk52. 
IRBESARTAN 300mg tablets bk53. 
APROVEL 75mg tablets bk54. 
APROVEL 150mg tablets bk55. 
APROVEL 300mg tablets bk56. 
COAPROVEL 150mg/12.5mg tablets bk57. 
COAPROVEL 300mg/12.5mg tablets bk58. 










Losartan LOSARTAN bk3.. 
LOSARTAN POTASSIUM 25mg tablets bk31. 
LOSARTAN POTASSIUM 50mg tablets bk32. 









COZAAR-COMP 50mg/12.5mg tablets bk36. 
LOSARTAN POTASSIUM 100mg tablets bk37. 
COZAAR 100mg tablets bk38. 
COZAAR-COMP 100mg/25mg tablets bk39. 
COZAAR-COMP 100mg/12.5mg tablets bk3A. 
COZAAR 12.5mg tablets bk3B. 
LOSARTAN POTASSIUM 12.5mg tablets bk3C. 
COZAAR 2.5mg/mL oral suspension bk3D. 
LOSARTAN POTASSIUM 2.5mg/mL oral 
suspension 
bk3E. 
ZOVENCAL 25mg tablets bk3F. 
ZOVENCAL 50mg tablets bk3G. 









Olmesartan OLMESARTAN bkB.. 
OLMESARTAN MEDOXOMIL 10mg tablets bkB1. 
OLMESARTAN MEDOXOMIL 20mg tablets bkB2. 
OLMESARTAN MEDOXOMIL 40mg tablets bkB3. 
OLMETEC 10mg tablets bkB4. 
OLMETEC 20mg tablets bkB5. 
OLMETEC 40mg tablets bkB6. 
OLMESARTAN+AMLODIPINE bkH.. 
SEVIKAR 20mg/5mg tablets bkH1. 
SEVIKAR 40mg/5mg tablets bkH2. 
















OLMETEC PLUS 20mg/12.5mg tablets bkC1. 
OLMETEC PLUS 20mg/25mg tablets bkC2. 
OLMETEC PLUS 40mg/12.5mg tablets bkC3. 
OLMESARTAN+HYDROCHLOROTHIAZID













OLMESARTAN MEDOXOMIL 10mg tablets bkB1. 
OLMESARTAN MEDOXOMIL 20mg tablets bkB2. 




SEVIKAR HCT 20mg/5mg/12.5mg tablets bkI1. 
SEVIKAR HCT 40mg/5mg/12.5mg tablets bkI2. 
SEVIKAR HCT 40mg/10mg/12.5mg tablets bkI3. 
SEVIKAR HCT 40mg/5mg/25mg tablets bkI4. 
SEVIKAR HCT 40mg/10mg/25mg tablets bkI5. 
Telmisartan TELMISARTAN bk8.. 
TELMISARTAN 40mg tablets bk81. 
TELMISARTAN 80mg tablets bk82. 
MICARDIS 40mg tablets bk83. 
MICARDIS 80mg tablets bk84. 
MICARDIS 20mg tablets bk85. 
MICARDISPLUS 40mg/12.5mg tablets bk86. 
MICARDISPLUS 80mg/12.5mg tablets bk87. 
MICARDISPLUS 80mg/25mg tablets bk88. 
TELMISARTAN+HYDROCHLOROTHIAZID
E 80mg/25mg tablets 
bk8w. 
TELMISARTAN+HYDROCHLOROTHIAZID
E 40mg/12.5mg tablets 
bk8x. 
TELMISARTAN+HYDROCHLOROTHIAZID
E 80mg/12.5mg tablets 
bk8y. 
TELMISARTAN 20mg tablets bk8z. 
VALSARTAN bk4.. 
Valsartan VALSARTAN 40mg capsules bk41. 
VALSARTAN 80mg capsules bk42. 
VALSARTAN 160mg capsules bk43. 
DIOVAN 40mg capsules bk44. 
DIOVAN 80mg capsules bk45. 
DIOVAN 160mg capsules bk46. 
CO-DIOVAN 160mg/12.5mg tablets bk47. 
CO-DIOVAN 160mg/25mg tablets bk48. 
CO-DIOVAN 80mg/12.5mg tablets bk49. 
DIOVAN 40mg tablets bk4A. 
DIOVAN 40mg tablets bk4A. 
DIOVAN 3mg/mL oral solution bk4C. 
VALSARTAN 80mg tablets bk4s. 
VALSARTAN 160mg tablets bk4t. 
VALSARTAN 3mg/mL oral solution bk4u. 
VALSARTAN 320mg tablets bk4v. 























EXFORGE 10mg/160mg tablets bkDx. 
EXFORGE 5mg/160mg tablets bkDy. 
EXFORGE 5mg/80mg tablets bkDz. 
 
6.12 Beta-adrenoceptor blocking drugs 
 
BNF Chapter 2.4 
Beta-Adrenoceptor 
Blocking Drugs 
Source: NHS TRUD dictionary 
CTV2 codes 
Beta blocker BETA-ADRENOCEPTOR BLOCKERS bd... 
Acebutolol ACEBUTOLOL bd2.. 
SECTRAL 100mg capsules bd21. 
SECTRAL 200mg capsules bd22. 
SECTRAL 400mg tablets bd23. 
*SECTRAL 10mg/2mL injection bd24. 
ACEBUTOLOL 100mg capsules bd2w. 
ACEBUTOLOL 200mg capsules bd2x. 
ACEBUTOLOL 400mg tablets bd2y. 
*ACEBUTOLOL 10mg/2mL injection bd2z. 
Atenolol Atenolol bd3.. 
TENORMIN 100mg tablets bd31. 
TENORMIN 25mg/5mL syrup bd32. 
TENORMIN 5mg/10mL injection bd33. 
TENORMIN LS 50mg tablets bd34. 
ATENOLOL 50mg tablets bd35. 
ATENOLOL 100mg tablets bd36. 
*TENORMIN CCU PACK bd37. 
*BETA-ADALAT 50/20mg capsules bd38. 
*TENIF 50/20mg capsules bd39. 
*ANTIPRESSAN 50mg tablets bd3a. 
*ANTIPRESSAN 100mg tablets bd3b. 
*TENORMIN 25 tablets bd3c. 
*VASATEN 50mg tablets bd3d. 




ATENIX 50mg tablets bd3f. 
ATENIX 100mg tablets bd3g. 
*TOTAMOL 50mg tablets bd3h. 
*TOTAMOL 100mg tablets bd3i. 
ATENOLOL 25mg tablets bd3j. 
*TOTAMOL 25mg tablets bd3k. 
*ANTIPRESSAN 25mg tablets bd3l. 
ATENOLOL 25mg/5mL syrup bd3x. 
ATENOLOL 5mg/10mL injection bd3y. 













KALTEN capsules bde7. 
TENIF 50/20mg capsules bdet. 
ATENIXCO 50/12.5mg tablets bdeo. 
ATENOLOL+NIFEDIPINE 50mg/20mg m/r 
capsules 
bdez. 
TENORETIC tablets bdeh. 
TENORET-50 tablets bdeg. 
TOTARETIC 100mg/25mg tablets bdeO. 
TOTARETIC 50mg/12.5mg tablets bdeN. 
Betaxolol  BETAXOLOL HCL [B-BLOCKER] bd4.. 
*KERLONE 20mg tablets bd41. 
BETAXOLOL HYDROCHLORIDE 20mg 
tablets 
bd4z. 
Bisoprolol BISOPROLOL FUMARATE bdf.. 
BISOPROLOL FUMARATE 5mg tablets bdf1. 
BISOPROLOL FUMARATE 10mg tablets bdf2. 
*MONOCOR 5mg tablets bdf3. 
*MONOCOR 10mg tablets bdf4. 
*EMCOR LS 5mg tablets bdf5. 
*EMCOR 10mg tablets bdf6. 





CARDICOR 1.25mg tablets bdf9. 
CARDICOR 2.5mg tablets bdfA. 
CARDICOR 3.75mg tablets bdfB. 
CARDICOR 5mg tablets bdfC. 
CARDICOR 7.5mg tablets bdfD. 
CARDICOR 10mg tablets bdfE. 
*BIPRANIX 5mg tablets bdfF. 




*SOLOC 5mg tablets bdfH. 
*SOLOC 10mg tablets bdfI. 
VIVACOR 10mg tablets bdfJ. 
VIVACOR 5mg tablets bdfK. 
CONGESCOR 1.25mg tablets bdfL. 
CONGESCOR 2.5mg tablets bdfM. 
BISOPROLOL FUMARATE 1.25mg tablets bdfw. 
BISOPROLOL FUMARATE 2.5mg tablets bdfx. 
BISOPROLOL FUMARATE 3.75mg tablets bdfy. 
BISOPROLOL FUMARATE 7.5mg tablets bdfz. 
Carvedilol CARVEDILOL bdl.. 
*EUCARDIC 12.5 tablets bdl1. 
*EUCARDIC 25 tablets bdl2. 
CARVEDILOL 12.5mg tablets bdl3. 
CARVEDILOL 25mg tablets bdl4. 
CARVEDILOL 3.125mg tablets bdl5. 
CARVEDILOL 6.25mg tablets bdl6. 
*EUCARDIC 3.125 tablets bdl7. 
*EUCARDIC 6.25 tablets bdl8. 
Celiprolol CELIPROLOL HYDROCHLORIDE bdj.. 
CELIPROLOL 200mg tablets bdj1. 
CELECTOL 200mg tablets 28-CP bdj2. 
CELECTOL 200mg tablets bdj3. 
CELIPROLOL 400mg tablets bdj4. 
CELECTOL 400mg tablets bdj5. 
Esmolol ESMOLOL HYDROCHLORIDE bdk.. 
ESMOLOL HCL 2.5g/10mL injection bdk1. 
ESMOLOL HCL 100mg/10mL injection bdk2. 
BREVIBLOC CONCENTRATE 2.5g/10mL 
injection 
bdk3. 
BREVIBLOC 100mg/10mL injection bdk4. 
ESMOLOL HYDROCHLORIDE 10mg/mL 
infusion solution 
bdk5. 
BREVIBLOC 10mg/mL infusion solution bdk6. 
Labetolol LABETALOL 50mg tablets bd5v. 
LABETALOL 100mg tablets bd51. 
LABETALOL 200mg tablets bd52. 
LABETALOL 400mg tablets bd53. 
LABETALOL HYDROCHLORIDE bd5.. 
*LABROCOL 100mg tablets bd54. 
*LABROCOL 200mg tablets bd55. 
*LABROCOL 400mg tablets bd56. 
TRANDATE 50mg tablets bd57. 
TRANDATE 100mg tablets bd58. 
TRANDATE 200mg tablets bd59. 
TRANDATE 400mg tablets bd5a. 
*TRANDATE 100mg/20mL injection bd5b. 
LABETALOL HYDROCHLORIDE 
50mg/10mL prefilled syringe 
bd5c. 




*LABETALOL 200mg tablets bd5u. 
*LABETALOL 100mg tablets bd5w. 
*LABETALOL 200mg tablets bd5x. 
*LABETALOL 400mg tablets bd5y. 
LABETALOL 100mg/20mL injection bd5z. 
Metoprolol METOPROLOL TARTRATE bd6.. 
*BETALOC 50mg tablets bd61. 
*BETALOC 100mg tablets bd62. 
BETALOC 5mg/5mL injection bd63. 
BETALOC-SA DURULES 200mg m/r tablets bd64. 
LOPRESOR 50mg tablets bd65. 
LOPRESOR 100mg tablets bd66. 
*MEPRANIX 50mg tablets bd67. 
*MEPRANIX 100mg tablets bd68. 
*LOPRESOR 5mg/5mL injection bd6a. 
LOPRESOR SR 200mg m/r tablets bd6b. 
*ARBRALENE 50mg tablets bd6c. 
*ARBRALENE 100mg tablets bd6d. 
*TENSOMEX 100mg tablets bd6e. 
METOPROLOL 100mg tablets bd6w. 
METOPROLOL 50mg tablets bd6x. 
METOPROLOL 5mg/5mL injection bd6y. 
METOPROLOL 200mg m/r tablets bd6z. 
Nadolol NADOLOL bd7.. 
*CORGARD 40mg tablets bd71. 
CORGARD 80mg tablets bd72. 
*NADOLOL 40mg tablets bd7y. 
NADOLOL 80mg tablets bd7z. 
Nebivolol NEBIVOLOL bdm.. 
NEBILET 5mg tablets bdm1. 
HYPOLOC 5mg tablets bdm2. 
NEBIVOLOL 2.5mg tablets bdmy. 
NEBIVOLOL 5mg tablets bdmz. 
Oxprenolol OXPRENOLOL 20mg tablets bd81. 
OXPRENOLOL 40mg tablets bd82. 
OXPRENOLOL 80mg tablets bd83. 
OXPRENOLOL 160mg tablets bd84. 
OXPRENOLOL HYDROCHLORIDE bd8.. 
*APSOLOX 20mg tablets bd85. 
*APSOLOX 40mg tablets bd86. 
*APSOLOX 80mg tablets bd87. 
*APSOLOX 160mg tablets bd88. 
*LARACOR 20mg tablets bd89. 
*LARACOR 40mg tablets bd8a. 
*LARACOR 80mg tablets bd8b. 
*LARACOR 160mg tablets bd8c. 
*SLOW-PREN 160mg m/r tablets bd8d. 
SLOW-TRASICOR 160mg m/r tablets bd8e. 
*TRASICOR 20mg tablets bd8f. 




*TRASICOR 80mg tablets bd8h. 
*TRASICOR 160mg tablets bd8i. 
*TRASICOR 2mg injection bd8j. 
*PARITANE 20mg tablets bd8k. 
*PARITANE 40mg tablets bd8l. 
*PARITANE 80mg tablets bd8m. 
*PARITANE 160mg tablets bd8n. 
*OXYPRENIX 160mg m/r tablets bd8o. 
OXPRENOLOL 160mg m/r tablets bd8u. 
Pindolol PINDOLOL bda.. 
VISKEN 5mg tablets bda1. 
VISKEN 15mg tablets bda2. 
*BETADREN 5mg tablets bda3. 
*BETADREN 15mg tablets bda4. 
PINDOLOL 5mg tablets bday. 




VISKALDIX tablets bdek. 
Propranolol PROPRANOLOL 40mg tablets bd12. 
PROPRANOLOL 80mg tablets bd13. 
PROPRANOLOL 10mg tablets bd11. 
PROPRANOLOL 5mg/5mL syrup bd1I. 
PROPRANOLOL 160mg tablets bd14. 
PROPRANOLOL HYDROCHLORIDE bd1.. 
*ANGILOL 10mg tablets bd15. 
*ANGILOL 40mg tablets bd16. 
*ANGILOL 80mg tablets bd17. 
*ANGILOL 160mg tablets bd18. 
*APSOLOL 10mg tablets bd19. 
*PROPANIX 10mg tablets bd1A. 
*PROPANIX 40mg tablets bd1B. 
*PROPANIX 80mg tablets bd1C. 
*PROPANIX 160mg tablets bd1D. 
PROPANIX SR 160mg m/r capsules bd1E. 
*BETADUR CR 160mg m/r tablets bd1F. 
BETA-PROGRANE 160mg m/r capsules bd1G. 
PROPRANOLOL 1mg/1mL injection bd1H. 
PROPRANOLOL 5mg/5mL syrup bd1I. 
PROPRANOLOL 50mg/5mL syrup bd1J. 
HALF-BETADUR CR 80mg m/r capsules bd1K. 
HALF BETA-PROGRANE 80mg m/r 
capsules 
bd1L. 
*SLOPROLOL 80mg m/r capsules bd1M. 
*PROBETA LA 160mg m/r capsules bd1N. 













HALF PROPANIX LA 80mg m/r capsules bd1S. 
PROPANIX LA 160mg m/r capsules bd1T. 
HALF PROPATARD LA 80mg m/r capsules bd1U. 
PROPATARD LA 160mg m/r capsules bd1V. 
PROPRANOLOL HYDROCHLORIDE 
5mg/5mL sugar free oral solution 
bd1W. 
PROPRANOLOL HYDROCHLORIDE 
10mg/5mL sugar free oral solution 
bd1X. 
PROPRANOLOL HYDROCHLORIDE 
50mg/5mL sugar free oral solution 
bd1Y. 
SYPROL 5mg/5mL oral solution bd1Z. 
*APSOLOL 40mg tablets bd1a. 
*APSOLOL 80mg tablets bd1b. 
*APSOLOL 160mg tablets bd1c. 
*BEDRANOL 10mg tablets bd1d. 
*BEDRANOL 40mg tablets bd1e. 
*BEDRANOL 80mg tablets bd1f. 
BEDRANOL SR 160mg m/r capsules bd1g. 
*BERKOLOL 10mg tablets bd1h. 
*BERKOLOL 40mg tablets bd1i. 
*BERKOLOL 80mg tablets bd1j. 
*BERKOLOL 160mg tablets bd1k. 
HALF-INDERAL LA 80mg m/r capsules bd1l. 
*INDERAL 10mg tablets bd1m. 
*INDERAL 40mg tablets bd1n. 
*INDERAL 80mg tablets bd1o. 
*INDERAL 160mg tablets bd1p. 
*INDERAL 1mg/1mL injection bd1q. 
*INDERAL-LA 160mg m/r capsules bd1r. 
*SLOPROLOL 160mg m/r capsules bd1s. 
*CARDINOL 10mg tablets bd1t. 
*CARDINOL 40mg tablets bd1u. 
*CARDINOL 80mg tablets bd1v. 
*CARDINOL 160mg tablets bd1w. 
PROPRANOLOL 160mg m/r capsules bd1x. 
PROPRANOLOL 80mg m/r capsules bd1y. 
SYPROL 10mg/5mL oral solution bd1z. 
PROPRANOLOL HYDROCHLORIDE [2] bdn.. 
SYPROL 50mg/5mL oral solution bdn1. 
BEDRANOL SR 80mg m/r capsules bdn2. 
*RAPRANOL SR 80mg m/r capsules bdn3. 
RAPRANOL SR 160mg m/r capsules bdn4. 
SYPROL 40mg/5mL oral solution bdn5. 
PROPRANOLOL HYDROCHLORIDE 
40mg/5mL sugar free oral solution 
bdn6. 
Sotalol SOTALOL HYDROCHLORIDE bdc.. 
BETA-CARDONE 40mg tablets bdc1. 




BETA-CARDONE 200mg tablets bdc3. 
SOTACOR 80mg tablets bdc4. 
*SOTACOR 160mg tablets bdc5. 
*SOTACOR 10mg/5mL injection bdc6. 
*SOTACOR 100mg/10mL injection bdc7. 
*SOTACOR 40mg/4mL injection bdc8. 
*SOTALOL 40mg/4mL injection bdcs. 
SOTALOL 40mg tablets bdcu. 
SOTALOL 80mg tablets bdcv. 
SOTALOL 200mg tablets bdcw. 
SOTALOL 160mg tablets bdcx. 
*SOTALOL 10mg/5mL injection bdcy. 
*SOTALOL 100mg/10mL injection bdcz. 
Timolol Maleate TIMOLOL MALEATE [B-BLOCKER] bdd.. 
BETIM 10mg tablets bdd1. 
TIMOLOL 10mg tablets bddz. 
PRESTIM tablets bdeb. 
COMPOUND BETA-
BLOCKERS 
COMPOUND BETA-BLOCKERS bde.. 
*CO-BETALOC tablets bde1. 
*CO-BETALOC SA m/r tablets bde2. 
*CORGARETIC-40 tablets bde3. 
*CORGARETIC-80 tablets bde4. 
*INDERETIC capsules bde5. 
*INDEREX m/r capsules bde6. 
KALTEN capsules bde7. 
*LASIPRESSIN tablets bde8. 












































TOTARETIC 50mg/12.5mg tablets bdeN. 




*TENBEN capsules bdeQ. 
COMBITENS m/r capsules bdeR. 
*MODUCREN tablets bdea. 
PRESTIM tablets bdeb. 
*PRESTIM FORTE tablets bdec. 
*SECADREX tablets bded. 
*SOTAZIDE tablets bdee. 
*SPIROPROP tablets bdef. 
TENORET-50 tablets bdeg. 
TENORETIC tablets bdeh. 
*TOLERZIDE tablets bdei. 
*TRASIDREX tablets bdej. 
VISKALDIX tablets bdek. 
*CO-PRENOZIDE tablets bdel. 
CO-TENIDONE 50/12.5mg tablets bdem. 
CO-TENIDONE 100/25mg tablets bden. 
ATENIXCO 50/12.5mg tablets bdeo. 
*ATENIXCO 100/25mg tablets bdep. 
*TENCHLOR 50/12.5mg tablets bdeq. 
*TENCHLOR 100/25mg tablets bder. 
BETA-ADALAT 50/20mg capsules bdes. 
TENIF 50/20mg capsules bdet. 

















6.13 Calcium channel blockers (CCB) 
 




Amlodipine AMLODIPINE blb.. 
AMLODIPINE 5mg tablets blb1. 
AMLODIPINE 10mg tablets blb2. 
ISTIN 5mg tablets blb3. 
ISTIN 10mg tablets blb4. 
AMLOSTIN 5mg tablets blb5. 
AMLOSTIN 10mg tablets blb6. 
OLMESARTAN+AMLODIPINE bkH.. 
SEVIKAR 20mg/5mg tablets bkH1. 
SEVIKAR 40mg/5mg tablets bkH2. 























EXFORGE 10mg/160mg tablets bkDx. 
EXFORGE 5mg/160mg tablets bkDy. 




SEVIKAR HCT 20mg/5mg/12.5mg tablets bkI1. 
SEVIKAR HCT 40mg/5mg/12.5mg tablets bkI2. 
SEVIKAR HCT 40mg/10mg/12.5mg tablets bkI3. 
SEVIKAR HCT 40mg/5mg/25mg tablets bkI4. 
SEVIKAR HCT 40mg/10mg/25mg tablets bkI5. 
Diltiazem DILTIAZEM HYDROCHLORIDE bl5.. 
TILDIEM 60mg tablets bl51. 
*CALCICARD 60mg tablets bl52. 
*BRITIAZIM 60mg tablets bl53. 
ADIZEM-SR 120mg m/r tablets bl54. 
DILTIAZEM HYDROCHLORIDE 120mg m/r 
tablets 
bl55. 
*ANGIOZEM 60mg tablets bl56. 
*ADIZEM 60mg tablets bl57. 
TILDIEM RETARD 90mg m/r tablets bl58. 
TILDIEM RETARD 120mg m/r tablets bl59. 
TILDIEM LA 300mg m/r capsules bl5A. 




ADIZEM-SR 120mg m/r capsules bl5C. 
ADIZEM-SR 180mg m/r capsules bl5D. 
ADIZEM-XL 300mg m/r capsules bl5E. 
DILZEM SR 60mg m/r capsules bl5F. 
DILZEM SR 90mg m/r capsules bl5G. 
DILZEM SR 120mg m/r capsules bl5H. 
ADIZEM-XL 240mg m/r capsules bl5I. 
ADIZEM-XL 180mg m/r capsules bl5J. 
ADIZEM-XL 120mg m/r capsules bl5K. 
DILZEM-XL 120mg m/r capsules bl5L. 
DILZEM-XL 180mg m/r capsules bl5M. 
DILZEM-XL 240mg m/r capsules bl5N. 
SLOZEM 120mg m/r capsules bl5O. 
SLOZEM 180mg m/r capsules bl5P. 
SLOZEM 240mg m/r capsules bl5Q. 
ANGITIL SR 90 m/r capsules bl5R. 
ANGITIL SR 120 m/r capsules bl5S. 
*METAZEM 60mg tablets bl5T. 
ANGITIL SR 180 m/r capsules bl5U. 
CALCICARD CR 90mg m/r tablets bl5V. 
CALCICARD CR 120mg m/r tablets bl5W. 
KENTIAZEM 60mg m/r capsules bl5X. 
*OPTIL 60mg m/r tablets bl5Y. 
TILDIEM LA 200mg m/r capsules bl5Z. 
DILTIAZEM HYDROCHLORIDE 90mg m/r 
tablets 
bl5a. 
DILTIAZEM HYDROCHLORIDE 300mg m/r 
capsules 
bl5b. 
DILTIAZEM HYDROCHLORIDE 90mg m/r 
capsules 
bl5c. 
DILTIAZEM HYDROCHLORIDE 120mg m/r 
capsules 
bl5d. 
DILTIAZEM HYDROCHLORIDE 180mg m/r 
capsules 
bl5e. 
DILTIAZEM HYDROCHLORIDE 60mg m/r 
capsules 
bl5f. 
DILTIAZEM HYDROCHLORIDE 240mg m/r 
capsules 
bl5g. 





ZIDE 150mg/12.5mg m/r capsules 
bl5i. 
*ADIZEM-XL PLUS m/r capsules bl5j. 
*ANGIOZEM CR 90mg m/r tablets bl5k. 
DILCARDIA SR 60mg m/r capsules bl5l. 
*ANGIOZEM CR 120mg m/r tablets bl5m. 
ZEMTARD 300 XL m/r capsules bl5n. 
VIAZEM XL 120mg m/r capsules bl5o. 




VIAZEM XL 240mg m/r capsules bl5q. 
VIAZEM XL 300mg m/r capsules bl5r. 
DILTIAZEM HYDROCHLORIDE 360mg m/r 
capsules 
bl5s. 
VIAZEM XL 360mg m/r capsules bl5t. 
*CALAZEM 60mg m/r tablets bl5u. 
DILCARDIA SR 90mg m/r capsules bl5v. 
DILCARDIA SR 120mg m/r capsules bl5w. 
ANGITIL XL 240 m/r capsules bl5x. 
ANGITIL XL 300 m/r capsules bl5y. 
DILTIAZEM HYDROCHLORIDE 60mg m/r 
tablets 
bl5z. 
DILTIAZEM HYDROCHLORIDE 2 blj.. 
ZEMTARD 120 XL m/r capsules blj1. 
ZEMTARD 180 XL m/r capsules blj2. 
ZEMTARD 240 XL m/r capsules blj3. 
*OPTIL SR 90 m/r capsules blj4. 
*OPTIL SR 120 m/r capsules blj5. 
*OPTIL SR 180 m/r capsules blj6. 
*OPTIL XL 240 m/r capsules blj7. 
*OPTIL XL 300 m/r capsules blj8. 
DILCARDIA XL 120mg m/r capsules blj9. 
DILCARDIA XL 180mg m/r capsules bljA. 
DILCARDIA XL 240mg m/r capsules bljB. 
BI-CARZEM SR 60mg m/r capsules bljC. 
BI-CARZEM SR 90mg m/r capsules bljD. 
BI-CARZEM SR 120mg m/r capsules bljE. 
*ZILDIL SR 60mg m/r capsules bljF. 
*ZILDIL SR 90mg m/r capsules bljG. 
*ZILDIL SR 120mg m/r capsules bljH. 
SLOZEM 300mg m/r capsules bljJ. 
BI-CARZEM XL 300mg m/r capsules bljK. 
BI-CARZEM XL 240mg m/r capsules bljL. 
ZEMRET 180 XL m/r capsules bljM. 
ZEMRET 240 XL m/r capsules bljN. 
ZEMRET 300 XL m/r capsules bljO. 
ADIZEM-XL 200mg m/r capsules bljP. 
*DISOGRAM SR 60mg m/r capsules bljQ. 
*DISOGRAM SR 90mg m/r capsules bljR. 
DISOGRAM SR 120mg m/r capsules bljS. 
DISOGRAM SR 180mg m/r capsules bljT. 
DISOGRAM SR 240mg m/r capsules bljU. 
DISOGRAM SR 300mg m/r capsules bljV. 
*HORIZEM SR 90mg m/r capsules bljW. 
*HORIZEM SR 120mg m/r capsules bljX. 
DILTIAZEM HYDROCHLORIDE XL 180mg 
m/r capsules 
bljY. 
DILTIAZEM HYDROCHLORIDE XL 240mg 
m/r capsules 
bljZ. 





RETALZEM MR 60mg m/r tablets bljb. 
UARD 120XL m/r capsules bljc. 
UARD 180XL m/r capsules bljd. 
UARD 240XL m/r capsules blje. 
UARD 300XL m/r capsules bljf. 
Felodipine FELODIPINE blc.. 
FELODIPINE 5mg m/r tablets blc1. 
FELODIPINE 10mg m/r tablets blc2. 
PLENDIL 5mg m/r tablets blc3. 
PLENDIL 10mg m/r tablets blc4. 
FELODIPINE 2.5mg m/r tablets blc5. 
PLENDIL 2.5mg m/r tablets blc6. 
CABREN 2.5mg m/r tablets blc7. 
CABREN 5mg m/r tablets blc8. 
CABREN 10mg m/r tablets blc9. 
FELOTENS XL 5mg m/r tablets blca. 
FELOTENS XL 10mg m/r tablets blcb. 
FELOGEN XL 5mg m/r tablets blcc. 
FELENDIL XL 5mg m/r tablets blcd. 
FELENDIL XL 10mg m/r tablets blce. 
KELOC SR 5mg m/r tablets blcf. 
KELOC SR 10mg m/r tablets blcg. 
FELOGEN XL 10mg m/r tablets blch. 
VASCALPHA 5mg m/r tablets blci. 
VASCALPHA 10mg m/r tablets blcj. 
CARDIOPLEN XL 5mg m/r tablets blck. 
CARDIOPLEN XL 10mg m/r tablets blcl. 
NEOFEL XL 5mg m/r tablets blcm. 
NEOFEL XL 10mg m/r tablets blcn. 
PARMID XL 5mg m/r tablets blco. 
PARMID XL 10mg m/r tablets blcp. 
PINEFELD XL 10mg m/r tablets blcq. 
CARDIOPLEN XL 2.5mg m/r tablets blcr. 
NEOFEL XL 2.5mg m/r tablets blcs. 
FELOTENS XL 2.5mg m/r tablets blct. 
FELODIPINE+RAMIPRIL bA1.. 
TRIAPIN MITE 2.5mg/2.5mg tablets bA11. 




FELODIPINE+RAMIPRIL 5mg/5mg tablets bA1z. 
Isradipine *ISRADIPINE bla.. 
*ISRADIPINE 2.5mg tablets bla1. 
*PRESCAL 2.5mg tablets bla2. 
Lacidipine LACIDIPINE ble.. 
LACIDIPINE 2mg tablets ble1. 
LACIDIPINE 4mg tablets ble2. 
MOTENS 2mg tablets ble3. 




Lercandipine  LERCANIDIPINE HYDROCHLORIDE blh.. 
LERCANIDIPINE HYDROCHLORIDE 10mg 
tablets 
blh1. 
ZANIDIP 10mg tablets blh2. 
LERCANIDIPINE HYDROCHLORIDE 20mg 
tablets 
blh3. 
ZANIDIP 20mg tablets blh4. 
Mibefradil MIBEFRADIL bli.. 
*MIBEFRADIL 50mg tablets bli1. 
*MIBEFRADIL 100mg tablets bli2. 
*POSICOR 50mg tablets bli3. 
*POSICOR 100mg tablets bli4. 
Nicardipine NICARDIPINE HYDROCHLORIDE bl7.. 
CARDENE 20mg capsules bl71. 
CARDENE 30mg capsules bl72. 
CARDENE SR 30mg m/r capsules bl73. 
CARDENE SR 45mg m/r capsules bl74. 
NICARDIPINE 45mg m/r capsules bl7w. 
NICARDIPINE 30mg m/r capsules bl7x. 
NICARDIPINE 20mg capsules bl7y. 
NICARDIPINE 30mg capsules bl7z. 
Nifedipine NIFEDIPINE bl8.. 
ADALAT 5mg capsules bl81. 
ADALAT 10mg capsules bl82. 
ADALAT RETARD 20mg m/r tablets bl83. 
ADALAT RETARD 10mg m/r tablets bl84. 
NIFEDIPINE 5mg capsules bl85. 
NIFEDIPINE 10mg capsules bl86. 




*VASAD 5mg capsules bl89. 
ADIPINE MR 20 m/r tablets bl8A. 
ADIPINE MR 10 m/r tablets bl8B. 
*UNIPINE XL 30mg m/r tablets bl8C. 
*NIMODREL MR 10 m/r tablets bl8D. 
*NIMODREL MR 20 m/r tablets bl8E. 
NIFEDIPINE 40mg m/r tablets bl8F. 
*ANGIOPINE 40 LA m/r tablets bl8G. 
*CARDILATE MR 10mg m/r tablets bl8H. 
TENSIPINE MR 10 m/r tablets bl8J. 
TENSIPINE MR 20 m/r tablets bl8K. 
FORTIPINE LA40 m/r tablets bl8L. 
ADALAT LA 20mg m/r tablets bl8M. 
*SLOFEDIPINE 20mg m/r tablets bl8O. 
*ANGIOPINE MR 10mg m/r tablets bl8P. 
GENALAT RETARD 10mg m/r tablets bl8Q. 
GENALAT RETARD 20mg m/r tablets bl8R. 
NIFEDIPRESS MR 10 m/r tablets bl8S. 




NIFEDIPRESS MR 20 m/r tablets bl8U. 
NIFEDIPINE 30mg m/r capsules bl8V. 
NIFEDIPINE 60mg m/r capsules bl8W. 
CORACTEN XL 30mg m/r capsules bl8X. 
Nifedipine CORACTEN XL 60mg m/r capsules bl8Y. 
NIVATEN RETARD 20mg m/r tablets bl8Z. 
*VASAD 10mg capsules bl8a. 
*CALCILAT 10mg capsules bl8b. 
*CALCIPINE 5mg capsules bl8c. 
*CALCIPINE 10mg capsules bl8d. 
CORACTEN SR 20mg m/r capsules bl8e. 
*ANGIOPINE 5mg capsules bl8f. 
*ANGIOPINE 10mg capsules bl8g. 
*NIFENSAR XL 20mg m/r tablets bl8h. 
ADALAT LA 30mg m/r tablets bl8i. 
ADALAT LA 60mg m/r tablets bl8j. 
CORACTEN SR 10mg m/r capsules bl8k. 
*CARDILATE MR 20mg m/r tablets bl8l. 
*ANGIOPINE MR 20mg tablets bl8m. 
*NIFELEASE 20mg m/r tablets bl8n. 
*CALANIF 10mg capsules bl8o. 
*CALANIF 5mg capsules bl8p. 
*HYPOLAR RETARD 20 m/r tablets bl8q. 
*NIFEDOTARD 20MR m/r tablets bl8r. 
*CORODAY MR 20mg m/r tablets bl8s. 
NIFOPRESS RETARD 20mg m/r tablets bl8t. 
NIFEDIPINE 10mg m/r capsules bl8u. 
NIFEDIPINE 20mg m/r capsules bl8v. 
NIFEDIPINE 10mg m/r tablets bl8w. 
NIFEDIPINE 30mg m/r tablets bl8x. 
NIFEDIPINE 60mg m/r tablets bl8y. 
NIFEDIPINE 20mg m/r tablets bl8z. 
BETA-ADALAT 50/20mg capsules bdes. 
CALCHAN MR 10mg m/r tablets bll7. 
CALCHAN MR 20mg m/r tablets bll6. 
VALNI XL 30mg m/r tablets bllg. 
VALNI XL 60mg m/r tablets bllh. 
VALNI 20 RETARD 20mg m/r tablets bllb. 
NIMODIPINE NIMODIPINE dt1.. 
NIMODIPINE 200microgram/mL intravenous 
infusion 50mL 
dt11. 
NIMOTOP 200micrograms/mL intravenous 
infusion 50mL 
dt12. 
NIMODIPINE 30mg tablets dt13. 
NIMOTOP 30mg tablets dt14. 
NIMODIPINE 50mg/250mL intravenous 
infusion 
dt15. 
NIMOTOP IV 50mg/250mL infusion dt16. 
Nisoldipine NISOLDIPINE blg.. 




*NISOLDIPINE 20mg m/r tablets blg2. 
*NISOLDIPINE 30mg m/r tablets blg3. 
*SYSCOR MR 10mg m/r tablets blg4. 
*SYSCOR MR 20mg m/r tablets blg5. 
*SYSCOR MR 30mg m/r tablets blg6. 
Slofedipine SLOFEDIPINE XL 30mg m/r tablets bll1. 
SLOFEDIPINE XL 60mg m/r tablets bll2. 
Verapamil VERAPAMIL HYDROCHLORIDE bb3.. 
VERAPAMIL 40mg tablets bb31. 
VERAPAMIL 80mg tablets bb32. 
VERAPAMIL 120mg tablets bb33. 
VERAPAMIL 160mg tablets bb3w. 
*BERKATENS 40mg tablets bb34. 
*BERKATENS 80mg tablets bb35. 
*BERKATENS 120mg tablets bb36. 
*BERKATENS 160mg tablets bb37. 
*CORDILOX 40mg tablets bb38. 
*CORDILOX 80mg tablets bb39. 
VERAPAMIL 240mg m/r tablets bb3A. 
HALF SECURON SR 120mg m/r tablets bb3B. 
VERAPAMIL 120mg m/r tablets bb3C. 
VERAPAMIL 40mg/5mL sugar free solution bb3D. 
VERAPAMIL HCL 5mg/2mL prefilled syringe bb3E. 
HALF-SECURON SR 120mg m/r tablets 
28CP 
bb3F. 
*HYPANEZE 40 tablets bb3G. 
*HYPANEZE 80 tablets bb3H. 
*HYPANEZE 120 tablets bb3J. 
*VERAPRESS MR 240 m/r tablets bb3K. 
*ETHIMIL MR 240 m/r tablets bb3L. 
Verapamil CORDILOX MR 240 m/r tablets bb3M. 
ZOLVERA 40mg/5mL oral solution bb3N. 
*RANVERA MR 240mg m/r tablets bb3O. 
VERA-TIL SR 240mg m/r tablets bb3P. 
CORDILOX 120mg tablets bb3a. 
*CORDILOX 160mg tablets bb3b. 
*CORDILOX 5mg/2mL injection bb3c. 
*SECURON 40mg tablets bb3d. 
*SECURON 80mg tablets bb3e. 
*SECURON 120mg tablets bb3f. 
*SECURON 120mg tablets 56CP bb3g. 
*SECURON 160mg tablets 56CP bb3h. 
*SECURON 160mg tablets bb3i. 
SECURON SR 240mg m/r tablets bb3j. 
SECURON SR 240mg m/r tablets 28CP bb3k. 
UNIVER 120mg m/r capsules x28 bb3l. 
UNIVER 180mg m/r capsules x56 bb3m. 
UNIVER 240mg m/r capsules x28 bb3n. 
SECURON IV 5mg/2mL injection bb3o. 




*GEANGIN 80mg tablets bb3q. 
*GEANGIN 120mg tablets bb3r. 
VERTAB SR 240 m/r tablets bb3s. 
VERAPAMIL 5mg/2mL injection bb3t. 
VERAPAMIL 120mg m/r capsules bb3v. 
VERAPAMIL 160mg tablets bb3w. 
VERPAMIL HCL 120mg tablets x56 bb3x. 
VERAPAMIL 240mg m/r capsules bb3y. 





HYDROCHLORIDE 2mg/180mg m/r 
capsules 
bk61. 
*TARKA 2mg/180mg m/r capsules bk62. 
CALCICARD CR 90mg m/r tablets bl5V. 





TRIAPIN MITE 2.5mg/2.5mg tablets bA11. 









2.2.1 Thiazides and Related Diuretics  
Thiazide THIAZIDE DIURETICS b2... 
Bendroflumethiazide BENDROFLUMETHIAZIDE b21.. 
BENDROFLUMETHIAZIDE 2.5mg tablets b211. 
BENDROFLUMETHIAZIDE 5mg tablets b212. 
APRINOX 2.5mg tablets b213. 
APRINOX 5mg tablets b214. 
*BERKOZIDE 2.5mg tablets b215. 
*BERKOZIDE 5mg tablets b216. 
*CENTYL 2.5mg tablets b217. 
*CENTYL 5mg tablets b218. 
NEO-NACLEX 5mg tablets b219. 
*NEO-BENDROMAX 2.5mg tablets b21A. 
*NEO-BENDROMAX 5mg tablets b21B. 
*URIZIDE 5mg tablets b21a. 
NEO-NACLEX 2.5mg tablets b21b. 
BENDROFLUMETHIAZIDE+POTASSIUM 








Chlorothiazide CHLOROTHIAZIDE b22.. 
*SALURIC 500mg tablets b221. 
DIURIL 250mg/5mL oral suspension b222. 
CHLOROTHIAZIDE 250mg/5mL oral 
suspension 
b22y. 
*CHLOROTHIAZIDE 500mg tablets b22z. 
CHLORTALIDONE CHLORTALIDONE b23.. 
KALSPARE tablets b518. 
HYGROTON 50mg tablets b231. 
*HYGROTON 100mg tablets b232. 
CHLORTALIDONE 50mg tablets b23y. 
*CHLORTHALIDONE 100mg tablets b23z. 
Clopamide PINDOLOL+CLOPAMIDE 10mg/5mg 
tablets 
bdeG. 
CLOPAMIDE [INGREDIENT see bdek] b24.. 
CYCLOPENTHIAZIDE CYCLOPENTHIAZIDE b25.. 




Hydrochlorothiazide HYDROCHLOROTHIAZIDE b26.. 
*ESIDREX 25mg tablets b261. 
*ESIDREX 50mg tablets b262. 
*HYDROSALURIC 25mg tablets b263. 
*HYDROSALURIC 50mg tablets b264. 
HYDROCHLOROTHIAZIDE 50mg tablets b26y. 
HYDROCHLOROTHIAZIDE 25mg tablets b26z. 
MODURETIC tablets b51b. 
MODURET-25 tablets b51a. 
Hydroflumethiazide HYDROFLUMETHIAZIDE b27.. 
*HYDRENOX 50mg tablets b271. 
HYDROFLUMETHIAZIDE 50mg tablets b27z. 
Indapamide INDAPAMIDE b28.. 
NATRILIX 2.5mg tablets b281. 
*NINDAXA 2.5mg tablets b282. 
*NATRAMID 2.5mg tablets b283. 
*OPUMIDE 2.5mg tablets b284. 
INDAPAMIDE 1.5mg m/r tablets b285. 
NATRILIX SR 1.5mg m/r tablets b286. 
ETHIBIDE XL 1.5mg m/r tablets b287. 
INDIPAM XL 1.5mg m/r tablets b288. 
MAPEMID XL 1.5mg m/r tablets b289. 




Mefruside MEFRUSIDE b29.. 
*BAYCARON 25mg tablets b291. 
*MEFRUSIDE 25mg tablets b29z. 




*ENDURON 5mg tablets b2a1. 
*METHYCLOTHIAZIDE 5mg tablets b2az. 
METOLAZONE METOLAZONE b2b.. 
*METENIX-5 5mg tablets b2b1. 
*XURET 500micrograms tablets b2b2. 
METOLAZONE 500micrograms tablets b2b3. 
*METOLAZONE 5mg tablets b2bz. 
POLYTHIAZIDE POLYTHIAZIDE b2c.. 
*NEPHRIL 1mg tablets b2c1. 
*POLYTHIAZIDE 1mg tablets b2cz. 
XIPAMIDE XIPAMIDE b2d.. 
DIUREXAN 20mg tablets b2d1. 







*BRINALDIX K tablets b911. 
*BURINEX K tablets b912. 
*CENTYL K m/r tablets b913. 
*DIUMIDE-K CONTINUS tablets b914. 
*ESIDREX K tablets b915. 
HYGROTON K tablets combination pack b916. 
*LASIKAL tablets b917. 
LASIX+K tablets 30day-CP combination 
pack 
b918. 
*NAVIDREX-K tablets b919. 
NEO-NACLEX-K tablets b91a. 
BUMETANIDE+POTASSIUM 
500micrograms/7.7mmol m/r tablets 
b91b. 
BENDROFLUMETHIAZIDE+POTASSIUM 










20mg/10mmol m/r tablets 
b91f. 
FRUSEMIDE tablets+POTASSIUM m/r 
tablets 40mg/10mmol pack 
b91g. 
BENDROFLUMETHIAZIDE+POTASSIUM 
2.5mg/8.4mmol m/r tablets 
b91h. 
Acetazolamide ACETAZOLAMIDE [GLAUCOMA] k81.. 
DIAMOX SUSTETS 500mg m/r capsules k811. 
DIAMOX 250mg tablets k812. 
*DIAMOX powder k813. 
DIAMOX PARENTERAL 500mg injection k814. 
DIAMOX SR 250mg m/r capsules k815. 
EYTAZOX 250mg m/r capsules k816. 
*ACETAZOLAMIDE powder k81v. 




ACETAZOLAMIDE 500mg m/r capsules k81x. 
ACETAZOLAMIDE 250mg tablets k81y. 
ACETAZOLAMIDE 500mg injection k81z. 
ACETAZOLAMIDE [EPILEPSY] dn1.. 
DIAMOX [EP] 250mg tablets dn12. 
DIAMOX [EP] 500mg injection dn13. 
ACETAZOLAMIDE [EP] 500mg m/r 
capsules 
dn1x. 
ACETAZOLAMIDE [EP] 250mg tablets dn1y. 
ACETAZOLAMIDE [EP] 500mg injection dn1z. 
2.2.1 Loop diuretics 
Loop LOOP DIURETICS b3... 
Furosemide FUROSEMIDE b31.. 
FUROSEMIDE 20mg tablets b311. 
FUROSEMIDE 40mg tablets b312. 
FUROSEMIDE 500mg tablets b313. 
*ALUZINE 20mg tablets b314. 
*ALUZINE 40mg tablets b315. 
*ALUZINE 500mg tablets b316. 
*DIURESAL 40mg tablets b317. 
*DIURESAL 20mg/2mL injection b318. 
*DIURESAL 50mg/5mL injection b319. 
MIN-I-JET FRUSEMIDE 250mg/25mL 
injection 
b31A. 
MIN-I-JET FRUSEMIDE 80mg/8mL 
injection 
b31B. 
FUROSEMIDE 80mg/8mL prefilled 
syringe 
b31C. 
FRUSEMIDE 250mg/25mL prefilled 
syringe 
b31D. 
FROOP 40mg tablets b31E. 
FRUSOL 20mg/5mL sugar free oral 
solution 
b31F. 
FRUSOL 40mg/5mL sugar free oral 
solution 
b31G. 
FRUSOL 50mg/5mL sugar free oral 
solution 
b31H. 
*DRYPTAL 40mg tablets b31a. 
*DRYPTAL 500mg tablets b31b. 
*DRYPTAL 20mg/2mL injection b31c. 
*DRYPTAL 50mg/5mL injection b31d. 
*DRYPTAL 250mg/25mL injection b31e. 
*FRUSETIC 40mg tablets b31f. 
*FRUSID 40mg tablets b31g. 
*LASIX 20mg tablets b31h. 
*LASIX 40mg tablets b31i. 
*LASIX 500mg tablets b31j. 
LASIX PAEDIATRIC 1mg/1mL liquid b31k. 
LASIX 20mg/2mL injection b31l. 




*LASIX 250mg/25mL injection b31n. 
*FRUMAX 40mg tablets b31o. 
*RUSYDE 20mg tablets b31p. 
*RUSYDE 40mg tablets b31q. 
FUROSEMIDE 20mg/5mL sugar free 
solution 
b31r. 
FUROSEMIDE 40mg/5mL sugar free 
solution 
b31s. 
FUROSEMIDE 50mg/5mL sugar free 
solution 
b31t. 
FUROSEMIDE 50mg/5mL injection b31u. 
*FRUSEMIDE 1mg/1mL liquid b31x. 







FUROSEMIDE 250mg/25mL injection b31z. 
LASILACTONE capsules b519. 
FRUMIL 40/5mg tablets b516. 
FRUMIL LS 20/2.5mg tablets b51o. 
FROOP 40mg tablets b31E. 
Bumetanide BUMETANIDE b32.. 
*BURINEX 1mg tablets b321. 
*BURINEX 5mg tablets b322. 
*BURINEX 1mg/5mL liquid b323. 
*BURINEX 1mg/2mL injection b324. 
*BURINEX 2mg/4mL injection b325. 
*BURINEX 5mg/10mL injection b326. 
*BETINEX 1mg tablets b327. 
*BETINEX 5mg tablets b328. 
BUMETANIDE 1mg tablets b32u. 
BUMETANIDE 5mg tablets b32v. 
BUMETANIDE 1mg/5mL liquid b32w. 
*BUMETANIDE 1mg/2mL injection b32x. 
BUMETANIDE 2mg/4mL injection b32y. 
*BUMETANIDE 5mg/10mL injection b32z. 
ETACRYNIC ACID ETACRYNIC ACID b33.. 
*EDECRIN 50mg tablets b331. 
*EDECRIN 50mg injection b332. 
*ETHACRYNIC ACID 50mg tablets b33y. 
ETHACRYNIC ACID 50mg injection b33z. 
PIRETANIDE PIRETANIDE b34.. 
*ARELIX 6mg m/r capsules b341. 
*PIRETANIDE 6mg m/r capsules b34z. 
TORASEMIDE TORASEMIDE b35.. 
TOREM 2.5mg tablets b351. 
TOREM 5mg tablets b352. 
TOREM 10mg tablets b353. 




*TOREM 20mg/4mL injection b355. 
TORASEMIDE 2.5mg tablets b356. 
TORASEMIDE 5mg tablets b357. 
TORASEMIDE 10mg tablets b358. 
*TORASEMIDE 10mg/2mL injection b359. 




POTASSIUM SPARING COMPOUND 
DIURETICS A-Z 
b51.. 
ALDACTIDE-25 tablets b511. 
ALDACTIDE-50 tablets b512. 
*AMILCO tablets b513. 
DYAZIDE tablets b514. 
*DYTIDE capsules b515. 
FRUMIL 40/5mg tablets b516. 
FRUSENE tablets b517. 
KALSPARE tablets b518. 
LASILACTONE capsules b519. 
CO-TRIAMTERZIDE 50/25mg tablets b51A. 






















*DELVAS tablets b51K. 
*ARIDIL 2.5mg/20mg tablets b51L. 
*ARIDIL 5mg/40mg tablets b51M. 
*ARIDIL 10mg/80mg tablets b51N. 
*SPIRO-CO 25mg tablets b51O. 
*SPIRO-CO 50mg tablets b51P. 
*ZIDA-CO 5mg/50mg tablets b51Q. 
*FRUSEMEK 5mg/40mg tablets b51R. 
*FROOP CO 5mg/40mg tablets b51S. 
*KOMIL 5/40 tablets b51T. 
MODURET-25 tablets b51a. 
MODURETIC tablets b51b. 
*MODURETIC mixture b51c. 
*NORMETIC tablets b51d. 
*SYNURETIC tablets b51e. 
*TRIAMCO tablets b51f. 




*LASORIDE tablets b51h. 
*CO-AMILOFRUSE tablets b51i. 
CO-AMILOZIDE 2.5/25mg tablets b51j. 
CO-AMILOZIDE 5/50mg tablets b51k. 
CO-AMILOZIDE 5mg/50mg/5mL mixture b51l. 
VASETIC CO-AMILOZIDE 5/50mg tablets b51m. 
*FRUSENE tablets 56CP b51n. 
FRUMIL LS 20/2.5mg tablets b51o. 
CO-FLUMACTONE-25 tablets b51p. 
CO-FLUMACTONE-50 tablets b51q. 
NAVISPARE 2.5/0.25mg tablets b51r. 
*AMILMAXCO 5/50 tablets b51s. 
*BURINEX A tablets b51t. 
*FRUMIL FORTE 80/10mg tablets b51u. 
*TRIAMAXCO 50/25mg tablets b51v. 
*KALSPARE LS tablets b51w. 
CO-AMILOFRUSE 2.5/20mg tablets b51x. 
CO-AMILOFRUSE 5/40mg tablets b51y. 
CO-AMILOFRUSE 10/80mg tablets b51z. 
 
2.2.3 Potassium sparing diuretics and aldosterone antagonists 
 POTASSIUM SPARING DIURETICS b4... 
Amiloride AMILORIDE HYDROCHLORIDE b41.. 
*MIDAMOR 5mg tablets b411. 
*AMILOSPARE 5mg tablets b412. 
AMILORIDE 5mg/5mL sugar free solution b413. 
*BERKAMIL 5mg tablets b414. 
AMILAMONT 5mg/5mL sugar free oral 
solution 
b415. 







NAVISPARE 2.5/0.25mg tablets b51r. 
KALTEN capsules bde7. 
CO-AMILOFRUSE 5/40mg tablets b51y. 
CO-AMILOFRUSE 10/80mg tablets b51z. 
CO-AMILOFRUSE 2.5/20mg tablets b51x. 
POTASSIUM 
CANRENOATE 
POTASSIUM CANRENOATE b42.. 




Spironolactone SPIRONOLACTONE b43.. 
ALDACTIDE-25 tablets b511. 
ALDACTIDE-50 tablets b512. 
SPIRONOLACTONE 25mg tablets b431. 
SPIRONOLACTONE 50mg tablets b432. 




ALDACTONE 25mg tablets b434. 
ALDACTONE 50mg tablets b435. 
ALDACTONE 100mg tablets b436. 
*DIATENSEC 50mg tablets b437. 
*LARACTONE 25mg tablets b438. 
*LARACTONE 100mg tablets b439. 
*SPIROSPARE 25mg tablets b43A. 
SPIRETIC 25mg tablets b43a. 
SPIRETIC 100mg tablets b43b. 
*SPIROCTAN 25mg tablets b43c. 
*SPIROCTAN 50mg tablets b43d. 
*SPIROCTAN 100mg capsules b43e. 
*SPIROLONE 25mg tablets b43f. 
*SPIROLONE 50mg tablets b43g. 
*SPIROLONE 100mg tablets b43h. 
*LARACTONE 50mg tablets b43i. 
*SPIROSPARE 100mg tablets b43j. 
SPIRONOLACTONE 5mg/5mL oral 
suspension 
b43k. 
SPIRONOLACTONE 10mg/5mL oral 
suspension 
b43l. 
SPIRONOLACTONE 25mg/5mL oral 
suspension 
b43m. 
SPIRONOLACTONE 50mg/5mL oral 
suspension 
b43n. 




TRIAMTERENE TRIAMTERENE b44.. 
DYTAC 50mg capsules b441. 







DYAZIDE tablets b514. 
CO-TRIAMTERZIDE 50/25mg tablets b51A. 
Eplerenone EPLERENONE b45.. 
INSPRA 25mg tablets b451. 
INSPRA 50mg tablets b452. 
EPLERENONE 50mg tablets b45y. 





Narrative interview topic guide 
 
The interview may cover topics that interviewees may find sensitive. 
Participants will be reminded of this prior to the interviews. It will be made clear 
to them that they do not have to answer any questions they do not wish to, and 
that they can pause or terminate the interview at any time. Due to the nature of 
topics to be discussed, it may be appropriate to open with general 
conversational questions to help put the participant at ease with the interview 
situation.  
 
The interview will be carried out in two parts, in order to accommodate for 
anticipated fatigue. 
 
INITIAL INTERVIEW - OLDER PEOPLE TOPICS GUIDE 
 
The topic guide describes questions that attempt to elicit from the participant 
themselves’ their own narrative.  
 
This topic guide is to be used in the initial interview. If not all topics are covered 
in the first session, the interview may return to questions not used in the second 
visit. The topic guide will be refined based on the themes and theories emerging 





(Throughout, try to ask people about concrete examples, ask them to describe 
scenarios etc) 
First interview 
Open first with biographical questions, changes/ crises 
Warm them up 
Lay out in the first what the difference between the 2, 2 chapters. Think about 
particular issues 
Might help you open up 
 
GENERAL OPENING QUESTIONS 
 
- Have you lived here a long time/ have you always lived here?  
- What did you do for a living? 
- Since when have you  been retired? How has that been? 
-  
LATER LIFE / GROWING OLDER / BECOMING FRAIL 
 
To explore perceptions and adjustments to growing older, and how people in 
later life adjust  (or not) themselves to became frail  
 
- In terms of where you are now what are the kind of things you enjoy 




- Can you tell me a bit about yourself and the kind of things you enjoy 
doing? 
- Could you describe a typical day? [+/- probes] 
- How has your daily life changed over time, over the past few years? 
- To what extent do you consider yourself an active person? 
 
- What are positive things of later life? [significance of family/ friends]  
 
- What are the difficulties about later life? 
 
- Do you have any health difficulties/ since when have you had ill health?  
- Could you explain me how a good day/ bad day look like? 




- When were you first diagnosed with high blood pressure? How did that 
come about? 
- Were there symptoms of low BP/ medications? 
- Did the patient take the initiative to seek the diagnosis? 
- Was there a change with treatment 




- Have you had any falls? 
- Do you ever feel dizzy when you stand up? 
- Has someone talked through the likely effects high blood pressure might 
have on you? 
- Do the medicines make any difference, for better, for worse? 
 




- Do the medicines make any difference, for better, for worse? 
 
- Would you consider stopping treatment? 
 
- What were you told re effects of treatment? 
 
- How far would you want to be involved in options open to them 
 
- Do they usually take the Dr’s advice? 
 
- Do they want to be responsible for themselves? 
 









- As you look back over your life, do you see any "turning points"; that is, a 
key event or experience that changed over the course of your life or set 
you on a different track? (consider timeline chart) 
 
- In particular are there turning points in your health you could identify? 
When were these? (consider timeline chart) 
 
- How do you see the significance of your blood pressure in terms of your 
overall health and the changes you’ve described? 
- What positive/ negative experiences have you experienced concerning 
your health? 
 
- What do you value as a good life now? [in what ways have you tried to 
compensate for losses/ optimise your life] 
 







How has your health been over the last intervening week? 
Specifically mention frailty-use it upfront.  
Would you consider yourself as frail? 
Give them the quandary: Re. BP management in frail old age: Drs don’t know 
Ask them about a current decision with respect to bp. Ask about stopping meds 
 
POTENTIAL FOR SELF MANAGEMENT 
Look at the logistics of the home environment 
- Where does the sbp monitor live 
- Strategies to fit it in 
- Struggle to fit it in 
- Energy to do that 
- Who does it, carer or family 
- How much of life is changing 
- How much do they get out of life day to day 
- Sense of control 
Are you monitoring BP? 




- What have your readings been 
- Do you worry about them? 
- Does it reassure you 
Self awareness 
- Where does hypertension fit in to their personal priorities? 




Throughout the interviews notes will be taken by the interviewer of the context 
in which the interview takes place, aspects of the setting, any distractions during 
the interview, facial grimacing, body language or non-verbal cues that the 
Dictaphone may not record. Features of displayed emotion will also be recorded 
alongside the timing of what is being said.  
 
 
 
 
 
